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This study focuses upon the characterisation of the genetic and epigenetic profiles of rare 
forms of sporadic renal cancers (RCC), by utilising the latest technology in genome wide 
methylation arrays, targeted quantitative Methylight analysis and whole exome 
sequencing (WES). The aim was to identify differential patterns of DNA methylation or 
somatic mutations that may permit distinction between different subtypes of RCC which 
could therefore facilitate disease prognosis or help to identify molecular pathways that 
could be targeted therapeutically. Illumina Infinium HumanMethylation 450K BeadChip 
permitted the comparison of the epigenome of the malignant chromophobe RCC and the 
benign renal oncocytoma. This study identified twenty-eight genes to be differentially 
hypermethylated in chromophobe RCC, and two differentially hypermethylated genes in 
renal oncocytoma showing that although both visually and pathologically similar, both 
tumours have a distinct methylation pattern. Comparison to the methylation data 
available, for clear cell and papillary renal cell carcinoma from The Cancer Genome Atlas 
(TCGA), identified two genes SPG20 and NPHP4 to be significantly methylated in 
chromophobe RCC. Targeted Methylight analysis of the RASSF gene family in sarcomatoid 
RCC identified that frequent hypermethylation of RASSF10 was significantly associated 
with the occurrence of metastasis and later stages of the cancer. WES of renal 
oncocytoma samples identified somatic mutations in eighteen genes involved in a variety 
of cellular functions. Sanger sequencing was then used to confirm the mutations 
identified, followed by further screening by Sanger in a cohort of additional renal 
oncocytoma samples to identify if the somatic mutations are recurrent. Modern high 
throughput and quantitative techniques have permitted further characterisation of these 
rare renal cancers and have enabled unique insights into their molecular genetic, findings 
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1.1 Cancer  
Cancer is the broad term given to a collection of diseases, characterised by 
unregulated cell growth that can spread and infiltrate surrounding tissues (King, 
2006; National Cancer Institute, 2015). 
Statistically, cancer is the world’s leading cause of mortality, associated with 
over 8.2 million reported deaths in 2012 alone (Stewart and Wild, 2014) and 
reported as the leading cause of death in the UK, Australia, New Zealand, Canada 
and Denmark (Wishart, 2015).  
It is predicted that there are 32 million people world-wide currently living with 
cancer (Ferlay et al., 2014). Within the UK, over 290,000 cancer diagnoses were 
registered in 2013; according to previously reported figures, this corresponds to 
an increase in incidence rate of 2.8% for males, and 8.3% for females over a 
course of ten years (Office for National Statistics, 2015a). However, it should be 
noted that the number of people surviving cancer is also increasing, current 
estimates predict that over 50% of people diagnosed with cancer survive the 
disease (Quaresma et al., 2015; Wishart, 2015).  
It is also predicted that at least 1/3rd of cancers are preventable, with many 
environmental stimuli promoting cancer formation. For example 42% of cancers 
diagnosed in the UK are reported to be a consequence of lifestyle and 
environmental risk factors (Parkin et al., 2011). One of the most recognised 
carcinogenic risks is tobacco smoking, which has been associated with a 
multitude of cancers ranging from cancer of the throat to cervical and kidney 
cancers. In the UK, smoking is estimated to be responsible for approximately 
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19.4% of all newly diagnosed cancer cases (Parkin et al., 2011) and 28% of fatal 
cancers (in 2005) (Swerdlow et al., 2010). Other environmental factors 
associated with the development of cancer include; diet, obesity and high body 
mass index (BMI), exposure to radiation, viral infections (e.g. Hepatitis C virus 
and Human papilloma virus) alcohol consumption and environmental 
carcinogenic pollutants (Benn et al., 2016; Stewart and Wild, 2014; Swerdlow et 
al., 2010).  
1.2 Cancer as a genetic disease 
Cancer may arise from virtually any tissue or cell type, although epithelium cells 
are the cell type from which most common cancers arise (such as lung cancer 
and colorectal cancer) (Ruddon, 2007). In normal cells, cellular growth is a 
tightly regulated process and is a balancing act between pro-growth factors and 
pro-apoptotic and senescence factors. In cancer this balance is tipped in favour 
of growth, by the augmentation of cellular processes and the accumulation of 
genetic alterations (including; genetic mutations, chromosomal translocations, 
copy number variations (CNVs) or epigenetic augmentation) (Burrell et al., 
2013).  
Carcinogenesis revolves around a central principle of clonal evolution proposed 
in 1976 by P Nowell. He proposed that tumours originate from a single founder 
cell that has acquired specific genomic alterations, enabling it to escape normal 
cellular regulatory mechanisms (including signals for growth, respiration and 
apoptosis) (Nowell, 1976). Successfully avoiding these cellular regulatory signals 
enables uncontrolled growth and proliferation. Further genetic variations may 
then be acquired in the tumour that provide a cellular growth advantage; the 
 
 3
clones containing this advantageous variant may then undergo, subclonal 
selection, a process which then drives the formation and progression of tumours. 
Sequential growth, acquisition of genetic variations and subclonal selection 
drives the formation of tumours. A multi-step process resulting in normal 
regulated cells, becoming pre–cancerous cells then cancerous cells and finally 
resulting in a tumour and metastasis (Greaves and Maley, 2012; King and Robins, 
2006; Nowell, 1976).  
To become a cancer, a cell has to acquire a collection of ten distinct biological 
capacities, dubbed ‘Hallmarks’ (Cavallo et al., 2011; Hanahan and Weinberg, 
2011).  These characteristic hallmarks possessed by cancer cells are described 
by Hanahan and Weinberg (2011) and include: sustaining proliferative 
signalling, evading growth suppressors, avoiding immune destruction, resisting 
cell death, genome instability and mutation, inducing angiogenesis, enabling 
replicative immortality, activating invasion and metastasis, tumour-promoting 
inflammation and deregulating cellular energetics (Hanahan and Weinberg, 
2011). 
 The acquisition of these biological hallmarks permits the formation of the 
tumour microenvironment, which supports and promotes tumour growth and 
development. But also provides possible therapeutic targets for the treatment of 
cancer. For example anti VEGF molecules (such as tyrosine kinase inhibitor  
(TKI) sunitinib) have been approved to inhibit angiogenesis in several cancers 
including kidney cancer (Garajová et al., 2015; Hanahan and Weinberg, 2011; 
Shuch et al., 2015). 
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 Intratumour heterogeneity, driver and passenger mutations 
Studies that aimed to show how genetic mutations can result in cancer, have now 
shown that in the majority of cases, a tumour is not made up of a single clonal 
population of cells, as previously thought, but can actually be made up of many 
different clonal populations of cells that have acquired pro-tumourigenic 
mutations (Burrell et al., 2013; McGranahan and Swanton, 2015; Tabassum and 
Polyak, 2015). 
Due to the genomic instability hallmark associated with cancers, as a tumour 
grows and proliferates, the cells acquire an increasing number of mutations 
(Burrell et al., 2013; Knudson, 2001). Some of these acquired mutations will have 
an indifferent effect within the tumour; these are known as passenger mutations 
(Pon and Marra, 2015; Vogelstein et al., 2013). Other mutations will provide an 
active growth advantage to the cell, and will promote tumour progression (these 
are known as driver mutations) (Pon and Marra, 2015; Tamborero et al., 2014; 
Vogelstein et al., 2013). Cellular clones that contain these driver mutations may 
undergo positive selection, thereby creating a new sub-clonal population within 
the tumour that drives tumour progression, microenvironment formation and is 
a major cause of intratumour heterogeneity and genetic diversity (Burrell et al., 
2013; McGranahan and Swanton, 2015). The presence of different subclonies 
within one tumour type in combination with genomic instability means that, high 
levels of genetic diversity can be present, with each subclone presenting with a 
different mutation profile.  For example a study by Gerlinger et al. 2014, on clear 
cell renal cell carcinoma, identified 49 driver mutations and 76 somatic CNVs of 
which 73%  and 75% respectively where identified to be subclonal (Gerlinger et 
al., 2014). As a consequence of the mosaic nature of tumours, the original 
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founding mutations maybe diluted and therefore identified at low-levels, making 
identifying the exact causes and pathways that have been deregulated a complex 
and challenging task. 
 Oncogenes and tumour suppressor genes 
In normally functioning cells, the genes responsible for promoting cell growth 
are known as proto-oncogenes, while those that prevent cell growth and 
proliferation and initiate apoptosis are known as tumour suppressor genes 
(Hanahan and Weinberg, 2011; Lee and Muller, 2010; Weinberg, 2013). When 
these genes become altered by intragenic mutations, chromosomal 
rearrangements, chromosomal duplications or deletions, for example, these 
proto-oncogenes and tumour suppressor genes can become oncogenic.  
Proto-oncogenes were initially identified via investigations into the retrovirus 
transforming gene (SCR) and its involvement in sarcoma formation in chickens in 
the 1970s (Bell, 2010; Stéhelin, 1995 and references within). This discovery led 
to the understanding that cancer could arise through genetic mutations; a 
ground breaking discovery that sparked a wide interest into how genetic 
mutations can result in cancer formation. Since then, a large amount of 
information has been gained into the genetic processes behind tumourigenesis. 
For example, it is now widely understood that a proto-oncogene can become an 
oncogene when a specific genetic alteration is inherited or acquired that causes 
the encoded protein to become permanently active or to become over expressed 
in the cell. This therefore results in the constitutive and unregulated activation of 
signals that promote cell growth and proliferation, which can then result in 
tumourigenesis (Lee and Muller, 2010; Thomas et al., 2007; Weinberg, 2013). 
 
 6
Since the identification of proto-oncogenes, their mechanisms of activation 
during tumourigenesis and the significance of their role in cancer has been 
widely studied. One such example is the RAS family of GTPases; some of the most 
well recognised oncogenes The RAS genes encode small GTPases that are 
involved in initiating and propagating signalling cascades that result in cell 
growth. The RAS GTPases function by cycling between an active GTP-bound state 
and an inactive GDP-bound state. This cycling occurs in the absence of external 
stimuli as the RAS protein has the intrinsic ability to perform GTP-hydrolysis, 
enabling it to regulate itself. For this reason, the presence of a specific genetic 
mutation that affects any of the amino acid residues responsible for GTP-
hydrolysis can inhibit the protein’s ability to cycle to the inactive GDP-bound 
state. This therefore causes the RAS protein to remain in a constitutively active 
GTP-bound state, resulting in a permanently active signalling cascade promoting 
growth and proliferation, which ultimately leads to tumour formation (Pylayeva-
Gupta et al., 2011). This method of tumour genesis is relatively common, for 
example it is predicted that >20% of cancers harbour an activating mutation for 
either KRAS, HRAS or NRAS, with the majority of GOF mutations located in 1 of 
three key amino acids Glycine-12 (G12), Glycine-13 (G13) and Glutamine-61 (Q61) 
which are essential for GTP-hydrolysis (Boichard et al., 2012; Frattini et al., 
2004; Gripp and Lin, 2012; Karakas et al., 2006; Rajalingam et al., 2007) 
 Tumour suppressor genes (TSGs) 
TSGs play a vital protective role in cells and are often involved in processes such 
as repressing cell growth, promoting cell cycle arrest, initiating DNA damage 
repair and inducing apoptosis (Hanahan and Weinberg, 2011; Lee and Muller, 
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2010; Weinberg, 2013). For this reason loss of function or reduced expression of 
these genes can result in unregulated and uninhibited cellular growth, 
proliferation and survival, thereby resulting in tumourigenesis (Hanahan and 
Weinberg, 2011). A well known example of this can be found in individuals who 
harbour mutations in either of the BRCA1 or BRCA2 genes. Pathogenic mutations 
in either of these genes can increase an individual’s predisposition to breast and 
ovarian cancer by approximately 88% (Antoniou et al., 2004). This is because 
BRCA1 and BRCA2 are tumour suppressor genes involved in regulating DNA-
damage repair; therefore loss of function of either of these genes deprives the 
cell of it’s ability to repair damaged DNA, which results in an increase in genomic 
instability and the formation of a tumour as a consequence of this (Antoniou et 
al., 2004).  
 Knudson two hit hypothesis (TSGs) 
Unlike oncogenes, where often only a single mutation, or ‘hit’, is sufficient to 
result in increased protein activity, TSGs often require two hits resulting in the 
loss of protein function, due to the fact that both alleles must be altered. This 
phenomena was originally described by Alfred Knudson in 1971, when he 
proposed the ‘two-hit hypothesis’ following his investigation into sporadic and 
inherited retinoblastoma, (a childhood cancer of the retina). Knudson observed 
that inheriting a single germline mutation in RB1, did not appear to be sufficient 
to cause the cancer in the offspring of parents that had previously presented 
with retinoblastoma. Knudson also made the observation regarding the age of 
the children that had inherited a germline mutation in RB1 who then developed 
retinoblastoma often did so at a much younger age than those children without a 
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familial link to the disease. He also noticed that the affected children with a 
family history of the disease often developed bilateral retinoblastoma in contrast 
to the, often, unilateral development of retinoblastoma of the children without 
family histories. He therefore, deduced that the development of retinoblastoma 
must be a bilateral event, requiring two mutations (one in each allele). 
Concluding that those affected children with a familial link to the disease must 
have inherited one mutation (hit one), while; the other must have been acquired 
somatically later in life (hit two). He suggested that the affected children that had 
not inherited the first hit, must have acquired both mutations somatically during 
life, which is why they developed cancer at a later age than the inherited cases 
(Knudson, 1971). In 1987, RB1 became the first TSG to be isolated, cloned and 
sequenced (Lee et al., 1987). These findings laid the foundations of what we now 
understand to be tumour suppressor genes, and initiated a new wave of 
investigations into how genetic mutations in either proto-oncogenes or tumour 
suppressor genes can result in cancer.  
1.3 Epigenetics 
Epigenetics is widely regarded as heritable alterations in DNA expression that do 
not alter the DNA sequence. Usually achieved by modifications to the DNA and 
chromatin, which alters or regulates the binding of transcription factors and 
other regulatory complexes and is essential form normal cell growth (Gibney and 
Nolan, 2010). Such epigenetic mechanisms identified, include histone 
modifications, DNA methylation and small non-coding RNAs such as microRNAs 
(miRNAs) and short interfering RNAs (siRNAs), and large non-coding RNA 
(Gibney and Nolan, 2010). 
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 Histone modifications 
Histones are highly conserved globular proteins, which form nucleosomes, vital 
for the packaging of DNA into chromatin. Posttranslational modifications to the 
N terminal tails of the histone proteins (histone tails) regulate the dynamic 
processes of transcription, DNA repair and replication, by altering either the 
chromatin density or transcription factor and other proteins accessibility and 
binding to the DNA (Gibney and Nolan, 2010; Kouzarides, 2007).  Nucleosomes 
form a key component of chromatin. Each nucleosome is comprised of an 
octamer core of histones (histone 3,4 2A and 2B), around which 147bp of DNA is 
wrapped, the N terminal tail of each histone protein projects from the core and is 
the target for posttranslational modifications (Figure 1-1-1A) (Gibney and Nolan, 
2010; Kouzarides, 2007; Venkatesh and Workman, 2015) 
Organisation of DNA into chromatin and then chromosomes is achieved through 
several levels of organisation, starting with the DNA being wrapped around the 
nucleosomes, the analogy ‘beads on a string’ is often used to describe the 
appearance of chromatin at this level of organisation. These strings are then 
folded into a chromatin fibre of 30nm diameter by the addition of linker histone 
H1. Followed by further packaging and folding is undertaken to achieve the 
higher order of structure observed in a mitotic chromosome (Figure 1-1                                                                                                                   







Figure 1-1: Depiction of histones structure and chromatin organisation A) Representation of a nucleosome, depicting the histone core, histone tails and the locations of common post translational modifications (Me: Methylation Ac: Acetylation, P: Phosphorylation and Ub: Ubiquitination) (adapted from (Kouzarides, 2007).  B) The levels of chromatin organisation within cells. Epigenetic regulation via DNA methylation occurs at the DNA level, while histone modifications affect the nucleosomes (as depicted in figure 1a) at the first level of organisation dubbed ‘Beads on a string’. Adapted from (Felsenfeld and Groudine, 2003) 
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The post-translational modifications of the nucleosomes histone tails can include 
acetylation, methylation and ubiquitylation of lysine residues, methylation of 
arginine residues and phosphorylation of serine or threonine (Kouzarides, 2007; 
Sawan and Herceg, 2010). These modifications are achieved through a myriad of 
enzymes, including; histone acetyltransferases (HATs) (such as Hat1, Hpa2 and 
P300), histone deacetylases (HDACs) (e.g. SirT2 and HDAC10), histone 
methyltransferase (such as the arginine methyltransferase PRMT4, or lysine 
methyltransferases such as the MLL family or SET1A), Serine/Threonine kinases 
(including MSK1/2 and Mst1) and Ubiquitilases (including Ring1A/B) (Ceccacci 
and Minucci, 2016; Kouzarides, 2007; Sawan and Herceg, 2010). 
Different histone modifications have been associated with different biological 
functions, for example acetylation of lysine residues within the histone tail is 
associated with increased gene expression via relaxation of chromatin structure.  
It is reported that, the addition of an acetyl group to a lysine residue, neutralises 
the positive charge of the histone tail, thus slightly reducing the strength of 
attraction to the negatively charged DNA and thereby weakening the 
nucleosome-DNA binding and nucleosome-nucleosome interaction. This in turn 
results in reduced chromatin stability, and permits transcription factors access 
to previously ‘locked away’ genes. (Baylin and Jones, 2011; Kouzarides, 2007; 
Rogenhofer et al., 2012b; Sawan and Herceg, 2010). 
Histone methylation on the other hand has a diverse range of functions, 
depending upon the level of methylation and which residue is methylated, 
including protein recruitment and regulating chromatin density, (Sawan and 
Herceg, 2010). For example, histone 3 lysine 4 methylation (H3K4m) is 
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predominantly present at the promoter region of actively transcribed genes 
(Gibney and Nolan, 2010). Additionally it has been shown that during foetal 
development H3K4 methylation maintains gene transcription at active promoter 
regions by inhibiting the binding of DNA methyltransferase 3 (DNMT3) and 3L 
(DNMT3L), preventing methylation of the DNA and subsequent gene inactivation 
(Cedar and Bergman, 2009). Furthermore methylation of histone 3 lysine 36 
(H3K36) and histone H3 lysine 79 (H3K79) are also associated with 
transcriptional activation and gene expression, with H3K36 tri-methylation 
enriched within the gene bodies (particularly the exons) of transcriptionally 
active genes (Gibney and Nolan, 2010; Sawan and Herceg, 2010; Venkatesh and 
Workman, 2015). Histone methylation modifications associated with 
transcriptional repression and heterochromatin formation include histone 3 
lysine 9 (H3K9), histone 4 lysine 20 (H4K20) and histone 3 lysine 27 (H3K27) 
(Sawan and Herceg, 2010). With H3K27 methylation associated with the 
recruitment of the chromodomain containing polycomb protein PC2, a protein 
associated with the maintenance of X- inactivation (Kouzarides, 2007).  
To add further complexity, histones tails can be methylated at three different 
levels, mono (me1), di (me2) and tri (me3) methylation. Conventionally the 
increasing number of methyl groups correlates with a more intense response, 
however this is not always the case, for example it is reported that mono-
methylation of histone 3 lysine 27 (H3K27me1) and histone 3 lysine 9 
(H3K9me1) is associated with transcriptional activation, while di- and tri -
methylation (me2 and me3) of the same residues is associated with 
transcriptional repression (Ellinger et al., 2010; Rogenhofer et al., 2012a, 
2012b). Histone modifications have a pronounced effect on chromatin stability 
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and gene expression and even regulate key biological features such as DNA 
repair and DNA replication (Baylin and Jones, 2011), it is therefore unsurprising 
that histone modifications are frequently associated with cancer (section 1.3.4) 
 DNA methylation 
DNA methylation, is also associated with gene repression, regulation of the 
chromatin architecture, tissues specific gene silencing and X-inactivation (Brena 
and Plass, 2009; Sharma et al., 2010)and almost exclusively occurs at cytosine-
guanine (CpG) di-nucleotides (Mikeska and Craig, 2014).  
It is estimated that between 70-80% of all CpG loci are methylated. The majority 
of CpG loci are located in CpG rich regions known as CpG islands, the 
surrounding less CpG dense areas are referred to as shores and shelves. CpG 
islands are characterised as regions with >50% CpG content. The shore regions 
are less dense than the CpG islands and located within 2kb up or downstream of 
a CpG island, while CpG shelves are located >4kb up or downstream of the CpG 
island (Dedeurwaerder et al., 2011; Malzkorn et al., 2011; Rodríguez-Paredes 
and Esteller, 2011).  Furthermore, a predicted 60% of gene promoter regions are 
believed to be regulated by CpG islands with reports also suggesting that 
methylation of the CpG shores too play an important role in the regulation of 
gene expression (Irizarry et al., 2009; Rodríguez-Paredes and Esteller, 2011). 
Additionally, intragenic DNA methylation is frequently observed within gene 
bodies, particularly within exonic regions. It is suggested that the presence of 
this intragenic methylation prevents random activation of gene transcription at a 
location that is not the proper transcription start site (TSS), promotes elongated 
transcription to ensure complete transcription of all exons and may even be 
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involved in post transcriptional splicing of the RNA (Jones, 2012). Furthermore, 
DNA methylation is also observed at highly repetitive intergenic elements, and is 
reported to promote chromosome stability by silencing transposable DNA 
elements (Jones, 2012; Karami et al., 2015; Sharma et al., 2010). 
During methylation the cytosine residue is converted to a 5-methylcytosine 
(5mC) by the covalent addition of a methyl group to the carbon-5 atom. The 
presence of a methyl group is reported to project into the major grove of the 
DNA, thus repressing gene transcription through inhibiting the binding of 
transcription factors such as CTCF or c-myc, (Gibney and Nolan, 2010; Jones, 
2012; Mikeska and Craig, 2014). Furthermore, there is a close link between DNA 
methylation and histone modifications, regarding regulation of gene expression 
and chromatin structure. Not only can DNA methylation provide binding sites for 
other proteins such as HDACs, resulting in histone modification and gene 
repressions (Sharma et al., 2010), histone modifications such as H3K9me2 have 
been reported to prevent DNA methylation from de-methylation ensuring 
prolonged gene silencing. This is achieved by the recruitment of Uhrf1, a protein 
which in turn recruits DNA methyltransferase 1 (DNMT1) and histone 
methyltransferase to maintain the methylation status of DNA and H3K9 
respectively (Cedar and Bergman, 2009; Rose and Klose, 2014). DNA 
methylation has also been linked to the repackaging of chromatin after mitosis. 
During the cell cycle histones are removed to permit replication of the DNA, 
while DNA methylation is maintained. Once the cell has divided the histones are 
then replaced. The DNA methylation provides binding sites for the histone 
modification enzymes and acts as reference for which regions of the DNA are 
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repressed (high DNA methylation) and should be packaged as heterochromatin 
(Cedar and Bergman, 2009).  
Co-ordination of DNA methylation is regulated by a family of DNA 
methyltransferases (DNMT) enzymes. Of note, are DNMT 3a and 3b, which are 
involved in denovo DNA methylation (Gibney and Nolan, 2010; Jones, 2012), and 
DNMT1, which is involved in maintaining the DNA methylation, and reproducing 
DNA methylation pattern during cell cycle, by replicating the methylation 
pattern of hemi-methylated DNA on to the newly synthesised DNA molecules 
during the cell cycle, thus ensuring heritability of the DNA methylation profile 
throughout cell passages (Avissar-Whiting et al., 2011; Heyn et al., 2012).  
 Other epigenetic regulation 
Further epigenetic mechanisms involved in the regulation of gene expression 
include some non-coding small RNA molecules, such as microRNAs (miRNAs) or 
small interfering RNS (siRNA). These are short fragments of RNA (approximately 
22 nucleotides in length) (Gibney and Nolan, 2010), which bind to 
complementary messenger RNA (mRNA) and either inhibit translation or 
prompt cleavage or degradation of the mRNA, thus inhibiting translation of the 
mRNA into protein. The mechanism by which miRNAs enforce gene repression is 
dependent on how complementary the miRNA is to the mRNA, perfect 
complementary binding, targets the mRNA for degradation, while less than 
perfect complementary binding simply inhibits ribosomes binding (Gibney and 
Nolan, 2010; Hoffman and Cairns, 2011; Sato et al., 2011). 
Most studies into the epigenetics of small noncoding RNAs, focus on miRNA. 
miRNA is transcribed as a pre-miRNA hairpin loop, which is then processed via 
 
 16
the proteins Drosha and Dicer into mature miRNA. Where it then incorporates 
with the RNA-induced silencer complex (RISC) to bind and regulate mRNA (Sato 
et al., 2011). Over 1000 miRNAs have so far been identified, many of which 
reside within intergenic regions of the genome with expression under the 
regulation of DNA methylation (Gibney and Nolan, 2010; Lopez-Serra and 
Esteller, 2012; Sato et al., 2011). The deregulation of miRNAs has been 
associated with several diseases including cardiovascular disease and cancer 
(Chuang and Jones, 2007; Hoffman and Cairns, 2011; Sato et al., 2011) while 
miRNA expression profile have also been investigated as a method to 
differentiate between different cancers types (Chuang and Jones, 2007; Youssef 
et al., 2011). 
Another epigenetic marker recently identified is 5-hydroxymethylcytosine 
(5hmc), generated by the removal of DNA methylation via TET enzyme (Roy et 
al., 2014; Sajadian et al., 2015). However, to date little is known about the 5hmC 
biological function, but it is predicted to play a role in DNA methylation, with loss 
of 5hmC having been associated with melanoma and the progression of 
hepatocellular cancer (Lian et al., 2012; Sajadian et al., 2015). However, analysis 
of 5hmC presents a challenge as conventional bisulfite modification techniques 
cannot distinguish between 5mC and 5hmC. Currently analysis therefore 
requires immunoprecipitation of DNA utilising 5hmC specific antibodies (Jin et 
al., 2010; Sajadian et al., 2015). 
 Epigenetics in cancer 
Epigenetic deregulation is widely associated with and studied in many different 
cancers. With aberrant epigenetic profiles identified as one of the mechanisms 
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contributing to the Knudson’s two-hit hypothesis for the loss of heterozygosity 
(Waldmann and Schneider, 2013). 
As introduced above, the epigenome is a complex system regulated by many 
factors and enzymes, deregulation at any stage may contribute to the formation 
of cancer hallmarks.  
Studies into the histone modification patterns of different cancers have identified 
frequent deregulation of the enzymes and co-factors that regulate the post-
translation histone modifications (Avvakumov and Côté, 2007; Cao and Zhang, 
2004; Dalgliesh et al., 2010; Feinberg, 2007), leading to abnormal chromatin 
packaging, gene expression and DNA methylation profiles (TCGA, 2013). For 
example, overexpression of histone methyltransferase EZH2 has been associated 
with poor prognosis in breast and prostate cancer, and is predicted to result in 
widespread transcriptional silencing by widespread methylation of H3 lysine-27 
(H3K27) (Cao and Zhang, 2004; Feinberg, 2007). Somatic mutations of the UTX 
gene, in several cancer types, including; colorectal adenocarcinoma, multiple 
myeloma, and oesophageal squamous cell carcinoma, results in decreased 
expression of the H3K27 de-methylase enzyme UTX, leading to increased H3K27 
methylation and wide spread transcriptional repression (van Haaften et al., 
2009).  
Furthermore, deregulation and mutations of components of chromatin 
remodelling complex’s such as the ATP-dependent SWI/SNF complex, (a 
complex associated with opening condensed chromatin to permit transcriptional 
activation) have been associated with abnormal nucleosome positioning, 
chromosomal rearrangements and alter gene expression in several cancers 
(Brock et al., 2007; Feinberg, 2007; Ferraro, 2016). For example INI1, SMARCA4, 
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SMARCAD1, ARID1A and PBRM1 have previously been reported to be frequently 
mutated or down regulated in various cancers, such as colorectal, kidney, 
ovarian, rhabdoid medulloblastoma and breast cancer, resulting in chromosomal 
instability, abnormal gene expression and subsequent tumourigenesis (Ferraro, 
2016; Pancione et al., 2013; Roy et al., 2014; Varela et al., 2011; Versteege et al., 
1998; Wilson and Roberts, 2011). 
INI1 (also known as SMARCB1) is a core component of the SWI/SNF complex, 
involved in DNA binding and chromatin stabilisation; loss of function mutations 
of INI1 have been associated with aggressive paediatric rhabdoid tumour and 
poor prognosis in colorectal cancer (Pancione et al., 2013; Sévenet et al., 1999; 
Versteege et al., 1998; Wang et al., 2016). SMARCAD1 has been reported to be 
lost in colorectal and head and neck squamous cell carcinomas, loss of this gene 
has been reported to lead to chromosomal instability, a characteristic hallmark 
of cancer (Berg et al., 2010; Cetin et al., 2008; Hanahan and Weinberg, 2011).  
Similarly mutations or alteration in expression of DNA methylation regulators 
such as the DNMT family or the  demethylation associated DNA hydroxylase 
enzyme TET are relatively frequent in cancers resulting in an abnormal global 
DNA methylation pattern, and have been associated with genomic instability and 
augmented gene expression (Heyn et al., 2012; Roy et al., 2014). For example; 
DNMT1, 3A and 3B are frequently overexpressed in colon, prostate, leukaemia 
and breast cancer (Subramaniam et al., 2014) while DNMT3A is frequently 
mutated in acute myeloid leukaemia (Roy et al., 2014) and TET is frequently 
mutated in multiple myeloid neoplasms (Roy et al., 2014). 
An initial study on DNA methylation in cancers by Gama-Sosa et al. in 1983, 
reported hypomethylation at many promoter regions associated with the 
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activation of gene transcription (Gama-Sosa et al., 1983). Subsequent 
investigations into promoter hypomethylation focused on proto-oncogenes, such 
as HOX11. A proto-oncogene identified to be hypomethylated in T-cell acute 
lymphoblastic leukaemia, resulting in increased HOX11 expression and cell 
growth (Ehrlich, 2002; Watt et al., 2000). Furthermore global hypomethylation 
has been observed in several cancer types, within intergenic regions of DNA and 
at repetitive elements(Ehrlich, 2009) and is believed to be involved in the 
relaxation of heterochromatin, genomic instability and activation of repetitive 
transposable elements such as LINE-1, resulting in DNA arrangements and gene 
disruption (Ehrlich, 2009; Lorincz et al., 2004). Recent investigations, suggest 
that the presence of global hypomethylation may be a biomarker for early stage 
cancer, having been identified in pre-cancerous breast tissue and early stage 
urothelial cancer (van Veldhoven et al., 2015; Wolff et al., 2010), allowing rapid 
intervention.  
However, the majority of studies on DNA methylation in cancers have primarily 
focused on hypermethylation and its role in silencing proteins encoded by TSG. 
Cancer-specific DNA hypermethylation has been reported to predominantly 
occur within CpG islands (Costello et al., 2000). It is currently predicted that 
between 5 – 10% of gene promoters are hypermethylated in cancer. This 
suggests that, in these cases, the mechanism of tumourigenesis likely involves 
the inhibited transcription of the associated genes, resulting in the repression of 
an array of downstream signalling pathways, ultimately resulting in unregulated 
and excessive cell growth (Figure 1-2) (Baylin and Jones, 2011; Esteller et al., 
2000; Heyn and Esteller, 2012; Lopez-Serra and Esteller, 2012; Mizuno et al., 








Figure 1-2: Schematic of DNA methylation at CpG island of a TSG Visualisation of the effect of DNA methylation on the transcription of TSG in cancer cells compared to normal cells. Each circle represents a CpG locus. In Normal cells, CpG islands are unmethylated (white circles), permitting the binding of transcription factors and the expression of the gene (green arrow). In cancer, CpG loci of TSG are methylated (black), inhibiting transcription of the gene. Image from Malzkorn et al., 2011.   
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The study of DNA methylation in cancers not only provides invaluable insights 
into the mechanisms of tumour development, but can also be used as a 
biomarker, which can be used to distinguish between tumour types, which 
therefore facilitate accurate diagnoses. For example, the frequent levels of 
methylation of MGMT, RASSF2 and WIF1 have been proposed as biomarkers for 
diagnosis with high sensitivity and specificity for colorectal cancer (Heyn and 
Esteller, 2012).  
Furthermore, DNA methylation status within a tumour has also been reported to 
be useful as a biomarker to provide an indication of prognosis, and can also be 
used to predict how these tumours might respond to various treatments (Heyn 
et al., 2013; Strimbu and Tavel, 2010). For example Exner et al 2015, reported 
that the presence of hypermethylation of CDKN2A shows a strong correlation 
with poorer prognoses and lower survival rates in colorectal cancer (Exner et al., 
2015). Other studies have found that CDKN2A methylation can act as a marker to 
indicate early stage adenocarcinoma, while other genes such as SFRP1 (a WNT 
pathway inhibitor) usually acquire methylation in the more advanced stages of 
cancer (Selamat et al., 2011).  
Another example of the diverse amount of information that can be gained by 
observing the DNA methylation status of a tumour is the associations between 
DNA methylation and the cancer's response to a particular therapeutic 
treatment. For example, it was recently found that hypermethylation of the 
MGMT gene in glioblastoma patients was associated with a better clinical 
response  for patients receiving the chemotherapy treatment, temozolomide, in 
comparison to those patients who did not exhibit MGMT hypermethylation 
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(Heyn and Esteller, 2012; Trabelsi et al., 2015). Suggesting that DNA methylation 
may also have an effect on the efficiency of drugs.  
As previously mentioned miRNAs have also been implicated in cancer 
development. Many studies have been undertaken to characterise the miRNA 
expression profile in different cancers and ascertain if there is an association 
between miRNA profile and cancer type (Chuang and Jones, 2007; Youssef et al., 
2011). Studies have identified that depending on the target of the miRNA, they 
may posses an oncogenic or tumour suppressive role (Chuang and Jones, 2007). 
The disruption of the expression of miRNAs, by, mutations, abnormal DNA 
methylation of the miRNA resulting in over or under expression or genomic 
instability resulting in copy number alterations (Lopez-Serra and Esteller, 2012) 
is often attributed to cancer development. For example miR-155 has been 
reported to be overexpressed in breast, colon and B-Cell lymphomas and 
associated with oncogenic development (Chuang and Jones, 2007), while miRNA 
let7 which targets oncogene RAS has been reported to be down regulated in lung 
cancer leading to tumour genesis (Chuang and Jones, 2007; Sato et al., 2011) 
The prevalence of epigenetic deregulation in cancer has led to investigations 
targeting epigenetic modifications therapeutically, with several drugs obtaining 
approval for clinical use (Azad et al., 2013). For example suberoylanilide 
hydroxamic acid was the first histone deacetylase inhibitor approved for the 
treatment of T cell cutaneous lymphoma (Gal-Yam et al., 2008). While DNMT 
inhibitors Decitabine and 5-azacytidine, have been approved for treating bone 
marrow disorders such as myelodysplastic syndrome and acute myeloid 
leukaemia (Subramaniam et al., 2014). With further clinical trials on going to 
assess other DNMT inhibitors in cancers including ovarian, lymphomas and non-
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small cell lung cancer (Subramaniam et al., 2014). However due to the 
ubiquitous expression of these epigenetic modifications across cell types, 
epigenetic targeted therapies tend to be present with high toxicity and adverse 
reactions (Azad et al., 2013; Gal-Yam et al., 2008; Heyn and Esteller, 2012; 
Peedicayil, 2006; Subramaniam et al., 2014). 
 CpG island methylator phenotype (CIMP)  
The term CIMP was first coined in 1999, in colorectal tumours, and refers to a 
subpopulation of samples with an abnormally high frequency of global 
hypermethylation in cancers (Toyota et al., 1999). Identified by clustering 
analysis of genome wide DNA methylation profiles, the CIMP pattern has been 
identified and is often associated with poor clinical outcomes including increased 
microsatellite instability (Issa, 2004; Toyota et al., 1999), poor overall prognosis 
(Issa, 2004), and more aggressive forms of cancer (Arai et al., 2012). However 
glioblastoma has been reported to be an exception to this observation, as when 
coupled with IDH1 mutation CIMP positive samples were associated with good 
prognosis and longer term survival (Noushmehr et al., 2010; Shinawi et al., 
2013). 
1.4 Kidney Cancer 
Recent studies have shown that kidney cancer is the ninth most common cancer 
globally, and is estimated to account for 2-3% of all adult cancers with over 
337,000 new cases reported in 2012 alone (Escudier et al., 2012; Henrique and 
Jer, 2015; Jonasch et al., 2014; Maher, 2013; Stec et al., 2009). Of these cases, 
studies have also shown that the highest incidence of kidney cancer occurs in 
developed countries (Jonasch et al., 2014). The exact reason as to why kidney 
cancers seem to be more prevalent in developed countries remains largely 
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unknown, however it is possible that differences in environmental exposures, 
diet or lifestyle may be responsible. Several risk factors have been associated 
with an increased risk of developing kidney cancer. Similar to many other 
cancers, smoking poses one of the highest kidney cancer risks; studies have 
shown that smokers may have a 52-54% increased risk of developing kidney 
cancer risk compared to non-smokers (Hunt et al., 2005). In addition, obesity is 
another factor, which has been associated with the development of kidney 
cancer. Some studies estimated obesity to play a role in up to 24% of kidney 
cancers, and suggested that there may be a direct correlation between increasing 
Body Mass Index (BMI) and increased kidney cancer risk (Kendall et al., 2015; 
Parkin and Boyd, 2011). These environmental and lifestyle associations with 
kidney cancer susceptibility could be the reason why this cancer is said to have 
such a higher prevalence in developed countries.  Consistently, it has also been 
shown that the incidence of kidney cancer is rising, in the United States (as has 
obesity); in fact it has been estimated that the number of kidney cancer cases 
diagnosed in 2014 had increased by approximately 20% in comparison to the 
number of cases reported in 2007  (Henrique and Jer, 2015), a staggering 
increase from the cases reported in 2007 (Ng et al., 2008; Vera-Badillo et al., 
2012),  with kidney cancer attributing to over 2% of cancer deaths in the US 
(Henrique and Jer, 2015; Ng et al., 2008).  
Interestingly kidney cancer has been shown to display a gender bias and is more 
frequently diagnosed in males compared to females, and is the seventh most 
common cancer in males and the ninth most common cancer in females 
worldwide (Escudier et al., 2012; Stec et al., 2009).  
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Data from the National office of Statistics has identified that the incidence of 
kidney cancer in the UK has increased by almost a third within the last decade 
(Figure 1-3a). Kidney cancer was recorded to account for 3% of all new cancer 
diagnosis in the UK in 2014, 62.6% of these new kidney cancer diagnosis were 
male (37.4% were female), with the majority of kidney cancers diagnosed in the 
over 60s (Figure 1-3b) (Office for National Statistics, 2015b). If diagnosed at an 
early stage (see section 1.4.1) survival rates for kidney cancer are very 
promising, with a stage I RCC predicted to have a 5 year survival rate of 70- 90% 
(Stec et al., 2009), in the UK five year survival rate of all kidney cancers in 2014 
was 57.6% for males and 60.8% for females (Office for National Statistics et al., 
2015). This could be due to a number of factors, including increasing levels of 
obesity in the UK for example, or could be due to the presence of other 
environmental stimuli. Although there are many environmental carcinogens and 
lifestyle habits which have been linked to increased susceptibility to kidney 
cancer, there are also a number of genes which, when altered, have been 
associated with increased kidney cancer susceptibility some examples of which 




Figure 1-3: Statistic for kidney cancer in the UK The incidence of kidney cancer is increasing for the whole population with the risk of disease greater in the older population and in males.  A) Incidence rates of all RCC diagnosis in the UK between 1993- 2001 separated by gender. B) Average number of new cases a year in relation to age and gender. Males over 60 years of age are those most likely to be diagnosed with a form of kidney cancer. Graphs from CancerResearchUK.org (2015).   
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 Staging  
Staging a cancer is a useful diagnostic tool  that helps provide a more accurate 
disease prognosis , which may then also help to determine the most appropriate 
treatment options. Grading is determined through combined clinical 
observations and conforms to a system known as the TNM staging system 
(Figure 1-4) (Egner, 2010).  
A summary of the TNM staging system for kidney cancer is as follows (Figure 
1-4)  
T refers to the tumour and is graded 0 (no evidence of primary tumour), to 
4(cancer has spread past the kidney and surrounding tissues). Sub-
classifications (a-c) are also documented to denote tumour size and location 
within the kidney, for example any tumour classified as T1 is located solely 
within the kidney, T1a is solely within the kidney and less that 4cm, T1b is still 
limited to the kidney but is between 4 and 7 cm, and T2 is greater than 7 cm but 
within the kidney. T3a is a tumour which extends into the adrenal gland or 
perinephric tissues, while a T3c tumour is classified as a tumour that extends 
into the vena cava, a T4 is a renal tumour which has extended beyond the 
connective tissue encapsulating the kidney (Egner, 2010; Ng et al., 2008). 
N refers to the regional lymph nodes around the kidney, and is graded 0-2, 
where 0 is no cancer in any lymph nodes and 2, cancer is in more than 1 lymph 
node. 
M is metastasis, a binary score given to whether the cancer has metastasised to 
another region of the body (1) or not (0). 
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As with most cancers, the lower the grade the better the prognosis. For RCC a 
tumour with a TNM score below T2 N0 M0 predicts a 5 year survival rate 
between 70 – 90%, while a T3a N0 M0 tumour that has invaded the perinephric 
fat has a survival rate of 60-80%, a T3c N0 M0 has a predicted survival rate of 0 – 
30% and any RCC tumour that has metastasised (M1) has a predicted survival 
rate of 0 – 10% (Ng et al., 2008). Kidney cancer tumours may also be referred to 
as Stage I-IV (Figure 1-4), this score is calculated based upon the TNM score 
where: 
Stage I: TNM score of T1 N0 M0 
Stage II: TNM score of T2 N0 M0 
Stage III: TNM scores of T1 N1 M0 to T3 N1 M0 
Stage IV: is any tumour categorised as T4, or any tumour with an N score of 2 or 
any metastasis (Egner, 2010; Ng et al., 2008) 
Currently, however, staging does not take into account other features that may 
impact on prognosis such as the presence of sarcomatoid cells (Humphrey, 




Figure 1-4: Visual representation of the 4 stages of kidney cancer classification. Diagram of the 4 stages of kidney cancer classification. Stages are calculated using the TNM score.  Images adapted from CancerResearchUK.org 2015 
   
Stage 1:Tumour <7 cm diameter and is completely inside the kidney Stage 2: Tumour >7 cm diameter and is completely inside the kidney 
Stage 3 : Tumour has spread to adrenal gland or one of that major blood vessels. Cancer may be present in neighboring lymph nodes 
Stage 4: The cancer has metastasised to other organs ie lungs.  
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 Renal cell carcinoma (RCC) 
Approximately 85% of all kidney cancers are classified as renal cell carcinomas 
(RCC) (Bodmer et al., 2002; Ng et al., 2008). RCCs are a heterogeneous group of 
tumours, which can be further categorised into several subtypes based upon 
their pathology histology, location, appearance, genetic and cytogenetic 
differences (Faisal et al., 1997; Kovacs et al., 1997; Linehan and Ricketts, 2014; 
Lopez-Beltran et al., 2009, 2006), some of these subtypes will be described in the 
following sections. 
Generally, symptoms tend to become apparent during the later stages of RCC 
when the prognosis is poor. In some cases, even at very late stages, many 
patients are asymptomatic, and for this reason, early diagnosis is vital (Morris 
and Maher, 2010). Patients may present with a variety of symptoms including 
pain, haematuria, an abdominal mass or paraneoplastic syndromes, which 
include hypercalcemia, fever or wasting syndromes (Escudier et al., 2012). 
However, for more than 50% of cases, diagnoses are often incidental, and 
detected through abdominal imaging for other reasons, especially for small 
asymptomatic masses (Escudier et al., 2012; Jonasch et al., 2014). Diagnosis is 
often achieved through a combination of techniques, including medical imaging 
(computed tomography (CT) the most frequently used imaging technique, 
although ultrasound and Magnetic Resonance Imaging (MRI) is also used), in 
addition to blood tests and biopsies to perform pathological analysis (Escudier et 
al., 2012; Vera-Badillo et al., 2012). Medical imaging is currently the most 
favoured tool in diagnosis, as it can provide clarification on location, grade, and 
can even help to determine the subtype. As the different subtypes often present 
with distinct imaging characteristics, such as an enhanced peripheral edge of the 
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tumour (associated with clear cell, papillary and collecting duct RCC) or 
homogenous CT enhancement (associated with chromophobe and oncocytomas). 
However, it remains radiographically challenging to differentiate chromophobe 
from oncocytomas (Baert and Sartor, 2006; Millet et al., 2011; Stec et al., 2009; 
Vera-Badillo et al., 2012).  
 Sporadic RCCs 
The majority of RCC cases are sporadic (over 96% of cases), with hereditary 
(familial) RCC accounting for less than 4% of all cases (Jafri et al., 2015; Lopez-
Beltran et al., 2009; Maher, 2013, 2011). A summary of current genetic and 





Clear cell 75% Solitary, solid tumour, cystic
clear cytoplasm; cells with eosinophilic cytoplasm seen 
occassionally 
Aggressiveness according to 
grade,stage and 
sarcomatoid change












Type 1 (basophilic) orType 2 (eosinophilic)
Aggressiveness according to 
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Table 1-1: Summery of the histological and genetic features associated with different RCC subtypes. (Adapted from Lopez-Beltran et al., 2009)
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1.4.2.1.1 Clear cell renal cell carcinoma (ccRCC) 
Amongst all classifications of RCC, clear cell renal cell carcinoma (ccRCC) is the 
most common, accounting for approximately 75-80% of all RCC diagnosed, of 
which, approximately 95% are sporadic. Although ccRCC is considered to be one 
of the more aggressive forms of RCC, ccRCC has a relatively high 5-year survival 
rate overall; up to 60%, provided that no metastasis has occurred (10% survival 
rate after the occurrence of metastasis) (Avissar-Whiting et al., 2011; Stec et al., 
2009). 
ccRCC originates from the proximal renal tubule cells and usually presents as a 
golden yellow solitary cortical neoplasm, which is histologically comprised of 
cells with clear cytoplasm with clustered eosinophilic cells in the core of the  
lesion (Faisal et al., 1997; Lopez-Beltran et al., 2006). The size of the tumour is 
variable, and other features which can be present include necrosis, sarcomatoid 
features, calcification and microvascular invasion; features which can all have a 
negative impact on the prognosis (Lopez-Beltran et al., 2009). 
ccRCC has been associated with several chromosomal alterations including gain 
of chromosome 5q22, and loss of chromosome 6q,8p, 9p and 14q (Lopez-Beltran 
et al., 2009). However the most commonly observed chromosomal alteration in  
sporadic ccRCCs is the frequent loss of the chromosome 3p arm (over 90% 
ccRCC cases) (Gnarra et al., 1994; Lopez-Beltran et al., 2010), in particular, the 
3p12-14, 3p21 and 3p25, often resulting in disruption of the VHL gene (Lopez-
Beltran et al., 2010, 2009; Maher, 2013).  
VHL is a well studied TSG located at 3p25-26 (Latif et al., 1993), that was 
originally identified as the causative gene for autosomal dominant disease von 
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Hippel–Lindau (VHL) (Section 1.4.2.2.1)(Gossage et al., 2015; Latif et al., 1993). 
The VHL gene encodes an E3 ubiquitin ligase tumour suppressor protein with a 
vital role in ubiquitinating and degrading hypoxia inducible factor-α (HIF-α) 
under normal conditions. Loss of VHL results in activation of HIF1α and HIF2. 
Subsequent binding to hypoxia response elements, promotes the transcription of 
target genes which regulate processes such as angiogenesis (Clifford and Maher, 
2001). HIF signalling is further associated with the activation and signalling of 
the PI3K/AKt/mTOR pathway and the AMPK pathway, further highlighting the 
wide impact the loss of VHL can have (Gossage et al., 2015; Linehan et al., 2010). 
For these reasons, loss of VHL can therefore result in constitutively active and 
unregulated signals for angiogenesis and growth, among others; factors which 
promote tumour development and progression. 
 Within sporadic ccRCC VHL is also observed to be the most frequently mutated 
gene (57% of samples tested). Furthermore, in agreement with Knudson’s two-
hit model (section 1.2.2.2), bi-allelic loss of VHL was often reported, a result of 
frequent loss of heterozygosity of chromosome 3p (Gnarra et al., 1994; Lopez-
Beltran et al., 2010), gene mutation or  frequent DNA methylation (Section 1.5) 
(Herman et al., 1994).  
Other genes frequently mutated, resulting in loss of function have been recently 
identified in sporadic ccRCC. These include; PBRM1 (41%) (Varela et al., 2011) 
BAP1 (14%) (Peña-Llopis et al., 2012), SETD2 (16%), JARID1C (4%) and KDM6A 
(3%) (Dalgliesh et al., 2010; Freier et al., 2010). Correlating with 
immunohistochemical studies which observed reduce protein expression 
ofPBRM1 and BAP1 in ccRCC (decrease of PBRM1 expression in 43% of samples 
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and BAP1 expression in 10% samples (Ho et al., 2015). Many of these genes are 
associated with chromatin regulation and remodelling; for example PBRM1 
(Polybromo-1) is a component of the chromatin remodelling complex SWI/SNF, 
while SETD2 is a histone 3 lysine 36 methyltransferase, JARID1C is a histone 3 
lysine 4 demethylase and KDM6A is a Histone 3 Lysine 27 demethylase. 
Additionally it should be noted that BAP1 and PBRM1 also reside on the 
frequently lost chromosome 3p arm and are therefore frequently lost in ccRCC 
(A. Hakimi et al., 2013). However no DNA methylation has been observed for 
PBRM1, BAP1, SETD2, JARID1C or KDMA in ccRCC (Ibragimova et al., 2013a). 
Clinically, BAP1 mutations have been associated with higher grades of ccRCC, 
metastatic disease and a poor prognosis and it is predicted to be a two-hit TSG 
(Kapur et al., 2013; S. Wang et al., 2014), while PBRM1 and BAP1 mutations are 
virtually mutually exclusive, with patients harbouring mutations in both genes 
rarely observed (Brugarolas, 2014; Kapur et al., 2013; Roy et al., 2014). 
Recent multi-platform studies comparing the global; mutation, DNA methylation 
and gene expression profiles have also confirmed the observations previously 
mentioned; in larger cohorts (A. Hakimi et al., 2013; Sato et al., 2013; TCGA, 
2013). Interestingly these larger studies have also identified significant 
mutations in mTOR (5.7-6% of samples tested), PI3KCA (3-4.7% of samples 
tested), TP53 (~2% of samples tested) and PTEN (1.8% of samples tested) in 
addition to focal copy number deletions in CDKN2A 9p21 and PTEN 10q23. 
Furthermore, the studies confirmed the presence of other chromosomal 
abnormalities associated with ccRCC, including chromosomal gains at 5q (65%-
67%) and 7q (41%), and LOH at 8p (20%), 9p (15%), and 14q (27%) (Faisal et 
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al., 1997; A. Hakimi et al., 2013; Sato et al., 2013; TCGA, 2013). Loss of PTEN and 
CDKN2A although rare, have been associated with worse overall survival in 
ccRCC (Feng et al., 2015). These studies highlight the wide variety of genetic 
alterations that can play a role in the development and progression of ccRCCs. 
Having a greater understanding of the roles and pathways involved in the 
progression of these cancers will enable the future development of more 
effective diagnostics, therapies and potential prophylactic treatments for these 
patients. For example, current invitro and invivo investigations have identified a 
potential PI3Kβ inhibitor which significantly reduces tumour formation when 
VHL and SETD2 mutations were present (Feng et al., 2015).  
1.4.2.1.2 Papillary renal cell carcinoma (pRCC) 
From all types of RCC the papillary form is the second most common RCC, 
accounting for 10–20% all cases These forms are less aggressive compared to 
ccRCC, and only approximately 4% are thought to be associated with a germline 
predisposing mutation (Courthod et al., 2015). Derived from cells of the proximal 
renal tubule, pRCC is categorised into two types Type I and Type II. Although the 
exact proportion of each type is largely unknown, a study by Klatte at al 
suggested that 32% of pRCC samples are type I and 68% of pRCC samples are 
type II (Klatte et al., 2009), additionally a mixed histology may also be frequently 
observed (Yang et al., 2005). 
Type I is characterised by the presence of small cuboidal cells with insufficient 
basophilic cytoplasm. This type is associated with a better prognosis and longer 
survival. Type II (eosinophilic) on the other hand is formed of large cells with 
higher nuclear grade, eosinophilic cytoplasm and pseudostratification. Type II is 
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associated with a poor prognosis (Faisal et al., 1997; Lopez-Beltran et al., 2006) 
(Faisal et al., 1997; Lopez-Beltran et al., 2006); this is likely due to the fact that 
type II tumours have been found to express higher numbers of receptors for 
vascular endothelial growth factor (VEGF) receptors, which consequently results 
in pro-tumourigenic effects including increased angiogenesis and micro 
vascularisation (Klatte et al., 2009). There are several well known alterations 
that are associated with pRCC;  particularly chromosomal gains at 3q, 7, 8, 12, 16, 
17, and 20, in addition to loss of chromosome Y with full or partial gains in 
chromosome 7 and 17 (which are frequent in both type 1 and type 2)(Albiges et 
al., 2014; Durinck et al., 2015; Faisal et al., 1997; Maher, 2013; Marsaud et al., 
2015).  
Several genes have been found to be associated with the hereditary forms of 
pRCC. For example, gain of function (GOF) mutations in MET are known to be 
frequently associated with the hereditary forms of pRCC type 1, while mutations 
in fumarate hydratase FH are associated with the inherited forms of type 2 pRCC 
(section 1.4.2.2.2) (Yang et al., 2005). In sporadic pRCC, GOF MET mutations have 
been reported in 15-20% of type 1 pRCC, (Albiges et al., 2014; Durinck et al., 
2015), and increased copy number of MET has been observed in  81% of type 1 
pRCC samples, showing significantly increased MET expression compared to 
ccRCC (Albiges et al., 2014; Cairns, 2010; Marsaud et al., 2015).  However 
methylation or mutations of FH are seldom observed in sporadic type 2 pRCC 
(Cairns, 2010). 
The MET gene encodes a hepatocyte growth factor receptor (HGF). The receptor 
plays a role in the activation of the PI3K pathway. When this pathway is 
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activated, it promotes the transcription of various nutrient transporters, which 
in turn may then activate the mTOR pathway, leading to cell growth and 
proliferation (Linehan et al., 2010). Due to its activating role in the PI3K 
pathway, MET has been found to play an oncogenic role in pRCC, with the 
majority of pathogenic mutations playing a gain-of-function role, resulting in 
constitutive protein activation and a subsequent downstream signalling cascade 
that results in an array of pro-tumourigenic effects, including cell growth and 
proliferation (Albiges et al., 2014; Durinck et al., 2015)  
In addition to the genes mentioned so far, studies into sporadic pRCC have also 
identified significant mutations in, NF2, (Neurofibromatosis 2, a well known 
tumour-associated gene involved in the HIPPO pathway) (Evans, 2009; Harvey et 
al., 2013)) and SETD2 (Durinck et al., 2015). As previously mentioned SETD2 is 
known to be frequently mutated in ccRCC, (Dalgliesh et al., 2010) with mutations 
in SETD2 being linked to abnormal DNA methylation profiles (TCGA, 2013)and 
thus may provide a pivotal role in RCC development. Interestingly, despite the 
known associations between PBRM1 and ccRCC, no mutations in PBRM1 have 
been identified in pRCC (Varela et al., 2011), this observation is largely 
collaborated by immunohistochemical staining identifying infrequent loss of 
PBRM1 in 3% and BAP1 in 0% of pRCC samples (Ho et al., 2015). 
1.4.2.1.3 Chromophobe renal cell carcinoma (chRCC) 
Chromophobe is a less aggressive from of cancer compared to ccRCC, accounting 
for around 3-5% of renal epithelial cases with a mortality rate of less than 10% 
(Lopez-Beltran et al., 2006; Faisal et al., 1997). chRCC is also associated with the 
development of sarcomatoid features and metastasis in around 10% of cases 
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(Stec et al., 2009; Yusenko et al., 2009), while the autosomal dominant Birt Hogg 
Dubé syndrome predisposes sufferers to chRCC and oncocytoma (Hagenkord et 
al., 2011) 
Pathologically, chromophobe presents as a solid orange tumour derived from the 
intercalated cell of the collecting duct with a mean size of 6 cm. Histologically, 
chromophobe cells are slightly opaque, and present with either pale cytoplasm 
in the majority of cells or eosinophilic cytoplasm (Stec et al., 2009).  It has very 
similar appearance and histology to the benign renal neoplasm oncocytoma 
making differentiation of the two subgroups challenging (Pires-Luís et al., 2015). 
Due to the malignancy of chRCC accurate early diagnosis is vital to the 
appropriate course of treatment.  
Immunohistochemistry has identified some variations between oncocytoma and 
chromophobe histology, such as, CK7, which stains strongly in chRCC but weakly 
in oncocytoma or kidney-specific cadherin, which is almost exclusively 
expressed in chRCC. However the immunohistochemical method of diagnosis 
and differentiation of the two histologies is not considered to be reliable or 
accurate (Ng et al., 2014). Chromosomal loss is a common feature of chRCC with 
the loss of between 5-13 chromosomes being reported in 75-100% samples. 
Chromosomal monosomy of chromosomes 1, 2, 6, 10, 13, 17, and 21 is the main 
feature in the majority of chRCC samples 58-93% of cases, while slightly less 
frequent are losses in chromosomes 3, 5, 8, 9, 11, 18 (12%–40%)(Cairns, 2010; 
Davis et al., 2014; Faisal et al., 1997; Yusenko et al., 2009).  
Karyotyping of tumours is one potential method to distinguish between chRCC 
and oncocytomas, as chRCCs are often found to harbour loss of 2 or more 
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chromosomes (predominantly chromosomes 2, 10, 13 and 17 in 93%, 93%, 87% 
and 70% of chRCC, respectively,); these chromosomes are less frequently lost in 
oncocytomas, hypothetically enabling a distinction to be made between the two 
forms. However, karyotyping is regarded to lack the reliability and specificity 
required to make concise distinction between the two subtypes. (Ng et al., 2014; 
Yusenko et al., 2009).  
Although the most common RCC susceptibility gene, VHL is not known to be 
mutated in chRCC (Cairns, 2010), other studies have identified significant 
number of mutations  in the TP53, PTEN, FAAH2, PDHB, PDXDC1 and ZNF765 
genes, with further recurrent mutations (not statistically significant) in; ARID1A 
and PRKAG2. Mutations in PRKAG2 are suggested to result in gain of protein 
function, causing activation of AMPK, ultimately leading to the activation of an 
array of downstream pro-tumourigenic signals, including activating cellular 
energy homeostasis, regulating cell growth and metabolism and regulating cell 
polarity  (Durinck et al., 2015).  
Information provided on the cancer genome atlas database (TCGA) showed that 
investigations into the molecular classification of chRCC undertaken by Davis et 
al. on the 66 chRCC showed frequent mutations in TP53 (32% cases) and PTEN 
(9% cases) with additional mutations reported in mTOR (3%), NRAS (1.5%), and 
TSC1 or TSC2 (4%) (Davis et al., 2014). However, it is not known whether the 
mutations identified in the tumours studied were actively pathogenic, or 
whether they had simply been acquired as passenger mutations. These findings 
concurred with a study by Durinck et al 2015, who investigated the genomic 
differences between pRCC chRCC and oncocytoma. In their study they also 
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reported finding frequent mutations in TP53 (21.3% of samples) and PTEN 
(6.4% of samples) (Durinck et al., 2015). 
Other observations of note made by Davis et al included frequent mutations in 
mitochondrial DNA particularly associated with the electron transport chain 
(18% samples) and the identification of a known cancer associated SNP in the 
TERT promoter in 4.5% of chRCC sample and abnormal structural variation of 
the TERT promoter in 12% of samples (see section 5.1.2) (Davis et al., 2014). 
1.4.2.1.4 Renal oncocytoma 
Oncocytoma is a benign and slow growing neoplasm of the kidney and accounts 
for around 5% of all renal neoplasms. Similarly to chRCC, it is predicted that 
oncocytomas are derived from cells of the intercalated cells of the distal tubule 
or collecting duct within the kidney. The tumours are usually large and often 
appear to be mahogany/brown or pale yellow in colour with a central scar 
(Faisal et al., 1997; Lopez-Beltran et al., 2006). Histological analyses have 
identified the cancer cells to be large with granular eosinophilic cytoplasm 
densely populated with mitochondria (Lopez-Beltran et al., 2006; Ng et al., 2014; 
Yusenko et al., 2009). Although these tumours are histologically similar to 
chromophobe, renal mass biopsy and imaging currently is the most effective 
method to diagnose oncocytoma prior to surgery (Ng et al., 2014). 
Little investigation has been conducted upon the genetics of oncocytoma. Of the 
studies that have been published, it has been identified that the most prevalent 
chromosomal abnormalities are often loss of chromosome 1 (33% of samples) or 
chromosome Y (29% of samples), however, there have also been reports of 
translocations at 11q13 (Faisal et al., 1997; Yusenko et al., 2009). Recurrent 
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mutations are thought to be uncommon in oncocytomas, however NGS studies 
have recently identified mutations in ERCC2 and C2CD4C to be associated with 
oncocytoma; although the biological role that these mutations play in 
tumourigenesis is yet to be ascertained (Durinck et al., 2015). Other studies 
investigating the increased density of mitochondria observed in oncocytomas 
have identified frequent mutations within the mitochondrial DNA of sporadic 
oncocytomas. It was therefore hypothesised that these mutations result in 
defective mitochondria, altering the cells energy production homeostasis and 
metabolism (Joshi et al., 2015; Lang et al., 2015). 
Most investigations involving oncocytomas have focused on identifying key 
molecular and genetic signatures to help differentiate between chRCC and 
oncocytoma. For example; investigations into the microRNA (miRNA) profile of 
the two cancers have identified statistically significantly and differentially 
expressed miRNAs, and these can apparently be used to differentiate between 
oncocytomas and chRCC with relatively high efficiency. This included 
comparisons of the expression levels of 12 miRNA, analysed computationally to 
calculate the tumour subtype (Youssef et al., 2011). 
 Further investigations into differentiating the chRCC histology from that of 
oncocytoma have focused on the expression profiles of the two subtypes, which 
have revealed, differentially expressed genes; in particular ADAP1, SDCBP2, 
HOOK2, BAIAP3 and SPINT1 have been found to be up-regulated in chRCC while 
ITGB3, MINOS1-NBL1 and ASB1 appeared to be upregulated in oncocytomas 
(Durinck et al., 2015). Although these findings represent progress in the attempt 
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to clearly and reliably distinguish between the two tumours, as of yet, a robust 
and reliable method to achieve this has yet not been established.  
 1.4.2.1.5 Sarcomatoid renal cell carcinoma (sRCC) 
It should be noted that sarcomatoid RCC is not a distinct RCC subtype, rather a 
feature of advanced tumour progression. However, due to the inclusion of clear 
cell derived sarcomatoid RCC samples in chapter 4 of this thesis, the current 
understanding of the sRCC histology and genetics shall be introduced below.  
Sarcomatoid renal cell carcinomas (sRCC) are large tumours (≈10cm), 
characterised pathologically by a cell type similar to that observed in sarcoma 
(densely populated elongated, spindle-shaped cells, with a typical cellular 
morphology), and other characteristics associated with aggressive tumours such 
as necrosis and micro-vascular invasion(Shuch et al., 2012a). Jones et al., 2005 
identified through analysis and observation that similar patterns of allelic loss 
and X-Chromosome inactivation patterns were present in sRCC and the 
surrounding ccRCC, which led to the conclusion that sRCC is derived from the 
pre-existing RCC. As a result, the majority of sRCC tumours are heterogeneous, 
with the parent tumour cell type most frequently observed.  
sRCCs were originally classified as a distinct tumour type, however subsequent 
investigations have found sRCC to be derived from many RCC histologies. This 
finding then altered the classification of sRCC from a distinct tumour type to a 
tumour characteristic that can be used as an indicator of cancer progression 
(Faisal et al., 1997; Lopez-Beltran et al., 2006).  
The presence of sRCC within a renal cell carcinoma is associated with advanced 
late stage tumours and therefore metastasis is a common observation (Delahunt 
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et al., 2013; Yan et al., 2015). It is predicted that sRCC is present in 
approximately 16-20% advanced renal cancers (Shuch et al., 2012a; Yan et al., 
2015). Clinically, over 90% sRCC patients present with symptoms including with 
pain and haematuria (Humphrey, 2012). Moreover the presence of sRCC is 
associated with extremely poor prognosis; patients diagnosed with sRCC have a 
mean survival of between 4-9 months after diagnosis, and only a 15-22% five-
year survival rate (Delahunt et al., 2013). Studies into survival of patients with 
sRCC identified that a high percentage of sRCC features is associated with poor 
prognosis and survival (Adibi et al., 2015; Mian et al., 2002). Furthermore it has 
also been reported that underlying histology from which the sRCC is derived has 
an implication on survival, with ccRCC derived sRCC conferring a lower risk of 
cancer-specific cell death compared to the non-clear cell subtypes (Nguyen et al., 
2015). 
The degree of sarcomatoid histology within a RCC tumour can vary greatly from  
as low as 1% up to 100% of the tumour histology. The percentage of sarcomatoid 
differentiation is usually determined visually by a trained pathologist. As 
mentioned previously, a negative correlation has been reported between the 
degree  of sarcomatoid differentiation and prognosis (Kim et al., 2015).  
Samples where the parent tumour can not be ascertained or sarcomatoid tissue 
forms 100% are defined as unclassified RCC however, these samples only  
account for between 2%–10% of all sRCCs (Humphrey, 2012; Shuch et al., 
2012a). Most commonly sRCC is derived form ccRCC, this form of sRCC  accounts 
for >80% of all sRCC identified (Shuch et al., 2012a) however only between 1 - 
8% of all ccRCC tumours diagnosis are identified to have a positive sRCC 
histology (Humphrey, 2012). For other RCC histologies from which the 
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sarcomatoid histology can derive, sRCC features have been observed in 25-29% 
of all collecting duct RCCs,  2 – 9% of all chRCCs and 2 – 5% of all pRCCs 
(Delahunt et al., 2013). 
Although limited, some molecular analysis has been undertaken on sRCC. 
Frequent loss of chromosomes 13q (75% of sRCC cases) and 4q (50% of sRCC 
cases) has been reported while chromosomal gains were observed with 
chromosome 17 (33% of cases ) and chromosome 8q (25% of sRCC cases) 
(Humphrey, 2012; Jiang et al., 1998). 
 Some mutational studies have reported frequent mutations in the TP53 gene in 
up to 78.5% of sRCC samples, which were not observed within the neighbouring 
ccRCC tissues. With 72% of the mutated sRCC presenting with a ‘hotspot’ 
mutation in exon 8 codon 278 (CCT-CTT) (Oda et al., 1995), suggesting that these 
mutations are specific and perhaps driving the formation of the sarcomatoid 
histology. However immunohistochemical analysis of P53 expression on sRCC 
cells has failed to identify alterations in p53 immuno-reactivity between sRCC 
and the parent cancer (in this study either ccRCC or pRCC) which would be 
expected if there was a loss of protein function. This suggests that p53 may not 
be a key feature in sRCC differentiation (Kanamaru et al., 1999). More recent 
mutational studies have not directly focused on sRCC positive cancers 
specifically as a subgroup, however they have made observations about the 
histology within the study. For example it was observed that mutations within 
JARID1c were significantly associated with sRCC positive ccRCC (Freier et al., 
2010). Another study investigating the prognosis and survival of ccRCC patients 
with BAP1 mutations, identified that tumours possessing BAP1 mutations were 
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also more likely to possess sarcomatoid histology and other aggressive features 
(Kapur et al., 2013). Although not directly analysing sRCC positive ccRCC 
samples, these studies suggest that there may be a genetic constituent to sRCC 
progression.  
Presently diagnosis of sarcomatoid histology is determined by core biopsies of 
the tumour followed by visual analysis for sarcomatoid-like cells. However, 
limitations of biopsies, including small sample size which may exclude 
phenotypically relevant cells when sampling a large tumour and tumour 
heterogeneity may impede accurate diagnosis, calculation of sarcomatoid 
prevalence and ultimately prognosis predictions (Shuch et al., 2012a) 
 Familial RCCs 
Familial RCC, also known as hereditary RCC is estimated to account for only 3% 
of all RCCs and unlike sporadic RCC, is usually characterised by an earlier age of 
onset and diagnosis and bilateral and/or multifocal tumour formation (Maher, 
2011). Several inherited syndromes have been associated with a predisposition 
to familial RCC. Investigating these syndromes and the genes and pathways 
involved in them can provide invaluable insights into the genetic and metabolic 
basis of both familial and sporadic RCC. Some examples of well characterised 
familial RCC syndromes are summarised below (Johansson et al., 2013; Linehan 
et al., 2009). 
1.4.2.2.1 Von Hippel-Lindau Disease (VHL) 
VHL is the most common inherited syndrome associated with familial RCC, in 
particular ccRCC. VHL is an autosomal dominant familial neoplastic disease, with 
a prevalence of 1:35,000 live births. Individuals affected with VHL disease have a 
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>70% chance of developing ccRCC within their lifetime (Maher, 2011).  It is 
reported that VHL syndromes are due to the inheritance of a pathogenic 
mutation in 80% of cases, while the remaining 20% are due to de-novo 
mutations (Hagenkord et al., 2011; Maher, 2013). Clinically characterised by 
systemic tumour formation, features frequently observed in VHL disease, 
include; retinal and cerebellar haemangioblastomas, phaeochromocytomas and 
pancreatic tumours and epididymal cysts (Gossage et al., 2015; Johansson et al., 
2013; Maher, 2011). The genetic basis of VHL disease has been shown to be 
associated with disruptions to the tumour suppressor gene VHL (Latif et al., 
1993), either through germline mutations or through somatic inactivation (e.g. 
by LOH or DNA methylation) frequently reported in virtually all (≈ 100%) VHL 
families (Johansson et al., 2013; Linehan et al., 2010).  
1.4.2.2.2 Hereditary papillary RCC  
Hereditary pRCC is a rare autosomal dominant syndrome with an incidence of 
approximately 1 in every 10,000 people.  (Maher, 2011). Classified according to 
the underlying genetics and histology observed. For example, hereditary 
papillary renal cancer type 1 (HPRC) is associated with pRCC type 1 histology, 
while hereditary leiomyoma renal cell carcinoma (HLRCC) is associated with 
pRCC type 2 histology (Section 1.4.2.1.2) (Johansson et al., 2013). HPRC is 
associated with an inherited alterations affecting the proto-oncogene MET, 
which lead to protein overexpression through mechanisms such as gain of 
function mutations, epigenetic deregulation or gene amplification (Courthod et 
al., 2015; Johansson et al., 2013; Maher, 2011). Reports have indicated that 
tumours are isolated to the kidneys only (Hagenkord et al., 2011). HLRCC on the 
other hand is associated with mutations in the gene FH at 1q42-43 (Courthod et 
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al., 2015; Linehan et al., 2010). FH encodes the fumarate hydratase enzyme, 
which is involved in the citric acid (TCA) cycle and protecting the cell against 
oxidative stress (Ooi et al., 2013). 
Clinically HLRCC is characterised by multiple cutaneous leiomyomas and uterine 
leiomyomas (fibroids) at a young age in up to 90% of affected females 
(Johansson et al., 2013). Although HLRCC does predispose to pRCC, the 
formation of renal tumours is relatively uncommon. However, HLRCC kidney 
tumours are an aggressive and volatile tumour type, known to have the ability to 
quickly metastasize; for this reason, immediate surgical removal is usually 
advised (Johansson et al., 2013; Maher, 2011). 
1.4.2.2.3 Birt-Hogg Dubé (BHD) syndrome  
BHD is another autosomal dominant syndrome, characterised by benign skin 
tumours (fibrofolliculomas) on the face and upper body. Over 80% of patients 
affected with BHD also harbour lung cysts and have an increased risk of 
spontaneous pneumothorax, in addition to a predisposition to develop bilateral 
renal tumours (Murakami et al., 2007). BHD occurs as a result of germline 
mutations in the FLCN gene.  The majority of patients harbour mutations within 
a hyper-mutable (hotspot) region of the FLCN gene in exon 11 (Johansson et al., 
2013; Murakami et al., 2007; Nickerson et al., 2002). BHD associated RCC 
histology is typically reported to be made up of chRCC (33% of cases), 
oncocytoma (5% of cases) or more frequently a mix of the two histologies 
(chRCC/oncocytoma mix 50% of cases) (Hagenkord et al., 2011). However, 
histopathology of BHD RCC is diverse with ccRCC and pRCC subtypes also 




1.4.2.2.4 Constitutional chromosome 3 translocations 
Familial RCC associated with constitutional chromosome 3 translocations occur 
in a rare autosomal dominant condition associated nonsyndromic ccRCC. This 
condition is diagnosed via karyotyping. The first reported chromosome 3 
translocation linked to familial ccRCC was t(3; 8)(p14;q24), although since this 
discovery, eleven different constitutional chromosome 3 translocations 
associated with ccRCC susceptibility have been identified (Maher, 2011). 
Investigations into chromosomal breakpoints have resulted in the further 
identification of numerous candidate tumour suppressor genes, including Nore1 
(alias RASSF5), LSAMP (Chen et al., 2003) and FHIT (Kvasha et al., 2008). All of 
which have also been reported to be frequently methylated in RCC.  
However not all translocation breakpoints span a candidate TSG, so there are 
likely to be alternative mechanisms such as the chromosomal instability, which 
is the driving factor behind constitutional chromosome 3 translocations RCC 
formation (Maher, 2011).  
1.5 Epigenetics of RCC 
Historically, investigations into the genetic and epigenetic profiles of RCC have 
predominantly been undertaken by a candidate gene approach focusing on 
ccRCC or familial RCC. Subsequent investigations undertaking either a candidate 
and/or global approach to analysis, have identified numerous hypermethylated 
genes and epigenetic modifications associated with RCC and RCC subtypes. 
Providing an insight into both the genetic and epigenetic profiles of RCC 
subtypes (Henrique et al., 2012; Maher, 2013; Morris and Maher, 2010). An 
example of the most noteworthy or frequently reported genes methylated in 
RCC, include the TSG VHL (Latif et al., 1993). Which despite frequent mutations 
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and LOH in sporadic ccRCC (see section 1.4.2.1.1), is also frequently observed to 
be inactivated by DNA methylation of the promoter region in approximately 19% 
of ccRCC samples (Dulaimi et al., 2004; Herman et al., 1994; Kluzek et al., 2015). 
However, frequent methylation of VHL is not observed within pRCC, chRCC and 
oncocytoma (Dulaimi et al., 2004). However, methylation of other genes 
associated with inherited RCCs (FH, FLCN, MET but excluding VHL) are not 
frequently methylated (Maher, 2013). 
Another example of a frequent methylated TSG is RCC is RASSF1A, located on 
chromosome 3p21.3, with regulatory roles in cell growth regulation via pro-
apoptotic signalling, cell cycle arrest and the Hippo pathway signalling (Lopez-
Beltran et al., 2010; Richter et al., 2009). RASSF1A has been identified to be 
frequently methylated in many RCC subtypes including ccRCC (46 - 60% 
samples) (Costa et al., 2007; Dulaimi et al., 2004; Maher, 2013; McRonald et al., 
2009; Morris and Maher, 2010; Morrissey et al., 2001), chRCC (17% of samples) 
and oncocytoma (14% of samples)(Dulaimi et al., 2004). However, the highest 
frequency of RASSF1A promoter methylation was associated with pRCC (70-
100% samples) (Costa et al., 2007; Dulaimi et al., 2004; Ellinger et al., 2011a; 
McRonald et al., 2009; Morris et al., 2010), but mutations within RASSF1A are 
rare in all RCC subtypes (Morris et al., 2011). Additionally other members of the 
RASSF family including RASSF5 (Nore1) have also been identified to be frequently 
methylated in 32% of sporadic ccRCC (Chen et al., 2003; Morris and Maher, 
2010), suggesting that loss of this family of genes may have a role in 
tumourigenesis.  
Further examples of frequently epigenetic silenced genes through DNA 
methylation in RCCs, include other of other chromosome 3 TSGs (such as TU3A, 
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DLEC1 and FHIT) (Maher, 2013), WNT pathway inhibitors (particularly members 
of the DKK and SFRP families of WNT inhibitors) (Maher, 2013; Morris et al., 
2010) and MET inhibitor SPINT2, methylated in 30% and 40% of ccRCC and 
pRCC promoter regions respectively (Morris et al., 2005) . These reports support 
current understanding that DNA methylation plays a dynamic and complex role 
in RCC tumourigenesis (Heyn and Esteller, 2012; Maher, 2013). 
The advent of high throughput technologies including microarrays, expression 
arrays, methylation arrays and next generation sequencing coupled with multi-
centre collaborative projects such as The Cancer Genome Atlas (TCGA) has 
permitted large scale genome-wide analysis, profiling and investigation of large 
cohorts of RCC subtypes (ccRCC, pRCC and chRCC). Linking together aberrant 
genetic mutation, expression and methylation profiles with the aim of gaining a 
clearer understanding of a tumours biology and the genomic factors driving 
tumourigenesis (Davis et al., 2014; TCGA, 2016, 2013). Approaches such as this 
have permitted the identification of recurrent mutations in genes encoding 
chromatin regulatory proteins such PBRM1, SETD2 and BAP1 in ccRCC; where 
mutations have been associated with remodelling of the tumour cells epigenetic 
profile and altering the gene expression profiles of the tumour (Kluzek et al., 
2015; TCGA, 2013). However, as previously mentioned no gene silencing DNA 
methylation has been observed for the aforementioned genes in ccRCC 
(Ibragimova et al., 2013a; Lasseigne et al., 2014).  
Investigations have also been conducted to identify the relationship between 
histone modifications and RCC. Mutations within SETD2 have been associated 
with a global decrease in histone modification H3K36me3 (Kluzek et al., 2015), a 
histone modification associated with active transcription and maintenance of 
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chromatin structure (Sims III and Reinberg, 2009; TCGA, 2013) . Studies 
attempting to identify prognostic histone markers reported poor prognosis in 
metastatic RCC patient presenting with high levels of H3K9me2 (associated with 
gene repression), (Harb-De la Rosa et al., 2015; Ramakrishnan and Pili, 2013), 
while low levels of H3K4 me1, 2 and 3 (associated with transcriptional 
activation) were associated with high grade, metastasis and poor survival 
(Ellinger et al., 2010). Additionally the study by Ellinger et al, compared the 
global H3K4 methylation state between RCC histologies including (ccRCC, pRCC, 
chRCC, sRCC and oncocytoma), in which they observed similar levels of 
H3K4me1 and 2 for ccRCC, pRCC, chRCC and sRCC, but higher H3K4me1 and 2 
levels for the benign oncocytoma (Ellinger et al., 2010). Following the 
identification of recurrent mutations in histone methyltransferases SETD2 in 
ccRCC and differential histone methylation patterns between oncocytoma and 
other RCCs, a recent study has explored the differential expression of histone 
methyltransferases as a method for distinguishing oncocytomas from 
chromophobe. Here they propose that increased expression of histone 
methyltransferases SMYD2 in chRCC can distinguish chRCC from oncocytoma 
with a sensitivity of 71.0% and specificity of 73.3%, thus potentially being of use 
as a novel biomarker (Pires-Luís et al., 2015).  
Detection of abnormal DNA methylation has been observed in RCC patients 
plasma and urine samples. Therefore it may be proposed that successful 
characterisation of the epigenetic and DNA methylation profiles of the different 
RCC subtypes within urine or plasma samples may provide a non-invasive 
method for diagnosis (Maher, 2013). Although many studies have attempted to 
characterise and define the different epigenetic profiles of RCC subtypes (Costa 
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et al., 2007; Dulaimi et al., 2004; Ellinger et al., 2010; Kluzek et al., 2015; Maher, 
2013; McRonald et al., 2009; Morris et al., 2011, 2005; Ricketts et al., 2013; 
Youssef et al., 2011), or differentiate RCC tumours from normal kidney tissue via 
the DNA methylation profile (Lasseigne et al., 2014), as yet no definitive 
epigenetic profile, which can distinguish one RCC subtype from another, has 
been agreed upon. As yet no clinical application of epigenetic profiling has been 
approved for the differentiation RCC subtypes, and such an application currently 
remains far off (Kluzek et al., 2015). 
1.6 Treatment of RCC 
Traditional chemotherapy and cytotoxic drugs is of limited success in the 
treatment of RCC (Bylow et al., 2009; Stec et al., 2009). Currently surgical 
removal via partial or full nephrectomy is widely considered the gold standard 
and most effective course of action (Jonasch et al., 2014). For RCC patients in the 
UK, the National Institute for Health and Care Excellence (NICE), recommend the 
full (IPG136) or partial (IPG151) nephrectomy or ablation techniques (e.g. 
Laparoscopic cryotherapy (IPG405) and radiofrequency ablation (IPG353) as 
treatment for small and low grade RCC, and targeted treatment with pazopanib a 
tyrosine kinase inhibitor (TKI) for advanced RCC (TA215) (“Renal cancer | 
Guidance and guideline topic | NICE,” 2016). 
Targeted therapy has shown some success in improving patient outcomes in 
advanced RCC, compared to treatment with cytotoxic drugs and immunotherapy 
treatments such as interleukin-2 (IL-2) (Escudier, 2012; Shuch et al., 2015). As a 
result, targeted therapy is now the first pharmaceutical line of treatment for 
advanced RCC with several therapies including the anti-VEGF molecules 
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(sunitinib Tyrosine-kinase inhibitor (TKI), pazopanib (TKI) and bevacizumab 
(monoclonal antibody) which inhibit angiogenesis and an mTOR inhibitor 
(temsirolimus) having been approved for clinical use (Garajová et al., 2015; 
Linehan and Ricketts, 2014; Shuch et al., 2015). However, for many patients, 
treatment with these therapies fails to produce prolonged clinical responses. 
Current investigations to combat this resistance to treatment are examining the 
benefits and limitations of combination therapy. The use of MET and VEGF 
targeted inhibitors when used in combination has shown promising results in 
treating RCC, however the adverse effects are pronounced (Garajová et al., 
2015). Other emerging therapies include the use of monoclonal antibodies, 
particularly monoclonal antibodies specific for immune check-point blockade 
molecules such as CTLA-4 (cytotoxic T lymphocyte antigen 4) and PD-1 
(programmed cell death 1). These are currently in clinical trial and displaying 
promising clinical activity, however there is also high toxicity associated with 
these treatment (Jonasch et al., 2014 and references within) 
The above treatment options are approved for all malignant RCCs, however the 
different RCC subtypes, may effect the therapeutic response. For example pRCC 
has been shown to be particularly resistant (more so then ccRCC) to 
chemotherapy and cytotoxic drugs (Bylow et al., 2009), furthermore the TKIs 
and mTOR inhibitors approved for malignant RCC have been reported little effect 
on the pRCC (Shuch et al., 2015). For chRCC, few clinical trials have been 
conducted evaluating therapy response in patients (Stec et al., 2009), although 
mTOR inhibitors have reported to have some clinical success (Shuch et al., 
2012b) . However a surgical removal is still regarded as the best treatment and is 
associated with a 83% recurrence free survival rate after 5 years (Vera-Badillo et 
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al., 2012). With regard to other RCC subtypes such as sRCC, it has been suggested 
that cytotoxic chemotherapy maybe more effective for tumours with a high 
sarcomatoid percentage, and targeted therapy is more beneficial for tumours 
with a lower sarcomatoid percentage (Haas et al., 2012; Shuch et al., 2015). A 
phase 2 clinical trial combining targeted anti-angiogenic therapy (sunitinib) in 
combination with cytotoxic chemotherapy for sRCC patients exhibiting a high 
sarcomatoid content, has shown positive clinical activity, and is generally well 
tolerated with limited toxic effects (Michaelson et al., 2015). 
Finally for oncocytoma patients, following diagnosis the course of treatment 
tends to be one of surveillance, with surgical removal performed on patients 
who’s tumours have become too large and symptomatic (Neuzillet et al., 2005). 
It is therefore important both economically and for the patients’ prognosis and 
well being that the correct subtype of RCC is diagnosed quickly and effectively. 
So the most efficient and appropriate cause of treatment can be initiated, as 
always with, cancer, the earlier the intervention the better the prognosis.  
1.7 Aims of the research 
At the onset of this study in 2011, investigation and comparison of the epigenetic 
or genetic profiles or variations of the rare renal cancer subtypes, chromophobe 
RCC, renal oncocytoma and clear cell derived sarcomatoid RCC (sRCC) was 
limited. To the best of our knowledge no investigation into the DNA methylation 
state of clear cell derived sRCC had been conducted, a recent PubMed search 
identified that most sRCC based papers, are reports on histological observations 
and case studies [NCBI PubMed search, Keywords; Sarcomatoid Renal Cell 
Carcinoma sRCC; conducted on 14th August 2015]. 
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For chRCC and oncocytoma some DNA methylation studies have been conducted 
on candidate genes, comparing the distinct histologies, however the small 
number of candidate genes studied did not yield any differential methylation 
profile between the two histologies (Costa et al., 2007; Dulaimi et al., 2004). 
Another study attempting to address the global methylation profile of chRCC and 
renal oncocytomas using BACS clones, identified similar DNA methylation 
profiles for the two histologies, with small regions of DNA methylation 
alterations that are specific to each neoplasm. However, further information as 
to the genomic locations and genes epigenetic regulation was lacking (Arai et al., 
2011). Other studies which directly compared chRCC and oncocytoma focused 
on comparison of DNA copy number profiles (Yusenko et al., 2009), single 
nucleotide polymorphisms (Tan et al., 2010), gene expression (Pires-Luís et al., 
2015; Tan et al., 2010), miroRNA profile (Fridman et al., 2010; Youssef et al., 
2011) and immunohistochemical differences of the two histologies (Ng et al., 
2014). These studies provided further evidence that chRCC and oncocytomas are 
distinct RCC subtypes. However, understanding of the two RCC subtypes global 
epigenetic and genetic profiles is still inadequate and until further understood 
classification and differentiation of the two subtypes by genetics profiling 
remains an aspiration.  Therefore, the overall focus of this thesis was to address 
this gap in knowledge, to investigate and characterise the genetic and epigenetic 
profiles of these rare RCC histologies (Research published in the subsequent four 
years is further discussed in relevant thesis chapters). The hope was to identify 
features, which may aid diagnosis of specific subtypes permitting the 
development of RCC subtype, tailored treatment plans and eliminating the 
current methods of pathological, cytogenetic and immunochemical analysis 
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which are widely regarded as lacking reliability and specificity (Ng et al., 2014; 
Yusenko, 2010). Furthermore, identification of genetic variation may enhance 
understanding of the deregulated pathways promoting specific subtype 
tumourigenesis.  
 The main aim of the thesis was subdivided into the following three-pronged 
format, each chapter will introduce the unique techniques utilised within that 
chapter and address the following objectives; 
1) To investigate and characterise the global DNA methylation patterns of 
chRCC and renal oncocytoma and to identify differential patterns of 
methylation between chromophobe and oncocytomas using the high 
throughput Illumina Infinium HumanMethylation450 BeadChip array and 
to compare our findings with the methylation data available from the 
TCGA. 
2) Undertake a targeted approach to characterise the methylation profile of 
the RASSF family of TSG in the advanced and aggressive RCC histology, 
sRCC. With further investigation to ascertain if there is any association 
between methylation status and clinical data. 
3) Identify the mutation profile of renal oncocytomas using whole exome 
sequencing and bioinformatic analysis, with the hope of identifying 
recurrent somatic mutations that may drive tumour formation. By the 
time this study was conducted the TCGA had published a multiplatform 
profile of chRCC including WGS (Davis et al., 2014), therefore the 
mutational landscape of chRCC was not studied in this thesis.  
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 Methods and Materials 
2.1  Samples 
 Renal cell lines 
The kidney tumour cell lines used in this study were kindly provided by 
Professor Eamonn Maher and Dr Michael Lerman. RCC4 cell line was a kind gift 
from CH Buys. The origin and the establishment of the cell lines used in this 
study are described in the following references: Anglard et al., 1992; Ebert et al., 
1990; Grossman et al., 1985. HEK293 cells were purchased from American Type 
Culture Collection (ATCC) (ATCC Number: CRL-3216). Mr Dean Gentle 
generously extracted DNA from 18 ccRCC cell lines (RCC1, RCC4, RCC11, RCC12, 
UMRC2, UMRC3, KTCL26, KTCL140, Caki 2, SKRC18, SKRC39, SKRC45, SKRC47, 
SKRC48, SKRC54, A498, A704, 796P) (section 2.6.5), and RNA extracted from 4 
ccRCC cell lines (UMRC3, KTCL140, RCC11, SKRC45) (section 2.6.6) with and 
without 5-Aza-2'-Deoxycytidine treatment (a DNA methyltransferase inhibitor 
which results in DNA demethylation) (section 2.6.4). 
 Primary DNA samples 
Normal age matched kidney DNA was previously extracted from control kidney 
samples retrieved during non-cancer related surgeries upon the kidney (mean 
age 57 years, range from 23-79 years).  
Anonymised primary DNA from tumour and matched normal from the following 
histologies of renal tumours; oncocytoma, chromophobe, papillary clear cell and 
clear cell with sarcomatoid histology were kindly extracted and provided by our 
collaborators, Dr G Kovacs (Department of Laboratory Medicine; University of 
Pecs Medical School; Pecs, Hungary) who supplied the European cohort and Dr M 
Yao (Department of Urology; Yokohama City University School of Medicine; 
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Yokohama, Japan) who provided  samples for the Japanese cohort. The clinical 
data available for all primary samples is displayed in Table 2-1. 
All DNA was stored at -20°C. Ethical approval was obtained from institutional 
and local research committees for the collection and use of all the 
samples.  Research was conducted according to the principles expressed in the 
Declaration of Helsinki (World Medical Association, 1974). 
 DNA concentration 
The concentration and purity of all DNA and RNA was determined via a 
Nanodrop spectrophotometer ND-1000 (Thermo Fischer Scientific Inc). The 
Nanodrop was primed and blanked with 2µl dH2O prior to quantification of DNA 
samples. 2µl of the sample was loaded on the Nanodrop pedestal and quantified 
in ng/µl.  Sample purity was determined by observation of 260/280 and 
260/230 ratios; values of 1.6 – 2.0 and 1.8 - 2.2 were observed in our samples. 
Generally 260/280 and 260/230 ratios of 1.8 for DNA and 2.0 for RNA are 
accepted as “pure” for DNA and RNA samples respectively. Values appreciably 
lower than these indicate the presence of protein, phenol or other contaminants 




Table 2-1: Clinical data for primary RCC samples used in this study Table summarises the clinical data for the primary tumours used within this study. Table details tumour: onco: oncocytoma, chRCC: chromophobe, ccRCC: clear cell RCC and sRCC: sarcomatoid RCC derived from clear cell RCC), the ethnicity of the samples (J: Japanese, E: European), patients age at diagnosis, gender of patient (M = male, F = female), tumour size and the chapter in which the samples were used (for chapter 3: 450K indicates the samples run on the methylation array, CoBRA indicated the samples used for secondary confirmation of methylation. For chapter 5, NGS: refers to the samples sent for next generation sequencing, screen: refers to the sample screened by Sanger sequencing, and mentioned: are samples that were screened by Sanger sequencing and explicitly mentioned within the chapter) . Whether the samples were tumours (T) only, or if matched normal (N) were available. If applicable, the grades of the tumour are displayed according to the 2002 UICC staging classification (stage I-IV) and whether metastasis was observed (see section 1.4.1), dashed line denotes data of this type not usually recorded. Patient survival time in months and the overall outcome of the patient is documented (where cd = cancer death, awd = alive with disease and ned = no evidence of disease). For all cases n.d = no data available. 
Chapter 3 Chapter 4 Chapter 5
Onco F = 16M = 12n.d = 16
59.9(30 - 76)n.d = 16
5.4(1 - 14)n.d = 18
T/N = 34T = 10 E = 32J = 12 - - - 450k E = 18450k J = 3 -
E Screen = 31J Sceen = 4J NGS = 5E Mentioned = 1J Mentioned = 3
chRCC F = 22M = 14n.d = 6
53.4(21 - 80)n.d = 6
7.0(1.8 - 15.5)n.d = 6
T/N = 36T = 6 E = 18J = 24
I = 11II = 7III = 4IV = 1n.d = 19
n.d n.d 450k E = 18450k J = 2CoBRA J = 22 - -
ccRCC F = 5M = 15 61.3(45 - 81) 6.3(2.3 - 16) T/N = 20 J = 20
I = 6II = 3III = 6IV = 5
n.d 79.9(6.6 - 156.3) - J = 20 -
sRCC F = 9M = 22 61.9(33 - 78) 8.4(2.5 - 20) T/N = 25T = 6 J = 31
I = 2II = 1III = 9IV = 19
No Metastasis= 16Matastasis= 15
42.1(1 - 195) - J = 31 -
Histology Gender Average Age(Years)






2.2 General techniques  
A key tool in the study of DNA is polymerase chain reaction (PCR), a technique 
employed to rapidly and accurately amplify regions of interest within a DNA 
sample for further analysis (Ishmael et al., 2008). Since its discovery, many 
different forms and adaptations of the traditional PCR have been developed, 
focussing on different areas of investigation. Below are detailed the key 
methodologies used throughout all the projects undertaken within the study. 
 Primer design 
In order to employ the various PCR techniques in this study, primers were 
required to provide the starting template for the Taq polymerase (see section 
2.3.2.1). The design of the primers varied depending on the PCR technique used, 
however all primers were designed to be specific for the region of interest and 
were usually between 18 and 30 nucleotides, with an average primer length of 
20 nucleotides, see the following sections for more information. . 
 Methylation primers 
Combined bisulfite restriction analysis (CoBRA) and Methylation Specific PCR 
(MSP) primers used in this study were designed manually unless otherwise 
specified. Primers were designed within the CpG islands as defined by University 
of California, Santa Cruz Genome Browser (genome.ucsc.edu). Preferably, the 
region interrogated was upstream of the transcription start site (TSS) and did 
not include the coding region. In the case of the work undertaken in Chapter 3, 
primers were designed to incorporate the CG dinucleotide of interest within the 
amplified region regardless of location to TSS or CpG island. All primers were 
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designed to be specific for bisulfite modified DNA. Dr Victoria Hill designed the 
CoBRA and MSP primers for the RASSF family of genes.  
 Combined bisulfite restriction analysis (CoBRA) Primers 
CoBRA primers are designed to amplify a region between 300-500bp containing 
at least one DNA sequence motif specific for the digestions enzymes BstU1 (5’-
CGCG-3’) or Taqα1 (5’-TCGA-3’). This permits methylation specific digestion of 
the PCR product. To avoid primer bias, any C belonging to a CG dinucleotide 
within the forward primer region was labelled ‘Y’ (indicating during synthesis a 
50:50 ratio of C:T at that particular nucleotide),  for the reverse primer (the 
reverse complement) any G belonging to a CG dinucleotide was labelled ‘R’ 
(indicating during synthesis a 50:50 ratio of G:A at that particular nucleotide). To 
increase specificity the 3’ region of the primer should incorporate a CAC or ACC, 
avoiding a CG dinucleotide at the 3’ end. High proportions of lone C nucleotides 
increases the specificity of the primer for bisulfite modified DNA (Xiong and 
Laird, 1997).  
 Methylight primers  
The Methylight primers and probes were previously designed by Dr Ashraf 
Dallol (Center of Excellence in Genomic Medicine Research, King Abdulaziz 
University, Saudi Arabia) to amplify a small region of approximately 100 ± 20 bp. 
Methylight primers were designed to be specific to methylated DNA. Methylight 
primers require multiple CG dinucleotide within the primer sequence, 
particularly towards the 3’ region to increase specificity and discriminate 
between methylated and unmethylated sequence (Davidović et al., 2014). To 
quantify methylation a 20bp probe was designed complimentary to the middle of 
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the amplified region, specificity for methylated DNA, with a fluorescent dye at 
the 5’ end and a quencher at the 3’ end.  
 Genomic and sequencing primers 
Primers for exome sequencing and standard amplification of genomic DNA were 
designed using Primer 3 (Koressaar and Remm, 2007) and Primer Blast (Ye et 
al., 2012) to ensure specificity, prevent self-complimentary binding and primer 
dimers. PCR amplification regions were between 200-500 bp. Primers were 
between 18 and 25bp in length and contained approximately 50% GC content 
with a melting temperature (Tm) of between 58°C and 62°C with the forward 
and reverse primer preferably not exceeding a tm difference of 1 ˚C to increase 
reliability and specificity (Lorenz, 2012).  
Primers were designed in the intronic region approximately 50 bp either side of 
an exon (boundary defined by Ensembl.org), or, in the case of specific mutations, 
primers were designed to include the base of interest. If the exon exceeded the 
maximum PCR amplification range, multiple primers were designed that 
overlapped to ensure all the exon was sufficiently investigated.  
Single nucleotide polymorphisms (SNPs) present in genomic DNA can affect the 
accuracy of PCR amplification and generate a PCR bias, by altering efficiency of 
polymerase extension, or primer specificity. It was therefore imperative to 
ensure primers annealed to regions devoid of SNPs. To minimize the risk of SNP 
induced primer bias all primers were visually compared to known SNPs in 
Ensembl and checked using on line bioinformatics tool SNPcheck3 (Snpcheck.org) 
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 Expression primers for RT-PCR 
Primers specific for cDNA were designed to evaluate the expression of genes 
following RT-PCR (see section 2.7). These primers shall be termed expression 
primers. Expression primers were designed following the same rules as Genomic 
and Sequencing primers (section 2.2.5), using Primer Blast and Primer 3. 
However, in this case cDNA was used as the template and ideally at least one 
primer should span an exon:exon boundary. 
 Loss of heterozygosity (LOH) primers 
To identify loss of heterozygosity (LOH), the nearest heterozygous micro-
satellites either side of the gene of interest (according to UCSC) were identified. 
The West Midlands Regional NHS Genetics laboratory provided information on 
the probability of heterozygosity and primer sequences for each micro-satellite. 
Unlike conventional primers, a FAM fluorescent tag was added to the 5’ region of 
the forward primer for detection. 
 PCR reagents and machines 
All PCR reactions were completed on either Biometra thermo-cycler or Bio-rad 
Tetrad 2 Pelther Thermal cycler unless otherwise specified. Unless otherwise 
specified all reagents used in PCR reactions were supplied from Roche (Roche; 
Cat #: 12158264001) except for the dNTPs, which were from Thermofisher 
Molecular Biology (Thermofisher; IBR stores; Cat #: IBR10297018). 
 Agarose gels  
Gel electrophoresis was employed to analyse PCR products. Electrophoresis 
separates DNA by fragment size, with the smallest fragments travelling through 
the gel matrix quicker, while the larger fragments travel slower and therefore a 
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smaller distance through the gel. The percentage of the agarose gel can be varied 
depending on the size of the DNA fragment, with a higher percentage being used 
to differentiate smaller fragments. Unless specified, all agarose gels used in this 
study were made at 2% (w/v).  
By dissolving 2% (w/v) agarose powder (Bioline; Cat #: BIO-41025) in 200 ml 
TBE buffer (90mM Tris-base, 90mM boric acid and 2mM EDTA, pH 8.0) a 2% 
agarose gel was made. TBE buffer was diluted from 10x stock (National 
Diagnostics; Cat #: EC-860) with dH2O prior to the addition of agarose gel. The 
agarose solution was heated until all powder had dissolved and solution was 
clear. Once cooled, but not set, 0.1µg/ml ethidium bromide (Sigma Aldrich; Cat #: 
E8751) was added. The agarose was then poured into a casting tray with comb 
and left to set at room temperature. Once set, the comb was removed leaving 
wells in which DNA could be loaded. Gels were placed in an electrophoresis 
chamber, submerged in TBE buffer, and DNA was loaded into wells. To aid the 
loading of DNA and to visualise the progress of the electrophoresis, 5µl loading 
dye was added to each DNA sample (Loading dye consisted of, 50% (v/v) 
glycerol (Sigma Aldrich; Cat #: G5516), 48.5% (v/v) distilled water, 1% (v/v) 
EDTA (Sigma Aldrich; Cat #: E9884 and 0.5% (w/v) Orange G (Sigma Aldrich; Cat 
#: O3756). In one well per row, 5µl 100bp DNA ladder (Invitrogen; Cat #: 
IBR15628019) was loaded as a size standard. Gels were then run at 170 V 
permitting the DNA to migrate through the gel towards the positive electrode, 
for as long as required to separate the PCR products. DNA bands were visualised 




2.3 Methylation studies 
Investigation of DNA methylation was undertaken on both an individual gene 
and a whole genome level basis. DNA methylation is not retained through PCR 
amplification, therefore all investigations undertaken in this project were 
performed on sodium bisulfite modified DNA. 
 Bisulfite modification 
Bisulfite modification of DNA allows the methylation status of DNA to be 
determined by permanently altering the DNA sequence to reflect the methylation 
status of the DNA. The method of action of bisulfite modification is described in 
section 3.1.1.1. Bisulfite modification of DNA was performed using Qiagen 
EpiTect Kit (Qiagen; Cat #: 59104), following the manufacturer’s instructions; all 
equipment and reagents were supplied in the kit unless otherwise specified. 
Aliquots of ‘bisulfite mix’ were completely dissolved in 800µl RNase-free water 
prior to setting up the reaction. Each reaction consisted of 1µg genomic DNA 
with 85µl of bisulphite mix and 35µl green DNA protection buffer (required to 
maintain and indicate pH during the reaction, blue colour indicates correct pH). 
Reactions were vortexed to ensure all reagents were homogenously distributed 
and run on a PCR machine with the reaction conditions shown in Table 2-2. 
Step Temperature ( ̊C) Time (Minutes) 
Denaturation 95 5 
Incubation 60 25 
Denaturation 95 5 
Incubation 60 85 
Denaturation 95 5 
Incubation 60 175 
Hold 20 ∞ 




Post bisulfite conversion, the reactions were transferred to 1.5ml micro-
centrifuge tubes (IBR stores; Cat #: IBR-EPP-1.5), and 560µl buffer BL and 
10µg/ml carrier RNA was added to each sample. Samples were then briefly 
vortexed and centrifuged before transferring to an EpiTect spin column.  
Samples were centrifuged at 16,300 x g for 1 minute at room temperature (all 
following centrifugation steps for bisulfite modification were performed with 
these conditions). Flow-through was discarded and column membranes were 
washed with 500µl buffer BW and centrifuged. Flow through was once again 
discarded. To de-sulphonate samples, 500µl buffer BD was added to each 
membrane and incubated for 15 minutes at room temperature, to avoid 
oxidation of the buffer it was imperative to ensure all lids were closed for the 
duration of this incubation. Following incubation, samples were again 
centrifuged and flow-through discarded and washed twice with 500µl buffer BW, 
between each wash, samples were again centrifuged and flow through discarded. 
EpiTect columns were then placed into fresh collection tubes and centrifuged to 
remove residual liquid. To ensure all liquid was removed from the membrane 
the EpiTect columns were transferred into fresh 1.5ml microcentrifuge tubes 
and incubated at 56 ˚C for 5 minutes. The bisulfite modified DNA was then eluted 
by the addition of 20µl buffer EB directly to the membrane and left to stand at 
room temperature for 5 minutes before centrifugation. To enhance the yield of 
bisulfite modified DNA obtained; the elution step was performed twice. 
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 Candidate gene methylation analysis 
To investigate the methylation status of candidate genes the following methods 
were conducted on bisulfite modified DNA.  
 Combined Bisulfite Restriction Analysis (CoBRA) 
Methylation sensitive digestion enzymes such as BstUI (Fermentas UK; Cat #:  
ER0921) and TaqαI (New England Biosciences; Cat #: R0149S) were used to 
distinguish the methylation status of regions of interest. Digestion of the bisulfite 
modified DNA is only observed if methylation is present.  
Each primary CoBRA reaction was conducted on 0.05µg bisulfite modified DNA. 
The PCR master mix consisted of 1x PCR buffer (diluted from 10x stock 
containing: 500mM Tris-HCL (pH 8.3), 100mM potassium chloride, 50mM 
ammonium sulphate, 2mM magnesium chloride), 2.5mM dNTP mix, 1x GC-RICH 
solution (from 5x stock), 0.8µM forward primer, 0.8µM reverse primer, and 0.5U 
FastStart Taq DNA polymerase (Roche; Cat #: 12158264001) made up to the 
final volume of 25µl with distilled water (dH2O). Unless specified, a second round 
of PCR was conducted on 5µl of the PCR product from the primary CoBRA 
reaction in order to increase the yield. The secondary reaction was conducted in 
a 50µl volume using either semi-nested or fully-nested primers. The 
concentrations of PCR master mix components remained the same as for the 
primary reaction, with the only exception being the increase of FastStart Taq to 
1U per reaction.   
The PCR reactions were run using either a PCR protocol optimised for 
amplification of CoBRA PCR products dubbed here as ‘methylation’ PCR protocol 
(Table 2-3) or a touchdown PCR program (used to avoid amplification of 
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unspecific sequences; Table 2-4). Primer sequences, annealing temperature, PCR 
program, cycle numbers and digestion enzyme for each region investigated are 
listed in Table 7-1.  
Following the CoBRA reactions, 5µl of PCR product was run by electrophoresis 
on an agarose gel, to determine a suitable volume of PCR product for digestion 
(between 5-20µl). To establish the methylation status, the predetermined 
volume of PCR product was digested either with BstUI (which recognises and 
cleaves DNA at CGCG) or Taqα1 (which recognises and cleaves DNA at TCGA) 
depending on restriction sites present. 
BstUI digestion involved incubating the desired volume of PCR product with 1 U 
BSTU1 and 1x Buffer R (10x stock; Fermentis UK supplied with BstU1). dH2O was 
added to make the reaction up to a total volume of 25µl. Samples were incubated 
for 16 hours at 37  ̊C.  Digestion via Taqα1 involved incubation for 1 hour at 65 ̊C 
of an appropriate amount of PCR product with 1U Taqα1 per 5µl PCR product, 1x 
BSA (from 100x stock), 1x NE Buffer (from 10x stock) (all reagents supplied with 
the Taqα1 enzyme) and dH2O to make the total volume up to 25µl.  After 









Denaturation 95 5   
Denaturation 95 1 
35 Cycles 40 Cycles Annealing Ta 1 
Elongation 72 2 
Final elongation 72 10   
Hold 10 ∞   









Denaturation 95 5 minutes   
Denaturation 95 45 seconds 
5 Cycles 5 Cycles Annealing Ta +5 ̊C (Decrease 1 ̊C per cycle) 
45 seconds 
Elongation 72 45 seconds 
Elongation 72 45 seconds 
35 Cycles 40 Cycles Annealing Ta 45 seconds 
Elongation  45 seconds 
Final elongation 72 10 minutes   
Hold 10 ∞   
Table 2-4: Touchdown PCR conditions for primary and secondary PCR reactions  
 
 Methylight 
Methylight is a sensitive, quantitative PCR technique using real time PCR. 
Primers are designed to be specific for methylated sequences, while the 
incorporation of a methylation specific probe increases specificity and allows 
quantification of methylation.   
A five point serial dilution was used to create a standard curve to quantify the 
results. This was done in duplicate, with fresh dilutions made for each 
Methylight run. A 1 in 5 serial dilution of EpiTect 100% in-vitro methylated 
control (Qiagen, Cat ♯: 59655) into nuclease-free water was created in order to 
achieve the final concentrations of 10ng, 2ng, 0.4ng, 0.08ng and0.016 ng per 
well. Bisulfite modified sample DNA was diluted to 5ng/µl with nucleases-free 
water before use. The Methylight PCR reaction was composed of 2µl (10ng) 
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bisulfite modified DNA or Standard curve dilution or 1µl (10ng) control DNA, 5µl 
TaqMan® Fast Universal PCR Master Mix (from 2x stock; Life technologies; Cat #: 
4366072), 1µl probe/primer mix (from 10x stock consisting of 4µM forward and 
reverse primers and 2µM TaqMan® probe diluted in nuclease free water to 
achieve the final concentration of 0.4µM primers and 0.2µM probe) and 2µl 
nuclease free water, resulting in a total volume of 10µl. The reaction was run on 
Bio-Rad I cycler IQ5 multicolour PCR detection system (Table 2-5), where 
fluorescence was imaged and quantified during the amplification step, providing 
a Cycle Threshold (Ct) value for each sample. 
 
Step Temperature ( ̊C) Time  
Denaturation 95 10 minutes  
Denaturation 95 15 seconds 
45 Cycles Annealing and 
image capture 60 1 minute 
Table 2-5: Methylight PCR conditions  
Each Methylight reaction was conducted in a 96 well plate and included 
investigation of the gene of interest (GOI- FAM labelled) and a house-keeping 
gene as an internal control (Alu (VIC labelled)) on the same plate. As additional 
controls 10ng 100% in-vitro methylated positive control and 10ng EpiTect 
unmethylated control (10ng/µl; Qiagen; Cat #: 59665) were included for each 
primer set and each repeat. The five point standard dilution was only included 
for the house keeping reference gene. 
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To increase reliability and reduce margin of error, all samples, standards and 
controls were performed in duplicate on a 96 well plate and each Methylight 
reaction was repeated in triplicate.  All primer sequences are described in Table 
7-1. 
2.3.2.2.1 Calculating percent of methylated reference  
The percent of methylated reference (PMR) is a method of quantifying and 
rationalising the level of DNA methylation in relation to the 100% methylated 
control. The stages undertaken to calculate the PMR, were as follows; first the Ct 
values of duplicate samples were averaged. Then, as described by Dallol et al., 
2011, a standard curve graph was produced by plotting the log10 standard 
concentration on the x axis against the Ct value recorded for each of the 
standards. The correlation of the standard curve was calculated via Pearson’s 
correlation coefficient. An ‘r’ value of greater than 0.9 was considered of 
sufficient correlation to progress with the analysis of the samples. The 
correlation of the standard curve was assessed after every run in order to ensure 
reliability and accuracy of the run. In addition to calculating the correlation, the 
trend line of the standard curve was also calculated using linear regression 
(Equation 1);  
= +  
Equation 1: Equation for a straight line Where m is the gradient and c is the y intercept. 
The next stage was to calculate the quantity of each sample (Q) (Equation 2); 
= e( ) 




Following the calculations of the above, the PMR was then calculated. This 




Equation 3: Percentage of methylated reference Where:  GOI = Gene of interest Alu =Alu house keeping gene s = sample cont  =100% in-vitro methylated control  Q = sample quantity 
PMR values for each sample were averaged across the three repeat reactions. A 
sample was determined to be positive for methylation if the PMR was >10 
(Buhmeida et al., 2011; Dallol et al., 2011). 
 Genome wide methylation array 
Investigation of the global DNA methylation profile was performed using the 
Infinium HumanMethylation 450 BeadChip methylation array (450K array), a 
comprehensive technology that interrogates the DNA methylation profile of over 
485,000 CpG loci, correlating to 99% coverage of RefSeq genes and 96% of CpG 
Islands (Illumina.com, 2015). 
Analysis of genome wide methylation profile of 4 normal kidney, 21 primary 
oncocytomas and 20 primary chromophobe (1 oncocytoma sample sent in 
duplicate to assess the reliability and reproducibility of the assay) was 
undertaken using the aforementioned Infinium HumanMethylation 450 
BeadChip methylation array. Samples were outsourced to J. Bauer, Cambridge 
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Genomic Services, Department of Pathology, University of Cambridge, UK to be 
run according to the manufactures instructions. In summary genomic DNA was 
bisulfite modified before hybridisation to the 450K array chip and interrogated 
following manufactures instructions. 
Data were obtained and normalised using Illumina Genome Studio software. Due 
to the chemistry and technology employed by the 450K array, it was observed 
that data should be corrected to avoid colour bias. This was achieved by the 
modification of an existing quantile pipeline, formally developed for the Infinium 
HumanMethylation27 Bead-Chips (Du et al., 2008). In summary, the two probes 
utilised in the 450K array (Type I and II) (see section 3.1.2.1) were separated 
and normalised independently to omit any colour bias and to ensure both probe 
types possessed the same distribution on the array, prior to running on the 
standard normalisation pipeline contained within the Illumina Genome Studio 
software.  
As part of the above pipeline the methylation status for each locus was then 
calculated and provided as an average β value (Equation 4), which compares the 
fluorescence intensity of methylation specific probes with unmethylated specific 
probes (Dedeurwaerder et al., 2011). A β value of 0 corresponds to completely 
unmethylated locus while a β value of 1 represents 100% methylation. 
= ( + + 100) 




When analysing the output data from the 450K array, a β value of greater than 
0.5 was considered to represent methylation of that particular CpG locus, with 
cancer specific methylation classified as probes with a β value greater than 0.5 in 
tumour samples but less than 0.25 in all normal samples (Weisenberger et al., 
2008).  
 Single colony sequencing 
Single colony sequencing is a method used to amplify and isolate single alleles of 
DNA for Sanger sequencing to determine the DNA sequence of a region of 
interest. This is a particular useful method for analysing methylation of bisulfite 
modified DNA, as the level of methylation can differ between alleles. 
 PCR amplification and gel extraction 
Genes and regions of interest were amplified on bisulfite modified DNA by 
CoBRA PCR (Section: 2.3.2.1). Following amplification, the full 50µl of the 
secondary PCR product was run on an agarose gel. Using a scalpel, each PCR 
product was excised, omitting as much agarose gel as possible without 
compromising the PCR band, and placed into individual labelled 1.5ml micro-
centrifuge tubes (IBR stores; Cat #: IBR-EPP-1.5), ready for gel extraction via the 
QIAquick Gel extraction kit (Qiagen; Cat #: 28704). The gel extraction process 
involved weighing of the extracted agarose/PCR band, followed by the addition 
of 3 x mass (in mg) of the agarose fragment in volume (μl) of Buffer QG. Prior to 
incubation, tubes were vortexed regularly at 50  ̊C for 10 minutes, or until all the 
agarose had dissolved. Buffer QG contains a pH indicator and should remain 
yellow throughout the above step indicating a pH < 7.5.  Once fully dissolved, a 
volume of 100% isopropanol (Sigma-Aldrich; Cat #: 190764) was added, the 
volume of isopropanol added in µl was equal to the mass of the agarose fragment 
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in mg. Samples were thoroughly vortexed prior to the solution being transferred 
to a QIAquick spin column, containing a membrane which binds the DNA, and a 
2ml collection tube. Samples were then centrifuged at room temperature for 1 
minute at 17,900 x g and flow-though was discarded. A further 500µl Buffer QG 
was added to each spin column and a second centrifugation step was conducted 
as before and flow-through was discarded. Samples were then washed by the 
addition of 750µl Buffer PE to the spin column, to ensure thorough washing and 
removal of salt, samples were left to stand at room temperature for 5 minutes 
before being centrifuged for a further minute using the same conditions as 
before. Flow-through was once again discarded. To remove any residual buffer, 
the centrifugation step was repeated. To elute the DNA, spin columns were 
transferred to a fresh 1.5 ml microcentrifuge tube, 30µl Elution Buffer EB was 
added directly to the column membrane and left at room temperature for 5 
minutes to increase DNA yield. Samples were then centrifuged for a final time at 
room temperature for 1 minute at 17,900 x g to elute the purified DNA from the 
column. The purified PCR product was either used immediately or stored at -20 
°C.  
 Ligation  
Gel extracted DNA was ligated into the Promega pGEM-T Easy vector system 
(Promega; Cat #: A1360), a method utilised to introduce PCR products into 
bacterial cells for amplification by cloning. The ligation involved an overnight 
incubation at 4 ̊C of 3.5µl purified gel extracted PCR product with 0.5µl pGEM 
vector, 1µl T4 DNA ligase, 1µl 10x ligation buffer and 4µl nuclease free water. 
The pGEM-T easy vector system was chosen due to the high ligation efficiency, 
ease of use and intrinsic selection processes once transformed into bacterial 
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cells. These selection processes included the presence of an ampicillin resistance 
gene, conferring resistance to the antibiotic, and a LacZ gene, which is disrupted 
upon successful insertion of the DNA fragment of interest.  
 Preparation of LB agar plates 
Prior to transformation of the ligated vector into bacterial cells, LG agar plates 
were made to provide the nutrients and optimal conditions for the bacterial cell 
colony formation. Plates were prepared by mixing 14 g LB agar (Sigma Aldrich; 
Cat #: L2897) in 400 ml distilled water to obtain a concentration of 35 g/L. This 
solution was then autoclaved and allowed to cool sufficiently (but not set) before 
the addition of 100µg/ml ampicillin (Sigma-Aldrich; Cat #: H0166). Molten agar 
solution was then poured into petri dishes (approximately 20 ml agar/petri 
dish) and left to set. Once set, plates were stored upside down to minimise 
evaporation, at 4 °C until required.  
 Transformation of bacterial cells and selection  
The ligated PCR/pGEM vector was transformed into α-select silver efficiency 
chemically competent cells (Bioline; Cat #: BIO-85026). Competent cells were 
defrosted on ice and aliquoted equally into 1.5ml micro-centrifuge tubes (to 
minimum volume of 50µl/ tube). 10% of the volume of the cells of PCR ligated 
pGEM vector was gently added (e.g. for 50µl of competent cells 5µl PCR-pGEM 
vector was added). Stirring gently mixed the samples, with care taken to 
minimise cell damage. The competent cells/PCR-pGEM vector mixture were then 
incubated on ice for 20 minutes, followed by a heat-shock step at 42 °C for 30 
seconds, and a further 2 minute incubation on ice. 500µl SOC media (Invitrogen; 
Cat #: 15544034) was then added and samples incubated for 90 minutes at 37 °C 
with gentle agitation at 200 rpm on a shaking heat block. 
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During the above incubation period, LB agar (+Ampicillin) plates were covered 
with 80µl 0.1 M IPTG (Life technologies; Cat #: 15529-019) and 20µl 50 mg/ml 
X-gal (Bioline; Cat #: BIO37035) and permitted to dry. Transformed cultures 
were then plated onto the LB agar (+ Ampicillin, + IPTG, + X-gal) plates by gently 
adding 200µl of culture to the agar and distributing evenly around the plate 
using a plastic spreader (IBR stores; Cat #: IBR-GC543). Plates were then 
incubated upside-down at 37 °C for 16 hours.  
The presence of the ampicillin within the agar permits only the growth of 
successfully transformed bacterial cells, as the pGEM vector containing the 
ampicillin resistant gene. Meanwhile the inclusion of X-gal and IPTG permits for 
selection of colonies containing the PCR insert within the vector, as successful 
insertion of the PCR product can be visualised by the formation of white colonies, 
due to the disrupted Lac-Z gene. Lac-Z encodes the β-galactosidase enzyme that 
hydrolyses X-gal and produces a blue pigment bi-product. When Lac-Z is 
disrupted the colonies remain white. The inclusion of IPTG assists in the 
transcription of the Lac operon, increasing the amount of β-galactosidase 
translated, resulting in enhanced hydrolysis of X-gal, emphasising the colour of 
the colonies.  
White colonies were selected using a pipette tip. Colonies were transferred into 
20µl dH20 and denatured at 95°C for 5 minutes. 
 Single colony-PCR  
Following colony selection and denaturation, a single colony (SC) PCR was 
performed to confirm the presence of the PCR insert.  
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In summary, 7µl of denatured selected colony solution was PCR amplified in a 
30µl reaction consisting of 1x PCR buffer, 2 mM magnesium chloride, 2.5 mM 
dNTP mix, 1x GC rich solution, 0.8µM forward primer (pGEM T4: 
TAATACGACTCACTATAGGG), 0.8µM reverse primer (pGEM-R: 
ACACTATAGAATACTCAAGC-3) and 0.5 ᴜ FastStart Taq DNA polymerase and run 
on a PCR machine with the following specialist touchdown reaction Table 2-6. 
 
Step Temperature ( ̊C) Time  
Denaturation 95 5 minutes  
Denaturation 95 30 seconds 
3 Cycles Annealing 60 30 seconds 
Elongation 72 30 seconds 
Denaturation 95 30 seconds 
3 Cycles Annealing 58 30 seconds 
Elongation 72 30 seconds 
Denaturation 95 30 seconds 
34Cycles Annealing 56 30 seconds 
Elongation 72 30 seconds 
Final elongation 72 10 minutes  
Hold 10 ∞  
Table 2-6: Single Colony PCR conditions 
Following PCR amplification 5µl of SC-PCR product was run on an agarose gel, to 
confirm the inserted DNA was the correct size and that the colonies selected 
were of sufficient quality. 
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 Exosap DNA clean up 
Originally, the selected SC-PCR products were cleaned prior to sequencing by an 
exosap reaction, a process that uses Exonuclease I (ExoI) to digest residual single 
stranded DNA primers into single dNTPs, and alkaline phosphatase, which 
dephosphorylates individual dNTPs rendering them inactive.   
The exosap reaction involved incubating 10µl SC-PCR product, with 1U FastAP 
alkaline phosphatase (Fermentas; Cat #: EF0651), 0.01U ExoI (New England 
Biolabs; Cat #: M0293S) and 1x FastAP buffer (from 10x stock containing 
supplied with Exo1 and consisted of: 100mM Tris-HCL (pH8), 50mM magnesium 
chloride, 1M potassium chloride, 0.02% Triton X-100 and 1 mg/ml bovine serum 
albumin (BSA)) at 37  ̊C for 30 minutes, with an additional 20 minutes at 80  ̊C to 
inactivate the exosap enzymes. Following exosap inactivation, 5µl of the 
exosaped SC-PCR product was sequenced and precipitated via the methods 
described in section 2.5.2. 
This exosap step was subsequently replaced by the more cost effective and 
efficient microclean DNA clean up step (section: 2.5.1). 
2.4 Genomic sequencing 
Genomic DNA was utilised for the study of candidate genes and identification of 
mutations within rare renal cancers (see chapter 5).  
 Whole exome sequencing (WES) 
A total of between 3 and 5ug of stock genomic DNA at a concentration of 
100ng/μl extracted from oncocytoma tumours was sent for Whole Exome 
Sequencing (WES) to Dr Michael Simpson (National Institute for Health 
Research, Guys and St Thomas’ Foundation Trust, King’s College London). In 
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summary, exons were captured and enriched via SureSelect All Exon v5 Target 
Enrichment System (Agilent; according to manufactories instructions), before 
massively parallel sequencing on an Illumina HiSeq2000 sequencer generating 
paired-end reads of approximately 100 bp.  
Sequence reads obtained were computationally mapped via Novoalign 
(Novocraft Technologies) to the reference human genome (GRCh37/hg19). 
Analysis of coverage and depth of the sequencing was calculated via a 
combination of custom scripts and BedTools package (Code.google.com). 
Coverage of the gene was considered sufficient if more than 80% of the exon was 
sequenced at a read depth of greater than 20. Further analysis to identify and 
validate variations such as single nucleotide substitutions, small insertions or 
deletions between the sequencing and reference genome, was undertaken via in-
house and SAMtools software package, and annotated via Annovar 
documentation tool. The frequency of variants, if they had been previously 
observed was annotated by comparison to the dbSNP132 and 1000 Genomes 
SNP calls databases (June 2011) and the in-house database of variants 
previously identified by exome sequencing of other samples by the same 
method.  
The exome data was supplied in ‘.txt’ format detailing all variants identified and 
additional information such as variant type, location, gene, and SNPdb reference 
for each sample after alignment to Human Genome (hg19/GRCh37). Raw data 
were supplied in ‘.BAM’ and ‘.BAM.BAI’ format and accessible via the Integrative 
genomics viewer (IGV (Robinson et al., 2011)). Files detailing the coding variants 
identified for each sample were also supplied. These files omitted all low quality 
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variants with a phred score of less than 20, corresponding to a 1% error rate of 
being falsely called. A phred score of 20 is widely considered the minimum 
threshold for sequencing quality (Guo et al., 2014; Koboldt et al., 2012). All 
variants located in the non-coding or intronic regions, were excluded, as these 
regions were not integrated to the same breadth, depth or quality as the exons. 
Bioinformatic analysis of the exome data to identify somatic oncocytoma 
variants was thus conducted on the remaining data.  
 Whole genome amplification (WGA) 
To preserve DNA stocks, whole genome amplification (WGA) was conducted on 
stock genomic DNA prior to targeted whole gene screening via Sanger 
sequencing. Any variants identified from the WGA DNA were subsequently 
confirmed by retesting the stock genomic DNA. WGA was performed using 
REPLI-g Mini kit (Qiagen; Cat #: 150025) following manufacturers instructions. 
In summary, 50ng genomic DNA (5µl of 10ng/μl) was mixed with 5µl Buffer D1 
(denaturation buffer) via vortexing then briefly centrifuged and incubated for 3 
minutes at room temperature. The reaction was neutralised by the addition of 
10µl Buffer N1 (neutralisation buffer), vortexed then briefly centrifuged. 30µl of 
WGA master mix (29µl REPLI-g Mini reaction Buffer and 1µl REPLI-g Mini DNA 
polymerase) was then added to the neutralised DNA sample resulting in a total 
volume of 50ul. The reaction was then incubated at 30 ̊C for 16 hours, before 
inactivation at 60 ̊C for 3 minutes. 1µl WGA was run on an agarose gel to confirm 
successful reaction, before being diluted 1:20 in nuclease-free water for use in 
Sanger Sequence gene screen. WGA DNA was stored at -20 ̊C until required.  
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 Standard genomic PCR  
To confirm the variants identified via WES and to screen candidate genes in 
additional samples, a targeted approach was undertaken. Two different PCR 
master mixes (outlined below) were utilised depending on the optimal mix 
identified during primer optimisation.  
1: Roche master mix PCR reaction, used to amplify 20ng genomic DNA (stock or 
WGA), using the same Roche master mix described in the primary CoBRA 
reaction protocol (section:2.3.2.1) 
2: Biomix Red PCR reaction, used to amplify 20ng genomic DNA (stock or WGA) 
The PCR master mix consisted of 12.5μl 2x Biomix Red (Bioline; Cat #: BIO-
25005), 0.8µM of each primer and 5.5µl nuclease free water.  
Reactions were either run on a standard PCR (std PCR (Table 2-7)) or using a 
touchdown PCR (Table 2-4) protocol depending on the primer optimisation. PCR 
products were run on agarose gels to confirm successful amplification. All 
primers and the optimal PCR conditions used to amplify and screen genomic 
DNA for mutations are listed in Table 7-2 and Table 7-3. 
 
Step Temperature ( ̊C) Time  
Denaturation 95 5 minutes  
Denaturation 95 30 seconds 
35 Cycles Annealing Ta 30 seconds 
Elongation 72 30 seconds 
Final elongation 72 5 minutes  
Hold 10 ∞  
Table 2-7: Standard PCR conditions 
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2.5 Sanger Sequencing 
Prior to running any sample on the Sanger sequencer the following preparation 
steps were undertaken for both genomic mutational study and methylation 
studies unless otherwise specified. 
 MicroCLEAN PCR clean up  
To remove any residual primers and salts from the PCR product that could 
impede sequencing, PCR products were cleaned using the microCLEAN spin 
clean up protocol.  Equal volumes of PCR product to microCLEAN (Microzone; 
Cat #: 2MCL-10) were added to a fresh plate (2.5µl of each was deemed to be the 
optimal for most PCR amplifications, although this volume was sometimes 
increased to 4µl if PCR product was weak when run on an agarose gel).  Plates 
were centrifuged for 40 minutes at 2254 x g. Residual microCLEAN was then 
removed by further centrifugation of the plate upside down (without sealing 
film) on a tissue at less than 40 x g for 30 seconds. Samples were then ready for 
the addition of sequencing master mix (section: 2.5.2). 
 Sanger sequencing reaction 
Sequencing reaction was conducted using Big Dye Terminator v3.1 Cycle 
Sequencing kit (Applied Biosystems; Cat ♯: No: 4336917).  A total volume of 10µl 
of sequencing reaction master mix was added to each well of microCLEANed PCR 
product. The sequencing reaction master mix contained 2µl 5x sequencing 
buffer, 0.5µl Big Dye, 0.5µM of either the forward or reverse PCR primer (one 
direction only per well) and 7µl nuclease free water.  
For exosap cleaned PCR products, the nuclease-free water volumes were 
adjusted accordingly so the final volume per well, remained 10µl. Samples were 
then amplified on a PCR machine using the following sequencing reaction 
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protocol (Table 2-8). From this stage onwards it was important to keep samples 
in the dark to avoid degradation of the Big Dye.  
 
Step Temperature ( ̊C) Time  
Denaturation 95 5 minutes  
Denaturation 95 25seconds 
29 Cycles Annealing Ta 25 seconds 
Elongation 72 4 minutes 
Hold 10 ∞  
Table 2-8: Sequencing reaction conditions  
 Ethanol precipitation clean-up 
Following the sequencing reaction, the samples were cleaned to purify the DNA 
and remove residual reagents.  2µl of 0.125 M sodium acetate and EDTA (Sigma-
Aldrich; Cat ♯: E7889) was added to each sample, followed by 30µl of 100% 
ethanol (Sigma-Aldrich; Cat ♯:459844). Samples were pipetted up and down to 
thoroughly mix, and centrifuged for 20 minutes at 563 x g. Supernatant was 
removed from the pellet by a 30 second spin at 29 x g with the plate unsealed 
upside down upon a tissue. The pellet was re-suspended in 90µl of 70% ethanol 
by pipetting up and down before a further centrifugation step at 563 x g for a 
further 10 minutes, followed by removal of the supernatant by the same method 
as described above. Samples were then permitted to air dry for 5 minutes in the 
dark at room temperature to remove residual ethanol. Samples were re-
suspended in 10µl HiDi Formamide (Applied Biosystems Cat ♯: 4311-329) and 
denatured for 5 minutes at 95°C before being sequenced via Sanger sequencing 
on 3730 DNA analyser (Applied Biosystems). 
 
 86
 Loss of Heterozygosity 
To establish if there was any LOH of RASSF10 in sRCC samples (see chapter 4), a 
PCR reaction (see below) was conducted to analyse microsatellite markers 
flanking the RASSF10 genomic location on genomic DNA from sRCC tumour and 
matched normal pairs. The microsatellites investigated had previously been 
identified by The West Midlands Regional NHS Genetics laboratory to possess 










(bp) Start site End Site 
D11S4116 Z52745 Chr 11: 12907174- 12907502 124796 126479 0.78 
205-224 
D11S1334 Z24022 Chr 11: 12835634-12835775 196336 198019 0.81 
134-150 
D11S1794 Z51378 Chr 11: 13292332-13292701 -260362 -258679 0.84 
249-273 
D11S926> Z17018 Chr 11: 13409034-13409183 -377064 -375381 0.75 
135-145 
       
 FORWARD REVERSE Ta F Ta R 
D11S4116 AACTGGTCCTTTAGACAGACAA GAAAGCATCTCTATCTGCTGTG 59.4 61.2 
D11S1334 TGCAGCATAGNCCTGT AGCTTTATTGAAAGTCATTTTTG 47.9 49.5 
D11S1794 GCTCCTAAAGGGTGGAGAC TGCACTCAAAGCTGACAA 57.0 49.8 
D11S926> TGAGTGTGATGTATATGCTCATT CAAGAGGTCAATTCTGGTGT 53.0 53.4 
Table 2-9: LOH primer information (Chr 11 refers to chromosome 11, F the forward primer, R the reverse primer) 
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Each PCR amplification contained 20ng genomic DNA, 0.4µM microsatellite 
marker primers (Forward and Reverse) and 5µl 2x Biomix red made up to a total 
volume of 10µl per well with dH2O.  A standard PCR reaction protocol was used 
(Table 2-7) for a total of 28 cycles. Once complete, each PCR product was diluted 
and mixed with 120µl dH2O. Separately, 5µl GeneScan 500 LIZ dye Standard 
(ThermoFisher Scientific; Cat #: 4322682) was mixed into 1 ml HiDi. In a fresh 
96 well PCR plate 1µl diluted PCR product was added to 10µl HiDi/size standard 
mix, samples were denatured at 95 °C for 5 minutes then snap chilled on ice 
before running on Sanger Sequencer 3730 DNA analyser using Genescan run 
settings, and analysed using GeneScan Analysis software (Applied Bioscience). 
Comparison of tumour to matched normal permits the detection of changes in 
heterozygosity status for microsatellites. If microsatellites were identified to be 
heterozygous in normal and homozygous in tumour, it was deemed that LOH 
was present. 
2.6 Tissue culture 
All tissue culture (TC) was performed under sterile conditions in a 
microbiological safety cabinet class II (Thermo Electron Industries Holten 
LaminaAir). All media and reagents unless otherwise specified were warmed in a 
water bath to 37 °C. Prior to use, all surfaces and equipment was thoroughly 
cleaned with 70% ethanol to maintain sterile conditions. Any water used was 
double distilled (ddH2O) and autoclaved prior to use. 1x phosphate buffered 
saline (PBS; OXOID; Cat #: BR0014G) was also autoclaved prior to use. 
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 Cell culture maintenance 
Cell lines were grown in 75 cm3 (T75) flasks (IBR stores; Cat #: IBR83.3911.002),  
in Dulbecco’s Eagle Medium (DMEM; SIGMA; Cat #: D6429), enriched (complete 
DMEM) with 10% foetal bovine serum (FBS; Sigma; Cat #: F7524SIG), 1% L-
Glutamine (L-Glut; Sigma; Cat #: G7513), 1% non-Essential amino acids (Sigma; 
Cat #: M7145), and 1% penicillin and streptomycin (100 units/ml penicillin, and 
100μl/ml streptomycin (Pen/Strep); Gibco; Cat #: 15070-063) and incubated in 
a Sanyo CO2 Incubator (model MCO-18AIC)  at  37 °C with 5% CO2.    
 Trypsination of cells 
The following protocol was used to detach cells from the surface of the flask for 
counting, transfection or simple cell passaging.  All media was aspirated from the 
flask prior to cells being washed gently in 10 ml PBS, which was subsequently 
aspirated from the flask and discarded. A volume of 0.25% Trypsin-EDTA (Gibco; 
Cat#: 25200-056) appropriate to the size of the flask or the plate (1ml for T75 
flask, 20µl per well in 6 well plate), was gently applied to the growing side of the 
flask and gently swilled to ensure even coverage of the growing surface prior to 
incubation at 37 °C for 2-3 minutes or until cells could be seen to be detaching. 
Gentle agitation assisted detachment of the cells.  Trypsin was quenched by the 
addition of complete DMEM to a ratio of 1:10 (i.e. 1 ml trypsin was quenched by 
the addition of 9ml media).  
 Counting cells 
Trypsinised cells were counted using a haemocytometer prior to transfection. 
Suspended cells were placed in a 15ml falcon tube before 20µl of the cell 
suspension was added under the coverslip to each grid of a clean 
haemocytometer. Cells located within the grid were counted under a light 
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microscope; total cell count per ml was the average count across the two grids, 
multiplied by the haemocytometers conversion factor (1x104). 
 Pelleting of the cells 
Following counting, the remaining cells in the falcon tube were centrifuged at 
250 x g for 5 minutes, media was aspirated off. The cell pellets were then, either 
resuspended in complete media to obtain a desired concentration of cells per ml, 
or DNA/ RNA was extracted from the cell pellet (sections 2.6.5 and 2.6.6). 
 Treatment of cell lines with 5-aza-2’deoxycitidine 
5-aza-2’deoxycitidne (5-Aza) treatment of the kidney cell lines (RCC11, UMRC3, 
A498, A704, KTCL140 and SKRC45) was conducted by Mr Dean Gentle prior to 
DNA or RNA extraction (sections 2.6.5 and 2.6.6). The DNMT inhibitor 5-aza-
2’deoxycitidne was used to demethylate the genomic DNA of cell lines, 
permitting the analysis of gene expression for selected genes with and without 
methylation.  
In summary, cell lines were grown to 30-50% confluency before starting 
treatment with 5-Aza. Once cell had reached the required confluency complete 
DMEM growth media was supplemented with 5μM 5-Aza (Sigma-Aldrich; Cat. 
No: A3656). The cell lines were then grown in this media for five days, with the 
supplemented growth media being replaced daily. For each cell line, a control 
non-treated cell line was grown simultaneously, in normal un-supplemented 
complete DMEM growth media. 




 DNA extraction 
DNA from cell lines was extraction by Mr Dean Gentle using the Qiagen DNeasy 
Blood and Tissue Kit (Qiagen; Cat #: 69506). Following the manufacturers’ 
instructions for ‘total DNA extraction from animal blood cells’ (all reagents and 
spin columns were supplied within the kit unless otherwise mentioned); cell 
lines were pelleted (see 2.6.3.1) then re-suspended in 200μl PBS, 20μl proteinase 
K (Thermofisher scientific; Cat #: EO0491) and 200μl buffer AL before vortexing. 
The samples were then incubated at 56˚C for 10 minutes, before the addition of 
200μl 100% ethanol. Samples were subsequently transferred to a DNeasy Mini 
spin column and collection tube, and centrifuged at room temperature for 1 
minute at 13,000 x g (centrifuge conditions remain the same for all subsequent 
centrifugation steps unless otherwise specified). The flow-through was 
discarded and 500μl buffer AW1 was added to the spin column. Samples were 
centrifuged again and flow-through was discarded. A fresh 2ml collection tube 
was then attached to the spin column, before the addition of 200μl buffer AW2 to 
the spin column. Samples were then centrifuged at room temperature for 3 
minutes at 13,000 x g and flow-through was once again discarded. The collection 
tube was then replaced with a 1.5ml microcentrifuge tube and DNA was eluted 
from the membrane by the addition of 200μl of buffer AE, applied directly to the 
spin columns membrane. To increase the yield of DNA, samples were incubated 
at room temperature for 3 minutes, before a final centrifugation step at 13,000 x 
g for 1 minute. Extracted DNA was stored at -20°C until required. 
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 RNA extraction  
RNA was extracted from the 5-Aza DNA treated and control (untreated) kidney 
cell lines mentioned above (section 2.6.4) (Extraction was performed by D. 
Gentle).  
In summary, cell pellets were homogenised by incubation for 5 minutes at room 
temperature in 1ml RNABee reagent (AMS Biotechnology; Cat #: CS-105B). 
Following this incubation 200μl chloroform (Sigma-Aldrich; Cat #:  288306) per 1ml 
RNA-Bee reagent was added and samples were shaken vigorously for 15-30 seconds 
before a further incubation on ice of 5 minutes. Samples were subsequently 
centrifuged at 12,000 x g for 5 minutes at 4˚C, this step separated the homogenate into 
3 distinct phases; the lower phase consisting phenol-chloroform, an opaque white 
interphase and an upper colourless aqueous phase.  
The RNA is located in the upper aqueous phase, which was carefully transferred into 
a fresh 1.5ml microcentrifuge tube. To precipitate the RNA, 500μl per1 ml RNA-Bee 
reagent was then added to the sample and mixed, before incubating for 5 – 10 
minutes. Following incubation, samples were at 16,300 x g for 5 minutes at 4˚C, after 
which a visible pellet should be observed. Supernatant was then carefully removed 
and discarded taking care not to dislodge the pellet. The pellet was then subsequently 
washed by the addition of 1ml 75% ethanol, before vortexing and centrifuging at 
7,500 x g for 5 minutes at 4˚C. supernatant was once again removed taking care not to 
dislodge the pellet formed. Samples were then permitted to air dry, before 




 siRNA transfection 
Small interfering RNA (siRNA) is commercially available, and an invaluable tool 
for transient knockdown of gene expression in-vitro.  For siRNA knockdown of 
RASSF10 (see chapter 4), the cell lines SKRC45 and KCTL140 were trypsinised, 
counted and seeded at 6x104 cells per well in 6 well plates and replaced in the 
incubator for 24 hours to settle and re-attach. Following incubation, the media 
was removed and cells were washed with 3ml PBS, the PBS was aspirated before 
the addition of 2.29 ml fresh growing media. A siRNA master mix was created 
containing; 6.25 nM of siRNA either targeted for RASSF10: Hs_LOC644943_6 
FlexiTube siRNA predesigned siRNA directed against human RASSF10 
(NM_001080521, XM_928030; Qiagen; Cat#: SI04229617) or siRNA with no 
target: AllStars Negative Control siRNA (Qiagen: Cat# 1027280), mixed into 
200µl serum-free OPTI-mem media (Gibco: Cat#: 31985-047). 10µl Interferin 
reagent (Polyplus; Cat#: 409-10) was then added to the siRNA/serum-free media 
solution and vortexed thoroughly before centrifuging down. The siRNA master 
mix was then added drop-wise to each well of the 6 well plate containing cells 
and incubated at 37 °C for 72 hours ready for protein isolation or soft agar assay. 
Final siRNA concentration was 2.5 nM per well. Each transfection was performed 
in triplicate. 
 Soft agar assay 
Soft agar assays were employed to assess the ability of a cell line to undergo 
anchorage independent growth, and is deemed a physiologically representative 
study for cancer growth (Borowicz et al., 2014). The assay was conducted in 6 
well plates, with 2 wells per transfection (transfections were repeated in 
triplicate (see section 2.6.4). The main set up, involved suspending cells in a low 
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density 0.35% agar, which is sandwiched between two layers of denser 0.7% 
agar.  
This was achieved by the following protocol: All reagents and utensils were pre-
warmed and stored in 42 °C water bath to prevent solidification until required. 
Firstly, 1.4% (w/v) Noble agar (BD biosciences; Cat #: 214220) was dissolved 
and superheated to sterilise in 100 ml sterile ddH2O before cooling to 42°C. 
DMEM media was made up to the following concentrations required for the two 
agars by the dilution of 10x DMEM (Sigma-Aldrich; Cat#: D2429).  
1x DMEM consisted of 10% 10x DMEM, 10% FBS, 5% of 7.5% Sodium 
bicarbonate (Sigma-Aldrich: Cat #: S5761), 1% Pen/Strep, 1% L-Glut and was 
made to a volume of 50 ml with ddH2O.  
 2x DMEM contained 20% 10 x DMEM, 20% FBS, 10% of 7.5% Sodium 
bicarbonate, 2% Pen/Strep, 2% L-Glut and was made to a volume of 100 ml with 
ddH2O. Mixing differing ratios of DMEM 1x and 2x with the nobel agar created 
the agar solutions (Table 2-10).  
Reagents 
0.7% Agar 0.35% Agar 
Volumes (ml) Final% Volumes (ml) Final% 
1X DMEM - - 20 50 
2X DMEM 75 50 10 25 









Table 2-10: Components and ratios for agars required for soft agar assay  
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To a 6 well plate, 2ml of the 0.75% agar (base layer) was added to each well and 
allowed to set at room temperature. Meanwhile transfected cells were 
trypsinised, counted and re-suspended in growth media to a concentration of 
5x105 ml-1, 100µl of cells (total 50,000 cells/well) was gently mixed with 1 ml 
0.35% agar (slightly cooled) and added to each well on top of the set base agar. 
This was allowed to set before a final 2 ml 0.75% agar (top layer) was added and 
left to set. Plates were incubated at 37 °C in a humidified incubator for 28 days, 
and prevented from drying out by the addition of up to 100µl growth media 
when required. Colonies were counted and imaged under a light microscope 
when ≥30 cells (≥100μm) could be observed.  
2.7 Expression and Protein analysis 
 DNase treatment of RNA 
DNase treatment was performed to ensure all residual DNA was removed from 
an RNA sample before cDNA synthesis (this was particularly important for 
analysis for RASSF10 a single exon gene, where due to the lack of exon:exon 
boundaries genomic DNA is not distinguishable from the RNA or cDNA).10µg 
RNA was gently mixed with 2U DNase1 and 0.1 x volume 10X DNase I Buffer 
(both from Ambion DNAs free Kit; Thermo Fisher Scientific; Cat ♯: AM1906) and 
incubated for 20 minutes at 37 °C. The reaction was inactivated by the addition 
of 0.1 x volume DNase Inactivation Reagent (Ambion DNAs free Kit) and 
incubated for 2 minutes at room temperature with occasional mixing. Samples 
were centrifuged for 5 minutes at 10,000 x g before the supernatant containing 
purified RNA was removed to a fresh tube and stored at -80 °C until required.  
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 cDNA synthesis 
Complementary DNA (cDNA) was synthesised using Superscript III reverse 
transcriptase kit (Life Technologies; Cat ♯: 18080-093). In summary, 1µl 20 ug 
random primers (Promega; Cat ♯: C1181), 1µl 10 mM dNTP and 11µl RNase free 
water was added to 1µg purified RNA, and gently mixed, before incubation at 
65°C for 5 minutes.  Samples were then placed on ice for 1 minute, before the 
addition of 6µl a second master mix, which consisted 4µl 5x First-Strand Buffer, 
1µl 0.1 M DTT, and 1U Superscript III Reverse Transcriptase (200 units/μl) 
bringing the total sample volume to 20µl. Samples were incubated on a PCR 
machine using the following reverse transcription PCR program (RT-PCR): 25°C 
for 5 minutes, 50°C for 60 minutes, before a further incubation step at 70°C for 
15 minutes. cDNA was stored at -20 °C until required.  
 Protein isolation 
To extract protein from cells, growth media was aspirated from cells and cells 
were gently washed with room temperature PBS that was then discarded. For a 6 
well plate, 100µl RIPA lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 0.1%(v/v) 
sodium dodecyl sulphate (SDS) (Sigma-Aldrich; Cat ♯: 71727), 1mM EDTA; 0.5% 
(v/v) Na-deoxycholate, 1% (v/v) Igepal and ‘cOmplete’ protease inhibitor 
cocktail (Roche; Cat #: 04693116001) which contained 15µg/ml Pancrease-
extract, 1.5µg/ml Pronase, 0.8µg/ml Thermolysin, 1.5µg/ml Chymotrypsin, 
0.2µg/ml Trypsin and 1 mg/ml Papain) was added to each well and incubated at 
room temperature for 5 minutes to allow cells to lyse. Cells were scraped with a 
cell scraper (IBR stores; Cat #:  IBR-BC323) and collected into a 1.5 ml tube, 
before being placed on ice for a further 20 minutes. Samples were then 
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centrifuged at 16,300 x g at 4°C for 30 minutes, before carefully transferring the 
supernatant to a fresh 1.5 ml tube and stored at -80 °C until required. 
 Protein quantification 
Protein concentration was measured using DC protein assay (Bio-Rad; Cat ♯:500-
0113) following the manufactures instruction.  
Firstly, a serial dilution in RIPA buffer of a protein standard was prepared from 
stock of 2mg/ml BSA standard (Pierce; Cat ♯: 23209), to achieve the final 
concentrations of 0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 and 1.4µg/μl. Next mixture C was 
created by the addition of 20µl Reagent S per every ml required of reagent A. 
Then to a flat-bottomed 96 well plate, 5µl of sample protein or size standard was 
added (each sample and standard was run in duplicate), followed by 25µl 
mixture C finally 200µl Buffer B was added to each well. Samples were mixed 
gently to avoid generation of bubbles, and incubated for 20 minutes at room 
temperature to allow the development of the colour. The plate was then run on 
Wallac Victor3 fluorometer (Perkin Elmer), which measured the optical density 
at 690 nm wavelength of each sample. A standard curve was generated from the 
absorption recorded for the protein standards (Pearson’s correlation r >0.9). The 
concentration of samples was then calculated using the regression equation 
derived from the standard curve.  
 Western blots 
 SDS-PAGE 
Proteins were separated according to their size, via Sodium dodecyl sulphate 
polyacrylamide gel (SDS-PAGE) electrophoresis. The SDS detergent is vital for 
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denaturing the protein and applying a negative charge to the peptide, thus 
allowing progression through the gel when subjected to an electrical current.  
Acrylamide gels were prepared with using 12% resolution gel (12% (v/v)  
Acrylamide Protogel (30% stock National Diagnostics; Cat ♯: ED-201), 375 mM 
TRIS pH 8, 0.1% (v/v)  SDS and polymerized with 10% (w/v) Ammonium 
persulfate (APS) and 5µl Tetramethylethylenediamine (TEMED; Sigma-Aldrich; 
Cat ♯: T9281). The gel was poured into glass gel plates, locked in a gel stand, up 
to 4/5 full. Water was gently added to the final fifth to ensure all bubbles on top 
of the resolution gel were removed. Once set, water was tipped off and the gel 
dried. A stacking gel (3% (v/v) Acrylamide Protogel, 50 mM TRIS pH 6.8, 0.1% 
(v/v) SDS with 10% (w/v) APS and 5μl (v/v) TEMED) was poured in the final 
fifth of the gel plates on top of the resolution gel and a loading comb mould was 
inserted. 
20µg of sample protein was mixed with 5x loading buffer (0.313 M Tris HCL pH 
6.8, 10% (v/v) SDS, 0.05% (w/v) Bromophenol blue, 50% (v/v) glycerol). 
Samples were denatured at 95 °C for 5 minutes, then snap chilled on ice prior to 
loading into the stacking gel. Gels were inserted into a gel tank, and submerged 
in 1 x SDS running buffer (25mM Tris, 192mM glycine, 0.1% (v/v) SDS, pH 8.3; 
Geneflow; Cat ♯:B9-0032)). Samples were run next to Pageruler Plus Pre-stained 
Protein Ladder (ThermoFisher/ Fermentas; Cat ♯: SM1811FER) at 100 V until 
loading dye had reached the resolution gel, then at 120 V for 60 minutes or until 
loading dye reached the bottom of the resolution gel. 
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 Wet Transfer  
To transfer protein from the acrylamide gel to a polyvinylidene fluoride 
membrane (PVDF; GE Healthcare; Cat ♯: 10600021), a sponge and 3 layers of 
3mm thick Whatman chromatography paper sheets (IBR stores; Cat ♯: IBR-
WHATMAN3) were saturated with transfer buffer (25 mM Tris, 192 mM Glycine 
and 20% MeOH; Geneflow; Cat ♯:B9-0056), before being placed in an open 
transfer cassette. Bubbles were removed by rolling over the top Whatman paper 
with a strippette. The PVDF membrane was cut to the size of the gel and 
activated by submersion in 100% methanol before being placed on top of the 
soaked Whatman paper and sponge with air bubbles carefully removed. Gel 
plates were then gently opened, and the stacking gel was discarded. The 
remaining resolution gel was placed on top of the membrane, and a further 3 
sheets of saturated Whatman paper and another saturated sponge was placed on 
the top of the gel, bubbles were gently removed again and the cassette was 
closed and locked, creating a sandwich of sponge, 3 Whatman papers, 
membrane, Gel, 3 Whatman papers and sponge. Cassettes were place in the 
transfer insert and replaced into a gel tank, filled with transfer buffer and an ice 
block. It was vital to ensure that the cassette was loaded with the gel closest to 
the cathode and the membrane further away. An electrical field was applied at 
100 V for 90 minutes.  
Once the transfer was complete, the membrane was removed and blocked by 
submersion in blocking solution (5% (w/v) milk powder (Marvel form IBR 
stores Cat #: IBR-MARVEL) in PBS with 0.1% (v/v) Tween (Sigma-Aldrich; Cat 
#: P2287) overnight at 4 °C.  
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 Immunodetection  
To visualise/ identify proteins of interest; blocked membranes were first probed 
with an antibody specific for the protein of interest . Primary antibodies were 
diluted to their optimal concentration in 5 ml blocking solution and incubated on 
a roller at room temperature for the optimised time. Rabbit-α-RASSF10 
(previously made in-house as reported by V K Hill et al., 2011) was diluted 
1:1000 and incubated for 4 hours, while mouse-α-Tubulin (house-keeping gene 
to ensure equal loading; Sigma; Cat #: T9026) was diluted 1:20,000 and 
incubated for 1 hour.  
Following incubation membranes were placed in a tray on a shaker and 
thoroughly washed three times in 10 ml PBS with 0.1% Tween, leaving the 
PBS/Tween solution on the membranes for 5 minutes between each wash to 
remove residual unbound antibody.  
Due to the primary antibodies being unconjugated, a secondary antibody step 
was required. Membranes were therefore reincubated with 5 ml blocking 
solution and 1:20,000 dilution of appropriate secondary antibody (α-Rabbit IgG-
HRP (Sigma; Cat ♯: RABHRP2) or α-mouse IgG-HRP (Sigma Cat ♯: RABHRP1) on a 
roller for 1 hour at room temperature. Membranes were then washed thoroughly 
3 times for 10 minute in 10 ml PBS with 0.1% tween on a shaker. In order to 
visualise bound antibodies, membranes were developed using Pierce ECL Plus 
enhanced chemiluminescence (ECL) solution (ThermoFisher; Cat ♯: 32132). ECL 
solutions were mixed 40:1, solution A:B (approximately 1ml total required per 
membrane). Membranes were then placed on saran wrap (IBR stores; Cat ♯: IBR-
SARAN), covered with the complete ECL mixture and left to incubate at room 
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temperature for 5 minutes. Post incubation, membranes were removed from the 
ECL solution, wrapped in fresh saran wrap and placed in a developing cassette. 
Medical X-Ray film (Kodak: Cat ♯: 525 3349) was then exposed to the membrane 
for as long as was required to detect a signal and film was developed using a 
SRX-101A medical film processor (Konica Minolta). A positive signal was 
identified as a black band on the X-ray film and protein size was established by 
comparison to the protein size standard ladder. 
 Quantification of Western blots 
In order to quantify the signal strength of the western blot, and ascertain protein 
abundance, the developed western blot film was imaged and bands were 
digitally quantified using the Gene Tool software (as used to image agarose gels). 
Band intensity was computationally calculated as the intensity of the band minus 
the intensity of the background film. 
 Stripping membrane 
In order to re-blot membranes to detect  housekeeping genes, membranes were 
stripped of all antibodies by boiling for 5 minutes. Membranes then required re-
blocking with blocking solution overnight before incubation with antibodies as 
before (see section 2.7.5.3).  
 Mass spectrometry  
A preliminary mass spectrometry (MS) study of a stable HEK293 cell line 
overexpressing RASSF10-Flag under different cell cycle synchronisation 
conditions was conducted by Dr. David Matallanas and team (Systems Biology 
Ireland, University College Dublin). The cell cycle synchronisation conditions 
investigated were as follows (Rosner et al., 2013):  
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 Control: un-transfected HEK293 included to rule out contaminates  
 Growth: HEK293-RASSF10-Flag under normal growing conditions  
 Noco 1x: HEK293-RASSF10-Flag incubated with 100 ng/ml Nocodazole 
for 21 hours, arresting cell cycle at G2/M phase  
 Thy-1x: HEK293-RASSF10-Flag incubated with 2 mM Thymidine for 21 
hours, blocking cell cycle at G1/S  
 Starved: HEK293-RASSF10-Flag incubated in serum free media for 16 
hours, cells arrested in G0/G1 phase.  
Each condition was repeated in triplicate and run twice on the mass 
spectrometer resulting in 6 datasets for each condition.  
In brief, cells were grown under the appropriate conditions before being lysed as 
described in section 2.7.3. Lysates were then immunoprecipitated (IP) with 
Protein G beads and antibodies specific to Flag. IPs were digested into peptides 
and centrifuged. The supernatant was eluted, alkylated to break di-sulfite bonds 
cleaned and enriched to remove all salts via spin column/tip before loading and 
running on LTQ OrbiTrap Mass Spectrometer (Thermo Scientific). Output files 
were analysed using MaxQuant (Version 1.3) and label free quantification 
intensity (LFQ) was calculated. Raw spectrometry data was exported to 
Microsoft Excel 2011, where the average output for each cell cycle 
synchronisation condition, the ratio between conditions, and the significance 
between conditions were calculated.  
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2.8 Bioinformatic Analysis 
 Human Genome Assembly 
Human genome assembly build Hg19/GRCh37 was used as the reference 
genome for all comparisons, primer designs and UCSC and Ensemble referencing 
throughout this project. 
 The Cancer Genome Atlas (TCGA) and cBioPortal 
The TCGA (Tcga-data.nci.nih.gov, 2015) is a multi-network collaboration funded 
by National Cancer Institute (NCI) and National Human Genome Research 
Institute (NHGRI), with the aim of interrogating the genetic constitutes of 
multiple cancers via multiple high throughput platforms and making the data 
publically available. To date, data from multiple platforms including clinical 
information, DNA methylation, somatic mutations, copy number variant, mRNA 
sequencing and gene expression is publically available for 34 cancer types in 
more than 11,000 samples. DNA methylation data (Level 3 from 
HumanMethylation450) was downloaded for analysis in chapter 3 and chapter 4 
(Downloaded: 02/10/2012). For the study in chapter 3, all 81 pRCC samples 
(Samples ID listed in Table 7-4) available at the time of download and 100 ccRCC 
(Samples ID listed in Table 7-5), (randomly selected via random number 
generator) were downloaded.  For chapter 4, methylation data of 160 ccRCC 
tumours and matched normal was downloaded from the TCGA (Samples ID 
listed in Table 7-6) (Downloaded: 01/03/2013). Summary of the clinical data for 
the TCGA ccRCC and pRCC samples downloaded is displayed in Table 2-11 In 
chapter 5 variants identified by exome sequencing were compared to TCGA data 
using cBioPortal (cbioportal.org, 2015; Gao et al., 2013) . cBioPortal provides a 
user friendly, accessible interpretation of all mutations and copy number 
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alterations compiled from TCGA data and other publications, for each gene 




Table 2-11: Clinical data TCGA  samples used in this study Table summarises the clinical data for the TCGA samples used within this study. The table details tumour type: ccRCC, clear cell RCC and pRCC: papillary RCC patients age at diagnosis, gender of patient (M = male, F = female), the chapter in which the samples were used. Whether the samples were tumours (T) only, or if matched normal (N) were available. If applicable, the grades of the tumour are displayed according to the 2002 UICC staging classification (stage I-IV) and the TNM scoring (see section 1.4.1). Patient survival time in days is also documented. For all cases n.d = no data available. 
T N M Chapter 3 Chapter 4 Chapter 5
ccRCC F = 67M = 132 62.2(29 - 90)
I = 80II = 18III = 58IV = 43
T1a = 55T1b = 27T2 = 25T3a = 52T3b = 29T3c = 1T4 = 8
N0 = 86N1 = 5n.d = 108
M0 = 158M1 = 41
801(18 - 2803)n.d = 117 100 160 -
pRCC F = 25M = 56
60.4(31 - 83)n.d = 3
I = 45II = 3III = 22IV = 8n.d = 3
T1a = 37T1b = 11T2 = 3T3a = 17T3b = 7T4 = 1
N0 = 19N1 = 8N2 = 4n.d = 50
M0 = 47M1 = 4n.d = 30
804(240 - 1556)n.d = 69 80 - -
Histology Gender Average Age(Years) UICC Stage(2002)





 Genomic structural, functional and variant information 
 UCSC Genome browser 
University of California Santa Cruz (UCSC) genome browser (genome-
euro.ucsc.edu) provides publically accessible information on genomic sequence, 
CpG island location , expression, regulatory features, ENCODE functional element 
locations, common SNPs and 450K humanbead methylation probe location. DNA 
sequences used for primer design were downloaded via UCSC DNA view tool.   
 Ensembl 
The Ensembl genome browser (Ensembl.org) is a publically accessible database, 
detailing among other things genomic sequence, exon boundaries, transcripts, 
known genetic variations, SNPs and FASTA sequence for multiple species. Data 
are collected from multiple sources including but not limited to dbSNP, 1000 
genomes project, Exome variant server, COSMIC and individual observations. 
Information regarding minor allele frequency (MAF) and variant prevalence 
across different populations was obtained from Ensembl and used to help 
identify potential variants of interest when analysing WES data (see chapter 5).  
 Genecards 
Genecards (Genecards.org) is an integrative database providing an overview of 
individual gene functions, expression and proteomics compiled from over 100 
sources. Genecards was used to obtain a foundation understanding of a genes 
function and expression levels in the kidney. This information was used to assist 




The Catalogue of Somatic Mutations In Cancer (COSMIC) (Cancer.sanger.ac.uk) 
provided detailed information for a multitude of cancers and genes, including the 
prevalence, distribution and somatic status of mutations identified in tumours. 
Additionally COSIMC also provides information regarding the methylation status 
and expression of genes within cancers although this data is mostly pooled from 
the TCGA datasets. 
 1000 genome project 
The 1000 genomes (1000genomes.org) project was established to generate a 
catalogue of ‘normal’ human genetic variations from different non-diseased 
populations. The aim was to sequence greater than 2,500 genomes at a minimum 
of 4x coverage. To date a total of 2,577 samples have been sequenced and 
published from 5 distinct ancestry groups (East Asian= 523, South Asian= 494, 
African= 691, European= 514, and American=335) with a total of 26 
subpopulations. In particular, for the study in chapter 5, 105 Japanese (Tokyo) 
samples have been screened (57 male and 48 female).  
 Exome variant server (EVS) 
The NHLBI Grand Opportunity Exome Sequencing Project (ESP) Exome variant 
server (EVS) (Evs.gs.washington.edu) was established to generate a database of 
whole exome sequenced European American and African American populations, 
from samples with diverse phenotypes, with the aim of identifying genetic 
variants associated with heart, lung and blood disorders. To date a total of 6503 
samples (2203 African-Americans and 4300 European-Americans) have been 
sequenced and variant frequency has been published for control and diseased 
samples, although individual phenotype data is not publically available.  
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 The Exome Aggregation Consortium (ExAC) 
ExAC is a database of exonic variants compiled from the whole exome sequences 
of over 60,700 unrelated individuals. All sequencing files were processed 
through the same pipeline to ensure consistency in the data.   
(Exac.broadinstitute.org, 2015) 
 Japanese specific databases  
 In Chapter 5, ethnic specific variant analysis was undertaken. Two databases 
were employed to assess the prevalence of specific variants associated with a 
Japanese population.  
1. Japanese Single Nucleotide Polymorphisms (JSNP) (Snp.ims.u-tokyo.ac.jp; 
Hirakawa, 2002). A dataset detailing frequent variations in a Japanese 
cohort. To date 197,195 variations have been characterised, with allele 
frequencies obtained from a pool of 752 unrelated Japanese samples. 
2. Integrated Japanese Project, (Nagasaki et al., 2015; 
Ijgvd.megabank.tohoku.ac.jp, 2015) which provided frequency data for 
over 4,300,000 single nucleotide variants (SNV) from 1070 Japanese 
individuals aged between 20 and 80 years. 
 Data analysis software 
 CpG Viewer 
CpG viewer is an integrated tool used to visualise and analyse the methylation 
status of bisulfite modified DNA after single colony sequencing. Providing the 
user a clear output of the methylation state of each CpG di-nucleotide 
interrogated, by comparing single colony sequencing data to a reference 
sequence (Carr et al., 2007).   
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 Clustering analysis 
Clustering analysis conducted in chapter 3 was achieved via use of Opensource 
Cluster v3.0 (de Hoon et al., 2004). Supervised hierarchical clustering using 
Euclidean distance was performed using Cluster v3.0 on the 450K data. The 
output file was then visualised using  Java tree view Version 1.1.6 (Saldanha, 
2004) .  
 Ingenuity Pathway Analysis (IPA) 
QIAGEN’s Ingenuity Pathway Analysis (IPA)  (ingenuity.com) software was 
employed in Chapter 3 to determine if any of the genes identified to be hyper or 
hypomethylated in specific RCC subtypes were associated with known networks, 
biological processes, functions, interactions, pathways or diseases. 
  String db 
STRING database (Jensen et al., 2009; String-db.org, 2015) is a web based 
resource, which was used in Chapters 4 and 5, to visualise known and predicted 
protein-protein interactions (both physical and functional). Additionally, string 
db generates protein network diagrams, and highlights proteins known to be 
associated with disease and key pathways.  
 Data for Annotation, Visualisation and Integrated Discovery (DAVID) 
DAVID Bioinformatics Resources 6.7 (Huang et al., 2009) was a tool that was 
used in all studies under taken in this thesis. DAVID uses multiple sources to 
group lists of genes according to pathways, known biological functions, or 
protein domains, which the genes have been associated with or encode.  
Permitting the identification of common features and functions from a large gene 
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list. Additionally, DAVID can provide information on diseases and which genes 
from the list have previously been associated.  
 Integrative Genomics Viewer (IGV) 
The Integrative Genomics Viewer (IGV) (Robinson et al., 2011) is a high 
performance tool used for the visualisation and exploration of the large raw BAM 
and BAM.BAI files produced via the whole exome sequencing. IGV displayed all 
reads mapped to the exons exonic regions of the reference genome Hg19 (Figure 
2 1 a), with quality and depth for each base displayed in a quality histogram. 
Deletions and single nucleotide variants were highlighted in the coverage 
histogram (either as a drop in histogram peak height (Deletion) or as two 
colours representing the two possible variants in the recorded proportions). 
Variants were also visible when analysing individual reads, with a deletion 
shown as gap in the read joined by a line, and a SNV identified as an the alternate 
nucleotide marked on the read (2 1 b-d). IGV was used in chapter 5 to assess the 
read depth, read quality and coverage of genes of interest and as a method to 
validate the somatic status of SNVs bioinformatically. By comparing the number 
of reads presenting with the variant to the number of wild type (wt) reads. 
Variants were considered somatic if present in greater than 15% of tumour 
reads and less than 5 %% of normal reads (threshold was set allowing forto rule 
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Figure 2-1: Example of IGV display output. Screen shots of the IGV display. A) Zoomed out view displaying the coverage and read depth of WES mapped to exons (Blue squares in reference genome). B) Example of a somatic deletion of ‘AA’ dinucleotide (represented by grey line and drop in histogram quality) in DERL2 (variant: T=42.2% and N=0% of reads). C) Exonic SNVs are displayed in individual reads and quality histogram (colours denote the proportion of each nucleotide). Two variants are shown for MIK67, a somatic SNV (variant: T=41.4% and N=0% of reads) and a germline SNP (rs4750936 MAF:0.23(T)). D) Somatic SNV in the exonic splice site region (variant: T=36.2% and N=0% of reads), identified in KSR1 in an intronic location with close proximity to the exon boundary. 
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 Mutation surveyor 
Softgenetics Mutation Surveyor DNA variant analysis software (Softgenetics.com, 2015) 
was used in Chapter 5 to analyse Sanger sequencing data produced when screening 
genes for recurrent mutations. Multiple sequencing files can be uploaded and analysed, 
with mutation surveyor producing a report on the sequencing quality and highlighting 
any regions where the sequence deviates from reference for manual inspection. Regions 
of lower sequencing quality were also investigated manually to confirm if a true variant 
could be detected or whether only background noise or sequencing artefact was 
observed. 
 Viewing electropherograms  
Sanger sequencing electropherograms were viewed either by 4Peaks (Nucleobytes.com, 
2015) for Mac, or Chromas (softpedia, 2015) for Windows. 
 Prediction of the functional effects of SNV’s in Chapter 5 
Online bioinformatics tools were utilised to aid the identification of potentially 
pathogenic SNV and splice site variants. The tools described below were employed in 
chapter 5, however it should be noted that the following tools provide a prediction of 
pathogenicity only, therefore tools were used in conjunction with each other to support 
a prediction. 
2.8.4.8.1 Polyphen-2 
Polymorphism Phenotyping v2 (PolyPhen-2)(Adzhubei et al., 2010) is a web based tool 
designed to assess the probability of a missense variant being deleterious. An iterative 
algorithm that compares the mutant amino acid change to the wild type amino acid 
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sequence and assesses a total of 11 criteria (eight sequence based and three structural) 
to predict if an amino acid substitution is detrimental. Scores are given between 0, 
representing a predicted benign substitution, and 1, predicted likely to be damaging.  
2.8.4.8.2 Sorting Tolerant From Intolerant (SIFT) 
SIFT (Kumar et al., 2009) was the second prediction tool used to analyse missense 
variants. Similar to Polyphen-2, SIFT provides predictions as to whether an amino-acid 
substitution would have a deleterious impact. However, SIFT differs from Polyphen in 
the approach undertaken to predict the effect of a variant. By assessing the conservation 
of an amino acid throughout evolution, SIFT predicts whether a variant is predicted 
damaging (with a score of 0) or tolerated (with a score of 1).  
2.8.4.8.3 Splice site variant prediction 
To assess whether variants located within the splice site region were likely to result in 
loss of the splice site, the in-silico prediction tool Berkeley Drosophila Genome Project: 
Splice Site Prediction by Neural Network (Fruitfly.org, 2015) was used. By using the 
NNSPLICE 0.9 version (1997) Fruitfly.org was able to predict, with a 5% false positive 
rate, if a splice site was maintained when a SNV was present. 
 Statistical analysis 
The data and statistical analyses were conducted using the following software Microsoft 
Excel (2011), IBM SPSS v21.0 (2012) and Graphpad Prism v5.0a (2007). Statistical tests 
included student t-test to test for significance between two groups with similar variance, 
Fisher’s exact test (small cohorts) and Chi-squared test (larger cohorts). These were 
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performed using Graphpad Prism and were used to compute significance from a 
contingency table of categorical data. Significance was taken as P<0.05.  
When analysing multiple groups of unequal sample size one-way ANOVA with Game-
Howell post hoc test was used to test for significance. This was performed using SPSS, 
with significance once again set as P<0.05.  
Statistical tests such as the Student t-test possess a 5% false detection rate, therefore to 
rule out genes (chapter 3) or proteins (chapter 4) falsely deemed significant, a false 
detection rate (FDR) correction was applied if more than 20 t-tests were conducted. The 
pre-calculated t-test P-values were ranked from smallest to largest (Rank), and the FDR 
was calculated according to Equation 5: 
=      
Equation 5: FDR formula  Statistical investigation into patient survival was performed in Graphpad Prism using 
Kaplan-Meier survival curves and statistical comparisons assessed via Mantel-Cox test. A 




 DNA methylation profiles of oncocytoma and chromophobe RCC 
3.1 Introduction 
 Techniques to analyse DNA methylation  
The study of DNA methylation can be achieved by several different techniques from 
analysing the DNA methylation of individual genes to the DNA methylation of the whole 
genome.  Some of the most commonly used techniques are described below.  
 Bisulfite modification  
As DNA methylation is not maintained during PCR amplification most investigation 
techniques used to analyse DNA methylation requires the DNA to be permanently 
modified to permit the identification of methylated CpG dinucleotides after PCR 
amplification.  
To overcome this limitation, DNA can be bisulfite modified. A method first described in 
the 1970’s but not generally used until the early 1990’s, bisulfite modification has 
become a foundation technique in analysing DNA methylation (Frommer et al., 1992; 
Hayatsu, 2008). Bisulfite modification involves chemically converting unmethylated 
cytosine residues into uracil, which are subsequently replaced with thymidine during  
PCR amplification. This occurs through the process of sulfonation (the addition of a 
bisulphite group) followed by a deamination step to remove of an amine group. Finally 









Following this conversion of cytosine to uracil, PCR based experiments can be used to 
ascertain DNA methylation status, as all unmethylated cytosine residue will have been 
converted to thymidine while methylated 5-methylcytosine residues remain intact 
(Figure 3-1b)(Activemotif.com, 2015; Hayatsu, 2008). An alternative technique to 
investigate methylation include Methylated DNA immunoprecipitation (MeDIP), where 
antibodies specific to methylated DNA are used to pull down and immunoprecipitate 
DNA which is methylated prior to real time PCR, sequencing and micro array analysis 
(Brena and Plass, 2009;Activemotif.com, 2015; Sims et al., 2014).  
 Methylation Specific PCR (MSP) 
MSP is a sensitive PCR method to determine the methylation status of candidate genes of 
interest. By using two sets of primers, one specific for the methylated DNA sequence (MSP) 
and a second set that specifically amplifies the unmethylated DNA sequence (USP 
unmethylated specific PCR), each sample is investigated twice to obtain the complete picture 
of the methylation status. Successful amplification of a PCR product is indicative of the 
region of interest being methylated (when using MSP primers) or unmethylated (when using 
USP primer) (Herman et al., 1996; Heyn and Esteller, 2012).  
As this technique directly interrogates the methylation status of the DNA to which the primers 
bind, it can offer a more sensitive approach to detecting methylation than CoBRA (see 
3.1.1.3). The specificity this technique provides makes it a very useful tool when 
investigating regions of known high methylation density such as the CpG island of 
RASSF1A (Herman et al., 1996; Heyn and Esteller, 2012).  
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 Combined bisulfite restriction analysis (COBRA) 
CoBRA is another PCR based methylation detection technique, first reported by Xiong 
and Laird, 1997 that is now frequently used.  CoBRA is an effective, rapid and simple PCR 
based method to analyse the DNA methylation status of regions of interest. Compared to 
MSP, CoBRA is a more quantitative test, providing an in insight into the overall level of 
methylation at a region of interest, a feature that is partially useful for investigating novel 
regions where the DNA methylation state is uncharacterised (Heyn and Esteller, 2012; Xiong 
and Laird, 1997)Bisulfite DNA is PCR amplified using primers that are designed to omit 
bias for methylated or unmethylated DNA, by containing a 50:50 T/C split for each 
possible methylated cytosine residue. Following amplification, DNA is then digested 
using enzymes such as BstUI, which recognises and cleaves 5’-CG|CG-3’, or Taqα1 which 
specifically cleaves 5’-TC|GA-3’. If DNA is unmethylated these sites are lost during the 
bisulfite modification becoming 5’-TGTG-3’ or 5’-TTGA-3’ respectively. Digested PCR 
products are run on a gel next to undigested PCR product. A positive result for 
methylation results in multiple bands being visible in the digested column.  
 Quantitative methylation techniques 
The above techniques identify if DNA methylation is present, however, the accuracy at 
which they are able to quantify the level of DNA methylation, is limited. The 
development of quantitative methylation techniques such as Methylight (discussed in 
section 4.1.1), quantitative MSP (which uses a fluorescent probe to quantify DNA 
amplification in real time, Brena and Plass, 2009; Trinh et al., 2001), DNA methylation 
arrays (discussed below 3.1.2) and bisulfite modified DNA sequencing, have since 
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addressed this limitation. Methylight and quantitative MSP are both PCR based methods 
that can provided quantitative information into the overall level of DNA methylation for 
a region of interest. But do not provided information as to the status of DNA methylation 
for each individual CpG locus within that region, unlike DNA methylation arrays or 
bisulfite modified DNA sequencing (Brena and Plass, 2009; Trinh et al., 2001).   
DNA sequencing of bisulfite modified DNA can be conducted by candidate gene Sanger 
sequencing, pyrosequencing or via sequencing the whole genome on a next generation 
sequencing platform, a technique known as whole genome bisulfite sequencing (WGBS) 
(Li and Tollefsbol, 2011). All of these techniques provided information about the 
methylation status of each individual CpG locus within the genome or region of interest 
investigated (Brena and Plass, 2009; Li and Tollefsbol, 2011) . Pyrosequencing is a 
sequence by synthesis technique conducted on bisulfite modified DNA, which records 
and measures the fluorescence emitted as of specific biotinylated nucleotides are 
incorporated into the newly synthesised DNA strand. As these biotinylated nucleotides 
are incorporated into the DNA, fluorescence is generated by a luciferase based enzyme 
cascade, and quantified. By releasing the biotinylated nucleotides into the sequencing 
reaction in a predetermined order, researchers are able to identify the sequence of the 
bisulfite modified DNA and therefore determine the proportion of C or T dinucleotides at 
a given CpG locus, thus providing a quantitative assessment of the methylation status of 
individual CpG locus (Brena and Plass, 2009; Tost and Gut, 2007). Within this study 
however DNA methylation was assessed using the latest quantitative DNA methylation 
Array (section 3.1.2) 
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 DNA Methylation Arrays 
DNA methylation arrays provide another method to quantitatively analyse the DNA 
methylation status of individual CpG dinucleotides, in a high-throughput and cost-
effective manner. DNA methylation arrays were originally adapted from SNP arrays, to 
identify DNA methylation in bisulfite modified DNA (section 3.1.2.1).  Since their 
development, they have become an increasingly popular tool for assessing global 
methylation (Goldengate BeadChip array 2006, Bibikova et al., 2006)). 
The Illumina Goldengate assay was the first array platform released to investigate DNA 
methylation. It contained 1,536 CpG probes (Figure 3-2) that mapped to 807 cancer 
associated genes. A total of 71.4% (577) of the cancer associated genes investigated by 
the Illumina Goldengate assay had their DNA methylation status determined 2 or more 
probes on the array (Bibikova et al., 2006; Illumina, 2006). The Goldengate array has 
revolutionised the study, and our understanding of DNA methylation. Permitting the 
identification of distinct patterns of hypermethylation when comparing between 
different tumour types, including the identification of possible CIMP+ phenotypes 
(McRonald et al., 2009; Wolff et al., 2010), and identifying associations between the 
prevalence of DNA hypermethylation and the invasiveness of tumours. As was reported 
by Wolff et al when comparing the DNA methylation profiles of different types of 











































Additionally, the Goldengate array permitted the identification of differentially 
methylated genes in different tumour types. For example a study in to pRCC and ccRCC 
methylation identified HOXA11 and HOXC6 to be preferentially methylated in pRCC when 
compared to ccRCC (McRonald et al., 2009). Another study coupling the Goldengate 
array with expression data, aimed to identify novel methylated genes that may 
contribute to tumourigenesis (Ricketts et al., 2013).  
The next stage in methylation array evolution was the release of the Infinium 
HumanMethylation 27 BeadChip (27K array), which interrogates the methylation status 
of 27,578 CpG loci (Figure 3-2) across 14,495 genes (Weisenberger et al., 2008). This 
array provided researchers with a greater breadth of information as to the DNA 
methylation status of the epigenome with studies identifying frequent methylation of 
novel genes not previously associated with cancer, such as OVOL1 (methylated in 40% 
ccRCC samples) and SST (methylated in 31% ccRCC samples) in ccRCC (Ricketts et al., 
2012). Other studies using this array have identified differentially methylated genes 
associated with clinical features, prognosis and survival. For example a study by Hill et al 
into DNA methylation of breast cancer identified 6 notable genes (RECK, SFRP2, UAP1L1, 
ACADL, ITR, and UGT3A1) to significantly reduce patient survival time when methylated 
(Hill et al., 2011). With further studies having identified novel frequently methylated 
genes that may be used as biomarkers to distinguish between oestrogen receptor (ER) 
positive (21 methylated genes) and ER negative (6 methylated genes) breast cancer 
subtypes (Fackler et al., 2011). 
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 Infinium HumanMethylation450 BeadChip 
The latest DNA methylation array, the Infinium HumanMethylation450 BeadChip (450K 
array), provides even greater genome coverage, interrogating the methylation status of 
482,421 CpG loci (Figure 3-2). This means that the methylation status of >99% of Refseq 
genes and 96% of CpG islands (CGIs) is investigated by one array (Bibikova et al., 2011; 
Illumina, 2012). Of the probes incorporated in the array >99.3% are targeted for CpG 
dinucleotides (Sandoval et al., 2011).  
The principle behind the 450K array is similar to the Goldengate array the 27K array. All 
three platforms identify C to T bisulfite conversion through quantitative genotyping by 
utilising an adapted SNP detection system. For the Goldengate and the 27K arrays this 
was achieved through the sole use of the Infinium I probe (Bibikova et al., 2006; 
Illumina, 2006; Weisenberger et al., 2008). For the 450K array however, two probe 
technologies are used; Infinium I and Infinium II. Infinium I probes account for 51.7% of 
the probes which map to CpG islands and only 15.9% of the probes which map to regions 
not associated to a CGI (>2000bp from CGI) (Dedeurwaerder et al., 2011). 
The two probes differ in the method by which methylation is detected (Figure 3-3); 
Infinium I probes (Figure 3-3a) require two beads for each CpG locus integrated. One 
bead specific for the methylated CpG locus and the second specific for the unmethylated 
CpG locus. If the sample sequence is complimentary to the probe’s methylation status for 
a CpG locus (‘CA’ unmethylated probe sequence, ‘CG’ methylated probe sequence), single 
base extension can occur and the incorporation the fluorescently labelled nucleotide is 











At sequences not complimentary to the probes methylation status for the interrogated 
the CpG locus, no extension is observed and thus no fluorescent detected allowing 
identification of the methylation state of that particular locus (Bibikova et al., 2011; 
Illumina, 2012).   
The Infinium II probe technology, (Figure 3-3b) uses only 1 bead containing probes 
specific for either the methylated sequence or the unmethylated sequence and 
interrogates the actual ‘C’ base in question of the CpG locus rather than the base just 
after. To differentiate between the methylated and unmethylated sequences the Infinium 
II technique relies on the detection and differentiation of the colour of the fluorescence 
emitted when the fluorescent nucleotides are incorporated (red=A or T and green=C or 
G nucleotide) (Bibikova et al., 2011; Illumina, 2012). The quantity of methylation at a 
CpG locus is displayed as a β-value. β-values are calculated by comparing the 
fluorescence recorded for methylation specific probes to that of unmethylated probes 
(section 2.3.3).  
The incorporation of two different techniques within one array, has not been without 
controversy, with studies showing variation in the range of β-values recorded, with 
Infinium II being less sensitive at detecting extreme methylation values (β-values close 
to 0 and 1) (Dedeurwaerder et al., 2011). Thus it is now widely accepted that 
normalisation of the two probe types should be conducted prior to analysis.  
The distribution of the 450K arrays CpG probes throughout the genome has been 
characterised and defined according to their location in relation to Refseq genes and CpG 





Figure 3-4: Distribution of the Infinium HumanMethylation450 BeadChip CpG loci 
Schematic diagram showing the prevalence and distribution of the CpG loci investigated by the Infinium HumanMethylation450 BeadChip array. CpG loci (white circles) are shown in relation to; A) CpG islands and B) Refseq genes. Abbreviations N: North S: South TSS: transcriptions start site, UTR: untranslated region. Image adapted from Bibikova et al., 2011 
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 30.9% of 450K CpG probes map to the CpG islands (CG content >50%), 23% map to CpG 
shores (CG rich regions less dense than CGI, located less than 2kb up or down stream of 
the CGI), 9.7% map to CpG Shelves (less dense CG content than the shores and around 
4kb up or downstream of the CGI) and 36.3% probes identified to reside in isolated CG 
dinucleotides referred to as ‘open seas’ (Bibikova et al., 2011; Sandoval et al., 2011). 
When mapped to Refseq genes, 74.4% of the total 450K CpG probes were associated 
with coding genes and classical mRNAs, 0.85% of total 450K probes were mapped to 
non-coding RNA (microRNA and long non coding RNA) and 24.6% of probes did not map 
to known transcripts, thus were defined as intergenic regions (Dedeurwaerder et al., 
2011; Sandoval et al., 2011).  
Additionally, probes were further characterised depending on where in a gene the CpG 
loci were located (Figure 3-4b); 41.3% of all CpG probes were identified to be located in 
the promoter region of genes (this was defined as all probes located within 1500bp of 
the Transcription start site (TSS) TSS1500, 200bp upstream of TSS (TSS200) 5’ 
untranslated region (5’ UTR) and the 1st exon), 3.16% of probes mapped to 3’UTR, 
30.9% to the gene body (intronic regions and exons except 1st exon) and as previously 
mentioned, 24.6% mapped to intragenic regions (Dedeurwaerder et al., 2011; Sandoval 
et al., 2011). 
The depth of information provided by the 450K array has led to a plethora of findings 
and studies. It is the predominant technology used by the TCGA consortium to analyse 
genomic methylation profiles of different cancers and has lead to the ability to compare 
across arrays, particularly with expression data. Promoting the identification of 
frequently hypermethylated genes which have been shown to inversely correlate with 
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gene expression, and elude to a particular methylation signatures which inhibits gene 
expression (Davis et al., 2014; TCGA, 2016, 2014, 2013, 2008). The 450K array has since 
been used to identify patterns of methylation and methylated genes in a plethora of 
different cancers. Some examples of which include HER2+ breast cancer (Lindqvist et al., 
2014) and cervical cancer (Lando et al., 2015). In addition to studies attempting to 
differentiate between tumours subtypes such as recurrent and non-recurrent chordoma 
tumours (Alholle et al., 2015), or different breast cancer subtypes  (Stefansson et al., 
2015) based on the DNA methylation patterns. Other studies have associated DNA 
methylation with pharmaceutical response, for example a study by Trabelsi et al, 
identified that methylation of MGMT in glioblastoma improves drug efficiency in 
chemotherapy, by making the tumour more sensitive to the drug (Trabelsi et al., 2015). 
Not all studies using the 450K array focus on cancer, with studies using the array to 
characterise variation within a population and to assess environmental effects on DNA 
methylation profiles (Argos, 2015; Busche et al., 2015; Heyn et al., 2013). 
 Study’s Aim 
As described in section 1.4.2.1.3 onwards, the malignant chRCC and the benign renal 
oncocytoma account for 3-5% and 5% of renal neoplasms respectively (Lopez-Beltran et 
al., 2010). However, these two subtypes are both histologically and visually (when 
imaged by medical imaging techniques) similar making diagnosis of the subtypes 
challenging even for experts (Baert and Sartor, 2006; Millet et al., 2011; Stec et al., 2009; 
Vera-Badillo et al., 2012).  Although cytogenetic and immunohistological differences 
have been reported in chRCC and oncocytomas the use of these features to aid diagnosis 
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lacks reliability and specificity (Ng et al., 2014; Yusenko, 2010), leaving histological 
interpretation of renal biopsies and medical imaging the current approved method of 
diagnosis (Ng et al., 2014). 
Despite the similar histologies and appearances, these two RCC subtypes have different 
patterns of progression (with chRCC being malignant and oncocytoma being benign) and 
therefore have different courses of treatment. chRCC is predominantly treated via 
surgery (Vera-Badillo et al., 2012), while the course of treatment for oncocytoma is 
usually one of surveillance with surgical intervention as a lest resort if the tumour 
become symptomatic (Neuzillet et al., 2005). As a result, correct diagnosis and 
identification of the RCC subtype is vital for efficient and effective treatment. Further 
investigations into potential distinguishing features could provide the key to reliably 
differentiating these two subtypes. One such feature could be DNA methylation; having 
been previously been proposed as a potential biomarker to identify cancer type, 
prognosis and drug sensitivity in several other cancers (section 1.3.4), (Exner et al., 
2015; Heyn and Esteller, 2012; Trabelsi et al., 2015).  
Though studies have previously been conducted to assess and compare the methylation 
profiles of different RCC subtypes including chRCC and oncocytoma, these have 
predominantly focused on identifying and comparing the methylation status of 
candidate cancer associated genes, previously reported to be methylated in RCC or other 
cancers, such as VHL, RASSF1A, FHIT and MGMT (Costa et al., 2007; Dulaimi et al., 2004; 
Maher, 2013; Morris et al., 2010). However, of the genes investigated no differential 
methylation was reported for chRCC and oncocytoma, this observation was attributed to 
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chRCC and oncocytoma possessing similar histology’s and deriving from the same cell 
type (Costa et al., 2007; Dulaimi et al., 2004).  
Other studies focusing on the analysis and characterisation of genome wide methylation 
profiles of RCC have primarily focused upon ccRCC (Lasseigne et al., 2014; Liu et al., 
2014; McRonald et al., 2009; Morris et al., 2011; Ricketts et al., 2014, 2013, 2012). 
Although the analysis had yet to be published by the onset of our study, the TCGA 
consortium had also begun screening the methylation profiles of chRCC (TCGA, 2013) 
and pRCC (TCGA, 2016) with the aim of profiling the genetic, methylation and expression 
profiles of the two RCC subtypes. At the time of formulating the aims for this study 
(September 2011) only one report had been published investigating the global DNA 
methylation profile of chRCC and renal oncocytoma. Here it was observed that although 
the DNA methylation profile was mostly similar between the two histologies, small 
regions of variation were identified. However, this study was conducted using BACS 
clones and the results where not related to genes which my be deregulated (Arai et al., 
2011).  The limited studies conducted into the methylation profiles of chRCC and renal 
oncocytoma mean that the DNA methylation profile of the two histologies is poorly 
understood. We therefore propose (see objective 1 (section 1.7)): 
 To investigate and characterise the global DNA methylation patterns of chRCC 
and renal oncocytoma using the high throughput Illumina Infinium 
HumanMethylation450 BeadChip array.  
 Identify differential patterns of methylation and methylated genes that may 




 Compare our findings with the methylation data available from the TCGA in order 
to identify methylated genes or patterns unique to chRCC or oncocytoma.  
3.2 Results 
 Global methylation analysis of oncocytoma and chromophobe RCC 
The following work was published in Epigenetics, March 2013 (Slater et al., 2013). 
  Infinium HumanMethylation 450 BeadChip 
A total of 4 non-diseased normal kidney samples, 21 oncocytoma (1 sample run in 
duplicate) and 20 chRCC (Table 2-1) were outsourced for bisulfite modification and 
analysis on the Infinium HumanMethylation 450 BeadChip (as described in section 
2.3.3).  
 Validation of the array 
At the time of this study, the 450K array was a relatively novel assay with previous 
genome wide methylation studies being conducted on the 27K array (Arai et al., 2012; 
Ricketts et al., 2013). Initial validation of the array focused on confirming the 
reproducibility and reliability of the data. To investigate this, one oncocytoma was sent 
in duplicate to be run on the 450K array. The correlation between the two replicates was 
determined, by comparing the β value recorded for all CpG loci between the two 
replicates and statistically tested. Pearson’s correlation coefficient identified a strong 






Figure 3-5: Validation of the reproducibility of the 450K array To validate that the 450k is a reliable and reproducible array, one oncocytoma was run on the array in duplicate. β-values for all CpG loci were plotted for each replicate and the correlation was calculated by Pearson’s correlation coefficient giving the values r=0.997. This is indicative of high level of correlation between the two run thus confirming the arrays reproducibility.   
r =0.997 



















To confirm the quality of the data and to ascertain how the β value actually corresponds 
to the level of DNA methylation present, single colony sequencing of bisulfite modified 
DNA (section 2.3.4) for three candidate genes (BNC1, FOXL1 and OVOL1), previously 
identified to be frequently methylated in ccRCC (Ricketts et al., 2012) was conducted. 
For each CpG locus within the sequenced region, that was interrogated by the 450K 
array, the methylation index (MI) (the percentage of methylated CpGs identified by 
single colony sequencing) was calculated and compared to the β value obtained form the 
450K array (Figure 3-6 to Figure 3-8).  Of the loci investigated, we identified that when 
the β value was >0.5, the methylation index for the same CpG dinucleotide was >50% 
indicating the presence of methylation, while low β values of <0.25 typically 
corresponded to a MI for the same dinucleotide of <0.25. For this study, a β value of >0.5 
was considered indicative of the presence of methylation at a given locus. This threshold 
is consistent with the 450K validation reports (Dedeurwaerder et al., 2011; Illumina, 





Figure 3-6: Validation of the 450K array: BNC1 Validation of β values by bisulfite single colony sequencing of BNC1 (previously reported as frequently methylated in ccRCC (Ricketts et al., 2012)). Encompassing CpG loci cg02713760 (south shore), cg07016258, cg06523224, cg17124224, cg26654798 and cg26429925, located in the TSS1500. Five of the CpG loci investigated resided within the BNC1 CpG Island. Eight samples (4 chRCC and 4 oncocytoma) with a range of β values for the aforementioned CpG loci were selected. Hypermethylated loci (β value > 0.5) presented with a high methylation index (MI > 50%), while low β value loci correlated with a low MI.  Diagram shows schematic for part of the gene (blue) and CpG island (green) with region interrogated by bisulfite sequencing marked by the dotted line. CpG loci are represented by the red marks on gene schematic and red arrows on the bisulfite clone sequencing readout. Bisulfite sequencing rows represent individual alleles, with each circle indicating location and methylation state of a CpG locus (black circle: methylated; white circle: unmethylated). Ch denotes chromophobe samples, Oc oncocytoma samples and MI the methylation index. 
CpG island:188 
Oncocytoma Chromophobe 
450K Probes:  cg02713760| cg07016258| cg06523224 cg17124224| cg26654798| cg26429925 
BNC1: NM_001717  
β value: 0.46/ 0.49/ 0.82/ 0.78/ 0.65/ 0.29 
MI: 50%/ 50%/ 100%/ 100%/ 80%/ 20% 
β value: 0.23/ 0.58/ 0.42/ 0.29/ 0.52/ 0.57 
MI: 10%/ 80%/ 80%/ 40%/ 100%/ 90% 
β value: 0.47/ 0.17/ 0.16/ 0.07/ 0.15/ 0.12 
MI: 55.5%/ 22.2%/ 0%/ 11.1%/ 11.1%/ 0% 
β value: 0.24/ 0.25/ 0.24/ 0.08/ 0.23/ 0.12 
MI: 14.3%/ 0%/ 42.8%/ 14.3%/ 14.3%/ 0% 
β value: 0.75/ 0.87/ 0.9/ 0.82/ 0.86/ 0.77 
MI: 100%/ 100%/ 100% 100%/ 90%/ 100% 
β value: 0.64/ 0.5/ 0.82/ 0.62/ 0.54/ 0.4 
MI: 80%/ 100%/ 80%/ 60%/ 50%/ 50% 
β value: 0.26/ 0.49/ 0.29/ 0.05/ 0.39/ 0.17 
MI: 12.5%/ 62.5%/ 37.5%/ 0%/ 25%/ 0% 
β value: 0.23/ 0.2/ 0.05/ 0.03/ 0.1/ 0.27 









Figure 3-7: Validation of the 450K array: FOXI1 Validation of β values using bisulfite single colony sequencing of FOXI1 (previously reported as frequently methylated in ccRCC (Ricketts et al., 2012)). Encompassing CpG loci cg00624737 and cg07748217 located within the 3’UTR and the CpG island. Eight samples (4chRCC and 4 oncocytoma) with a range of β values for the aforementioned CpG loci were selected. Hypermethylated loci (β value > 0.5) presented with a high methylation index (MI > 50%), while low β value loci correlated with a low MI.  Diagram shows schematic of the gene (blue) and CpG island (green) with region interrogated by bisulfite sequencing marked by the dotted line. CpG loci are represented by the red marks on gene schematic and red arrows on the bisulfite clone sequencing readout. Bisulfite sequencing rows represent individual alleles, with each circle indicating location and methylation state of a CpG locus (black circle: methylated; white circle: unmethylated). Ch denotes chromophobe samples, Oc oncocytoma samples and MI the methylation index  
β value: 0.19/ 0.25 
MI: 11.1%/ 22.2% 
β value: 0.32/ 0.28  MI: 16.6%/ 16.6%  
Oncocytoma 
β value: 0.55/ 0.76 
MI: 44.4% 88.9% 
β value: 0.53/ 0.82 MI: 40%/ 87.5% 
β value: 0.88/ 0.87 
MI: 87.5%/ 100% 
β value: 0.56/ 0.83 
MI: 57.1%/ 85.7% 
β value: 0.2/ 0.19 
MI: 0%/ 0% 
β value: 0.19/ 0.24 
MI: 0%/ 16% 
Chromophobe 
CpG island:154 
FOXL1: NM_005250  









Figure 3-8: Validation of the 450K array: OVOL1 Validation of β values using bisulfite clone sequencing of OVOL1 (previously reported as frequently methylated in ccRCC (Ricketts et al., 2012)). Encompassing CpG loci cg11569703 located within the gene body and the south shore. Eight samples (4chRCC and 4 oncocytoma) with a range of β values for the aforementioned CpG loci were selected.. Hypermethylated loci (β value > 0.5) presented with a high methylation index (MI > 50%), while low β value loci correlated with a low MI.  Diagram shows schematic of the gene (blue) and CpG island (green) with region interrogated by bisulfite sequencing marked by the dotted line. CpG loci are represented by the red marks on gene schematic and red arrows on the bisulfite clone sequencing readout. Bisulfite sequencing rows represent individual alleles, with each circle indicating location and methylation state of a CpG locus (black circle: methylated; white circle: unmethylated). Ch denotes chromophobe samples, Oc oncocytoma samples and MI the methylation index   
CpG island:204 
Oncocytoma Chromophobe 
450K Probe: cg11569703 
OVOL1: NM_004561  
β value: 0.48 
MI: 50% MI: 57.1% 
β value: 0.61 
β value: 0.23 
MI: 16.6% 
β value: 0.39 
MI: 40% 
β value: 0.85 
MI: 100% 
β value: 0.77 
MI: 100% 
β value: 0.16 
MI: 0% 








 Identification of aberrant cancer specific methylation  
The 450K produces a large comprehensive dataset detailing the genome wide 
methylation profile for multiple samples. However, to identify cancer specific 
methylation, bioinformatic analysis was undertaken to remove technical and biological 
bias and generate a workable dataset. Raw data was supplied as .txt file detailing probe 
information, average β value and detection P value for each probe and sample. The 
pipeline we employed to filter the data is visualised in Figure 3-9. The first step was to 
assess the reliability of each probe, this was determined by analysis of the detection P-
value. The detection P value was calculated by comparing the intensity recorded for each 
probe to an internal negative control. Multiple factors can affect the detection P value 
such as weak hybridisation of the DNA sample to the probe, low read intensity, and 
mutations within the DNA samples (Dedeurwaerder et al., 2011). Probes that did not 
comply with the reliability criteria, defined as a detection P value of <0.01 (Infinium, 
2012; Sandoval et al., 2011) in all samples were omitted, 5607 probes were removed at 
this step.  
The next stage was to omit gender bias, as epigenetic X- chromosome inactivation within 
females and single X chromosomes in males, can skew the methylation profile (Chen et 
al., 2013).  This was achieved by the removal of all probes located on the X or Y 




Figure 3-9: Flow chart depicting the steps undertaken to process 450K data   
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This was followed by the removal of all probes located over known SNPs and known 
imprinted genes, which may also skew and misrepresent the methylation profile (Chen 
et al., 2013). A total of 91561 such probes were removed. 
Following removal of probes associated with SNPs or imprinted genes, the data 
processing diverged depending upon whether cancer specific hyper- or hypomethylation 
was to be identified.  
3.2.1.3.1 Cancer specific hypermethylation 
As previously described hypermethylation was defined as a β value of >0.5, however to 
identify cancer specific hypermethylation, the difference in β values between tumour 
samples and normal kidney samples should be at least a 2 fold. Therefore, any probe that 
presented with a β value >0.25 in any of the 4 normal kidney samples was omitted. This 
resulted in the removal of 238222 probes. The remaining probes were then utilised for 
further analysis into cancer specific hypermethylation (β value >0.5). The criteria of 
removing probes in which the normal samples β value of >0.25 was originally utilised in 
several HumanMethylation 27 Beadchip assay as the defining point between methylated 
and unmethylated loci (Hill et al., 2011; Morris et al., 2011). 
3.2.1.3.1 Cancer specific hypomethylation 
In order to study cancer specific hypomethylation, the opposite criteria was applied. Any 
probe presenting with a β value <0.5 in any on the 4 normal kidney samples was 
removed. A total of 197570 probes were removed. All remaining probes were then ready 
to be analysed for cancer specific hypomethylation. To conform with the 2 fold criteria 
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applied for hypermethylated probes (section 3.2.1.3.1) hypomethylation was 
determined to be any probe with a β value <0.25 within the cancer samples.  
 Global methylation profile 
3.2.1.4.1 Overview of methylation 
To ascertain the methylation profile of the oncocytoma and chRCC samples compared to 
the frequently studied pRCC and ccRCC histologies, we first identified the number of 
cancer specific probes presenting with hypermethylation >0.5 or hypomethylation <0.25 
in at least one sample between the 4 histologies. A small randomly selected cohort of 30 
papillary and 30 ccRCC were downloaded from the TCGA (sample IDs listed in Table 7-4 
and Table 7-5) for this mini study. The number of probes with at least one sample 
meeting our criteria for hyper or hypomethylation were counted (Figure 3-10). It was 
observed that the more malignant tumours pRCC and ccRCC, presented with a higher 
proportion of hypermethylated probes (83.87% pRCC; 81.38% ccRCC cancer specific 
probes) than hypomethylated probes (16.13% pRCC; 18.62% ccRCC cancer specific 
probes). When analysing our chRCC and oncocytoma data, the reverse trend was 
observed with hypomethylated probes (71.64% chRCC; 81.40% oncocytoma cancer 
specific probes) being more prevalent that hypermethylated probes (28.36% chRCC; 





Figure 3-10: Cancer specific methylation profile for RCC subtypes Methylation profiles were characterised as all cancer specific probes presenting with either hypermethylated (β value >0.5) or hypermethylated (β value <0.25) in at least 1 sample.  Cancer specific hypomethylation was observed to be more prevalent in the less aggressive subtypes of RCC investigated, chRCC (71.64% of chRCC cancer specific methylated probes were hypomethylated) and the benign renal oncocytoma (81.40% of oncocytoma cancer specific methylated probes were hypomethylated). Cancer specific hypermethylation on the other hand was observed to be more prevalent in the more malignant RCC subtypes pRCC (83.87% of cancer specific methylated probes were hypermethylated) or ccRCC  (81.38% of ccRCC cancer specific methylated probes were hypermethylated). Chromophobe (chRCC) n=20 and Oncocytoma (Onco) n=21 were our samples, while papillary (pRCC) n=30 and clear cell (ccRCC) n=30 were randomly selected and downloaded from the TCGA. 
   



































3.2.1.4.2 Clustering analysis 
To analyse the overall methylation profile of the chRCC and oncocytomas subtypes, we 
conducted, supervised hierarchical clustering using Euclidean distance complete linkage 
for the 500 most variable (probes with the greatest standard deviation between 
samples) cancer specific hypermethylated loci (Figure 3-11a) and hypomethylated loci 
(Figure 3-11b) was conducted. 
Within the hypermethylation cluster (Figure 3-11a), two major cluster groups were 
identified. Cluster I was the largest cluster (n=34) and contained samples associated 
with lower levels or an absence of methylation. Within this cluster, a further 3 sub-
clusters were identified, in which samples appeared to further segregate into clusters of 
the same histology. For example, Cluster I-I presented with a total of 9 samples; 
predominantly oncocytoma (7:2 oncocytoma: chRCC). Cluster I-II presented with 8 
samples, all of which were oncocytoma, while Cluster I-III presented with 16 samples, 
predominantly chRCC; subdivided into 6:10 oncocytoma: chRCC, with 1 chRCC sample 
not falling into any of the three sub-clusters. The second major cluster (II) consisted of a 
total of 7 chRCC samples, 6 of which were sub-clustered and one sample excluded from 
the cluster, which presented with the highest levels of widespread methylation, 
reminiscent of a CIMP. 
For the clustering analysis of hypomethylated probes (Figure 3-11b), segregation into 
the two distinct histologies was once again observed, with a total of 3 major clusters 
identified. Cluster I contained samples with the lowest methylation levels, and consisted 




Figure 3-11: Supervised hierarchical clustering using Euclidean distance with complete linkage 
Clustering of the 500 most variable cancer-specific hypermethylated (A) and hypomethylated (B) loci. Clusters are denoted below the heatmap.  Low β values (0) are represented as green and high β values (1) are red. Sample information is displayed below the cluster tree with chromophobe (orange) and oncocytoma (blue). Gender: female (black) and male (grey), and patient age 30–49 y (light purple); 50–69 y, (mid purple); 70–89 y, (dark purple). Crosses denote missing data. 
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 included in either sub-cluster.  The second and third clusters showed less 
hypomethylated probes than cluster I and predominantly contained chRCC samples with 
Cluster II containing 2 oncocytoma and 15 chRCC. The final cluster, Cluster 3 identified 
samples with the least hypomethylated probes, and contained 5 oncocytoma samples 
and 4 chRCC samples.  
Both cluster analysis criteria undertaken showed no segregation or clustering within the 
clinical data available (age or gender) (Table 2-1). Furthermore, from this clustering 
analysis it was identified that the methylation profiles of renal oncocytoma and chRCC 
are distinct and can be separated, with chRCC presenting with more hypermethylated 
probes, while oncocytomas showed a pattern for more hypomethylated probes.  
3.2.1.4.3 Frequent methylation profile  
Within this study, frequent differential methylation was determined as all cancer specific 
probes presenting with either hyper- or hypomethylated in >30% of samples for each 
RCC histology, when compared to the normal kidney. This criteria identified the global 
differential methylation profile for frequently aberrant methylation (hyper and hypo) for 
each histology, compared to normal kidney DNA . 1.2% (4,439) loci were identified that 
met this criteria for chRCC samples while for oncocytoma, the frequency was lower, with 
0.6% (2,383) of loci identified (Figure 3-12a). Within the frequently differential 
methylated cancer specific probes identified for chRCC, 416 probes were frequently 
hypermethylated (Table 7-7) and 4023 probes were frequently hypomethylated in 
chRCC . For oncocytoma 125 probes were frequently hypermethylated (Table 7-8) and 




Figure 3-12: Methylation profile of chRCC and oncocytoma A) The global methylation profile of differentially methylated cancer specific probes in relation to normal kidney. Defined as probes that are either frequently hypermethylated (β value >0.5) or hypomethylated β value (β value <0.25) in >30% of samples. 1.2% of all probes were identified to be frequently differentially methylated cancer specific loci for chRCC and 0.6% of probes for oncocytoma. B) Breakdown of differentially methylated cancer specific probes, showing the proportions that were identified as hypermethylated (9.4% chRCC and 5.2% oncocytoma) and those that were hypomethylated (90.6% chRCC and 94.7% oncocytoma)   
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The total frequent cancer specific hyper- or hypomethylated probes was identified to 
only account for a small proportion of all CpG probes interrogated. A total of 1.2% of CpG 
probes were identified as frequently methylated and cancer specific (combined hyper 
and hypo) in chRCC samples while for in oncocytomas only 0.6% of probes were 
identified as frequently methylated and cancer specific (combined hyper and hypo). 
However, when comparing frequently hypomethylated (>30% samples) cancer specific 
probes to the normal, both cancer histologies identified a large proportion of probes to 
be cancer specific, with 4,023 probes (90.6%) frequently hypomethylated and cancer 
specific in chRCC, and 2,258 probe (94.7%) identified for oncocytoma (Figure 3-12 and 
Figure 3-10). Frequent hypermethylation was identified to account for 9.4% of all chRCC 
frequently methylated cancer specific probes (416 loci, mapped to 204 genes; Table 7-7), 
while for oncocytoma 5.2% of frequently methylated cancer specific probes were 
hypermethylated (125 loci mapped to 70 refseq genes; Table 7-8). 
To investigate the possible relevance of the hyper- and hypomethylation profile, the 
genomic distribution of identified probes in relation to Refseq genes was investigated 
(Figure 3-13a). Little variation in genomic distribution was identified between the two 
histologies, nor was much variation identified when analysing the percentage of probes 
located within the promoter region (defined as probes within the TSS1500, TSS200, 
5’UTR or 1st exon), 3'UTR or gene body of Refseq genes when comparing between hyper- 
and hypomethylation.  
However, variation was identified when investigating probe location in relation to CpG 




Figure 3-13: Genomic distribution of cancer specific hyper- and hypo-methylated loci 
A) Genomic distribution of cancer-specific, hyper- and hypo-methylated CpG loci in relation known genes. The promoter region indicates loci residing within the 1st exon, 5’UTR, TSS200 and TSS1500. B) Genomic distribution of cancer-specific hyper- and hypo-methylated CpG loci in relation to CpG features and density. The majority of hypermethylated loci map to CG rich regions (predominately CpG islands, shores and shelves 79.1% for chromophobe samples and 76.0% for oncocytoma samples). Hypomethylated cancer-specific probes predominately map to lone CpG loci in open sea regions (65.7% for chromophobe samples and 67.3% for oncocytoma samples).   
Functional genomic distribution 














































A. Distribution of CpG probes 
















































With hypomethylated probes showing a distinct trend to be located to lone isolated loci 
within the ’open sea’ with 65.7% hypomethylated probes in chRCC and 67.3% 
hypomethylated probes in oncocytoma. Meanwhile hypermethylated probes were 
identified to predominantly be located in GC rich regions, associated with CpG islands 
and the surround areas (shores and shelves), with a total of 79.1% chRCC 
hypermethylated probes and 76.0% of oncocytoma hypermethylated probes located in 
these three regions.  
 Analysis of hypermethylated probes 
Initial investigation of hypermethylated loci was focused on characterisation of the 
genes identified, and identification of interactions, networks and pathways that may be 
disrupted due the presence of abnormal methylation. To investigate this, IPA analysis 
was conducted on the full, frequently hypermethylated cancer specific gene list for each 
histology.  
For the hypermethylated chRCC genes, the top three IPA identified networks included; 
embryonic development, tissue development and tissue morphology (13 associated 
genes), cell signalling, molecular transport and vitamin and mineral metabolism (12 
associated genes) and cell death and survival, cell cycle and cancer (11 associated genes) 
(Figure 3-14, Table 7-7).  
For the hypermethylated oncocytoma genes, IPA analysis identified the following key 
networks: cell signalling and molecular transport (10 associated genes), cell 








Figure 3-15: IPA analysis of frequently hypermethylated genes in oncocytoma The top three networks identified by IPA functional network analysis of genes hypermethylated in > 30% of chromophobe RCC samples. Frequently hypermethylated genes are shown in grey and connecting genes in white. Solid arrows show direct interaction; dashed arrows represent indirect interactions and solid joining lines show protein binding.  
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(10 associated genes) and cancer, cellular growth and proliferation and renal and 
urological disease (10 associated genes) (Figure 3-15, Table 7-8). 
When comparing the frequently methylated cancer specific probes, between the two 
histologies we investigated, 48 genes (53 CG loci) were identified to be present in both 
the oncocytoma and chRCC data sets, which accounted for 17.5% of all gene identified as 
methylated. Of all the frequently hypermethylated genes identified, only 7 (PCDH17, 
ASCL2, NKX6-2, HOXA9, PITX2, TLX3 and ZNF177) had previously been identified as 
methylated in other cancer studies (Arai et al., 2012; Costa et al., 2011; McRonald et al., 
2009; Ricketts et al., 2012).  
From the IPA analysis, it was shown that multiple networks may be affected, however 
the association of genes with cell survival, growth, cancer and other renal abnormalities 
suggests that the identified genes may be involved with the promotion or at least 
increased susceptibility to tumourigenesis. 
3.2.1.5.1 Identification of differentially hypermethylated genes 
The next focus of the study was to identify differentially hypermethylated genes that 
may distinguish chRCC histology from oncocytoma histology at the epigenetic level.  
Differential hypermethylation was defined as CpG loci hypermethylated  (β value > 0.5) 
in more than 30% of samples in one histology, and a β value < 0.3 in 90% of the samples 
of the other. Statistical significance was defined by Student’s t-test analysis with FDR 
correction.   
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This approach identified 30 genes, which were significantly differentially 
hypermethylated, 28 of which were chromophobe-specific genes and 2 of which were 
oncocytoma-specific genes (ALCAM cg05645404 and TRPC4AP cg01154966; FDR 
P<0.05 (Table 3-1).    
All except SOX2OT cg24513480 (North shelf) resided in the CpG rich island or shores. 
Genomics locations for these differentially hypermethylated genes varied with 24 probes 
located within the genes promoter region, broken down as 4 in the TSS1500 region, 3 
probes in the TSS200 region, 3 in the 5’ UTR and 1 in the 1st exon, while 15 probes were 
located in the gene body and 4 in the 3’ UTR. Furthermore, 12 of the probes were 
mapped to a CpG rich region associated with a gene promoter. Probes that resided 
within promoter regions and within GC rich regions were henceforth referred to as 
promoter CGIs probes and are considered highly interesting and likely to influence gene 
expression. 
For all differentially hypermethylated genes, pathway and network analysis was 
conducted using DAVID, Panther and IPA analysis. DAVID and Panther analysis identified 
several key pathways associated with the hypermethylated genes, including the Wnt 
signalling pathway (EN2), the MAPK signalling pathway (CACNG7), the Hippo pathway 
(NPHP4), the TGFβ signalling pathway (AMH) and associations with highly regulated 
processes such as cell death and apoptosis (SPG20, NKX6-2, PAX3, BAG2), as well as other 
functions such as the cell cycle, cell migration and cell adhesion that are frequently 




Table 3-1: Differentially hypermethylated genes between chRCC and oncocytoma  Table of the differentially hypermethylated probes, defined as β value >0.5 in  >30% samples of one histology and β value <0.3 in 90% of the second histology. Multiple gene names represent the different transcripts to which a CpG locus maps. The CpG location in ‘relation to gene’ is then displayed for each transcript.  CH, chromophobe; Oc, oncocytoma; Chr, Chromosome  













ALCAM Oc cg05645404 Body N_Shore 12/21 (57.1%) 0/20 (0.0%) 0/4 4.2E-05 3




TSS1500 Island 7/21 (33.3%) 0/20 (0.0%) 0/4 3.40E-03 20
HOXA9 Ch cg03217995 Body N_Shore 0/21 (0.0%) 8/20 (40.0%) 0/4 3.65E-03 7
DBC1 Ch cg03625109 TSS1500 Island 0/21 (0.0%) 7/20 (35.0%) 0/4 3.79E-03 9
CACNG7 Ch cg21477176 3'UTR S_Shore 1/21 (4.8%) 6/20 (30.%) 0/4 4.28E-03 19
NKX6-2 Ch cg11174855 3'UTR Island 1/21 (4.8%) 7/20 (35.0%) 0/4 4.33E-03 10
NPHP4 Ch cg20383686 TSS200 Island 0/21 (0.0%) 6/20 (30.%) 0/4 4.80E-03 1
AMH Ch cg05345154 Body Island 0/21 (0.0%) 6/20 (30.%) 0/4 6.46E-03 19
DPP4 Ch cg19350270 Body N_Shore 0/21 (0.0%) 7/20 (35.0%) 0/4 6.58E-03 2
SOX2OT Ch cg24513480 Body N_Shelf 1/21 (4.8%) 8/20 (40.0%) 0/4 7.24E-03 3
EN2 Ch cg12034383 TSS1500 Island 0/21 (0.0%) 6/20 (30.%) 0/4 7.26E-03 7
SPG20; SPG20; 









N_Shore 0/21 (0.0%) 6/20 (30.%) 0/4 0.0096 8












N_Shore 0/21 (0.0%) 6/20 (30.%) 0/4 0.0184 2
PITX1 Ch cg00396667 3'UTR Island 1/21 (4.8%) 6/20 (30.%) 0/4 0.0188 5
SH3PXD2A Ch cg18735015 Body Island 1/21 (4.8%) 6/20 (30.%) 0/4 0.0213 10




5'UTR Island 1/21 (4.8%) 6/20 (30.%) 0/4 0.0224 20
HAPLN1 Ch cg12199221 TSS200 N_Shore 0/21 (0.0%) 6/20 (30.%) 0/4 0.0226 5
IRX6 Ch cg01064265 Body Island 1/21 (4.8%) 7/20 (35.0%) 0/4 0.0230 16
NKAPL Ch cg17384889 TSS200 Island 0/21 (0.0%) 6/20 (30.%) 0/4 0.0236 6
LBX1 Ch cg03053579 Body Island 0/21 (0.0%) 6/20 (30.%) 0/4 0.0237 10
BAG2 Ch cg10230427 Body S_Shore 1/21 (4.8%) 7/20 (35.0%) 0/4 0.0242 6
MKX Ch cg26298409 Body Island 0/21 (0.0%) 6/20 (30.%) 0/4 0.0262 10
SLITRK1 Ch cg16727923 1stExon Island 1/21 (4.8%) 7/20 (35.0%) 0/4 0.0376 13
BAG2 Ch cg27164797 Body S_Shore 0/21 (0.0%) 6/20 (30.%) 0/4 0.0401 6
KRT27 Ch cg02399249 Body Island 0/21 (0.0%) 6/20 (30.%) 0/4 0.0421 17
HHEX Ch cg09721427 TSS1500 Island 0/21 (0.0%) 6/20 (30.%) 0/4 0.0476 10
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Moreover, IPA analysis of the complete gene list, identified genes to be associated with 
networks involved in connective tissue development and function, embryonic and organ 
development, cancer, reproductive system disease and cellular development (Figure 
3-16). The next stage of the study was to investigate whether any of the differentially 
hypermethylated loci identified were specific for either chRCC or oncocytoma, when 
compared to TCGA data for the RCC subtypes ccRCC and pRCC. To achieve, this the 28 
differentially hypermethylated chRCC loci previously identified (section 3.2.1.5.1), were 
now compared to 450K array methylation data for papillary RCC (n=81) and ccRCC 
(n=100) samples downloaded from the TCGA (section 2.8.2). One-way Anova with 
Games-Howell post hoc test was performed. From this analysis, 3 genes (SPG20, NPHP4 
and TFAP2B) were identified to be significantly hypermethylated in chRCC compared to 
oncocytoma, ccRCC and pRCC. SPG20 and NPHP4 loci were shown to reside within the 
CpG dense regions for the North shore and island and to be associated with the promoter 
regions of the associated gene, while TFAP2B cg05437823 was located in the CpG island 
mapped to the 3’UTR of the gene. 
Using the same method described above the 2 genes identified to be differentially hyper-
methylated in oncocytoma were also compared to ccRCC and pRCC. This processes 
identified ALCAM cg05645404 to be the only locus significantly differentially 
hypermethylated in oncocytoma when compared to the three other renal cancer 













The ALCAM CpG locus mapped to the north shore and the refSeq gene body. However, for 
HOXA9, a gene originally investigated due to differential hypermethylation in chRCC. We 
observed instead that of presenting with chRCC specific methylation, HOXA9 
cg03217995, displayed as significantly hypermethylated in all investigated renal cancer 
histologies when compared to oncocytoma. In oncocytoma average -value was across 
all samples was 0.13 and thus were deemed unmethylated 
 
3.2.1.5.2 Confirmation of differential methylation 
Due to the aforementioned association of NPHP4 and SPG20 with the Hippo pathway, cell 
death and apoptosis respectably, single colony bisulfite sequencing was conducted on 2 
chRCC samples presenting with methylation and 2 oncocytoma samples lacking 
methylation. Bisulfite sequencing confirmed the differential methylation pattern 
identified by the 450K array (Figure 3-18, Figure 3-19). 
To confirm frequent methylation in chRCC, a separate cohort of 22 Japanese chRCC were 
analysed for methylation of SPG20 and NPHP4 by CoBRA analysis.  Here we identified 
that methylation was present at varying frequencies in 54.5% and 77.3% of chRCC 
samples for SPG20 and NPHP4 respectively (Figure 3-20). This is higher than the 
frequencies observed via the 450K array in which 35.0% of chRCC samples presented 
with SPG20 methylation and 30.0% chRCC samples presented with methylation of 
NPHP4. This variation could be attributed to the technique employed to assess the 
methylation status, as the 450K is more sensitive identifying methylation at a individual 
CpG locus, rather than Cobra, which identifies the presence of methylation within a 
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region of interest (Xiong and Laird, 1997). Secondly variation in methylation frequency 
could be due to the second cohort being of different ethnic origin and exposed to a 














Figure 3-20: CoBRA analysis of NPHP4 and SPG20 methylation. CoBRA analysis of NPHP4 and SPG20 methylation on an independent cohort of 22 primary Japanese chRCC. Methylation was observed in 54.5% and 77.3% of chRCC samples NPHP4 and 54.5% of the samples tested for SPG20. CoBRA PCR product was incubated with Taqα1 and undigested PCR product (U) was run next to Taqα1 digested product (D), with digestion of the band is indicative of methylation (also marked by the red arrows).  
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 Analysis of hypomethylated probes 
Following on from the investigations undertaken in profiling the hypermethylation of 
chRCC and oncocytoma, a similar analysis was concurrently undertaken, investigating 
the hypomethylation profile between chRCC and oncocytoma histologies.  
The study of hypomethylated loci initially focused on frequently differentially 
hypomethylated cancer specific CpG loci. Once again frequent hypomethylation was 
deemed to be loci presenting with  value <0.25 in > 30% of samples of each histology.  
For the chRCC cohort, a total of 2,134 genes (4,023 loci) were deemed to be frequently 
hypomethylated. IPA analysis identified multiple networks, with the top three shown in 
Figure 3-21.  Here IPA identified hypomethylated genes associated with networks 
involved in cell to cell signalling, hereditary disorders, neurological diseases, 35 post-
translational modification genes, 33 tissue morphology genes, cancer and 33 
gastrointestinal disease genes. 
For the oncocytoma cohort, the same analysis identified 1,239 genes (2,258 loci) to be 
frequently hypomethylated. With further IPA analysis, predicting network interactions 
associated with hereditary disorders, neurological disease, skeletal and 33 muscular 
disorders genes, cancer, cellular development, 33 cellular function and maintenance 
genes, embryonic development, lymphoid tissue structure and development, and 30 
organ development genes within the top three networks (Figure 3-22). Comparison of 
the two frequently hypomethylated probe lists identified 943 genes (1,543 loci) to be 
hypomethylated in both histologies, which accounted for 27.9% of all hypomethylated 








Figure 3-22: IPA analysis of frequently hypomethylated genes in oncocytoma The top three networks identified by IPA functional network analysis of genes hypermethylated in > 30% of renal oncocytoma samples. Frequently hypomethylated genes are shown in grey and connecting genes in white. Solid arrows show direct interaction; dashed arrows represent indirect interactions and solid joining lines show protein binding.   
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3.2.1.6.1 Identification of differentially hypomethylated genes 
Similar to the differential methylation analysis undertaken for hypermethylation, 
differentially hypomethylated genes were identified as loci with a β value < 0.25 in > 
30% of the samples for one of the histologies, while the other histology presents with a β 
value > 0.45 in 100% of the samples. Student’s t-test with FDR correction was conducted 
to identify significant differentiation. This analysis identified a total of 43 loci 
encompassing 41 genes; 5 genes in oncocytoma and 36 genes in chRCC samples (Table 
3-2: Differentially hypomethylated ). Of these 41 differentially hypomethylated genes, it 
was identified that 6 chRCC specific genes were located within promoter associated CpG 
shores and none within promoter CGIs. 
 IPA analysis of these 41 genes identified involvement with networks including 
cardiovascular system development and function, cell cycle, cell death and survival, 
cellular development, skeletal and muscular system development and function, and 






Gene Symbol Cancer Target ID
Relation to Gene CpG region
Meth in Onco (B value 
<0.25)
Meth in 
Chromo (B value <0.25)
Normal Kidney 
FDR P Value Chr
ITGB5 Oc cg00171092 Body Open Sea 7/21 (33.3%) 0/20 (0.0%) 0/4 2.7E-08 3
GTF2IRD1; 
GTF2IRD1 Ch cg20448594 Body; Body Open Sea 0/21 (0.0%) 7/20 (35.0%) 0/4 2.91E-08 7PABPC4L Ch cg15867829 3'UTR Open Sea 0/21 (0.0%) 9//20 (45.0%) 0/4 1.20E-07 4
PRKCE Ch cg04035064 Body Open Sea 0/21 (0.0%) 7/20 (35.0%) 0/4 2.97E-07 2
CTDSPL; 








Open Sea 0/21 (0.0%) 6/20 (30.%) 0/4 3.33E-07 11
TSPAN5 Oc cg03234557 Body Open Sea 9/21 (42.8%) 0/20 (0.0%) 0/4 8.95E-07 4
SCG3; SCG3 Ch cg08884979 3'UTR; 3'UTR Open Sea 0/21 (0.0%) 11/20 (55.0%) 0/4 4.81E-06 15CSRP2BP; CSRP2BP Ch cg14329508 3'UTR; Body Open Sea 0/21 (0.0%) 7/20 (35.0%) 0/4 1.54E-05 20
MIR141 Ch cg19794481 TSS200 Open Sea 0/21 (0.0%) 6/20 (30.%) 0/4 1.59E-05 12
SLC44A3; 
SLC44A3 Ch cg22608160 Body; Body Open Sea 0/21 (0.0%) 7/20 (35.0%) 0/4 3.39E-05 1
MICAL2 Oc cg00286773 Body Open Sea 7/21 (33.3%) 0/20 (0.0%) 0/4 3.57E-05 11
PHTF2; PHTF2 Ch cg27457191 5'UTR; 5'UTR S.Shore 0/21 (0.0%) 6/20 (30.%) 0/4 0.0000 7
RORA Ch cg03952578 Body Open Sea 0/21 (0.0%) 6/20 (30.%) 0/4 0.0000 15
ARID1B; ARID1B; 
ARID1B
Ch cg04924555 Body; Body; Body Open Sea 0/21 (0.0%) 6/20 (30.%) 0/4 0.0001 6








S.Shore 0/21 (0.0%) 7/20 (35.0%) 0/4 0.0001 21
ITPRIP Ch cg16301004 5'UTR Open Sea 0/21 (0.0%) 7/20 (35.0%) 0/4 0.0001 10
RAB3B Ch cg00714309 Body Open Sea 0/21 (0.0%) 8/20 (40.0%) 0/4 0.0001 1
MIR141 Ch cg02624246 Body Open Sea 0/21 (0.0%) 6/20 (30.%) 0/4 0.0001 12
GBE1 Ch cg05514531 Body Open Sea 0/21 (0.0%) 6/20 (30.%) 0/4 0.0002 3
SLC27A3 Ch cg15930240 Body S.Shore 0/21 (0.0%) 6/20 (30.%) 0/4 0.0002 1
MKLN1; 
MKLN1 Ch cg02776119 Body; Body S.Shelf 0/21 (0.0%) 6/20 (30.%) 0/4 0.0002 7C14orf169; 
HEATR4 Ch cg02935494
TSS1500; 
Body N.Shore 0/21 (0.0%) 9//20 (45.0%) 0/4 0.0002 14VPS13B; 
VPS13B Ch cg18520777 Body; Body Open Sea 0/21 (0.0%) 7/20 (35.0%) 0/4 0.0002 8MYO3B; MYO3B; 
MYO3B
Ch cg16066505 Body; Body; Body Open Sea 0/21 (0.0%) 8/20 (40.0%) 0/4 0.0002 2




Table 3-2: Differentially hypomethylated genes between chRCC and oncocytoma Table of the differentially hypomethylated probes identified between chRCC and oncocytoma. Hypomethylation is defined as β value <0.25 in >30% samples of one histology and β value >0.4 in 100% of the second histology. Multiple gene names represent the different transcripts to which a CpG locus maps. The CpG location in ‘relation to gene’ is then displayed for each transcript. CH, chromophobe; Oc, oncocytoma; Chr, Chromosome 
  
Gene 













RNPEP Ch cg16047663 3'UTR Open Sea 0/21 (0.0%) 6/20 (30.%) 0/4 0.0005 1
















5'UTR Open Sea 0/21 (0.0%) 6/20 (30.%) 0/4 2.10E-03 12
CDKAL1 Ch cg00682125 Body Open Sea 0/21 (0.0%) 7/20 (35.0%) 0/4 3.11E-03 6
HOXC4; 
HOXC6; HOXC5 Ch cg18040878
TSS1500; 
TSS1500; TSS1500
S.Shore 0/21 (0.0%) 6/20 (30.%) 0/4 4.61E-03 12
ACTN2 Ch cg18381395 Body Open Sea 0/21 (0.0%) 6/20 (30.%) 0/4 5.00E-03 1





Ch cg02074956 Body; Body; Body; Body N.Shore 0/21 (0.0%) 6/20 (30.%) 0/4 9.04E-03 16










N.Shore 0/21 (0.0%) 6/20 (30.%) 0/4 1.69E-02 5
NDUFAF1 Ch cg13897914 TSS1500 S.Shore 0/21 (0.0%) 6/20 (30.%) 0/4 2.34E-02 15
ACCN4; 




Figure 3-23: IPA analysis of differentially hypomethylated genes in between chRCC and oncocytoma (See next page for figure legend) 
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The top two networks identified by IPA functional network analysis of differentially methylated genes between chRCC and oncocytoma. Differential hypermethylation was defined as defined as β value <0.25 in >30% samples of one histology and β value >0.5 in 100% of the second histology hypermethylated in > 30%. Frequently hypomethylated genes are shown in grey and connecting genes in white. Solid arrows show direct interaction; dashed arrows represent indirect interactions and solid joining lines show protein binding.  




chRCC and oncocytoma are both believed to be derived from distal renal tubules and 
possess a similar morphology and appearance, that can be difficult to differentiate 
visually through imaging and biopsies due to only a fraction of the tumour being 
analysed, and the full cellular architecture not being represented (Ng et al., 2014; 
Pierorazio, 2014). Fast and accurate identification is vital to ensure appropriate 
treatment and management is undertaken. As a result, much focus has been invested on 
identifying biochemical and genetic differentiation between all renal carcinoma 
subtypes. Current methods include analysis of known chromosomal abnormalities 
frequently identified in the histologies, such as the loss of chromosome 1p and Y in 
oncocytoma or Chromosomes 1, 2, 6, 10 and 17 in chRCC (Yusenko et al., 2009), or use 
immunohistochemistry to differentiate between histologies. Examples of this include 
staining for CK7, which is strong in chRCC but weak in oncocytoma, and CD15, which is 
absent in chRCC but 70% oncocytomas stain positive, while staining for CD10 can 
distinguish between ccRCC, chRCC and oncocytoma being positive in ccRCC and negative 
in the other two histologies. Hale’s or Modified Mowry’s colloidal iron stain is reported 
to strain more strongly in chRCC than oncocytomas, while comparison of cadherin gene 
family expression can also distinguish between histologies, with kidney-specific 
cadherin almost exclusively being expressed in chRCC. However none of the cytogenetic 
or immunohistochemistry techniques are regarded as accurate or reliable at 
differentiating the two histologies (Ng et al., 2014).  
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 Summary of findings 
Within this study, we aimed to identify the methylation profiles of rare RCC subtypes 
using a whole genome wide high throughput methylation array, the Infinium 
HumanMethylation 450 BeadChip. 
 Genome wide methylation analysis 
The methylation profiles of 21 oncocytoma and 20 chRCC were analysed using the 
Infinium HumanMethylation 450 BeadChip, where >480,000 CpG loci were interrogated 
for methylation status. The array was validated in house by single colony bisulfite 
sequencing of three candidate genes, while the reproducibility of the array was 
ascertained by the inclusion of a duplicate sample on the array. Following a manually 
developed pipeline to identify cancer specific probes, we identified that chRCC and 
oncocytoma exhibit similar patterns of global DNA methylation with the highest 
proportion of cancer specific probes presenting with hypomethylation (>70% cancer 
specific probes), while <30% of all cancer specific probes were identified to be 
hypermethylated. The benign oncocytoma presented with the higher percentage of 
hypomethylated cancer specific probes when compared to our chRCC data and TCGA 
methylation data for a small cohort of ccRCC and pRCC. This observation of frequent 
hypomethylation may be a distinguishing feature for the less malignant RCC subtypes. As 
the more malignant RCC subtypes, ccRCC and pRCC presented with hypermethylation 
within the majority of cancer specific probes (>80% cancer specific probes).  This 
finding is consistent with the generally accepted observation that methylation is more 
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prevalent in malignant and aggressive tumours. Other recent publications on the 
methylation profile of RCCs include: a TCGA chRCC specific publication where chRCC 
450K methylation was compared to that of ccRCC (Davis et al., 2014), a study using 27K 
Infinium methylation array of RCC subtypes (ccRCC, pRCC, chRCC and oncocytoma) 
(Ibragimova et al., 2013b), and a candidate gene methylation analysis between RCC sub 
groups (Costa et al., 2007; Dulaimi et al., 2004; Ellinger et al., 2011b). We identified pRCC 
(TCGA data) to present with the most cancer specific hypermethylated probes, it was 
calculated that pRCC presented with 3.4x more hypermethylated probes than ccRCC. 
This observation echoes the findings of McRonald et al., 2009, where Goldengate 
methylation analysis identified much higher numbers of methylated loci in a pRCC 
cohort compared to ccRCC. 
Supervised clustering of hypermethylated probes, did differentiate the majority of 
oncocytoma and chRCC into groups with group cluster 1.1 and 1.2 predominantly 
oncocytoma while cluster 1.3 and cluster 2 were predominantly chRCC. This clustering 
analysis did identify one chromophobe sample that presented with widespread 
hypermethylation, a feature that may be reminiscent of a CIMP phenotype (Issa, 2004).  
However, further investigation and samples would be required to confirm such an 
observation.  
This study has permitted the identification and characterisation of frequently (>30% of 
samples) hypermethylated and hypomethylated loci within a chRCC and renal 
oncocytoma cohort. When comparing the two histologies, we identified that chRCC 
presents with more frequent hypermethylation of CpG loci (416 probes) than the 
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oncocytoma subgroup (125 probes), which is consistent with chRCC being a malignant 
form of cancer compared to renal oncocytoma. Furthermore mapping of the 
hypermethylated and hypomethylated loci position in relation to gene, identified no 
obvious association between the methylation status and position in relation to genes, 
unlike a study conducted by Sandoval et al 2011, where hypomethylated probes were 
mainly identified in the gene body (38-40%), although Sandoval et al drew no 
conclusions from this observation, other studies have reported that loss of DNA 
methylation within the genes bodies may act as a mechanism combat gene over 
expression (Yang et al., 2014)  When mapping the location of the hypermethylated and 
hypomethylated probes in relation to CpG islands distinct profiles were observed. 
Hypermethylated probes were more frequently located in GC rich regions of the CpG 
island, shores and shelves (>75% hypermethylated probes for both histologies) while 
hypomethylated probes predominantly resided in lone GC poor regions known as open 
seas (>65% hypomethylated probes for both histologies). This finding is consistent with 
the study by Sandoval et al., 2011, who identified hypermethylation to reside in 66-68% 
CpG islands, while identifying 67-70% of hypomethylated probe reside in open sea.  
Differential analysis was conducted with the aim of identifying genes with abnormal 
methylation patterns that may provide a biomarker for differentiating between RCC 
subtypes.  By identifying probes frequently hypermethylated in one histology compared 
to the other, we were able to identify 30 significantly differentially hypermethylated 
genes, 12 of which were located within promoter associated CpG islands, shores or 
shelves. A study by Irizarry et al., 2009 reported that differential methylation in colon 
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cancers was most prevalent in the CpG shores (up to 2kb away from the promoter) 
suggesting a that distal methylation may also regulate gene expression. For 
hypomethylated differential analysis, a stricter criterion could be applied due to the 
abundance of frequently hypomethylated probes identified (>1239 gene associated 
probes). This analysis identified 41 differentially hypomethylated genes, of which only 6 
were located within promoter associated CpG shores and none within promoter CGIs. 
This is consistent with reports that hypomethylation is less frequent at regulatory 
regions of the genome (Ehrlich, 2009).  
From our study, we identified two genes (SPG20 and NPHP4) of interest to be 
significantly methylated in chRCC when compared to our oncocytoma cohort and TCGA 
ccRCC and pRCC data. ,A recent publication of the chRCC TCGA data, comparing multiple 
platforms, investigated the chRCC expression profile compared to normal and ccRCC. 
Investigation of the supplementary data identified a decrease in average fold difference 
(FD) of -2.04 NPHP4 (FDR 1.73 e-14) and -0.61 SPG20 (FDR 1.59e-5) in chRCC expression 
when compared to normal, while ccRCC expression was a FD of 1.74  NPHP4 (FDR 2.27 e-
51) and -0.80 SPG20 (FDR 3.61e-2) more than chRCC. However, the CG probes identify in 
our investigation were not included in the lists significant probes within the TCGA 
supplementary data. (Davis et al., 2014).  
SPG20 encodes a protein known as spartin, which has been shown to play a role in 
preventing cytokinesis arrest (Lind et al., 2011), while mutation within SPAG20 are 
attributed to Troyer syndrome (an autosomal recessive spastic paraplegia syndrome 
characterised by spastic paraplegia, muscular atrophy and motor and cognitive delays) 
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(Tawamie et al., 2015). Furthermore methylation of SPG20 has been suggested as a 
biomarker for early colorectal cancer, with methylation reported in 89% colorectal 
cancer and 78% adenoma (Lind et al., 2011), and has been shown to be highly 
methylated in Non-Hodgkin lymphoma (NHL), with frequent methylation identified in all 
NHL (75%- 100%) subgroups tested, with 0% in normal controls (Bethge et al., 2014).  
NPHP4 has been identified as a cilia-associated protein nephrocystin-4, which is 
involved in the correct formation of primary cilium. NPHP4 has been identified to have 
an antagonistic involvement in the canonical Wnt signalling through interactions with 
inversin (NPHP2) (Lienkamp et al., 2012). Within the pro-apoptotic Hippo pathway, 
NPHP4 has been identified to bind to LATS1 and inhibit the interaction and subsequent 
phosphorylation of the YAP/TAZ complex. Resulting in the transcription of growth 
factors such as CTGF. This suggests that NPHP4 is a negative regulator of the Hippo 
pathway, suggesting oncogenic tendencies (Habbig et al., 2011). Therefore, further 
investigation would be required to identify the role DNA methylation may have on 
NPHP4 function. 
Mutations in NPHP4 have been linked with nephronophthisis, while a particular 
truncating mutation, c.2044C>T, p.R682*, has been identified to cause cerebello-oculo-
renal syndrome with renal cysts and linked to male infertility (Alazami et al., 2014). 
Finally, other studies into methylation of NPHP4 promoter have also identified high 
levels of methylation within chronic and rapid kidney disease (Wing et al., 2014). 
The differentially methylated genes identified in this study may provide an insight into 
disease progression and could potentially be used as biomarkers to distinguish between 
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RCC subtypes. However, before such conclusions can be drawn, further functional 
analysis should be conducted.  
Since the publication of our study, a further study by Ibragimova et al has been 
published with a similar aim of investigating the methylome profile of different RCC 
subtypes, including ccRCC, pRCC, chRCC and oncocytoma. Methylation analysis was 
conducted using the Infinium 27K array.  This study identified 8 genes, to be 
differentially methylated in oncocytoma when compared to ccRCC, and 5 ccRCC genes to 
be differentially methylated in ccRCC. It was subsequently proposed that the methylation 
status of these genes could provide a gene panel, which would permit discrimination of 
renal oncocytomas from ccRCC. Regarding the comparison of oncocytoma and chRCC, 
methylation, only one gene RAC2 was reported to be differentially methylated in 
oncocytoma samples. No observations were reported regarding the methylation of 
SPG20  and NPHP4 (Ibragimova et al., 2013b). Disparities between our data and this 
study are likely due to; differences within the tumour histopathology of the samples 
used, the different arrays (NPHP4 cg20383686 is only present on the 450K array), 
filtering criteria applied and different methylation thresholds (Ibragimova et al set 
differential methylation as a as  value <0.15 in all samples of an unmethylated histology 
but methylated ( value >0.45) in at least one sample for a separate histology). 
Highlighting the lack of consensus as to how to process this data, and what is biologically 
relevant.   
Recently, the TCGA has published data on 66 chromophobe samples, investigating the 
genome wide methylation profile (450K analysis), expression profile (RNA-sequencing 
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and miRNA seq) and mutation and SNP profile (Whole genome sequencing and SNP 
array), to identify the genomic and the epigenomic landscape of chRCC (Davis et al., 
2014).  Within this study, Davis et al, also identified more global hypomethylation than 
hypermethylation when comparing chRCC to ccRCC. Furthermore, they identified 
distinct patterns in methylation corresponding to the lineage of the two cancer subsets, 
with chRCC derived from intercalated cells in the distal convoluted tubules (associated 
genes were unmethylated in chRCC and methylated in ccRCC) while ccRCC are derived 
from the proximal tubules (thus genes associated with this cell lineage were 
hypermethylated in chRCC and unmethylated in ccRCC). 
Other studies investigating biomarkers, allowing ccRCC and oncocytoma subtypes to be 
distinguished, included an investigation in the SNP profile which observed that copy 
number alterations were more prevalent in chRCC than oncocytoma, and frequent 
deregulation mTOR signalling pathway in chRCC.  Furthermore, expression analysis and 
immunohistochemistry distinguished three potential biomarkers: parafibromin (CDC73), 
aquaporin 6 (AQP6) expressed in oncocytoma and synaptogyrin 3 (SYNGR3) expressed 
in chRCC (Tan et al., 2010). A further study into differentially expressed biomarkers has 
identified HNF1b and S100A1 to be strong candidates for immunohistochemical 
differentiation between chRCC and oncocytoma, with significantly more frequent and 
intense staining within oncocytomas (HNF1b = 73% (P =0.001) and S100A1 = 80% P < 
0.001 of oncocytoma samples presenting with moderate to strong staining). Moreover, 
no chRCC tested presented with positive staining for either protein (Conner et al., 2015). 
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Profiling the micro-RNA signature of each RCC histology has identified unique 
expression patterns that can accurately differentiate between normal, ccRCC, pRCC 
chRCC and oncocytoma. Algorithms have been created that differentiate subgroups 
based on expression of specific mirco-RNA, for example miR-200b and hsa-miR-139 had 
increased expression in chRCC when compared with oncocytoma, while hsa-miR-200c 
was increased in oncocytoma (Fridman et al., 2010; Youssef et al., 2011). 
 Limitation of this study 
The major limitation of this study was the small cohort size. The cancers investigated in 
this study are rare and at the time of investigation only a limited number of samples 
were available, making it challenging to draw meaningful. Additionally, the size of the 
array limited the number of samples that could be analysed, as additional arrays would 
have been required to profile a larger cohort. This would not only effect the costing’s of 
the experiment, but would also open up issues of variability between arrays, and thus 
further normalisation of the data would be required (Harper et al., 2013).  
Another limitation is regarding the histology of the tumours  samples. This study is 
reliant on the accurate differentiation and identification of the two RCC subtypes, chRCC 
and oncocytoma. As previously discussed (sections 1.4.2.1.3 and 1.4.2.1.4) distinguishing 
of the two subtypes can be challenging, relying on visual characterisation of the 
histopathology (Ng et al., 2014; Yusenko, 2010), which maybe further complicated by 
intratumour heterogeneity present in the majority of cancers (section 1.2.1) 
(McGranahan and Swanton, 2015; Tabassum and Polyak, 2015). Identification and 
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classification of the chRCC and oncocytoma histologies was conducted by our 
collaborates Dr G Kovacs and Dr M Yao, both of whom are experienced in the 
identification and classification of renal cancer histologies.   
Furthermore, a limitation with the technology itself, is the chemical differences between 
the two Infinium probe technologies employed by the 450K. It has been identified that 
the two different technologies produced different  value ranges, with the Infinium II 
probe producing a narrower range of β values, skewing recordings at the extremes of the 
β value range (0 and 1). This observation suggests that the Infinium II technique is not as 
sensitive as Infinium I (Bibikova et al., 2011; Sandoval et al., 2011). However, Infinium 
argue that the differences between the two technologies should not affect reliability or 
reproducibility and that the array was designed for probes to be analysed individually 
across samples and not compared between the two technologies within the same sample 
(Illumina, 2012). Despite this statement, it is widely agreed that all data should be 
normalised prior to analysis, so that both techniques are representative of the same 
range of β values. For our data this was achieved by the use of the Lumi pipeline, (Du et 
al., 2008), however other packages such as BMIQ (Beta MIxture Quantile dilation) 
(Teschendorff et al., 2013) and Subset-quantile Within Array Normalisation (SWAN) 
(Maksimovic et al., 2012) are now also available (reviewed by Morris and Beck, 2015). 
Another limitation was raised by Harper et al, regarding the distribution of the CpG 
probes in relation to genes. It was identified that some genes may be represented by 
more CpG probes than others, generating a bias that results in some genes of interest 
being disproportionately represented (Harper et al., 2013). 
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Furthermore, the global nature of the 450K analysis results in huge data files that 
require bioinformatic interpretation. This analysis itself can limit the functionality of the 
genome wide methylation studies, with many probes excluded throughout the various 
stages of filtering. Another limitation was defining where to set the thresholds for 
methylation, and as previously mentioned, there was a lack of consensus as to what 
thresholds should be applied and should be regarded as biologically relevant 
(Ibragimova et al., 2013b; Sandoval et al., 2011).  However, more recent studies are 
moving away from the threshold method to detect differential methylation instead are 
applying statistical methods employed by multiple pipelines to assist the filtering of  the 
450K data (Morris and Beck, 2015). 
Regarding the to analysis of the 450K data, another limitation to be aware of is the 
misrepresentation of samples methylation profile due to the presence of imprinted 
genes, X chromosome inactivation and CpG probes associated with known SNPs. All of 
which may skew the global methylation profile and could be misrepresented as a true 
result (Chen et al., 2013). However, for our data, this limitation was overcome by 
omitting all associated probes.  
 Future work 
Much of the methylation observed through high throughput studies such as this, is 
passenger methylation, defined as methylation that does not effect the expression of the 
gene, or dive the formation of the observed phenotype. This may be due methylation 
occurring at genomic locations not associated with a gene or gene regulation or due to 
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methylation be acquired at a gene that was previously repressed within the tumour 
sample (Kalari and Pfeifer, 2010; Roy et al., 2014). Therefore future work would include 
identifying if the differential methylation observed for SPG20 and NPHP4 was driver 
methylation or passenger methylation. Expression analysis by RT-PCR (section 2.7.2) 
should therefore be conducted on cDNA to identify if the presence of methylation 
inhibits the transcription of mRNA.  Additionally it should be identified whether 5’Aza 
treatment to remove methylation (in cell lines) restores mRNA expression, to identify 
that it is the DNA methylation that is resulting is loss of mRNA expression and not other 
regulatory features within the cell. If the presence of methylation was confirmed to 
reduce mRNA expression, the next stage would be to knockdown the protein and 
investigate the effect that loss of the protein has on cell growth and identify if SPG20 or 
NPHP4 may play a role in tumourigenesis. Furthermore, other non chRCC subtypes 
should be tested to confirm that SPG20 and NPHP4 are unmethylated in separate 
independent cohorts.  
Further investigations should also focused upon identifying if any of the differentially 
hypomethylation genes identified by comparing chRCC and oncocytoma 
hypomethylation, are also differentially hypomethylated when compared to TCGA pRCC 
and ccRCC. Further functional analysis should be undertaken on any identified genes, 
such as colony formation studies should be conducted. Transfecting cells to overexpress 
the gene of interest, to ascertain if expression promotes tumour growth. Although 
hypomethylation is fairly common in cancer, it is often overlooked. However, as DNA 
hypomethylation is predominantly associated with repeats elements, such as long 
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interspersed elements (LINE-1) repeats and tandem, features which are highly prevalent 
in the genome. It is suggested the hypomethylation permits activation of transposable 
elements by relaxing the intergenic chromatin structure, resulting in DNA 
rearrangements and promotion of tumourigenesis (Ehrlich, 2009; Lorincz et al., 2004). 
Moreover reports have been published suggesting global reduction in methylation, is a 
marker of pre-cancerous breast cancer and early stages of urothelial cancer (van 
Veldhoven et al., 2015; Wolff et al., 2010). 
Finally, open sea and intragenic probes identified to be frequently hypomethylated and 
hypermethylated within chRCC and oncocytoma should be mapped to identify if the loci 
reside within enhancer regions (identified on Encode) or map to microRNAs, which have 
previously been reported to have a regulatory role lost in the progression of cancer (Ge 
et al., 2015; Lujambio et al., 2010; Su et al., 2015). This may identify other regulatory 
features which are deregulated by DNA methylation. 
 Final summary 
This study aimed to identify a differential methylation profile that may be used to 
distinguish chRCC from oncocytoma. By utilising the high-throughput genome wide 
450K array, the methylation status >96% of CpG sites in more than 99% of RefSeq genes 
were interrogated. Through this analysis it was identified that both chRCC and 
oncocytoma RCC subgroups, presented with low levels of global hypermethylation and 
high levels of global hypomethylation, epically when compared to the more malignant 
ccRCC and pRCC TCGA data. Furthermore two promoter CGIs mapped to SPG20 and 
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NPHP4 were identified to be frequently methylated in chRCC with no methylation 
observed within the oncocytoma, ccRCC or pRCC cohorts. Further investigation would be 
required to confirm if the presence of methylation at these genes has any implication 
chRCC tumourigenesis and if these two genes may provide a suitable biomarker of 
chRCC. However, this line of investigation was unable to be continued in this thesis due 
to time constraints. This was because the data from the whole exome sequencing of 
oncocytoma samples had been returned and required analysis (chapter 5). 
 
As previously mentioned this work was published in Epigenetics 8, 2013 by Slater, AA et 
al. Additionally this work was presented at a poster session at:  Epigenetics Europe, 




 Methylight analysis of RASSF gene family in sarcomatoid Renal Cell Carcinoma (sRCC) 
4.1 Introduction 
 Methylight 
Methylight is an adapted form of the Taqman® real-time PCR technique, specifically for 
use with bisulfite modified DNA. It is a highly sensitive and quantitative method 
developed to assess DNA methylation status within regions of interest.  
Methylight works by combining primers specific for methylated bisulfite modified DNA 
with a highly specific Taqman® style probe also specific for methylated bisulfite 
modified DNA. The probe is designed with a fluorescence tag (FAM or VIC) at the 5’ end 
of the probe and a quencher molecule (TAMAR or BHQ) at the 3’ end of the probe. 
During PCR amplification the methylation specific probe is degraded by the taq 
polymerase, this releases the 5’ fluorescence tag from being in close proximity to the 3’ 
quencher molecule, allowing the fluorescent tag to emit a signal that is then detected as 
successful amplification of 1 strand of DNA. Methylation of the sample is quantified in 
relation to an in-vitro methylated control and a housekeeping gene (e.g. Alu or GAPDH) 
and displayed as Percentage of Methylated Reference (PMR) (section 2.3.2.2.1) 
(Buhmeida et al., 2011; Dallol et al., 2011; Selamat et al., 2011).  
 Unlike MSP where it is solely the primers that differentiate between the methylated and 
unmethylated sequence (Herman et al., 1996) or CoBRA and bisulfite sequencing, where 
the PCR product is interrogated for methylation (Xiong and Laird, 1997). Methylight 
identifies methylation within both the primers and the product (fluorescent probe), 
providing high specificity and accurately determining and quantifying the methylation 
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status (Coleman and Rivenbark, 2006; Eads et al., 2000; Trinh et al., 2001). Another key 
advantage to Methylight is the sensitivity of the assay, meaning that much less template 
DNA (as little as 10ng) is required for accurate analysis (Dallol et al., 2011; Ogino et al., 
2006) and valuable patient samples can be preserved for future investigation. 
Additionally, Methylight can be run in a semi high-throughput manner permitting 
analysis of multiple samples at one time (Coleman and Rivenbark, 2006; Eads et al., 
2000).  
Methylight has since been used for many studies including quantifying the methylation 
status of RASSF1A in breast cancer (Buhmeida et al., 2011), and hepatocellular 
carcinoma (Xu et al., 2013) or identifying differential methylation between different 
stages of adenocarcinoma (Selamat et al., 2011). More recent studies have utilised 
Methylight to identify methylated genes associated with negative prognosis within rectal 
cancer (Exner et al., 2015). Furthermore Methylight has also proved invaluable for 
studying the methylation profiles for diseases such as myelodysplastic syndrome or 
aplastic anaemia where large DNA quantities of samples are rare and difficult to obtain 
(Li et al., 2015). 
Further advances in Methylight technology are being focused on improving efficiency; 
Olkhov-Mitsel et al., 2014 reported a method to multiplex Methylight. By utilising probes 
specific to 4 different target genes with each probe possessing a different coloured 
fluorescent dye, selected to have sufficient spectral separation to avoid overlap. They 
successfully managed to simultaneously amplify, detect and analyse 4 genes (IAPC, 
HOXD3 TGFBP2 and ALU) within one well, with high specificity and reproducibility 
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(Olkhov-Mitsel et al., 2014). Other approaches have been to adapt the novel droplet 
digital PCR (ddPCR) method for use within the Methylight system (Yu et al., 2015). The 
ddPCR is a method developed to allow high throughput PCR analysis. Samples are 
fractionated into multiple droplets containing template DNA and PCR reagents, PCR 
amplification then occurs in each individual droplet. By suspending the PCR reaction 
and template DNA in water-in-oil droplets, each droplet acts as a separate PCR reaction 
and amplification. This technique first described by Hindson et al., 2011 has been 
reported to allow standard Taqman analysis of ~2 million PCR reactions per 96 well 
plate. The adaptation of the technology to encompass Methylight primer and probe 
design has permitted the identification and quantification of alleles and infrequently 
methylated genes within normal colon tissue, which may serve as an early warning 
biomarker for colorectal cancer. Furthermore this technique is reported to identify 
infrequent methylation with 25-fold more sensitivity compared to the standard 
Methylight and with less variation between samples being recorded (Yu et al., 2015).  
 Sarcomatoid renal cell carcinoma (sRCC) 
As described in section 1.4.2.1.5, sarcomatoid RCC is a characteristic feature of advanced 
RCCs rather than a district subset of RCC and is associated with poor prognosis and 
metastasis (Delahunt et al., 2013; Yan et al., 2015). The sarcomatoid features are usually 
diagnosed using core biopsies of the tumour, followed by visual analysis of the 
sarcomatoid-like cells. These areas are often densely populated with elongated, spindle-
shaped cells, and usually exhibit micro-vascular invasion and necrosis (Shuch et al., 












It is predicted that sarcomatoid features present in 1-8% of all ccRCC tumours 
(Humphrey, 2012) and in a total of 16-20% of advanced renal cancers and can be 
derived form virtually any malignant RCC histology including pRCC, chRCC and collecting 
duct RCC  (Shuch et al., 2012a; Yan et al., 2015)(Delahunt et al., 2013). However, the 
amount of sarcomatoid features can vary hugely within individuals from 1% to 100% of 
the tumour histology though this is not always reported (Kim et al., 2015). 
 RASSF Family  
The RASSF family are a group of 10 tumour suppressor proteins (RASSF1-RASSF10) 
frequently identified to be downregulated in many cancers including RCC (Maher, 2013). 
The RASSF family of proteins have been associated with important regulatory roles in 
cell growth regulation via pro-apoptotic signalling, cell cycle arrest and the Hippo 
pathway (section 4.1.3.1) (Richter et al., 2009). Structurally, RASSF proteins are 
characterised by the presence of a RAS-association domain (RalGDS/AF-6) (RA domain), 
which facilitates the binding of RASSF protein to RAS or RAS-GTP (Agathanggelou et al., 
2005). Although all RASSF family members contain the RA domain, the presence of other 
highly conserved domains (detailed below) allows for sub-classification of the family 
into the following two groups; 
1) Classical RASSF proteins 
Classical RASSF proteins (RASSF 1-6) possess a Sav-RASSF-Hpo domain (SARAH 
domain), a domain that is highly associated with protein: protein interactions and 
protein heterodimerisation (Agathanggelou et al., 2005). The presence of a 
SARAH domain has been associated with the binding of RASSF proteins with the 
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Hippo pathway associated proteins SAV, MST1 and MST2. RASSF1A, RASSF2, 
RASSF3, RASSF4 and RASSF5, have all previously been identified to bind to the 
core hippo pathway proteins MST1 and MST. Promoting activation of the 
pathway, thus activating the downstream Hippo pathway signalling and driving 
apoptosis (Bao et al., 2011; Chan et al., 2013; Cooper et al., 2009; Fausti et al., 
2012; Guo et al., 2007; Hwang et al., 2014; Iwasa et al., 2013; Matallanas et al., 
2007; Romano et al., 2010; Shivakumar et al., 2002).Additionally RASSF3 and 
RASSF6 have been associated with p53 induced apoptosis by ubiquitinating and 
facilitating the degradation of p53 inhibitor MDM2 (Withanage et al., 2012) 
suggesting that RASSF proteins have more than one method of action for 
regulating cell growth. 
2) N terminal RASSF proteins 
The N terminal RASSF proteins (RASSF 7- 10) are characterised by their lack of a 
SARAH domain, and as yet their exact method of action and associated regulatory 
mechanisms still remains unclear (Underhill-Day et al., 2011a). However, reports 
have suggested that these N-terminal RASSF proteins may play a role in mitosis 
and cell cycle progression. For example RASSF7 has been reported to be required 
for correct microtubule and spindle formation during mitosis (Recino et al., 
2010), while RASSF10 has been shown to be localised to the centrosomes during 
mitosis (V K Hill et al., 2011). Furthermore, it should be noted that the SARAH 
domain lacking RASSF7 has also been identified to bind the hippo pathway 
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protein MST1, and is predicted to incite activation of the hippo pathway as seen 
with the classical RASSF proteins (Chan et al., 2013; Dittfeld et al., 2012). 
Additionally, both classical and N-terminal RASSF proteins have been shown to lack 
enzymatic activity. Thus, it is now widely regarded that they elicit Hippo pathway 
activation by acting  as scaffold proteins and bringing proteins such as MST1 and MST2 
together to form the core complex of the Hippo pathway, (Donninger et al., 2007; Pfeifer 
et al., 2010; Romano et al., 2014). 
In cancer, the RASSF family of TSGs have been identified to be frequently 
underexpressed, prompting investigation into the DNA methylation status. As previously 
mentioned in section 1.5 frequent methylation of RASSF1A and RASSF5 have been 
observed multiple RCC subtyped including ccRCC, pRCC, chRCC and oncocytoma (Costa 
et al., 2007; Dulaimi et al., 2004; Ellinger et al., 2011b; Maher, 2013; Morrissey et al., 
2001). RASSF1 promoter methylation was first identified by Dammann et al 2000, in 
small cell lung carcinomas (Dammann et al., 2000). Since this identification methylation 
of RASSF1A has been reported in numerous cancers such as breast, glioma, 
hepatocellular and adenocarcinoma (Hesson et al., 2007; Selamat et al., 2011), with 
several studies linking hypermethylation to poor prognosis and advance cancer stage 
(Buhmeida et al., 2011; Selamat et al., 2011).  
Further studies investigating the promoter methylation of other members of the RASSF 
family, have identified frequent methylation of RASSF2, RASSF6 and RASSF10 in multiple 
cancers, including; pheochromocytoma (Richter et al., 2015), breast cancer (Hagrass et 
al., 2013), colorectal cancer (Heyn and Esteller, 2012), thyroid cancer (Schagdarsurengin 
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et al., 2010), lung cancers (Grawenda and O’Neill, 2015) hepatocellular carcinoma (Dong 
et al., 2015; Xu et al., 2013), brain gliomas (Hesson et al., 2004) and leukaemia (Hesson 
et al., 2009) to mention but a few. With other studies linking the downregulation of the 
RASSF TSG family with increased and unregulated transcription of oncogenic genes such 
as AREG, which can lead to tumourigenesis (Ahn et al., 2013),  
 Hippo pathway 
The Hippo pathway is frequently deregulated in cancer. Originally characterised in 
Drosophila, the Hippo pathway is a highly conserved pathway with important roles in 
the regulation of organ size, cell proliferation, cell cycle and cell death (Bao et al., 2011; 
Pan, 2010)(Yabuta and Nojima, 2013). With activation of the Hippo pathway, leading to 
apoptosis and cell death (Hong et al., 2014).  
In brief, the Hippo pathway is formed of a core cascade of proteins, Starting with a 
complex of serine/threonine kinases (MST1, MST2 and SAV1), this complex 
phosphorylates a second complex (formed of LATS1, LATS2 and a scaffold protein 
MOB1A) which in turn phosphorylates the oncogenic transcriptional co-activator 
complex YAP/TAZ. Preventing its transition into the nucleus and thus preventing gene 
transcription of pro-growth genes such as cyclin E, AREG and CTGF (Johnson and Halder, 




Figure 4-2: Schematic of the Hippo pathway. Schematic of the mammalian hippo pathway showing the basic core pathway when activated (ON) and un-activated (OFF) and Green represents proteins that promotes activity of YAP/TAZ and red, identifies proteins which inhibit YAP/TAZ activity.  Image is adapted form Johnson and Halder, 2014. 
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Additionally, phosphorylated YAP/TAZ, has been associated with pro-apoptotic 
functions of p73, while LATS2 causes reduced degradation of P53 through interactions 
with MDM2 (a known P53 suppressor) (Harvey et al., 2013). These observations 
highlight the complexity of the Hippo pathway and some of the mechanisms of action. As 
previously mentioned (section 4.1.3) the RASSF family of proteins have been identified 
to play an important role as scaffold proteins promoting the interaction of MST1 and 
MST2, and subsequent activation of the downstream components of the Hippo pathway 
signalling (Bao et al., 2011; Matallanas et al., 2007; Romano et al., 2010). The role of 
RASSF1A in the Hippo pathway is the most frequently studied, it has been identified that 
RASSF1 can dissociate MST1 and MST2 from inhibitory proteins such as Raf-1, and by 
forming homo and heterodimers (with other RASSF family members i.e. RASSF5) 
promotes the formation of the MST1/ MST2 complex and Hippo pathway activation (Bao 
et al., 2011; Matallanas et al., 2007; Romano et al., 2010), 
The role of the Hippo pathway in cancer is a common focus of studies, especially since 
transcription of growth factors such as CTGF have been associated with chemotherapy 
resistance (Johnson and Halder, 2014). Mutational analysis of the Hippo pathway has 
identified that somatic mutations within the core Hippo cascade proteins are rare 
(Harvey et al., 2013; Morris et al., 2011). However, upstream activators and regulators of 
the pathway such as the tumour suppressor NF2 have been observed to possess a high 
frequency of somatic mutations (>5% samples) in many cancers including glioblastoma, 
pituitary cancers and Schwannoma haemangioblastoma. Such mutations can result in 
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abnormal signalling of the Hippo pathway (Cancer.sanger.ac.uk, 2015; Harvey et al., 
2013; TCGA, 2008).  
Though mutations of the core Hippo pathway proteins is uncommon, frequent DNA 
methylation resulting in reduced expression of MST1/ MST2 and LATS1 has been 
reported in ccRCC (Chen et al., 2014), and soft tissue sarcomas, neurogenic sarcoma and 
liposarcomas (Seidel et al., 2007). 
Furthermore, the frequent loss of expression of the RASSF family of TSG through DNA 
methylation reported in many cancers including RCC (section 4.1.3) has been shown to 
correlate with decreased activation of the Hippo pathway leading to a decrease in 
apoptosis (Ahn et al., 2013).Moreover, a recent study by Schütte et al 2014, has also 
identified that aberrant signalling of the Hippo pathway is associated with more 
aggressive, invasive and metastatic ccRCC (Schütte et al., 2014). Providing further 
evidence that the Hippo pathway is one of the key pathways defective in RCC. 
 Study’s aim 
As previously described (section 1.4.2.1.5 and section 4.1.2), sarcomatoid RCC is a 
histological feature observed in between 1-8% of all ccRCC tumours and associated with 
advanced, aggressive and metastatic RCC and poor prognosis (Delahunt et al., 2013; 
Humphrey, 2012; Mian et al., 2002; Yan et al., 2015). However, little research has been 
conducted into epigenetic profiles of sRCC, with a recent PubMed search identifying that 
most sRCC based papers, are reports on histological observations and case studies [NCBI 
PubMed search, Keywords; Sarcomatoid Renal Cell Carcinoma sRCC; conducted on 14th 
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August 2015]. We therefore propose to undertake a candidate gene methylation study to 
identify methylation profiles of sRCC. 
Due, to the identification of frequent methylation of the RASSF family of TSG in non 
sarcomatoid RCCs (Costa et al., 2007; Dulaimi et al., 2004; Maher, 2013; Morris et al., 
2011). The observation that high levels of RASSF1A hypermethylation, were associated 
with advanced cancer grade and patient prognosis (Buhmeida et al., 2011; Selamat et al., 
2011). In addition to the identification of RASSF family proteins playing a key role in the 
activation of the pro-apoptotic Hippo pathway (Bao et al., 2011). A pathway that has 
been identified to be deregulated in several cancers, including advance and aggressive 
ccRCC (Johnson and Halder, 2014; Schütte et al., 2014). It was determined that the RASSF 
family of genes were good candidates, in which to investigate DNA methylation within a 
cohort of aggressive and metastatic sRCC. 
We therefore propose to undertake a candidate gene approach using Methylight analysis 
to characterise the methylation profile of the frequently methylated RASSF family of 
genes members RASSF1a, RASSF2, RASSF6 and RASSF10 in a cohort of sRCC samples 
derived from ccRCC. With further investigation conducted to ascertain if there is any 
association between methylation status and clinical data (objective 2 section 1.7).  
 Results 
 Methylation profile of RASSFs via Methylight  
The methylation status (section 0) of RASSF1a, RASSF2, RASSF6 and RASSF10 was 
determined in 31 Japanese samples of sRCC derived from ccRCC previously isolated and 
classified by Dr M Yao (section 2.1.2) and compared to normal non-diseased kidney 
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(Figure 4-3). However, data regarding the percentage of sRCC features within the 
tumours was not supplied. As previously described, RASSF1a, RASSF2, RASSF6 and 
RASSF10 are frequently methylated in several cancers; therefore, we undertook a 
targeted approach to investigate the methylation status within the rare and aggressive 
sRCC.  
Methylight is a highly sensitive technique, therefore in concordance with the literature a 
PMR of >10 was considered to represent the presence of methylation in a sample 
(Buhmeida et al., 2011; Dallol et al., 2011). Of the candidate genes investigated, we 
identified frequent methylation of RASSF2 and RASSF10 promoter regions in sRCC 
samples when compared to normal kidney. RASSF2 was identified to be methylated in 
25.8% (8/31) of sRCC samples, however this was not statistically significant when 
compared to RASSF2 methylation in normal kidney DNA (t-test for unequal variances 
P>0.5) 
 RASSF10 on the other hand was identified to be significantly methylated when 
compared to normal kidney DNA (t-test for unequal variances P<0.005). With a RASSF10 
methylation identified in a total of 48.4% (15/31) of sRCC samples. No methylation was 
observed within the normal kidney samples for either of these two candidate genes.  
Analysis of the range of PMR values identified large variation for both RASSF2 and 
RASSF10. For RASSF2 the PMR values observed, ranged from 0% to 100.5% (with a 
median PMR of 0% and a mean PMR of 14.9%).  For RASSF10 the PMR values observed, 















































RASSF1a presented with high levels of methylation in both the sRCC samples (median 
PMR = 117.1%, mean PMR = 112.2%, with a PMR range of 0% to 296% PMR) and the 
normal kidney (median PMR= 120.5% mean PMR = 122.8% and a PMR range of 85% to 
165.2%), therefore the methylation was not cancer specific.  
RASSF6 presented with no PMR value >10 in sRCC or normal kidney (sRCC samples 
presented with: median PMR=0%, mean PMR = 0.9%, and a PMR  range of 0% to 5%) 
and was therefore defined to be unmethylated in this cohort of sRCC .  
It was occasionally observed; particularly for RASSF10 and RASSF1a, that a PMR value 
exceeded 100%. Selamat et al., 2011 suggesting this may be due to the in-vitro 
methylated control not being fully methylated at the particular region investigated, but 
is still representative of high methylation within the region investigated.  
 Association with Clinical Phenotype and Survival 
To investigate if there is any association between the clinical data available for the sRCC 
(Table 2-1). Investigation into patient survival and the methylation status of RASSF2 and 
RASSF10, Kaplan-Meier survival analysis was conducted using Mantel-Cox analysis 
(Figure 4-4). No significant difference was identified between survival rate and 
methylation status (methylated samples had a PMR>10%) for RASSF2 (P>0.8) or 
RASSF10 (P>0.5). Further investigation examined a possible association between 
methylation status of RASSF2 and RASSF10 in sRCC and the occurrence of metastasis 
(defined according to the M stage of the TNM score (section1.4.1)  (Figure 4-5). Here we 
identified a potential trend, between and the methylation status of RASSF10 (P=0.04 




Figure 4-4: Kaplan-Meier survival curves  
Kaplan-Meier survival curves of A) RASSF2 and B) RASSF10, comparing patients’ survival (months) to methylation state (Methylated (Red); Unmethylated (Black). No significant difference in survival between patients with methylation and those that were unmethylated was observed (Mantel-cox analysis; RASSF2 P=0.81; RASSF10 P=0.50) 
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Figure 4-5: Association between methylation status and metastasis 
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It was observed that there was a higher occurrence of metastasis in samples presenting 
with methylation of RASSF10 (Figure 4-5b). This trend was not observed for RASSF2 
methylation (Figure 4-5a). No further clinical data was available as to the location of the 
metastasis. No further trends or associations were identified when comparing between 
methylation state, size of tumour, patient age or gender, nor were any further 
observations made when comparing clinical data with methylation status of RASSF2 and 
RASSF10 combined (Table 2-1). 
 RASSF10 Methylation in ccRCC 
As previously mentioned the sRCC samples investigated within this study are derived 
from ccRCC, and sRCC is identified as a late stage and aggressive tumour. We therefore 
hypothesised that frequent RASSF10 methylation maybe a potential feature of advanced 
late stage aggressive tumours.  
To test this hypothesis, firstly, we investigated the methylation of RASSF10 in all paired 
normal TCGA ccRCC samples from the Illumina 450K data [correct as of 1st March 2013] 
(clinical data shown in Table 2-11). Identified no overall methylation of RASSF10 
associated probes, however it should be noted that the CpG probes of the 450K array 
does not map to the same region of the RASSF10 CpG island which is interrogated by the 
Methylight primers, so further validation of the methylation status of RASSF10 in ccRCC 





Figure 4-6: TCGA 450K analysis of RASSF10  
Methylation of RASSF10 from TCGA 450K methylation data for 160 ccRCC with matched 
normal. Methylation status of each probes is shown as overall average of  values (top) and summary of the number of samples that were methylated as a percentage and 
frequency (bottom).  Methylation was defined as  value >0.5. 
450K probes (red) are mapped to a schematic of the RASSF10 gene (blue) and CPG island (Green).  Black line depicts the region covered by bisulfite sequencing and purple arrow depicts the region investigated by Methylight.  
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To further identify whether RASSF10 methylation was a feature of advanced stages of 
RCC, a further Methylight study investigating the methylation status of RASSF10 was 
conducted on an additional cohort of 20 Japanese ccRCC of various stages (6 = UICC 
stage I, 3 = UICC stage II, 6 = UICC stage III and 5 = UICC stage IV) (samples are separate 
from those analysed in chapter 3) (Figure 4-7). We identified 30% (6/20) of ccRCC 
samples presented with RASSF10 methylation (PMR>10). The methylation was 
distributed across the 4 stages of ccRCC as follows; 
 UICC stage: I 16.6% of samples (1/6 samples methylated) (average PMR=6)  
UICC stage II :0% of samples (0/3 samples methylated) (average PMR=0)  
UICC stage III: 16.6% of samples (1/6 samples methylated) (average PMR=3.7) 
UICC stage IV: 66.6% of samples (4/6 samples methylated) (average PMR=27)  
Moreover, statistical analysis suggested UICC stage IV to be significantly more 
methylated than stage I (t-test P=0.043), but not significantly different from the sRCC 
cohort (t-test P=0.28), when analysed using a student t-test for unequal variance. 
However, analysis using Fishers exact test identified no significant difference between 
any stages or ccRCC and sRCC (P>0.05). From this Methylight study we propose that 
there maybe a trend for increased frequency of RASSF10 methylation in later ccRCC 
stages, when visually analysing the data (Figure 4-7), however the small cohort size 




Figure 4-7: Methylight analysis of RASSF10 in ccRCC The methylation status of ccRCC samples separated according to stage is displayed as PMR and compared to normal non-diseased kidney. Black line depicts the overall mean PMR for each stage.   Samples with PMR >10 were deemed methylated, as depicted by dashed threshold line. Student t-test  * P<0.05 
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 Confirmation of Methylight 
Validation of the results obtained via the sensitive Methylight technique was conducted 
via single colony sequencing (section 2.3.4) on a small selection of sRCC (n=3) and ccRCC 
(n=3) samples to ascertain the methylation status of each individual CpG dinucleotide. 
Primers were selected to sequence a region of the RASSF10 CpG island that also 
encompassed the CpG dinucleotides interrogated via the RASSF10 Methylight primers.  
As displayed in Figure 4-8 the region of the RASSF10 CpG island sequenced is shown as a 
schematic against the gene. For the sample sequenced, the methylation status of each 
CpG dinucleotide is also displayed either as black (methylated) or white (unmethylated), 
with each row representing an individual allele.  
For each sample, the methylation index (MI) for the entire region was calculated. 
Additionally, the MI for the CpG dinucleotides interrogated by the Methylight assay was 
also calculated and compared to the Methylight PMR for each sample. 
The MIs calculated for the Methylight region were identified to be similar to the PMR 
values recorded for each sample in both histologies, thus validating the Methylight 
technique.  Additionally, it should be noted that the Methylight region MI and PMR were 
also similar to the overall MI for the whole region sequence, suggesting that the 
‘snapshot’ of methylation status provided by Methylight, is a valid representation of the 




Figure 4-8: Validation of the Methylight PMR The methylation status of RASSF10 NM_001080521 was confirmed by single colony sequencing in 3 sRCC sample and 3 ccRCC. Each block represents a different sample with each row an individual allele, each circle depicts a CpG loci location and colour depicts methylation status; methylated (black) or unmethylated (white). The region investigated within the Methylight study is shown by the purple line above each sample. The total methylation index (MI) for the whole region single colony sequenced together with the recorded PMR and the MI for the Methylight region is shown. Schematic of the RASSF10 gene (blue), CpG island (green) and the region investigated by Single colony sequencing (dashed lines) are shown. 
CpG island: 2254 bp ; 209 CpGs  
5’ UTR: 154bp Exon 1: 1524bp  3’UTR: 10064bp  
  
Chr11: 13030331 Chr11: 13033653 
sRCC ccRCC 
Total MI: 97.5%  Methylight region MI: 100%  PMR:116.4% 
Total MI: 84.4%  Methylight region MI: 81.9%  PMR:78.5% 
Total MI: 54.5%  Methylight region MI: 56.9%  PMR: 49.9% 
Total MI: 33.2%  Methylight region MI: 20.0%  PMR: 17.6% 
Total MI: 6.2%  Methylight region MI: 3.3%  PMR: 0% 
Total MI: 33.6%  Methylight region MI: 38.1%  PMR: 34.3% 
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 Mutation Screen of RASSF10 
Further investigations were conducted in order to establish if any other genetic features 
of RASSF10 were present in the 31sRCC samples. The first approach was to establish if 
RASSF10 was frequently mutated in sRCC and so the whole coding region of the single 
exon gene was examined via Sanger sequencing (section 2.5). No mutations were 
identified, within the 31 samples except for a known SNP, rs55909156 G>C at location 
11:13010964 resulting in a non-synonymous change of p.C463S (Minor allele frequency 
(MAF) of 0.08 (8%) assessed via the 1000 genome project).  
 Loss of Heterozygosity of RASSF10 
Loss of heterozygosity (LOH) is a common feature in cancer, particularly within the 
widely accepted two-hit paradigm (section1.2.2.2). Having found no somatic mutations, 
our attention was focused on identifying if any LOH may be present for RASSF10 in sRCC. 
LOH was investigated using a known size standard and primers specific for 
microsatellites flanking the RAFFS10 gene that were previously characterised to have a 
discernible range of product sizes (± 25bp) and a high probability of being heterozygous 
(> 0.6 probability) (section 2.2.7). LOH was detected by identifying if the primers both 
upstream and downstream of the GOI were homozygous, while the matched normal 
remained heterozygous. However, in 31 sRCC and matched N samples tested no LOH 




 Expression analysis  
Expression analysis was then undertaken on renal cancer cell lines (ccRCC derived) to 
confirm that methylation of RASSF10 corresponds to reduced expression of mRNA. 
Firstly, the methylation status of RASSF10 in the ccRCC cell lines was established via 
CoBRA (Figure 4-9a). It was identified that for the RCC cell lines RCC11, UMRC3, A498 
and A704 cell lines RASSF10 was methylated while the KTCL140 and SKRC45 cell lines 
were unmethylated.  
In order to determine the effect of DNA methylation on expression, the aforementioned 
cells lines were cultured by Mr D. Gentle in the presence of de-methylating agent 5-aza-
2’-deoxycitidine (5-aza) (section 2.6.4), with a second untreated culture used as control. 
Following 4 days in culture RNA was extracted (conducted by Mr Dean Gentle) 
Due to the single exon nature of RASSF10 all RNA was subjected to an additional DNase 
clean up step, to remove residual DNA, prior to RT-PCR generation of the cDNA library 
and examination of RASSF10 expression (section 2.7.2). 
For the methylated cell lines, removal of methylation via 5-Aza treatment resulted in 
increased RASSF10 mRNA expression when compared to the untreated controls. For the 
unmethylated cell lines (SKRC45 and KTCL140), demethylating treatment had no visible 
effect on the expression of RASSF10 (Figure 4-9b). We therefore concluded that RASSF10 
methylation inhibits expression of the mRNA, however removal of the DNA methylation 






Figure 4-9: RASSF10 expression analysis Methylation status and expression of RASSF10 in kidney cancer cell lines. A) CoBRA analysis identifies RASSF10 methylation in kidney cancer cell lines; samples are displayed as Undigested (U), compared to BSTU1 digested (D) arrows depict samples that are methylated. B) RT-PCR examining RASSF10 mRNA expression between control (C) and 5-Aza treated (A) kidney cancer cell lines. Methylated cell lines did not express RASSF10 mRNA. Expression of RASSF10 mRNA was restored upon removal of DNA methylation after 5-Aza treatment. Unmethylated cell lines showed no difference in expression between control and 5-Aza treatment. GAPDH was included as a control for expression. 
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 Soft agar assay of RASSF10 knockdown 
At the time of this study little was known as to the function and method of action of 
RASSF10 (Underhill-Day et al., 2011b). Due to the high homology with other RAS binding 
proteins of the RASSF family, it had previously been predicted that RASSF10 is a TSG. 
Studies in other cancers have previously identified frequent methylation of the RASSF10 
promoter associated in reduced expression of the RASSF10 mRNA. Further in-vitro 
studies identified an increase in cell growth when RASSF10 was knocked down in cell 
lines, a characteristic feature of TSGs (Hesson et al., 2009; V K Hill et al., 2011) . 
To test that loss of RASSF10 results in increased cell growth within kidney cancers, we 
performed an anchorage independent growth assay (soft agar assay) in ccRCC cell lines 
(section 2.6.8). The use of soft agar assays is considered to be a more biologically 
relevant technique for investigating potential carcinogenic features such as knockdown 
of TSGs, as it allows for anchorage independent growth of the cell, a hallmark of 
carcinogenesis (Borowicz et al., 2014). RASSF10 was knocked down (KD) via siRNA 
transfection in cell lines previously identified to express RASSF10 (SKRC45 and 
KTCL140) (section4.1.12). Soft agar analysis of RASSF10 knockdown via siRNA 
(RASSF10-KD) in SKRC45 and KTCL140 cell lines resulted in a significant increase in 
colonies formation for both cell lines. For SKRC45 (Figure 4-10), negative control 
nonsense-siRNA (-ve Control) produced an average 102 colonies (n=5), while RASSF10-
KD produced an average of 250 colonies (n=4, P = 2.39e-05). KTCL140 -ve control 
produced an average 134 colonies (n=5) while RASSF10-KD produced an average of 201 
colonies (n=6 P=0.0026).  
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Western blots were conducted to analyse and quantify protein expression to confirm 
that siRNA KD of RASSF10 had resulted in reduced protein levels (Figure 4-11). 
Normal convention would be to validate and control for off target effects of siRNA 
knockdown by performing a second knockdown of RASSF10 and soft agar assay, 
repeating the experiment using a different siRNA targeted for RASSF10. However, in this 
case the siRNA used had previously been validated in our lab and compared to a second 
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Knocking down RASSF10 via siRNA resulted in reduced protein expression and a 
significant increase in cell growth and colony formation in soft agar, suggesting that 
RASSF10 acts in a similar manner to a TSG, and the presence of the protein restricts and 
limits cell growth. 
 Preliminary investigation of RAFFS10 binding partners 
RASSF10, is a member of the N-terminal RASSF family.  Although N-terminal RASSF 
proteins have been identified to display TSG activity (V K Hill et al., 2011; Wei et al., 
2013), the protein-protein interactions and tumour suppressive mechanisms of action of 
this subset of  RASSF family of proteins remains poorly understood (Underhill-Day et al., 
2011b).  
The identification that many of the classical RASSF proteins (RASSF 1- RASSF 6) play 
a pivotal role in the regulation of cell cycle and apoptosis through activation of the Hippo 
pathway (Fausti et al., 2012). Coupled with, previous studies identifying that RASSF10 
localises to the centrosomes during mitosis (V K Hill et al., 2011). Led us to formulate the 
hypothesise that RASSF10 may too play a role in cell cycle regulation. 
We therefore proposed to investigate the protein interactions of RASSF10. By using 
immunoprecipitation (IP) to isolate the proteins interacting with RASSF10 at different 
stages in the cell cycle and mass spectrometry (MS) to identify the interacting proteins. 
We hope to identify if RASSF10 interacts with known cell cycle proteins, and at which 
stage in the cell cycle do these interactions occur.  
However, in order to associated any protein interactions with specific stage of the cell 
cycle, cells must first be synchronised so they the majority of cells are at the same stage 
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in the cell cycle prior to IP and MS. By subjecting growing cells to different treatments or 
agents, it is possible to synchronise cell cycle so that the majority of cells are in the same 
phase. In this study (conducted by Dr. D. Matallanas and team (Systems Biology Ireland, 
University College Dublin)) stable HEK293 cell line overexpressing RASSF10- Flag were 
cultured under the following conditions: growing (under normal conditions, control 
group), serum starved, arresting cell cycle at G2/M phase ,100 ng/ml Nocodazole (noco 
x1) arresting cell cycle at G2/M phase and 2 mM Thymidine (T1) arresting cell cycle at 
G1/s phase) (section2.7.6) ((Rosner et al., 2013)). Following synchronisation, a co-IP 
specific for the Flag tag was performed, this would pull down and all proteins currently 
bound to the overexpressed RASSF10-Flag protein. Bound proteins were then identified 
and quantified (label free quantification (LFQ) by MS. 
Dr. Matallanas and myself conducted joint analysis of the output data (section2.7.6) , 
firstly the specificity of the original immunoprecipitation was confirmed, this ensured 
that the IP was specific for RASSF10-Flag, and as a check for contamination and was 
achieved analysing an untransfected control IP MS output, where the bait protein 
(RASSF10) should not be observed. Secondly the quality of the IPs and the MS was 
assessed. This was achieved by comparing the abundance of the bait protein RASSF10, 
calculated as label free quantification intensity ((LFQ) a quantitative value relating to the 
abundance of a protein, determined by the MS signal intensity), across all growing 
conditions containing the RASSF10-Flag transfection, the LFQ for RASSF10 should be 
present at similar levels across all conditions. We observed that the bait protein 
RASSF10 was present in all conditions, however it was noted to be lower in the normal 
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growing condition compared to the cell cycle synchronised conditions. It is therefore, 
imperative that the mass spectrometry be repeated, before definitive conclusions can be 
drawn from the data. Despite this set back, it is still possible to obtain a preliminary 
indication into potential RASSF10 binding partners, at different cell cycle stages, 
although it is imperative that validation and confirmation is conducted. 
To identify RASSF10 binding proteins, firstly the LFQ of each protein identified for each 
condition was compared to the negative control. Proteins with a LFQ fold difference of 
>1 and a P value <0.001 in the condition compared to the negative control were 
classified as specific RASSF10 binding proteins. Samples that did not meet these criteria 
were excluded and deemed to be contaminants. The next stage was to compare between 
the growing conditions, here the criteria was set to a fold difference in LFQ intensity of 
>2 fold and a P value of <0.05 (FDR corrected student t-test). When comparing the cell 
cycle synchronisation growing condition to that of standard growth, MS identified 199 
proteins (42 + 27 ribosomal proteins increased in starved, 22 + 17 ribosomal proteins 
increased in Noco-x1 and 53 + 41 ribosomal proteins increased in Thy x1) with a 
significant increase in LFQ (FDR<0.05), and thus are candidate RASSF10 binding 






Table 4-1: Protein list of candidate RASSF10 binding partners significantly increased in G1/S cell cycle stage compared to normal growth.  Table displays RASSF10 binding proteins identified by mass spectrometry, protein name, the fold difference of RASSF10 binding proteins between the two growth conditions (LFQ ratio) calculated as LFQ starved/LFQ growth. Proteins identified in other growing conditions are highlighted in yellow, with the most interesting in bold and RASSF10 (Bait protein) in green.  
Protein LFQ ratio FDR Protein LFQ ratio FDR
PGAM5 2.754 8.08E-09 MTMR14 4.061 2.99E-03
EIF3F 3.861 2.92E-08 SRSF3 2.349 2.99E-03
ACAP2 2.185 6.69E-07 ACIN1 3.687 3.13E-03
RASSF10 3.619 6.67E-06 SF3B2 2.189 3.89E-03
BCLAF1 3.196 1.25E-05 INTS7 3.197 3.89E-03
THRAP3 3.478 1.57E-05 OTUD4 3.248 4.85E-03
EIF3E 3.148 1.62E-05 HUWE1 2.068 0.01
EIF3H 2.608 3.85E-05 SAFB 4.248 0.01






GTPBP10 7.239 3.65E-04 KIF4A;KIF4B 2.147 0.01
EIF4G2 2.189 4.98E-04 RBMX;RBMXL1 4.649 0.01
TRA2A 5.674 5.13E-04 NCOA5 4.240 0.01
RALY 2.733 0.01
PRSS1;PRSS2;TRY6 17.551 0.01
GATAD2A 2.278 1.65E-03 HIST3H2BB 17.983 0.02
SPIN3 2.953 1.65E-03 UHRF1 2.514 0.03



















Table 4-2: Protein list of candidate RASSF10 binding partners significantly increased in G2/GM cell cycle stage compared to normal growth. Table displays RASSF10 binding proteins identified by mass spectrometry, protein name, the fold difference of RASSF10 binding proteins between the two growth conditions (LFQ ratio) calculated as LFQ Nocodazole (noco x1)/LFQ growth. Proteins identified in other growing conditions are highlighted in yellow, with the most interesting in bold and RASSF10 (Bait protein) in green.  
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Table 4-3: Protein list of candidate RASSF10 binding partners significantly increased in G0/G1 cell cycle stage compared to normal growth Table displays RASSF10 binding proteins identified by mass spectrometry, protein name, the fold difference of RASSF10 binding proteins between the two growth conditions (LFQ ratio) calculated as LFQ Thymidine (T1)/LFQ growth. Proteins identified in other growing conditions are highlighted in yellow, with the most interesting in bold and RASSF10 (Bait protein) in green. 
Protein LFQ ratio FDR Protein LFQ ratio FDR
EIF4G2 0.40140861 4.00E-04 RASSF10 0.20732901 0.02
PDCD4 0.11345595 4.00E-04 AARS2 1.2996E-06 0.02
USP7 0.46819728 4.00E-04 EIF3A 0.34532816 0.02
DDX28 0.05377929 2.10E-03 TP53BP2 0.18589489 0.02
ERLIN2 0.37590089 2.10E-03 WDR26 0.33352871 0.02
DHX40 0.32353075 2.42E-03
SLC25A10 0.28908757 2.80E-03
GTPBP10 0.37763337 2.80E-03 GALK1 0.38650469 0.02
WNK1 0.14970391 3.25E-03 LRCH2 0.15418427 0.02
EIF3B 0.40932966 3.96E-03 CECR5 0.47582966 0.02
RPS19BP1 0.23810026 3.96E-03 EXOSC6 0.49289435 0.02
NKRF 0.31887929 4.26E-03 NDUFB8 0.34568703 0.02
USP9X 0.38416164 4.26E-03 EIF3G 0.39995842 0.02
EIF3K 0.456397 4.61E-03 EIF3J 0.32779262 0.02
SMC2 0.44158279 4.96E-03 ICT1 0.18973703 0.02
EIF3F 0.42294883 0.01 GTF3C5 0.47772165 0.02
ARMC6 0.19216297 0.01 DBT 0.3798879 0.03
C8orf33 0.49243977 0.01 TBC1D4 0.28415098 0.03
WRNIP1 0.10658945 0.01 EIF3I 0.47334517 0.03
SMEK1 0.48817113 0.01 NDUFS6 0.34937595 0.03
ERC1 0.2797408 0.01 HEATR3 0.47393869 0.03
VANGL1 2.8185E-06 0.01 NDUFS7 0.43002809 0.03
PDAP1 0.49591734 0.03
YTHDC2 0.39746368 0.04
GPKOW 0.46609774 0.01 GADD45GIP1 0.24798912 0.04
DIAPH1 0.42005677 0.01 PELP1 0.14102917 0.04
PRPS2 0.47669961 0.01 HIBCH 0.31917763 0.05
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String-db Kegg pathway analysis identified all three synchronisation conditions to be 
significantly associated with the ribosomal network (FDR: P = 3.560e-21 starved; P = 
1.59e-9 Noco x1; P= p2.339e-23) or the splicosome network (FDR: P = 2.459e-8 starved; 
P = 1.59e-9 Noco x1; P = 7.179e-4. Other statistically significant pathways and networks 
that were highlighted, were associated with DNA conformational and chromatin 
assembly change (FDR P = 1.798e-13 starved), thyroid hormone signalling pathway (FCR 
P= 2.073-1 Thy x1, mitochondrial electron transport and ATP synthesis coupled electron 
transport (P=<1.97e-9 Thy x1) (Figure 4-12 -Figure 4-14). 
Three proteins (excluding RASSF10) were identified in two cell synchronisation 
conditions (starved (cell cycle stage G0/G1) and thy x1 (cell cycle stage G1/S) EIF3F, 
EIF4G2 and TP53BP2 (tumour protein 53 binding protein 2; ASPP2). EIF3F and EIF4G2 
were associated with RNA transport network (Kegg FDR P= p 7.38e-4 starved and P= p 
8.099e-4 Thy x1) (Table 4-1 and Table 4-3). TP53BP2 is a particularly interesting 
protein due to its association with P53, a protein previously identified as a TSG involved 
in many key regulatory pathways including multiple cell cycle check points, DNA repair 
and apoptosis (Giono and Manfredi, 2006). The LFQ for TP53BP2 is shown in Figure 
4-15 and although not significant after FDR correction, it was observed that the LFQ for 
TP53BP2 within Noco x1 growing conditions was 4.6 fold greater than the recorded LFQ 
for growing conditions. Combined with the identification within the starved and thyx1 
growing conditions, it is suggested that TP53BP is an interesting binding partner of 
RASSF10 during the cell cycle. Additionally P53 is frequently mutated in many cancers 
(Muller and Vousden, 2013; Rivlin et al., 2011). Targeted hindsight analysis of the MS 
data identified TP53 within the original output file, however it was excluded during 
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analysis as one of the control replicates presented with a high LFQ (Figure 4-16a). If the 
anomaly was to be excluded, TP53 appeared to show a significant increase in cell cycle 
associated conditions when compared to growing (T-Test: P>0.001 starved; P=0.036 
Noco x1, Thy1 P=0.005) (Figure 4-16b). If a true observation, it maybe proposed that 
RASSF10 acts as scaffold protein between TP53 and TP53BP2. However, this proteomics 
data is from a preliminary study only and ideally requires optimising and repeating. 











Figure 4-13: String db network analysis: Noco x1 v growth String-db prediction networks for proteins significantly more abundant in Noco x1 compared to normal growth. Blue lines indicate confidence of interaction, all interactions shown are more than median confidence classified as a score >0.4. White nodes are additional predicted connecting nodes and are not present in predicted RASSF10 binding protein list. Ribosomal associated nodes were excluded from string-db image to allow visualisation of other protein networks and interactions. 














































Figure 4-16: Mass Spectrometry reading for TP53 A) Raw LFQ recorded for each replicate of the negative control. Sample 3 was identified to have a much higher LFQ reading for TP53 than the other two repeats. This observation is indicative of contamination within sample 3 B) Shows the average LFQ recorded for TP53 within each growing condition, (abnormal repeat within negative control excluded). Student T-Test identifies significance between group * P>0.05, and *** P>0.001  










































































sRCC is a rare and highly aggressive advanced staged RCC, associated clinically with a 
high rate of metastasises and poor prognosis. However, despite the aggressive nature of 
the tumour, little research has been conducted into the epigenetic profile of sRCC. Here 
we have undertaken quantitative Methylight analysis of frequently methylated genes 
RASSF1a, RASSF2, RASSF6 and RASSF10 with the aim of identifying differential DNA 
methylation, which may provide an insight into the progression and development of 
sRCC. 
 Methylation analysis 
Within this study we identified RASSF1A, RASSF2 and RASSF10 to be frequently 
methylated in 93.5%, 25.8% and 48.3% sRCC samples respectively. 
RASSF1A has been frequently reported as being hypermethylated in a cancer specific 
fashion in a multitude of cancers including, but not limited to, pRCC, ccRCC, chRCC and 
oncocytoma (Costa et al., 2007; Ellinger et al., 2011b; Morrissey et al., 2001) 
pheochromocytoma (Richter et al., 2015), lung cancers (Grawenda and O’Neill, 2015), 
brain gliomas (Hesson et al., 2004)  breast cancer where RASSF1a methylation is 
associated with advance stage  (Hagrass et al., 2013) and hepatocellular carcinoma 
(Dong et al., 2015; Xu et al., 2013). Despite this plethora of cancer specific methylation, 
we identified methylation of the RASSF1A promoter region in 100% (4/4) of the normal 
non-diseased kidney, and thus deemed RASSF1A methylation to be a general event and 
not specific to sRCC. Furthermore quantitative-MSP (q-MSP) upon hepatocellular 
 
 227
carcinoma identified a subset of normal tissue (5%) to present with high methylation of 
RASSF1a with a PMR>50 (Xu et al., 2013). However, it should be noted that q-MSP is not 
as sensitive or as specific as Methylight and thus the PMR values are not directly 
comparable. A further study utilising the sensitive Methylight technique, aimed  to assess 
the possibility of analysing RASSF1a methylation within the serum of patients with  
hepatocellular carcinoma, in the hope that RASSF1A methylation could be used as a non-
invasive biomarker for disease diagnosis. This study demonstrated that methylation 
could be observed in patient serum and correlated with progression and prognosis 
(Dong et al., 2015). These findings demonstrate that RASSF1a methylation can be 
identified in many different tissues type and although more frequently observed as 
methylated in cancers, it may not be solely cancer specific.  
RASSF2 was identified to be differentially methylated in 25% of sRCC samples when 
compared to the normal kidney, however the level of methylation was not identified to 
be statistically significant. Further comparison with clinical data identified no trend 
between methylation status and survival, age, gender, size of tumour or occurrence of 
metastasis thus RASSF2 was not investigated further.  
RASSF10 on the other hand was identified as the most interesting candidate of the genes 
tested, with frequent methylation observed in 48.3% of sRCC samples and an average 
PMR of 17%. Furthermore we identified higher methylation levels (average PMR 27% in 
UICC stage IV ccRCC compared to the PMR average of 6% in UICC stage I) and occurrence 
in the more advanced stages of ccRCC without sRCC components, suggesting that 
RASSF10 methylation is a late stage event that may be involved in the transformation of 
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ccRCC histology to that of sRCC. However, it is should be noted that the number of 
samples we were able to investigate for each stage of ccRCC was limited and that 
frequency and average PMR is likely to be lower than we observed in this study. 
Additionally we observed a trend that RASSF10 methylation correlated with increased 
occurrence of metastasis (P >0.05).  This observation requires further investigation and 
confirmation in an independent cohort. Although we identified no somatic mutations, or 
LOH, we did show that RASSF10 methylation reduced mRNA expression within kidney 
cancer cell lines consistent with the current view on the effect of DNA methylation. 
Additional soft agar assays were also conducted, in which we knocked down RASSF10 
expression via siRNA, this resulted in an increase in cell growth and colony formation. 
This result coincided with two independent studies and provides further evidence that 
RASSF10 is a tumour suppressor gene, which when lost, results in increased cell growth 
(V K Hill et al., 2011; Richter et al., 2012; Wei et al., 2013)  
Many other reports have observed frequent methylation of RASSF10 in many different 
cancers such as, childhood leukaemia’s (88%) (Hesson et al., 2009), gastric cancer (75%) 
(Wei et al., 2013) ( although a further study of 300 gastric cancer samples put the 
frequency of methylation much lower at 30% but identifies a significant decrease in 
cancer-specific survival in patients presenting with RASSF10 methylation (Deng et al., 
2014)), adrenal medulla tumour pheochromocytoma (73%) (Richter et al., 2015) and 
Sarcoma (17%) (Richter et al., 2012). Helmbold et al., 2012 identified RASSF10 promoter 
methylation in 68% of primary malignant melanoma. However, when analysing the 
secondary tumours resulting form malignant melanoma metastasis (including skin 
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lymph node and brain) the frequency of RASSF10 methylation was identified in 91% of 
the secondary cancers. The differentiation in occurrence of RASSF10 methylation 
between primary and secondary tumours, further strengthens our hypothesis that 
RASSF10 has a role in metastasis. Hill et al., 2011 studied RASSF10 methylation in 
relation to WHO giloma stage. Here they identified RASSF10 methylation to be absent in 
grade I giloma, but present in grade II, III and IV (60%, 80% and 65% respectively) 
suggesting that RASSF10 methylation occurs fairly early on in tumour development but 
is also associated with the more aggressive form of the cancer. Li et al., 2014 identified a 
significant increase in the observation of RASSF10 methylation in gastric cancer patients 
with lymph node metastasis compared to patients without lymph node metastasis. 
Finally, Guo et al., 2015 studied the methylation status of RASSF10 within 89 primary 
colorectal cancer samples and identified 60.7% of samples to be positive for RASSF10 
methylation, with no methylation identified within the normal colorectal mucosa. 
Moreover, analysis of the clinical data identified RASSF10 methylation to be significantly 
associated with the more advanced stages of colorectal cancer, it was also identified that 
RASSF10 methylation was significantly associated with metastasis to the lymph nodes. 
These findings correlates with our hypothesise that RASSF10 methylation is associated 
with advanced and aggressive tumours such as sRCC.  
 Limitations and future work 
The biggest limitation of this study was regarding the histopathology of the sRCC 
samples. Cancers are very heterogeneous tissues by nature due to clonal evolution in 
combination with genomic instability and high mutation rates, levels of genetic diversity 
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can be extremely high, within a single tumour (Gerlinger et al. 2014). sRCC derived from 
ccRCC, are by definition heterogeneous. This heterogenetic diversity has led to the 
visually distinct histology, the sarcomatoid features.  Furthermore, the extent of 
sarcomatoid features within a tumour can vary drastically, ranging from 1% to 100% of 
the tumour histology (Kim et al., 2015). For our cohort, DNA was extracted from the 
whole tumour by our collaborator Dr M Yao, therefore our analysis was conducted on a 
mix of sarcomatoid and ccRCC DNA. These heterogeneous samples being investigated, 
coupled with no clinical data regarding the extent or percentage of sarcomatoid features 
within the tumours makes the interpretation of this data challenging and limiting. For 
example, we in this study we identified a PMR range for RASSF10 of 0 to 116.4. Therefore 
if RASSF10 methylation is truly as we hypothesise and associated with the later stages of 
advanced and aggressive ccRCC, then one would expect the highest levels of RASSF10 
methylation to correlate with higher percentage of sRCC subtype, however, we are 
unable to draw such conclusions in this study. Furthermore, no data was provided 
regarding the extent of sarcomatoid features in the ccRCC cohort, therefore objective 
comparisons between methylation status and stage in this tumour type may be flawed. 
To overcome this limitation, it would be preferable to obtain sRCC samples, from which 
the sarcomatoid features have been microdissected from the tumour, not only would this 
provided a ‘pure’ histology to analyse, but would also permit the direct comparison of 
sarcomatoid to the matched ccRCC allowing for investigations into differential 
methylation of the two histologies (Gillespie et al., 2001; Yoshihara et al., 2013) 
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Another major limitation, was the number of samples investigated, however due to the 
rarity of sRCC it was not possible to source a larger cohort, additionally our cohort size 
for ccRCC examination was limited to the samples for which we had clinical data 
regarding their stage. Additionally we had no access to sRCC patient RNA or sRCC cells 
lines so were unable to assess the effect of RASSF10 methylation in a sRCC model, 
although the cell lines utilised were derived for a ccRCC cancer, the same tumour type 
from which the sRCC we studied were derived. A larger cohort would also help to clarify 
if the observation between RASSF10 methylation and metastasises is a true association 
or whether it was just a coincidental observation. 
Additionally it should be noted that RASSF10 methylation was not identified within a 
ccRCC cohort of TCGA methylation. We propose that this discrepancy in findings may be 
due to the TCGA 450K characterising the methylation status of individual CpG 
dinucleotides which may be infrequently methylated in the less aggressive form of 
cancer, furthermore as shown in figure 4-6 none of the CpG probes mapped to the region 
investigated by single colony sequencing or Methylight.  
Limitations with the Methylight technology are similar to that with standard PCR based 
methylation studies, in which only a small fragment of the DNA is analysed for 
methylation and relies on the general assumption that the DNA methylation pattern 
identified within a small region is indicative of CpG methylation in the surrounding area 
(Bibikova et al., 2011; Eckhardt et al., 2006). For Methylight the region investigated is 
usually smaller than MSP, with primers designed to amplify a product length of between 
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50- 200bp as longer products can affect the efficiency of the fluorescence of the probes 
(Trinh et al., 2001). 
Furthermore due to the sensitivity of the array it can be highly susceptible to 
experimental error such as variation within pipetting volume or contamination. 
However, despite these limitations, bisulfite sequencing confirmed that the PMR was 
representative of the surrounding area. Furthermore, by conducting each sample in 
duplicate on the plate and each plate in triplicate, the risk of outliers was reduced within 
the data. On the whole we found the array to be reliable, consistent and representative of 
the DNA methylation status. 
Within our study we observed PMR values of >100 for some samples when testing for 
the methylation status of RASSF1a and RASSF10. This had previously been attributed to 
incomplete methylation of the intro-methylated control at that particular region 
(Selamat et al., 2011; Xu et al., 2013). However no further mention as to the effect of this 
observation was reported and it is assumed that the sample is fully methylated at that 
given region.  
Future work would involve the further characterisation and investigation of the role of 
RASSF10 in tumourigenesis. Also we should conduct a second soft agar assay using a 
different siRNA targeted for RASSF10, in order to validate and confirm that the result 
observed, that loss of RASSF10 results in increased cell growth was not the result of off 
target effects of the siRNA transfection. Additionally, further functional studies such as  
scratch migration assays should be under taken to investigate the association identified 
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between RASSF10 and metastasis, and to identify if RASSF10 knockdown effects cell 
migration. 
Further work on the sRCC samples would be to investigate the less frequently 
methylated members of the RASSF family, using this sensitive technique to identify if 
there is any further differential methylation patterns. For example RASSF3 was identified 
to be frequently methylated in pituitary tumours although no observation between 
methylation state and grade was observed (Peng et al., 2013), although other studies 
have not identified any further methylation of RASSF3 in other cancers. RASSF5A 
methylation on the other hand is fairly common. Several studies on cancers including 
thyroid and skin cancer identified RASSF5A methylation at high frequency within the 
normal, thus it was not deemed cancer specific (Richter et al., 2013; Schagdarsurengin et 
al., 2010). 
Other work would require sourcing a second independent cohort of sRCC derived from 
ccRCC and confirming methylation frequency and association with tumour stage and 
metastasis. Additionally if RNA could be sourced then we would be able to assess the 
effect of RASSF10 methylation on mRNA expression within primary tumour samples. 
 RASSF10 proteomics 
At the time of this study limited investigation had been conducted into the pathways or 
binding partners with which RASSF10 was associated. A study by Richter et al., 2013 
investigated the effect of PKA overexpression on RASSF10 expression and concluded 
that PKA is likely to be an upstream activator of RASSF10. A second study, identified that 
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RASSF10 overexpression induced apoptosis via inhibition of the Wnt/β-catein signalling 
pathway (Wei et al., 2013). 
Previous studies have identified an association and role for other RASSF family members 
(predominately RASSF1a, RASSF2, RASSF3, RASSF5 and RASSF6) within the HIPPO 
pathway, apoptosis and cell cycle regulation (Cooper et al., 2009; Iwasa et al., 2013; 
Matallanas et al., 2007; Romano et al., 2010; Shivakumar et al., 2002). Another study 
identified RASSF10 localisation during mitosis to the centrosomes (V K Hill et al., 2011). 
As a result of this, and due to the high homology observed between members of the 
RASSF family, our initial investigations focused on the analysis of RASSF10 binding 
protein within cell cycle checkpoints via MS. 
Through a preliminary study, it was identified that TP53BP2 maybe an interesting 
candidate as a RASSF10 binding protein, with intensity of binding significantly increased 
in cells that had had their cell cycle synchronised (Starved and thy x1).  Noco x1 
identified an increase in TP53BP2/RASSF10 binding, although this was not a statistically 
significant observation.  
TP53BP2 (Tumour Protein p53 binding protein 2; aka ASPP2 (Apoptosis-stimulating of 
p53 protein 2)) as its name suggests, binds the C-terminal of the P53 TSG and is involved 
in the regulation of apoptosis and cell growth through many complex interactions and is 
associated with impeding cell cycle progression at G2/M phase (Genecards.org, 2015; 
Chen et al., 2003). ASPP2 is categorised as a TSG and has widely been investigated as a 
pro-apoptotic gene, driving p53 mediated apoptosis in response to DNA damage (Z. 
Wang et al., 2013). Together with its counterpart (ASSP1) it has been identified that 
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ASSP2 activation by the oncogene RAS is required to enhance the tumour suppressive 
effects of p53. Thus ASPP2 is an important negative regulator of oncogenic RAS 
associated growth (Godin-Heymann et al., 2013; Y. Wang et al., 2013). Additionally 
ASPP2 elicits a tumour suppressor function and regulation of RAS by facilitating RAS 
induced senescence (Y. Wang et al., 2013; Z. Wang et al., 2013). Normal cells possess 
multiple safety features in order to protect against tumourigenesis; one particular 
feature is senescence. This is where a cell permanently exits the cell cycle and can no 
longer proliferate, this feature is lost in cancer. When an oncogene such as RAS is 
activated, so too is the senescence pathway of the primary cell and the cell is withdrawn 
from the cell cycle; a process known as oncogene-induced senescence (Dimauro and 
David, 2010; Karnoub and Weinberg, 2008). A recent study characterising the N-
terminal of APSS2, binding to RAS-GTP and inducing Ras/Raf/MEK/ERK signalling this 
in turn facilitates activation of RAS-induced senescence independently of P53 activation 
(Wang et al., 2013).  
Other studies have identified additional roles for ASSP2 with regards to cell polarisation, 
cell junction formation and central nervous system development. Reporting that loss of 
ASPP2 resulted in shortened cell cycle length (possible due to the cell cycle arrest and 
check points being missed) in neural progenitor cells (Sottocornola et al., 2010) 
Having identified TP53BP2, as an interesting potential binding partner of RASSF10 we 
went back to analyse the raw MS data to investigate if TP53 was identified and why it did 
not pass our thresholds. This hindsight analysis identified that one of the negative 
control samples presented with a high LFQ reading for TP53, resulting in the TP53 not 
 
 236
passing our reliability thresholds of >1 fold difference in RSSF10-FLAG+ cells with a 
significance of P<0.001. This outlier may have been due to contamination within one 
sample, however excluding the sample resulted in a n=2, so we were unable to repeat 
the t-test to confirm if TP53 met our reliability criteria. Although this casts doubt over 
whether TP53 is a genuine RASSF10 binding partner, we did observe the LFQ for TP53 
to also be significantly increased in cell cycle synchronised samples. The association of 
p53 as a cell cycle regulator, particularly its involvement in G1/S and G2/M cell cycle 
checkpoints (Giono and Manfredi, 2006; Harris and Levine, 2005), makes this 
observation highly interesting and may indicate a role for RASSF10 in cell cycle 
regulation. Moreover the identification of another N-terminal RASSF protein, RASSF8, to 
form protein: protein interactions with the ASPP proteins and stimulate p53 activation 
in Drosophila provides further evidence that this interaction observed between RASSF10 
and ASPP2 may be genuine and of high interest (Langton et al., 2009). 
Other RASSF proteins previously associated with the cell cycle, include RASSF3, RASSF5 
and  RASSF6, which is predicted to stabilise p53, and augment ubiquitination of the p53 
suppresser MDM2, with RASSF6 knockdown resulted in increased p53 degradation 
(Iwasa et al., 2013). RASSF1 has been associated with promoting cell cycle arrest at the 
G1/S stage and decreasing cyclin D expression, while other evidence suggests a further 
role of RASSF1 regulating microtubule polymerisation within mitosis (Donninger et al., 
2014; Richter et al., 2009; Shivakumar et al., 2002). 
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 Future work and limitations  
Future work would revolve around validating the MS, by co-immunoprecipitation (co-IP) 
to confirm that  
1) RASSF10 binds to TP53BP2 and potentially TP53.  
2) Identify if binding is alerted under different growing conditions.  
Investigation should also be conducted to ascertain the role and function of RASSF10. It 
is widely considered that the RASSF family do not possess catalytic activity but instead 
act as scaffold proteins mediating protein-protein interactions (Cooper et al., 2009; 
Donninger et al., 2007; Fausti et al., 2012; Ferrell, 2000), we therefore predict RASSF10 
to function in a similar way. To confirm this RASSF10 should be transfected into cells in 
increasing concentrations and co-IPs conducted. If this hypothesis is true, comparison 
between bound proteins such as TP53BP2 should possess the strongest signal when 
RASSF10 expression is optimal. 
Additionally, the effect of RASSF10 on cell cycle should also be undertaken. This could be 
achieved by knocking down RASSF10, or overexpressing RASSF10 in cell lines and 
analysing the cell cycle via flow cytometry.  
Before any of this can be conducted, certain limitations of this study need to be 
addressed. Firstly, being a preliminary study aimed at ascertaining if RASSF10 had any 
involvement in cell cycle and interaction with cell cycle regulators, rather than fully 
characterising RASSF10’s association in cell cycle. The samples run on this array were 
not fully optimised for cell cycle synchronisation nor was synchronisation confirmed via 
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flow cytometry. Additionally, not all conditions tested within this MS were successful 
and achieved a n=3, for example an additional cell synchronisation group (Thyx2) failed 
in one sample so had to be excluded as no statistics could be conducted. We have 
identified that TP53 may bind to RASSF10, however due to one of the negative control 
samples presenting with a high LFQ this protein was omitted as contamination. This 
outlier may be a genuine feature of HEK293 MS, or alternatively may have been a result 
of contamination; this can only be confirmed by repeating the MS. 
These concerns would be omitted following optimisation of cell synchronisation before 
repeating the MS, and hopefully more light would be shed on the likely binding of 
RASSF10 to TP53 and TP53BP2.  
Furthermore, experience of Dr D. Matallanas and team suggests that the high occurrence 
of ribosomal proteins identified within our analysis is likely to be a contaminate of the 
co-IP specific for FLAG undertaken to produce the samples run within this study and 
unlikely to be biologically relevant. Furthermore Dr D. Matallanas has frequently 
observed the presences of ribosomal proteins during Flag-co-IPs for other studies and 
proposes a GFP based co-IP to be cleaner. For our study this would require generation of 
a RASSF10-GFP construct and generation of a HEK293-RASSF10-GFP stable cell line.  
 Recent publication 
As previously mentioned, a recent study by Guo et al., 2015 has since shown RASSF10 to 
be frequently methylated in 60.7% primary colorectal cancers, additionally they 
identified a significant association between methylation of RASSF10, cancer stage  and 
metastasises. They subsequently investigated the function of RASSF10 and identified that 
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overexpressing RASSF10 in cell line that did not endogenously express RASSF10, 
resulted in a significant decrease in colony formation, thus confirming its function as a 
TSG. Investigation into the cell cycle of these cells, showed that RASSF10 expression 
increase in the G2/M phase cell cycle phase, further analysis of key markers (cdc-2 and 
cyclin-B) associated with cell cycle progression from G2 into M were downregulated. 
Thus Guo et al. concluded RASSF10 induces G2/M cell cycle arrest. They then conducted 
microarray experiments for gene expression between the cell lines expressing RASSF10 
and the vector control. Here they identified expressions of the p53 suppressor protein 
MDM2 to be significantly decreased when RASSF10 was expressed.  Further analysis of 
the role RASSF10 played on p53 and MDM2 was conducted by subjecting cells to UV DNA 
damage. Guo et al. showed that in cells with DNA damage, expression of RASSF10 
resulted in increased p53, BAX and cleaved caspase-3 expression and reduced mdm2 
expression. Knockdown of RASSF10 in cell lines endogenously expressing RASS10 
resulted in impaired p53 expression. The final section of this study was to establish the 
effects of RASSF10 in-vivo here it was shown that RASSF10 expression in xenograft mice 
models resulted in reduced tumour formation.  
From this study it was concluded that RASSF10 is a tumour suppressor gene which is 
frequently lost in late stage cancers and metastasis, furthermore they conclude that 
RASSF10 is involved in p53 activation and can elicit apoptosis and G2/M cell cycle arrest 
in colorectal cancer cells. 
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This study corresponds with our hypothesis that RASSF10 methylation is associated 
with advanced cancer stage and metastasis, and that RASSF10 is involved in cell cycle 
regulation, via association with P53. 
  
 Final summary 
In this study we have identified RASSF10 to be frequently methylated in sRCC tumours 
derived from ccRCC. We propose that methylation of RASSF10 is associated with 
increased cancer stage and an increased risk of metastasis, an observation that seems to 
be consistent with reports of RASSF10 methylation in other cancers. Moreover we 
identified RASSF10 methylation has a negative impact on mRNA expression, which is 
reversed when DNA methylation is removed by 5-Aza treatment. Additionally we 
concluded that RASSF10 functions as a TSG, suppressing growth in-vitro, with 
knockdown of RASSF10 via siRNA resulting in an increase in colony formation. This too 
is consistent with current literature.  
Finally an attempt to understand the proteomics of RASSF10 and its associated binding 
partners, identified association with TP53BP2 (ASSP2) within cells with synchronised 
cell cycle. Although further investigation is required to confirm and characterise the 
binding and role of RASSF10 with TP53BP2, this data does suggest that RASSF10 may be 
involved in cell cycle regulation via P53. A hypothesis supported by J. Guo et al., 2015. 
The work undertaken in this chapter was presented at a poster session at: 10th NCRI 
Cancer Conference; 2014 November 2-5; Liverpool, UK by Slater, A. et.al.   
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 Whole Exome Sequencing (WES) of sporadic oncocytomas 
5.1 Introduction 
 Next Generation Sequencing 
Next generation sequencing (NGS) has provided researchers the tools to compile 
extensive maps and databases of genetic variation including single nucleotide 
polymorphisms (SNP), small insertions and deletions, and structural variants (Cooper 
and Shendure, 2011).  
Since 1977 when the original Sanger sequencing protocol was published by Sanger et al., 
1977, revolutionising the field of DNA investigation, sequencing technology has 
significantly improved. Leading to the development and release of high-throughput 
multi-parallel sequencing platforms termed Next Generation Sequencers (Bayés et al., 
2011). NGS is therefore a broad term encompassing multiple sequencing techniques 
such as, RNA-sequencing, targeted sequencing, bisulfite sequencing, whole exome 
sequencing (WES) and whole genome sequencing (WGS) (Bell, 2010; Reis-Filho, 2009; 
Simon and Roychowdhury, 2013).  
RNA-sequencing, involves the sequencing of the mRNA to identify variants and 
translocations within the transcriptome, and can also quantify gene expression levels 
(Reis-Filho, 2009). RNA sequencing has proved invaluable for the identification of novel 
gene fusions such as BCOR-CCNB3 fusion in undifferentiated spindle-cell sarcoma (11% 
of samples) (Peters et al., 2015), or MITF-TFE  translocation involved in RNA splicing in 
translocation RCC, (a rare subtype of kidney cancer (accounting for 15% of RCC in 
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patients under 40 years of age) that is characterised by translocations involving the 
transcription factor genes TFE3 or TFEB) (Malouf et al., 2014).  
Targeted sequencing uses predesigned or custom designed capture panels to isolate 
specific genes associated with a phenotype prior to sequencing (Jamuar et al., 2015). 
Such as the ion ampliSeq cancer hotspot panel (Thermo Fisher Scientific), a panel of 46 
critical cancer associated genes to capture and sequence a panel of candidate genes of 
interest (GOI) (Thermo Fischer Scientific, 2015), or the TruSight gene panel range from 
Illumina. Where gene panels have been developed to capture and sequence GOI 
associated with inherited disease, cardiac conditions, cancer, (including specialist panels  
for solid tumours and myeloid malignancies) and many more (Illumina, 2016). 
Targeted sequencing is a method favoured by many laboratories due to being cost 
effective, covering candidate genes with a deeper read depth than WES and requiring 
less bioinformatic analysis to interpret and identify somatic variants compared to other 
techniques such as WES (Jamuar et al., 2015). However, a major limitation is that 
potentially pathogenic novel variants in genes not targeted by the panel would be 
missed. Targeted sequencing is also a popular tool within diagnostic laboratories, due to 
the cost benefit while prior clinical predictions of diagnosis based on patients 
phenotype, allows for candidate GOI to be selected prior to sequencing (Dietel et al., 
2015).  
WES, (section 5.1.1.1) uses a capture method targeting virtually all exons, providing a 
global picture of genetic variation and copy number alterations within exonic regions 
within the genome. WGS, on the other hand sequences the whole genome, providing 
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additional information for the intronic, promoter and enhancer regions, in addition to 
the exonic regions (section 5.1.1.2) (Lelieveld et al., 2015).  
Since 2007 the cost of NGS has substantially decreased, (Figure 5-1), exceeding the 
original trend predicted by Moore’s Law. (Moore’s law was a trend originally observed 
within computer science, which states that the processing power of computer chips will 
double every two years. Resulting in a linear trend line (Waldrop, 2016). The reduced 
costs has made this technology more accessible for smaller laboratories as well as 
permitting the analysis and profiling of large cohorts of samples such as those 
undertaken by the TCGA (Davis et al., 2014; TCGA, 2013, 2008) or NHS England 100,000 
genome project (Siva, 2015). The influx of data has permitted the generation of 
comprehensive databases collating information on genetic variation and single 
nucleotide polymorphisms (SNP) within a general population (such databases include 
dbSNP, 1000 Genome project, JSNPs, Integrative Japanese Genome Variation Database 
and ExAC) and cancer associated variants (COSMID), all of which are key bioinformatic 
tools when interrogating the large data sets produced by NGS. It is widely regarded that 
identification and characterisation of genetics variants will provide unprecedented 
insight into disease progression and prognosis and permit predictions of how 
individuals may respond and metabolise drugs. Paving the way for personalised 





Figure 5-1: Cost to sequence a Mega-base of DNA in comparison to Moore’s law Graphical illustration of the decline in sequencing cost per mega-base of DNA over the last 15 years, in relation to Moore’s law. Graph from National Human Genome Research institute Genome.gov. 2015 
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 Whole Exome Sequencing 
As previously mentioned WES involves isolation and sequencing of the exonic regions 
within the genome. To date several capture and sequencing technologies are 
commercially available with different methods use to analyse the DNA sequence. Exon 
capture kits are estimated to isolate 95% of all exons (Lelieveld et al., 2015; Rabbani et 
al., 2014a). Although other kits are available, in this study exon capture was achieved 
using the SureSelect exon capture kit (Agilent). This was achieved via PCR amplification 
of the genomic DNA sample with sequencer specific adaptors, exons were identified via 
hybridisation to biotinylated RNA library baits specific for exonic regions. These 
captured exonic regions are then separated from the intronic fragments by streptavidin 
beads prior to analysis on a NGS sequencer (Figure 5-2). Currently, the market leader in 
NGS sequencers is Illumina, with sequencers such as the HiSeq2500 being highly popular 
due the high number of reads per run it can achieve (Sims et al., 2014) . The Illumina 
sequencers utilises a clonal amplification technique known as bridge amplification, 
where the template DNA attaches to the array by the binding to adapters, and is 
amplified by forming ‘bridges’ with adjacent primers. This generates clusters, each 
derived from one fragment of DNA, which are then sequenced (Figure 5-3a). The DNA 
sequence is identified by the incorporation and identification of modified 3’ blocked 
reversible fluorescent nucleotides, cleavage of the fluorescent label permits detection 
and identification of the incorporated base, and allows the continued extension and 
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Other technologies such as Roche 454 or ION torrent PGM, immobilise and amplify the 
template in emulsion on micro-beads. Roche 454 uses fluorescence and the 
pyrosequencing technique to determine the DNA sequence. While the ION torrent PGM, 
determines the DNA sequence by measuring a change in the pH as a nucleotide base is 
incorporated (Metzker, 2010).  
The main advantage of WES, is that it is targeted to the 1.5% of the genome that encodes 
proteins (Koboldt et al., 2012; Meynert et al., 2014), although this is a small percentage 
of the total genome it is reported that around 85% of disease causing variants are 
located within the exons (Rabbani et al., 2014a), thus reducing the volume of redundant 
data produced and the bioinformatic analysis required to mine it (compared to WGS). 
However there are some limitations, these mainly revolve around the exon capture 
technology, firstly not all the exons will be captured and secondly of those that are, 
coverage and representation may not be equal due to PCR bias (described as the unequal 
amplification of PCR products). This is usually associated with GC rich regions of DNA. 
These regions usually have increased melting temperature and the ability by which PCR 
products of these regions can form stable secondary structures, both of which impede 
PCR amplification (Mamedov et al., 2008).  Within WES this PCR bias can result in 
variation in the number of reads (read depth) of a particular fragment (Ku et al., 2012; 
Lelieveld et al., 2015).  
Additionally the small fragments that are sequenced via the WES technologies (75 -
100bp Illumina; 300bp Roche 454 (Metzker, 2010)) can result in misalignment issues 
when mapped to the reference genome particularly in highly repetitive regions. 
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Although WES attempts to combat some of these issues by sequencing at greater depth 
of multiple short-paired end reads, with the longer reads, providing more accuracy when 
aligning to the genome. This alone cannot counteract all the issues of alignment 
especially within repetitive regions that exceed the fragment length (Meynert et al., 
2014; Patel et al., 2014; Robinson et al., 2011). Finally, WES is a cheaper technology than 
WGS, both financially and in terms of labour and computational experience, and is 
currently the most utilised technique for identifying novel variants in disease (Watson et 
al., 2013).  
 Whole Genome Sequencing (WGS) 
Unlike WES, WGS does not require PCR based enrichment of the sample prior to 
sequencing. This means that the whole genome is mapped and aligned to a reference. 
The WGS platforms are adapted to permit longer read length allowing more accurate 
alignment to the reference genome particularly across repetitive regions. Furthermore, 
WGS platforms are reported to offer improved, more uniform and reliable coverage of 
coding regions (Lelieveld et al., 2015; Meynert et al., 2014). In addition WGS can provide 
information on intronic translocations and breakpoint enhancer regions and promoter 
regions (e.g. the TERT promoter see 5.1.2), however the volume of data that is produced 
makes alignment and interpretation computationally challenging.  
Regardless, these challenges are not limiting the use and application of WES and WGS, 
with studies now being undertaken to identify and characterise unique mutation 
signatures and frequently mutated pathways such as the focal adhesion pathway, P13k-
Akt pathway, Rap1 pathway, and calcium signalling pathways associated with many 
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different cancers. An investigation that previously would have been limited to candidate 
genes and expensive and labour intensive to conduct (Alexandrov et al., 2013; Cline et 
al., 2013; Davis et al., 2014; Neapolitan et al., 2015). 
 Applications of NGS to investigate human disease 
NGS, has provided unprecedented insights into genetic and structural variations within 
the general population or diseases. Permitting the identification and characterisation of 
common single nucleotide polymorphisms (SNPs) present within a general population, 
or the identification of variants associated with disease phenotype (Cooper & Shendure 
2011). One of the major aims and challenge of genetic studies, is identifying pathogenic 
variants from a vast quantity of non-pathogenic variants and SNPs, and to elucidate the 
roles they play in disease ( Cooper & Shendure 2011).  
Within human genetics NGS has been of immense success in the identification of 
causative variants responsible for inherited Mendelian disease. Especially in the case of 
autosomal recessive disorders, where homozygous pathogenic variants are often 
identified homozygous in affected individuals, these can then be mapped to both parents 
who will be carriers of the disease (Jamuar et al., 2015).  One of the first inherited 
Mendelian disorders from which WES was used to identify the causal variant was Miller 
syndrome in 2010 (Ng et al., 2010). In the following 2 years, WES had identified the 
causal variant in over 100 Mendelian disorders (Rabbani et al., 2012). Identification of 
causative variants of Mendelian disorders, will enable improved diagnostics and 
prenatal screening and genetic counselling (Jamuar et al., 2015). 
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In addition, NGS has made many notable contributions to the investigation into the 
genetics of familial and sporadic cancer. With the identification of driver mutations, and 
deregulated cancer associated pathways a notable aim of these studies (Rabbani et al., 
2014b).  By examining the mutations identified between both tumour and normal tissue 
from an individual, many WES studies have identified somatic cancer-associated variants 
and alterations. In fact it has been reported that over 150 genes have been identified to 
possess cancer associated variants (Rabbani et al., 2014b), with most genes identified 
being classified into 12 signalling pathways, associated with core cellular processes such 
as metabolism, chromatin modification, transcription, and mRNA processing (Chmielecki 
and Meyerson, 2014; Kadoch et al., 2013; Vogelstein et al., 2013). However, due to the 
heterogeneous nature, genomic instability and accumulation of variants with variable 
penetrance within cancers, identifying driver mutations is a particularly complex 
challenge (Chmielecki & Meyerson 2014). Despite this challenge, it has not deterred 
investigations and there have been many advancements in ours understanding of cancer 
genetics. One such example, by Varela et al 2011, identified the frequently mutated 
ccRCC associated gene PBRM1 following WES on 7 ccRCC and matched normal DNA 
(Varela et al. 2011). While WGS studies have been instrumental in the identification and 
characterisation of recurrent somatic mutations and structural rearrangements  within 
the cancer genome (Alexandrov et al., 2013; Davis et al., 2014; Guo et al., 2013; Huang et 
al., 2013; TCGA, 2013). Furthermore, large collaborative projects being undertaken are 
revolutionising our understanding of cancer and other diseases, projects such as TCGA 
(which permits public access to provide a wealth of WGS data from 34 primary tumour 
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type in over 11,000 cases (Tcga-data.nci.nih.gov, 2015) and the Genomics England 
100,000 genome project (Siva, 2015), aim to obtain a comprehensive understanding of 
the genetics and molecular biology of rare diseases and cancers. As more cancer samples 
are sequences and NGS continues to improve, so too does our knowledge and 
understanding of diseases.  It is hoped that this added understanding will manifest in 
improving predictive, diagnostic, prognostic and therapeutic management of cancer 
patients (Jafri et al., 2015; Rabbani et al., 2014b; Wheeler and Wang, 2013). 
 
  
 TERT promoter 
While undertaking this study, a high recurrence of somatic telomerase reverse 
transcriptase (TERT) promoter mutations have been reported, in a multitude of cancers, 
including but not limited to; central nervous system, bladder and thyroid cancers 
(Vinagre et al., 2013) skin melanoma (Horn et al., 2013; Huang et al., 2013), 
hepatocellular carcinoma (Nault et al., 2013; Totoki et al., 2014) and urothelial cancer 
(Borah et al., 2015). TERT is involved in maintaining genomic stability and DNA repair; it 
had been reported to be upregulated in over 90% of cancers with most research focusing 
on somatic mutations within the TERT promoter (Rathmell et al., 2015).  
Two mutations in particular, have been highlighted as single nucleotide variants (SNV) 
hotspots, within the TERT promoter 1) C228T the more frequently mutated of the two 
variants (chr5; 1,295,228 located -124bp upstream of the ATP start site) and 2) C250T 
(Chr5: 1,295,250 located -146bp upstream of the ATP start site). The SNVs generate new 
 
 253
binding sites for the TERT transcription factor motif E-twenty six/ ternary complex 
factors (Ets/TCF) resulting in an increase of TERT promoter activity and in turn 
increased expression of TERT. Which has been associated with poor prognosis, and more 
advanced forms of cancer (Horn et al., 2013; Huang et al., 2013; Koelsche et al., 2014).  
Investigation into the two aforementioned TERT promoter SNVs in renal carcinomas, 
concurs that TERT mutations are associated with more aggressive tumours and poor 
outcome; with Hosen et al., 2015 reporting TERT promoter mutations in 6.4% (12/188) 
ccRCC tested. Wang et al., 2014 identified TERT promoter mutations is 9.3% (9/96) 
ccRCC and 13% (1/8) chRCC they further report that of the 10 mutated tumours, 9 
possess the C228T variant, and 1 the C250T variant.  A larger cohort of chRCC has since 
been investigated via the TCGA collaboration. Within this study 4.5% (3/66) were 
identified with the C228T SNV although the TERT mRNA levels for these samples was 
not increased. Interestingly however via whole genome sequencing, a structural 
breakpoint was identified 10kbp upstream of the TERT transcription start site, through 
which a further 12% (6/ 50) chRCC tumours were identified to possess a structural 
variation (e.g. Tandem duplication or translocation) that affected the TERT promoter. 
These samples where also reported to have increased mRNA expression of TERT (Davis 
et al., 2014; Rathmell et al., 2015).  However, as yet no study of the TERT promoter in 
renal oncocytoma samples had been conducted. We therefore included a screen of the 
TERT promoter hotspots in our study.  
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 Study’s Aim 
The key aims of this thesis were to identify and profile the genetic and epigenetic 
variations that exist between two, histologically similar, sporadic forms of RCC; chRCC 
and renal oncocytoma. The successful identification of specific epigenetic and genetic 
differences between these two histologies may then potentially, be used to aid and 
improve the diagnoses of the specific subtypes, thereby enabling the application of more 
effective personalised and tailored treatments (section 1.7).   
Prior to the beginning of this project, only limited investigations had been performed 
into the genetics of chRCC and renal oncocytoma. Of the studies that had been published, 
the main observations were of cytogenetic differences between the two histologies; for 
example, chRCC is frequently found to harbour loss of chromosomes 1, 2, 6, 10 and 21, 
while oncocytomas are often associated with loss of chromosome 1 and Y (Faisal et al., 
1997; Yusenko et al., 2009) (outlined in section 1.4.2.1.3 and section 1.4.2.1.4).  Despite 
these observations, the chromosomal differences alone were still not sufficient to 
distinguish clearly between the two subtypes. It was thought that perhaps the 
identification of tumour-specific variants between the two subtypes might provide a 
more informative and effective method to differentiate between them (Ng et al., 2014).  
Consistently, in 2014, the TCGA performed a study, which aimed to identify somatic 
mutations in chRCC samples. To achieve this, they performed a multiplatform 
investigation (including data obtained from WGS) on 66 sporadic chRCC samples. 
Through their study, they identified frequent mutations in the TP53 and PTEN genes, in 
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addition to frequent alterations to the cancer-associated TERT promoter (outlined in 
section 5.1.2) (Davis et al., 2014).  
In light of the above multi-platform study, a WES investigation of chRCC was not 
necessary; however, as no mutational analysis had yet been conducted on renal 
oncocytoma, this led us to question whether we could identify any specific genes that 
may be playing a role in somatic oncocytomas.  We therefore decided to perform whole 
exome sequencing and bioinformatic analysis on DNA obtained from oncocytoma 
tumours in an attempt to investigate, identify and characterise specific somatic 
mutations. Following candidate gene selection, the project then aimed to carry out 
mutational screening using Sanger sequencing in a larger cohort of patients, in order to 
identify any potentially recurrent somatic mutations.  It was hoped that the successful 
identification of disease-associated genes and specific pathogenic variants may provide 
invaluable information regarding the biology, and pathogenesis of these tumours, which 
may ultimately be of clinical benefit in the future.  
5.2 Results  
 Sample data 
A total of five sporadic oncocytoma samples of Japanese origin; three tumour normal 
pairs (T1-3 and N1-3) and two tumours only (T4-5), were exome sequenced courtesy of 
Dr Michael Simpson, Kings College London. However this was achieved in two stages; 
samples T1, N1, T4 and T5 were exome sequenced first, following some analysis detailed 
below (round 1), the decision was made to sequence a further two T/N pairs, T2, N2 and 
T3 and N3. Analysis was conducted on the previously mentioned ‘coding’ files detailing 
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the high quality and coding region variants, with additional investigation being 
conducted upon the raw .BAM and BAM.BAI files via IGV. Firstly the gender of the 
samples was confirmed, by analysing the number of heterozygous X chromosome 
variants, in males this is typically <100 and in females >200. N1 and T1, T4 and T5 were 
correlated with the clinical data and confirmed as female with >200 het X variants (227, 
218, 218 and 219 variants respectively). Samples N2 and T2, and N3 and T3 were 
confirmed as male with <100 het X variants, which corresponds with the known clinical 
data (53, 44, 63 and 66 variants respectively). Due to the high homology within the Y 
chromosome to other chromosome both genders identified variants in the Y 




































































 Variant Profile of Oncocytoma  
The total number of variants within the coding regions for each sample is displayed in 
Figure 5-4 a. A total 199,498 variants were identified, N1= 24,551 variants, T1=23,289 
variants, N2=25,645 variants, T2=25,419 variants, N3=25,765 variants, T3=25,790 
variants, T4=24,627 variants, T5=24,412 variants. It was noted that slightly more 
variants were called in the normal samples than the tumour samples; this variation was 
attributed to a difference in DNA quality, with normal DNA usually being of a higher 
quality compared to the tumour. As a result during sequencing more variants were likely 
to pass the phred quality threshold of >20 and therefore be called in the coding file.   
Investigation into the types of variants called; show synonymous and missense 
mutations are the most prevalent in both tumour and normal samples accounting for 
84.4% of all variants (44.3% synonymous and 40.07% missense). Splice site variants 
were called as variants located in the intron within 10bp of the exon boundary, hence 
the high frequency of 11.7% of total variants; probability dictates most of these variants 
will have no effect on the protein expression. Variants more likely to be deleterious such 
as frameshift and nonsense mutations are much less frequent accounting for, 0.5% and 
0.3% of the total variants identified (Figure 5-4b).  
The high prevalence of synonymous and missense mutations is not unexpected; the 
majority will have very little or no detrimental effect on the proteins they encode thus 
having little effect on the well being of the cell. As a result these mutations are likely to 




 Manual data processing and candidate gene identification 
 Round 1-Targeted approach 
The original investigation was conducted on the three oncocytoma samples (T1, T4 and 
T5) and one paired normal (N1), which were in the first batch of exome sequencing. 
A manual approach to filter the 72,328 identified variants listed for the three tumours 
was undertaken as follows and described in Figure 5-5 Firstly any variant present in 
both the tumours and the normal was removed, a total of 61,065 variants were removed; 
leaving 11,263 variants in the tumours (T1=539 variants, T4=8,282 variants, T5=2,442 
variants). All non-deleterious, synonymous mutations were removed, totalling 1,650 
variants removed in this step; leaving 9,613 variants in the tumours (T1=378 variants, 
T4=4,694 variants, T5=4,541 variants).  
Any variants characterised as a SNP with a minor allele frequency (MAF) >1% within 
dbSNP and ensemble was removed, a total of 7,089 variants were removed leaving 2,524 
variants in the tumours (T1=247 variants, T4=1,140 variants, T5=1,137 variants). A MAF 
of <1% is deemed to be a rare variant (Ramsey et al 2012; Kelly A et al). Thus this step 
removed any variants common to the general population, as they are unlikely to be 
pathogenic regarding oncocytoma. To remove any high frequency unclassified SNPs or 
polymorphisms, or common sequencing errors any variant previously identified more 
than 10 times ‘in-house’ by the alignment and variant calling pipeline utilised by Dr 
Simpson were also removed, totalling 1,071 variants removed; leaving 1,453 variants 




Figure 5-5: Round 1-Targeted approach pipeline Flow diagram depicting the targeted approach undertaken to identify somatic variants in oncocytoma. Pipeline was applied to WES data from N1, T1, T4 and T5. 
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To further reduce the gene list, gene prioritisation was initially focused on identifying 
deleterious variations within key pathways identified by KEGG and Panther with focus 
directed upon the: AMPK pathway, MAPK pathway, PI3K-AKT pathway, Hippo pathway, 
TGF-β pathway, p53 pathway, SWI/SNF complex (widely associated with RCC (TCGA, 
2013; Varela et al., 2011)) and as well as genes associated with apoptosis and the 3p 
chromosomal arm, which has previously been associated with cancers and RCCs (Gnarra 
et al., 1994; Lovell et al., 1999; TCGA, 2013; Zabarovsky et al., 2002). All frameshift and 
nonsense variants were classified as deleterious, due to the disruption caused on the 
protein sequence, causing premature termination of the protein, though currently no 
computational software to predict the severity of these variants is available. For splice 
site variants, in-silico investigation identified the probability of a splice site variant 
resulting in a loss of splice site was undertaken via prediction software from Berkeley 
Drosophila Genome Project (Reese et al., 1997). For the missense single nucleotide 
variants (SNV) further in-silico analysis was undertaken using two online prediction 
software, Sorting Tolerant From Intolerant algorithm (SIFT) (Kumar et al., 2009) and 
Polyphen (Adzhubei et al., 2010). Both programmes assess and score the probability of 
an amino acid change impacting on the protein function by assessing protein sequence 
homology, conservation between species and the physical properties of amino acids. 
This method yielded 10 variants of interest in 9 genes associated with candidate 
pathways. Lamb2 displaying two variants at exon 27 and 24 for sample T4. Via Sanger 
sequencing, of both the tumour and normal samples, these 10 variants were investigated 
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Table 5-1: Sanger sequencing to confirm somatic status of WES variants associated with known cancer pathways Table detailing gene name accession number, information on the variant information including type of variant and variant position and base or amino acid change in relation to cDNA (c.) and protein (p.), associated pathway, and the probability of mutation being damaging (Y=damaging, P=Possibly damaging) predicted by SIFT and Polyphen2.  Somatic status was confirmed by Sanger sequencing, S= somatic, G=Germline and F=False positive variant called in WES.  Variant is highlighted by a red arrow for SNV, or red bar for multiple nucleotide variants.  
 
 264
Focus was then turned to identifying recurrent genes, characterised as genes with 
multiple variants in different tumour samples. This identified 79 genes presenting with 
variants in two or more of the oncocytoma samples, of which 21 variants were the same 
between the samples leaving 59 genes with unique recurrent variants. No gene was 
identified to possess variants in all three samples and not in the normal.  
Another approach undertaken was to look at the high impact variants, here high impact 
variants were defined as nonsense, splice site mutations <5bp from splice site 
(investigation into severity via fruitfly.org identified a variant >5bp was unlikely to be 
damaging) and frameshift variants. From this analysis, a total of 141 variants were 
identified across the three tumours, (20 nonsense, 20 frameshift and 101 splice sites of 
which 41 were uncharacterised) 
The gene lists returned from these approaches proved to remain immense and 
unsatisfactory and could not be logically reduced. Additionally previous experience has 
led us to believe that the majority of variants are likely to be germline, especially when 
lacking the normal exome sequencing data for two of the samples. The methods 
undertaken to filter the data possess a bias towards previously characterised genes and 
pathways and high impact variants, excluding many novel and missense variants. It was 
therefore decided a further two tumour samples together with corresponding normals 





 Round 2- Manual approach 
The following, manual approach was applied with the aim of identifying novel candidate 
genes, associated with oncocytoma development while remaining unbiased as to the 
function and included the exome sequencing data of an additional 2 T/N pairs (T2/N2 
and T3/N3) (Figure 5-6) 
In a similar starting methodology as was originally undertaken when investigating the 
candidate genes in round 1, initial filtering omitted any variant common to both tumour 
and normal samples in all oncocytoma samples sequenced (a total of 115,393 variants 
were removed in this step; leaving 8,144 variants T1=311 variants, T2=222 variants, 
T3=290 variants, T4=3,739 variants, T5=3,582 variants). Followed by the removal of any 
synonymous variant (a total of 3,247 variants were removed; leaving 4,897 variants 
T1=238 variants, T2=165 variants, T3=219 variants, T4=2,195 variants, T5=2,080 
variants).  
The next stage was to disregard any variants previously characterised as an SNP with a 
MAF >1% within dbSNP and ensemble. In addition, all variants recorded >10 times ‘in-
house’ the alignment and variant pipeline were removed. A total of 3,436 probes were 
removed due to the SNP MAF and in-house observations, 2,795 and 641 variants 
respectively; leaving 1,461 variants T1=52 variants, T2=45 variants, T3=64 variants, 
T4=660 variants, T5=640 variants. 
It was at this point the filtering method diverged from the processes undertaken in 
round 1, and the splice site mutations were investigated. As previously mentioned splice 




Figure 5-6: Round 2-Manual approach pipeline Flow diagram depicting the manual approach undertaken to identify somatic variants in oncocytoma. Pipeline was applied to WES data from N1, T1, N2, T2, N3, T3, T4 and T5.   
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From our previous investigation it was identified as highly improbable that variants 
>5bp away from the slice site would be damaging, thus all variants >5bp from the splice 
site were removed. All splice site variants under 5bp were investigated in-silico using  
fruitfly.org, any variant that was predicted to not cause a loss of splice site were removed 
(a total of 240 variants were removed). 
This pipeline identified 1,221 variants of interest distributed accordingly, T1= 41 
variants, T2= 29 variants, T3= 37 variants, T4= 571 variants, T5= 543 variants). Due to 
the sheer volume of variants still remaining in the unmatched tumours, and no logical 
method to further reduce this number, the following filtration was conducted on all 
variants identified from T1-3 the tumour normal pairs. For matched tumour normal 
samples, the raw BAM files for the remaining 107 variants was analysed using IGV 
(Integrative Genomics Viewer v2.3.40). Read depth and mutation frequency was 
compared between tumour and normal samples, where variants that were present in 
>15% tumour reads and <5% Normal reads were deemed to be likely somatic variants 
and unlikely to be false positives, this is the same criteria applied by Dr Michael Simpson 
when using the computational pipeline Varscan2 (Koboldt et al., 2012). The result of this 
process identified 28 somatic variants, 64 germline (Normal >5% of reads), and 15 
variants did not meet the criteria. These variants identified as somatic were confirmed 
via Sanger sequencing on the original samples, of the 28 identified variants; 18 were 





































































































































Novel 36.2% (21/58) 0% (0/52) 0% (0.32) 0% (0/41) S
Mut. Reads in IGV files Sanger 


































Novel 39.2% (56/143) 0% (0/121) 0.9% (1/114) 0% (0/197) S
Gene ID Exome Sequencing 
variant
Novel Mut. Reads in IGV files Sanger Seq. Tumour Matched Normal
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Novel 43.9% (54/123) 0.4% (1/278) 0% (0/166) 0% (0/220) S
Sanger 








Table 5-2: Sanger sequencing to confirm somatic status of WES variants identified through manual pipeline. Table details gene name and accession number, the sample in which the variant was identified, information on the variant including type of variant position and base or amino acid change in relation to cDNA (c.) and protein (p.), novelty status, summary of IGV files documenting the percentage of reads presenting with the variant.  Somatic status was confirmed by Sanger sequencing, where S= somatic, G=Germline and F=False positive variant called in WES.  Variant is highlighted by a red arrow for SNV, or red bar for multiple nucleotide variants.   











(MAF:0.23%) 38.5% (30/78) 0% (0/30) 0% (0/67) 0% (0/68) S
ZNF717 T1
Missense: NM_001128223  
c.C2694A: p.D898E
In-house: 5 75% (3/4) N/A N/A N/A G
Gene ID Exome Sequencing 
variant




The Varscan2 program is a computation pipeline, which utilises algorithms to determine 
the genotype of paired normal and tumour sample and call somatic mutations By 
simultaneously analysing the tumour and normal SAM-tools pileup output (created from 
the raw BAM files), and performing a direct pairwise comparison of bases called and 
sequence read depth at each position; Varscan2 is able to identify variations between the 
normal and tumour sequences (Figure 5-7). If a variation is identified in both the tumour 
and normal, then it is deemed to be a germline variant. If a variant is identified in one 
sample and not the other (or low frequency in the other), then the variation is subjected 
to a one-tailed Fisher’s Exact test, where the read counts of the variation (number of 
reads that present the variation) compared to read counts of wild type (wt) is compared 
between the tumour and the normal. If the resulting P-value is significant then the 
variation is deemed to be somatic. If the threshold of significance is not met then the 
variant is classified germline. 
In addition to assessing the somatic status of a variant, Varscan2 can also identify Loss of 
Heterozygosity (LOH) and Somatic Copy Number Alterations (SCNAs). LOH is calculated 
by analysis of the variant read counts and comparing between the tumour and the 
normal. A variant present in >75% of reads was classified as homozygous. LOH was 
classified as a variant that was homozygous in the tumour and present but heterozygous 
in the normal. SCNAs are defined as deviations in the log-ratio of the sequence coverage 
depth within a tumour-normal pair, identified by direct comparison of the normalised 





Figure 5-7: Varscan2 pipeline 
Flow diagram of the pipeline employed by Varscan2. Adapted from Koboldt et al., 2012.   
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Further to the aforementioned calculations, Varscan2 also utilises a false-positive filter, 
which interrogates each variant for nine empirically derived criteria, with the aim of 
distinguishing true variants from sequencing or alignment related artefacts. In addition 
to ruling out false positives Varscan2 further categorises somatic variants, into high and 
low quality; by analysing read depth and mutation frequency and comparing between 
tumour and normal samples, (similar to the method employed when analysing the IGV 
files during manual processing). The default filter is set at, variants that were present in 
>10% tumour reads and <5% Normal reads were deemed to be high quality somatic 
variants. However, to improve the stringency for the pipeline Dr Michael Simpson used 
the threshold of >15% tumour and <5%, when analysing our samples.  
It should also be mentioned that by default, VarScan2 requires a minimum depth 
coverage of 3× and a minimum phred base quality of 20, however the higher the 
coverage and quality of sequencing the less likely it is to yield both false positive and 
false negative results. Additionally it should also be noted that, due to the calculations 
undertaken, Varscan 2 is only applicable for tumour normal pairs that have been 
exposed to identical hybridisation conditions therefore required to have been analysed 
on the same sequencing array (Koboldt et al., 2012).  
As previously mentioned, Dr Michael Simpson kindly ran our data for the 
tumour/normal pairs (T/N1, 2 and 3) through the Varscan2 pipeline. Adjusting the 
present criteria to the more stringent >15% tumour reads and <5% normal reads, this 
identified a total of 318 somatic variants that would be of interest (T1= 293, T2= 12 
variants, T3= 13 variants). The discrepancy in somatic variant hits for T1 was 
 
 277
attributed to the fact that N1 and T1 had being sequenced on separate arrays and thus 
presented a hybridising bias, as a result the varscan2 pipeline identified an unrealistic 
number of somatic variants for this paired sample. When comparing the manually 
identified and validated genes to the Varscan2 list, 94% (17 out of 18) of the confirmed 
somatic genes were also identified by Varscan2 pipeline (Figure 5-8). 




Figure 5-8: Varscan2 gene list compared to the validated genes from the manual pipeline 
Venn diagram comparing Varscan2 predicted somatic genes to the validated and confirmed somatic genes identified via the manual pipeline for each T/N pair. 94% (17/18) confirmed somatic genes were also identified by Varscan2. 
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 The candidate genes 
Of the 18 confirmed somatic variants, 1 was a stop gain variant (MYOM1), 4 were 
frameshift variants (RNF146, DERL2, CNBD2 (C20orf152), OBSCN), 1 splice site variant 
(KSR1) and 12 were missense SNV (AKAP1, CRIM1, DCAF4L2, ETFB, FOXI1, MKI67, 
MRPL9, NOLC1, NPBWR2, TEKT5, ULK1, ZC3H7A). The predicted effect of variant, 
function of gene and prioritisation of each candidate gene is summarised in Table 5-3. 
Once the candidate gene list was obtained, prioritisation was then performed. Initially 
the list was screened against the whole exome data of the two unpaired samples, to 
establish if any genes had recurring variants, in more than one sample. This process 
identified two additional variants in NOLC1 and KSR1. An indel (non-frameshift) deletion 
of TCT in T4 for NOLC1 c.1132_1134del:p.378_378del. For KSR1 a non-synonymous 
variant in T5 was identified; c.C629T:p.T210M. 
Next we identified the probability of a variant being deleterious to the protein.  As 
previously mentioned in the round 1 filtration, the splice site variant was previously 
predicted to be damaging during the filtering process while all frameshift and nonsense 
variants were classified as damaging, due to the resulting truncation of the protein 
sequence. 
For the three somatic frameshift variants, it was possible to calculate how many amino 
acids (aa) were altered from the original sequence before the truncation of protein 
sequence. The frameshift of RNF146, (NM_001242852) c.980_981insTTCG resulted in 
4aa change including the stop codon that truncated the protein sequence (FS4). As a 
result RNF146:FS was truncated 27aa prematurely at p.332 while ordinarily RNF146:wt 
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terminates at p.359. For DERL2, (NM_016041) c.210_211del a deletion of two TT 
nucleotides results in a frameshift, and FS2 (2 amino acids changed prior to truncation of 
the sequence) thus DERL2:FS truncated 167aa prematurely at p.73, in the wild type 
DERL2:wt terminates at p.240. CNBD2 (C20orf152), (NM_080834) c.1322delT causing FS5 
(5 amino acids changed prior to truncation of the sequence), resulting in CNBD2:FS 
truncating at p.445, 128aa premature, CNBD2:wt terminated at p.573. 
For the missense SNV, the predicted severity was assessed following the aforementioned 
methods for Polyphen2 and SIFT. Of the 12 missense candidate variants that were 
investigated 4 variants were predicted to be damaging in both SIFT and Polyphen 
(DCAE4L2, ETEB, FOXI1, NPBWR2), 5 variants were predicted to be damaging in one of 
the two software and were therefore classified in this study as potentially damaging 
(CRIM1, MKI67, MRPL9, NOLC1, ULK1), while 3 variants (AKAP1, TEKT5, ZC3H7A) were 
predicted to be tolerated in both prediction programs, and were therefore not 
investigated further. 
In addition to identifying the impact of the variant on the protein, each gene was also 
assessed to ascertain whether mutations have previously been identified in other 
cancers (via COSMID and cBioportal analysis of TCGA data), the prevalence of high-
impact mutations within the gene in a general population (Ensembl; which encompasses, 
Exome Variant Server and, 1000 genome project, Hapmap project multiple observation 
and COSMIC, in addition the Japanese SNP database and ExAC and the known function of 
the gene (Table 5-3). 
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Polyphen SIFT COSMIC Ensembl




Nucleolar and coiled-body 
phosphoprotein; Involved in 
snoRNA formation and regulation 
of MDM2 transcription (Hwang et al 
2009)
P 0.01 0.03 SG:6(5) FS:8(5) ID:3(1) MS:72(45) Sy:17(15)
SG:16 FS:26 S:24 
SR:95 InD:57 
MS:679 Sy:259






Kinase Supressor of Ras1: 
Scaffolding protein connecting MEK 
to RAF, promotes activation of the 
NOTCH signalling pathway in 
several cancers.
Y N/A N/A SG:7(0) FS:24(6) MS:103(73) Sy:36(27)
SG:37 FS:36 S:13 
SR:145 MS:975 
Sy:490
ULK1 T2: MS: NM_003565 c.A314G: p.H105R -
Unc-51 Like Autophagy Activating 
Kinase 1: Regulates autophage in 
response to starvation, regualted 
by mTOR and AMPK pathways. 
Regulates FLCN in BHD
P 0.98 0.55 SG:6(5) FS:12(3) MS:119(77) Sy:61(44)





T1: FS: NM_080834 
c.1322delT: p.L441fs -
Cyclic nucleotide binding domain 




SG:41 FS:19 S:15 
MS:522 Sy:148




SG:20 FS:1 InD:1 
MS:217 Sy:83
DERL2 T1: FS: NM_016041 c.210_211del: p.70_71del -
Derlin 2: Associated with 
degradation of misfolded 
glycoproteins and may play a role in 
cell proliferation
Y N/A N/A SG:3(2) FS:1(0) MS:20(10) Sy:6(3) SG:12 SR:87 MS:131 Sy:84
ETFB T3: MS: NM_001985 c.T53G: p.V18G -
Electron-transfer-flavoprotein, 
beta polypeptide: involved in 




SG:11 FS:13 S:6 
SR:24 InD:10 
MS:244 Sy:127






Polyphen SIFT COSMIC Ensembl
FOXI1 T3: MS: NM_144769 c.C517A :p.H173N -
Forkhead box I1: Transcriptional 
activator involved with kidney 




SG:3 FS:7 S:1 SR:6 
MS:184 Sy:121




SG:69 FS:21 S:44 
SR:198 InD:3 
MS:1164 Sy:504
NPBWR2 T1: MS: NM_005286 c.G473A: p.R158H -
Neuropeptides B receptor: 
neuroendocrine system regulator. 
May be involved with MAPK 
mediated proliferation in 
adrenocortical cancers (Andreis et 
al 2005).
Y 0.99 0.00 SG:2(1) FS:1(1) ID:1(0) MS:59(44) Sy:26(20)
SG:3 FS:1 InD:2 
MS:105 Sy:69
OBSCN T1: FS: NM_001098623 c.21278_21279insC: p.P7093fs -
Obscurin; signaling protein 
associated with titin, and may have 











RNF146 T3: FS: NM_001242852 c.980_981insTTCG: p.R327fs -
Ring Fingure Protein 146: E3 
ubiquitin-protein ligase,Maybe 
involved in cell survival and 
proliferation. Overexpression 
associated with increased 
proliferation in lung cancer (Song et 
al 2014) 
Y N/A N/A SG:5(3) FS:4(4) MS:43(29) Sy:13(8)
SG:20 FS:6 SR:28 
InD:5 MS:314 
Sy:130
CRIM1 T2: MS: NM_016441 c.G2140T: p.V714L -
Cysteine Rich Transmembrane 
BMP Regulator 1: May be involved 
in tissue development and 
capiliaryformation after TGFβ 
activation.
P 1.00 0.28 SG:10(5) FS:3(3) MS:116(76) 
Sy:42(30)
SG:11 FS:8  S:9 
SR:38 InD:3 
MS:300 Sy:166
Deleterious Database SearchGene Confirmed Somatic WES variant
Recurrent WES 





Table 5-3 : Candidate genes identified and confirmed as somatic in oncocytoma 
List of the 18 confirmed somatic genes identified via WES of oncocytoma. Table details the gene name, function and accession numbers; type of variant (see below for definitions), variant position and base or amino acid change in relation to cDNA (c.) and protein (p.), samples in which the mutation was identified, the variant identified, the probability of variant being damaging (Y: Damaging, predicted to be damaging in both Polyphen and SIFT; P: possibly damaging, predicted to be damaging in either Polyphen or SIFT, T:  Tolerated, mutation predicted as benign in both Polyphen and SIFT).  Also listed is the frequency of mutations identified for the gene in COSMIC and Ensemble (Both include TCGA data). 
(MS: missense; FS: Frame shift; SG: Stop Gain; S: Splicing; SR: Splice region (within 10bp of intron) Sy: Synonymous)
Polyphen SIFT COSMIC Ensembl
MKI67 T1: MS: NM_001145966 c.C2558T: p.T853I -
Marker of Proliferation Ki-67: 







SG:124 FS:96 S:9 
SR:53 InD:18 
MS:2567 Sy:952
MRPL9 T1: MS: NM_031420 c.C770T: p.A257V - Mitochondrial ribosomal protein L9. P 0.79 0.79 FS:1(1) MS:26(13) Sy:11(7)
SG:4 FS:6 S:6 
SR:64 MS:109 
Sy:44





SG:84 FS:39 S:23 
SR:94 InD:43 
MS:1559 Sy:900




SG:8 FS:5 S:2 
SR:36 MS:271 
Sy:126




SG:18 FS:8 S:20 
SR:177 InD:4 
MS:657 Sy:338
Database SearchGene Confirmed Somatic WES variant




Notably KSR1 and ULK1 showed to have potentially interesting functions regarding a 
role in cancer. 
Firstly, Kinase Suppressor of RAS1 (KSR1) has been identified as a scaffold protein, 
facilitating signal transduction within the Ras signalling pathway leading to ERK/MAPK 
activation by bringing phosphorylated Raf1, into close proximity to MEK thus allowing 
the activation of ERK/MAPK complex and transcription (Kolch, 2005).   
KSR1 (Kinase Suppressor of RAS 1) has been reported to present oncogenic activity via 
its involvement in ERF/MAPK activation in Ras-dependent cancers such as pancreatic 
cancer and lung carcinomas (H. Zhang et al., 2015). Recently reports suggest that high 
expression of KSR1 to be associated with upregulation of NOTCH and activation of 
NOTCH signalling in papillary thyroid cancer (Lee et al., 2015). A study has also 
suggested that KSR1 inhibition may the method of action and a target for a current anti-
cancer drug Terbinafine. The loss of KSR1, results in reduced Raf-MEK-ERK signalling 
and subsequently resulting in an increase in apoptosis (Li et al., 2013). 
 However for non- Ras-mediated cancers such as breast cancer, it has been reported that 
KSR1 may act as a tumour suppressor gene, preventing the ubiquination and 
degradation of TSG BRCA1, and correlating with increased survival (Stebbing et al., 2015; 
H. Zhang et al., 2015), suggesting KSR1 has multiple and complex roles within cancer. 
ULK1 (Unc-51 Like autophagy activating Kinase 1) is a serine/threonine kinase involved 
in driving autophagy and mitophagy of defective cells component and mitochondria 
respectively, although as yet the underlying mechanisms and substrates have yet to be 
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confirmed. ULK1 activation is regulated by several cancer-associated pathways including 
AMPK and MTOR signalling pathways (Nazio et al., 2013; Petherick et al., 2015; Tian et 
al., 2015). Additionally ULK1 has been recently associated with the regulation of the TSG 
FLCN (frequently mutated within BHD renal tumours) by inducing FLCN 
phosphorylation with Dunlop et al., 2014 reporting a disruption in autophagy within the 
BHD associated renal tumours investigated.  
This analysis, allowed for us to prioritise the screening of the candidate genes; 
1. NOLC1 and KSR1: Identified to have mutations in more than one sample. 
2. ULK1: Selected due to function particularly the association with FLCN, and cancer-
associated pathways AMPK and MTOR. 
3. CNBD2 (C20orf152), DCAF4L2, DERL2, ETFB, FOXI1, MYOM1, NPBWR2, OBSCN and 
RNF146: Predicted to be damaging in both SIFT and Polyphen. 
4. CRIM1, MKI67, MRPL9: Predicted to be damaging in one of the two prediction 
software 
 Screen of candidate genes 
All exons of the candidate genes were screened via Sanger sequencing in 40 additional 
oncocytoma samples, of either Germanic (n=32) or Japanese (n=8) ethnic origin. 
To preserve the supply of patient DNA, samples were whole genome amplified (WGA) 
prior to the Sanger sequencing screen. Analysis was initially conducted on mutation 
surveyor with a manual visual assessment using 4-peaks to visually confirm the 
mutation surveyor report. Inconclusive sequences or sequences with unacceptably high 
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background noise were re-sequenced in the alternative direction, while any potential 
variant was first mapped in Ensembl and COSMIC to identify whether variant had been 
previously reported and whether the variant was non-synonymous. Following, these 
checks potentially novel variants were re-sequenced in the original unamplified tumour 
DNA and corresponding normal where possible.  
Dr. James Whitworth (University of Birmingham) screened the WGA DNA, for genes 
FOXI1, RNF146, ETFB, DERL2 with any potential variant or inconclusive result being 
repeated by myself on the original stock DNA. Where a variant was confirmed, 
sequencing of the matched normal (if available) was conducted to test whether the 
variant was somatic, after first confirming within ensemble that variant was neither a 
SNP nor synonymous variant.   
For NOLC1 and KSR1 the status of the recurrent variant identified by WES was 
investigated in stock tumour DNA and corresponding normal, (Figure 5-9) however both 
variants were identified as germline.  It should also be noted that since receiving the 
exome data NOCL1 variant c.1132_1134del:p.378_378del, has since been reclassified 
from a novel variant to a known SNP rs548784326; with a MAF of <0.01 globally (1000 







Figure 5-9: Electropherogram of WES recurrent variants NOLC1 and KSR1 Sanger sequencing showing both variants identified as recurrent in the WES files are germline in the additional sample. A) NOLC1; variant c.1132_1134del:p.378_378del, reclassified as SNP: rs548784326 (MAF <0.01). B) KSR1; variant c.1132_1134del: p.378_378del (in WES identified as unclassified SNP with a observational frequency of 0.000239  
NOLC1: Indel variant iden fied in WES for T4- Germline 
N4  
T4  







CNBD2 (C20orf152), DCAF4L2, DERL2, ETFB, FOXI1, KSR1, MYOM1, NOLC1, NPBWR2, 
RNF146, ULK1 were successfully screened and confirmed in the stock DNA. However, 
OBSCN, CRIM1, MKI67 and MRPL9 were unfortunately unable to be screened due to time 
constraints within the project.  
Results of the genes screened are displayed in Table 5-4. For CNBD2 (C20orf152), CRIM1, 
DCAF4L2, DERL2, ETFB, KSR1, MYOM1, NOLC1, NPBWR2, RNF146 and ULK1, no further 
novel damaging mutations were confirmed. Instead only synonymous and characterised 


















































































































































Onco= 37/40 (21 
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  FOXI1 
FOXI1, was identified to possess a somatic SNV predicted to be damaging (Polyphen 0.99 
Sift 0.00) NM_144769; exon1, c.C517A, p.H173N  in the WES data in oncocytoma sample 
T3. Further screening of the 40 additional oncocytoma samples also identified the same 
variant in a further three samples, two of Japanese decent and one of German decent, 
these were confirmed by Sanger sequencing in both directions on the original stock DNA 
three times. Our collaborator Dr. M. Yao, managed to obtain an additional 4 Japanese 
oncocytoma samples, which were also screened, one of these samples was also identified 
to possess the c.C517A, p.H173N variant.  Unfortunately, however for the additional 
samples identified, the matched normal were unavailable; therefore the somatic status is 
unable to be confirmed (Figure 5-10). 
In summary a total of 5 oncocytoma samples were confirmed as possessing SNV c.C517A, 
totalling 10.2% of oncocytoma samples with a MAF 0.05 within our samples. From the 
small cohort investigated, 23.5% of Japanese samples (4/17) presented with this variant  
compare to the 3.1% German (1/32). Fishers exact test identified a significant difference 
between the frequency of the SNV within Japanese samples compared to samples from a 
German population (P=0.043), leading us to hypothesise that this variant  maybe linked 
to ethnicity, and could act as a precursor or increase susceptibility for oncocytomas 
within a Japanese population.  
To increase confidence that this mutation is tumour specific and not an uncharacterised 
SNP, all available matched normals for oncocytomas were screened and identified to be 




































A further screen of 101 Japanese N was also undertaken. It should be noted, the normal 
samples in which the ethnicity was known were from non-tumorous kidney tissue of 
patients with a renal cancer, the subtype of renal cancers varied with 61 ccRCC, 14 
sarcomatoid ccRCC, 14 chRCC, 7 pRCC, 3 Collecting Duct RCC (cdRCC), 1 mutinedus  
tubular + spindle cell and 1 Angiomyolipoma. These normals shall henceforth be 
referred to as cancer Normals (cN).  All cN were identified to be wt.  
To identify if FOXI1 p.H173N  was oncocytoma specific the matched tumours of the 
aforementioned normals were also sequenced in addition to an extra 14 pRCC, 12 
sarcomatoid + ccRCC, 10 chRCC, 5 Angiomyolipoma, 4 cdRCC, 2 Unclassified, 1 Papillary 
type 2 + Sarcomatoid, 1 AML epithloid type, 1 Juxtaglomerular cell tumours all of  
Japanese origin (total non-oncocytoma tumours tested n=151).  
An ethnicity targeted database search was also undertaken focusing on the Japanese 
population including a search of the 1000 genome project  (105 non-diseased Japanese), 
the Japanese SNP database (JSNPS; 752 unrelated Japanese samples), and the Integrative 
Japanese Genome Variation database (1070 Japanese volunteers aged between 20 and 
80 years). The SNV c.C517A, p.H173N was not identified in any databases.  
When compared to other cancers samples from the TCGA and the published data sets 
represented on cBioportal, FOXI1 was most frequently mutated in skin melanoma (6.6% 
8/121), while gene application was frequently reported in the TCGA ccRCC 17.3% 
(72/415) and breast cancer 10.3% (3/29) subsets (Figure 5-11). When analysing the 
mutation prevalence, was the most frequently mutated although no cancers were 
reported to contain our SNV of interest, nor any variant mutated to such high a 
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frequency (Figure 5-11 Figure 5-12a-b). In cosmic, skin cancers also presented with the 
most frequent mutation rate, of 3.47% (30/864). Once again no other cancer presented 
with our SNV of interest. Investigation into the location of our SNV, identified it to be 
located in exon 1 and present in both transcripts of FOXI1 (Figure 5-12c). Our SNV was 
located within the highly conserved and functional fork head domain (Figure 5-12b), 
with our particular amino acid being conserved across multiple species (Figure 5-12d).  
Furthermore, expression profiling of FOXI1 identifies FOXI1 to be expressed in the 
kidney ((Figure 5-13a). String db network analysis of human FOXI1 (Figure 5-13b) 
predicted two functional partners PAX8 and Wnt1 with high confidence of integration 
(0.924 and 0.715 respectively) that are associated with known KEGG cancer pathways 
with Wnt1 also associated with the Hippo pathway (though n=2 and n=1 means that the 
association of FOXI1 within the cancer pathways or Hippo pathway was not deemed to 
be significant). Another 5 other genes (SLC26A4, TG, DUOXA2, DUOX2 and PAX8) within 
the network were associated with Thyroid hormone synthesis (P = 5.289e-8) highlighting 
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Figure 5-13: Biological characteristics of FOXI1 A) FOXI1 mRNA expression in human tissue. Characterised by RNAseq and Microarray adapted from Genecards.org. FOXI1 mRNA  expression via RNA-Seq was identified to be particularly increased in kidney (Red arrow). B) String-db prediction of human FOXI1 interaction network. Blue lines indicate confidence of interaction, with probability of an interaction documented in ‘score’ column, high confidence is classified as a score >0.7 Legend also details predicted biological interaction. 
   
Major Tissues 





 TERT promoter 
To investigate whether the recently identified TERT promoter hotspots C228T or 
C250T were associated with oncocytoma, targeted Sanger sequencing of the TERT 
promoter hotspots was conducted in 45 oncocytoma samples. Although neither 
hotspot variant was detected this result is not wholly unexpected as the hotspot 
mutations have been associated with more aggressive cancers, rather than a benign 
tumour such as oncocytoma. However two alternative known SNPs were identified 
firstly C>T SNV at -348 bp upstream of TSS (chr 5:1295373, rs35226131; global MAF 
0.01 (T: 61/C: 4947 alleles)) found in 4.4% oncocytoma samples tested (2/45 with a 
MAF: 0.02 within our samples). The second SNP identified was A>G -245bp upstream 
of TERT TSS (chr 5:1295349, rs2853669, MAF 0.3 (G: 1492/ A: 3516)) was found in 
44.4% of oncocytoma samples tested (20/45 with a MAF: 0.25 within our samples). 
Interestingly the presence of rs2853669 is predicted to disrupt a pre-existing Est2 
binding site; Hosen et al., 2015 report worse survival in ccRCC patients with the 
classical hotspot mutations but lacking rs2853996, compared to those possessing the 
hotspot mutations and the rs2853996 (though the cohort of hotspot mutated 
samples with and with out rs2853996 was too small for conclusive stats to be 
preformed). However there is a suggestion that rs2853996 may have a regulatory 
function in modulating TERT activity within cancer, and added another level of 
complexity into the importance to the TERT promoter in malignant disease. 
Investigation into structural variation of the TERT promoter within oncocytoma was 
not conducted, due to the exome sequencing not interrogating and identifying the 
types of variations present (if any) in oncocytoma at the breakpoint region identified 




The advances and applications of NGS have provided researchers with a high 
throughput, in-depth and informative insight into the genetic continuants of many 
types of cancers and diseases (Rabbani et al., 2014a). WGS can provide additional 
information into non-coding intronic regions, enhancer regions and identify 
structural variations and break points; however, as yet WGS remains expensive and 
requires huge volumes of data processing and bioinformatic analysis with 
increasingly complex computational pipelines, in order to draw meaningful 
conclusions. As such it is a technology beyond the capacity both financially and 
technologically of many laboratories. WES however provides a generally more 
affordable and accessible alternative. By interrogating the sequence of the exons, at a 
deeper coverage than WGS, (95% of all exons are covered) (Ku et al., 2012; Rabbani 
et al., 2014a), WES provides detained information on human exome, corresponding 
to around 1.5% of the whole genome (Koboldt et al., 2012; Meynert et al., 2014). 
However, it has been reported that around 85% of disease causing variants are 
located within the exons (Rabbani et al., 2014a), thus WES is able to identify 
numerous protein coding variants, and ascertain the biological relevance due to 
identifying the disruption to the protein sequences. Although WES also generates 
large data files the release of more and more computational pipelines and 
bioinformatic techniques to mine the data for somatic variants, LOH and somatic 
copy number alterations such as Varsan2, MutSigCV (Koboldt et al., 2012; Lawrence 
et al., 2013) and other bioinformatic techniques; increases the accessibility and 
reduces the data processing time, promoting a flood of information on somatic 
mutations in a multitude of cancers and disease such as: small-cell lung cancer (Peifer 
et al., 2012), ccRCC (Varela et al., 2011), chRCC (Davis et al., 2014), breast cancer 
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(Fackler et al., 2011), glioblastoma (“TCGA,” 2008), and hepatocellular carcinoma 
(Totoki et al., 2014). 
 Summary of findings 
The focus of this study was to employ WES to identify somatic mutations that may 
drive the formation of the rare benign renal tumour, oncocytoma. Following a manual 
bioinformatic data processing pipeline described, a total of 18 variants were 
identified and confirmed via Sanger sequencing to be somatic, 15 of which were 
predicted to be damaging in at least one of the in-silico prediction software utilised. 
Eleven of these genes were screened via Sanger sequencing in a cohort of 
oncocytoma samples totalling 45 samples, with the aim of identifying further 
recurrent somatic mutations that may attribute to the progression and development 
of oncocytoma. Of these screened genes FOXI1, was identified to possess a recurrent 
variant, c.C517A p.H173N; first identified within the exome sequencing. This SNV was 
observed to be more frequent in tumours from a Japanese cohort, 23.5% of samples 
compared to 3.1% of samples with German ancestry. Further in-house investigation 
of oncocytoma normals, Japanese cN and other Japanese non-oncocytoma renal 
tumours did not identify any recurrence, suggesting that the SNV identified is  
oncocytoma specific. Furthermore studies of publicly accessible databases, with 
particular focus upon ethnicity (Japanese) revealed no reports of the aforementioned 
SNV. 
The frequency of c.C517A, p.H173N observed, within renal oncocytoma samples 
suggests this SNV may be an oncocytoma unique hotspot mutation, which could 
potentially be involved in driving tumourigenesis and inferring a growth advantage 
(Pon and Marra, 2015; Tamborero et al., 2014; Vogelstein et al., 2013). However, this 
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variant cannot be confirmed as an oncocytoma specific hotspot mutation until the 
rest of the FOXI1 gene is screened in the non-oncocytoma tumours and cN, as 
alternative pathogenic variants may be identified in the additional samples.     
However, the concept of tumour specific hotspot variants is not unique, with Weinreb 
et al and Ueno-Yokohata et al also reporting unique tumour specific hotspot variants 
and alterations. Weinreb et al 2014 conducted a study into polymorphous low-grade 
adenocarcinomas (PLGA) of the salivary glands. They identified a somatic hotspot 
with two activating missense changes (c.2130A>T or c.2130A>C), that resulted in the 
same aa change p.Glu710Asp in PRKD1; 43 of 59 (72.9%). This variant was associated 
with increased metastasis free survival and reduced cell migration in-vitro. 
Subsequent database (TCGA and cBioportal) and literature searches led the authors 
to conclude that p.Glu710Asp in PRKD1 was a PLGA specific hotspot (Weinreb et al., 
2014). Ueno-Yokohata et al 2015 investigated paediatric renal tumours, in particular 
clear cell sarcoma of the kidney (CCSK). They identified that a tandem duplication of 
between 30-38 aa in exon 16 of BCOR in 100% (20/20) of CCSK cases tested, while 
investigation into a further 193 alternative (non-CCSK) primary paediatric renal 
tumours identified no duplication or structural abnormality on BCOR exon 16. 
Therefore proposing tandem repeat in BCOR is CCSK unique (Ueno-Yokohata et al., 
2015). Characterisation of a tumour specific mutation may therefore provide a useful 
marker by which the type of tumour can be identified and diagnosed, in addition to 
providing insights into the biology and pathogenesis of the tumour.                
Interestingly, c.C517A, p.H173N was not only identified as an oncocytoma specific 
SNV, but the variation in frequency of the SNV between the two ethnic populations 
studied was also interesting, with the SNV being far more frequent within samples 
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from a Japanese ancestry. It has long been accepted that different ethnicities have 
different susceptibilities to disease, for example type 2 diabetes is 6 times more likely 
to occur in someone of south Asian and 3 times more likely in people of African 
decent (Diabetes.co.uk). According to Cancer Research UK, the incidence of all types 
of cancers between ethnic groups and gender varies, with the incidence of any type of 
cancer in white males ranging from 408.2 to 416.8/ 100,000 and similar reports in 
black males (316.7 to 488.3/100,000), while the incidence of cancer in Asian males 
was reported to be much lower (168.3 to 258.9/100,000). In females the trend was 
different with white females having the highest incidence of cancer (from 351.0 to 
358.4/ 100,000) compared to and black and Asians women (incidence of 168.4 to 
249.8/100,000 and 215.0 to 322.0/100,000 respectively) (Cancer Research UK).  
Moreover, studies into the prevalence of mutations within BRCA1 (associated with 
increased risk of breast cancer), , have identified a disparity between different ethnic 
groups (National Cancer Institute). US studies, on an American population showed 
that Hispanic (3.5% n=393) (significance not declared) (John et al., 2007) and white 
US population (2.2% (n=508) – 2.9% (n=1145) presented with a higher frequency of 
the harmful BRCA1 mutation than black and African-American population (1.3% 
(n = 341)-1.4% (n=483)) P <0.05 ( Malone et al., 2006). Moreover, both studies 
identified that the prevalence of harmful BRCA1 mutations was much greater in 
women of Ashkenazi Jewish descent 10.2% (n = 86) P <0.001(Malone et al., 2006), 
and 8.3% (n=41) (significance not declared) (John et al., 2007) with the majority of 
mutations were reported to be of one of three key deleterious mutations 185delAG, 
5382insC, and 6174delT. 
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Other genome wide association studies and linkage disequilibrium analysis focusing 
on the association of cancer risk markers between different ethnicities, remarked 
that characterised risk loci are often poorly linked and not reproducible between 
ethnic groups. Meaning that where one ethnic population may present with a 
significant association of a variant with cancer risk, this association may not present 
as a significant association in another. This suggests a diverse genetic and 
environmental variation on the association of cancer risk between ethnic groups 
(Jing et al., 2014). 
Large whole exome sequencing investigation by Totoki et al of the mutational 
landscape of hepatocellular carcinoma (HCC) across different ethnic groups (total of 
503 HCC cases +105 TCGA HCC of Japanese, US Asian and European ancestry) 
identified distinct mutational signatures between, not only ethnic groups but also 
between genders. HCC is reported to be most prevalent in East Asian and African 
population, but the incidence is increasing in western populations, with many 
etiological cofactors being associated, however the finding of Totoki et al also suggest 
a mutational process that is associated to ancestry, further highlighting the variation 
and complexity ethnicity can present, even when studying the same disease (Totoki 
et al., 2014). No association between FOXI1 c.C517A p.H173N SNV occurrence and 
gender was noticed. 
FOXI1 is a member of the Fork head binding proteins, a family of at least 43 DNA 
binding proteins, subdivided into smaller groups, although all FOX proteins are 
characterised by a highly conserved 100aa DNA binding domain that form a winged-
helix domain, with many FOX proteins having been associated with a multitude of 
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cancers (Katoh and Katoh, 2004). The most extensively studied of the FOX family 
appear to be FOXM and FOXO subgroups.  
FOXM has been summarised to be amplified in 5.6% of breast cancers and 42% of 
non-Hodgkin’s lymphomas, (particularly; diffuse large B-cell lymphoma, follicular 
lymphoma, and B- cell chronic lymphocytic leukaemia) and unregulated in a plethora 
of cancers including lung, head and neck squamous cell carcinoma and bladder 
cancer, among others. FOXM1, transcription is induced by hedgehog signalling, and 
FOXM1 is self activated by the RAS signalling pathway, transcribing growth 
associated factors and promoting malignant phenotypes (Katoh et al., 2013). Thus 
overexpression has been suggested to be a biomarker for poor prognosis in non-
small cell lung cancer (J. Zhang et al., 2015) 
In the absence of insulin or growth factors, the FOXO family transcribes genes 
promoting cell cycle arrest, cell differentiation, stress resistance, or apoptosis; 
determining cell fate under different external conditions and factors and different 
binding partners. Thus FOXO’s have been described to act as tumour suppressors 
(Greer and Brunet, 2005). For example, upon interacting with SMAD, FOXO 
transcribes p21, resulting in cell cycle arrest, but when associated with p53, 
FOXO/P53 reduces p53 inhibition of SIRT, which in turn deacetylases FOXO driving 
the transcription of stress resistance factors and responses (Calnan and Brunet, 
2008; Greer and Brunet, 2005; Milan et al., 2015). Activation of the PI3K-AKT 
signalling pathway by insulin or growth factors (e.g. TGFB) results in the 
phosphorylation of FOXO (Fu and Tindall, 2008), while FOXO1 and FOXO3, are also 
phospholated by MST1/2 core members of the Hippo pathway (Pan, 2010).  Several 
of the FOXO family have been associated with chromosomal breakpoints and gene 
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fusions in several diseases, for example PAX3:FOXO1(t(2:13)(q35;q14)) or 
PAX7:FOXO1 (t(1:13)(p36;q14))  fusions are associated with alveolar 
rhabdomyosarcomas, while FOXO3:MLL t(6;11)(q21;q23) and FOXO4:MLL 
t(X;11)(q13;q23) has been identified in acute leukaemia (Greer and Brunet, 2005; 
Katoh et al., 2013) 
Additionally FOXO1 is often deleted in prostate cancer, while in Ewing sarcoma, 
binding of the oncogenic EWS-Fli1 fusion to the FOXO1 promoter, results in down 
regulation of the mRNA (Katoh et al., 2013; Yang et al., 2010). 
Point mutations in FOXA1, have been associated with prostate cancer, with FOXA1 
binding to the dense chromatin, inducing relaxation of the chromatin and allowing 
transcription (Katoh et al., 2013). FOXF has been characterised as a TSG in-vitro, in 
several different cancer cell lines, with knockdown of FOXF resulting in increased 
cancer cell migration and invasion. Moreover it was shown that FOXF was up-
regulated by p53 (Tamura et al., 2014). Although not all FOX genes have been 
classified as possessing tumour suppressive activity, FOXG for example is regarded as 
an oncogene due to its inhibitor effect preventing FOXO binding to the p21 promoter 
(Calnan and Brunet, 2008; Fu and Tindall, 2008; Katoh et al., 2013).  
Little has been investigated into the role of FOXI1 in regards to cancer, however 
FOXI1 has been identified to bind to condensed chromatin and remains bound even 
during mitosis, in a similar manner as TATA and GAGA transcription factors, 
potentially having a role in modulating chromatin structure (Yan et al., 2006). In 
addition, FOXI1 has an important role in the complex signalling networks of 
embryogenesis and organogenesis particularly in the development of the kidney, jaw 
and inner ear in zebra-fish (Aghaallaei et al., 2007; Yan et al., 2006) and mice. (El-
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Dahr et al., 2008). Within the kidney, FOXI1 has been identified to mediate the 
terminal differentiation of epithelial cells within the collecting duct into intercalated 
cells, with FOXI1 transcription driven by the p53/p73 transcriptional network (El-
Dahr et al., 2008; Guo et al., 2015). Furthermore, FOXI initiates the transcription of 
intercalated cell-specific genes, including vacuolar H+-ATPase Proton Pump subunit 
transcription, particularly the A4 subunit where expression was additionally 
localised in FOXI1 positive epithelial cells in the inner ear, kidney and epididymis 
(Blomqvist et al., 2004; Vidarsson et al., 2009). While, the loss of FOXI1 has been 
identified to result in a lack of intercalated cells in renal collecting duct, and distal 
renal tubular acidosis (Blomqvist et al., 2004; El-Dahr et al., 2008). Thus FOXI1/p53 
expression promotes intercalated cell identity, the cell type from which oncocytoma 
are derived (Lopez-Beltran et al., 2006) . 
Within the inner ear epithelium development, FOXI1 has also been reported to up 
regulate oncogenic associated transcription factor PAX8 (Aghaallaei et al., 2007), a 
gene that has since been characterised as a biomarker for non-mucinous surface 
epithelial ovarian  carcinomas (Nonaka et al., 2008). However the role of FOXI1 on 
cancer genesis has yet to be investigated. 
It was hypothesised, that FOXI1 c.C517A p.H173N is an oncocytoma specific hotspot 
variant that is primarily associated with a Japanese ancestry. The SNV resides in the 
highly conserved fox head DNA binding domain, therefore, c.C517A p.H173 may be 
involved in the formation or susceptibility for developing renal oncocytoma. It is 
however vital, that before any definitive conclusions can be drawn that more 
Japanese oncocytoma samples, preferably with matched normal controls are sourced. 
Furthermore the, whole FOXI1 gene should sequenced in both non-oncocytoma 
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tumour samples and cN, this would identify if alternative somatic variants are 
present in other tumours or whether the variant FOXI1 c.C517A p.H173N is an 
oncocytoma specific hotspot variant. At present we have applied to our collaborator 
for further samples. Additionally the effect of this mutation on cell growth should be 
investigated in-vitro, to establish if any pathogenic effect is observed. This currently 
being assessed by the generation and transfection of a plasmid construct containing 
the mutated FOXI1 open reading frame, with the specific mutation induced in-vitro by 
site directed mutagenesis into a kidney cell line such as HEK293. The effect on 
growth will be assessed via anchorage independent colony formation assays (section 
2.6.8) .   
Until in-vitro studies investigating the effect of FOXI1 SNV have been conducted, it is 
impossible to hypothesise if FOXI1 possesses tumour suppressor qualities, like other 
members of the FOX family, such as FOXF1 or if it is associated with oncogenic 
functions that are exacerbated or unregulated by the presence of c.C517A, p.H173N. 
With the rise of the TCGA, WES and WGS, many genetic profiles of cancers have been 
analysed, with more emphasis being placed on the rare cancers. Recently 
multiplatform analysis of chRCC, identified frequent somatic mutations in TP53 32% 
of cases (33% 21 of the 66 samples) and PTEN (9% 6 of 66 samples), and multiple 
genomic rearrangements were identified with in the TERT promoter (6/50) (Davis et 
al., 2014). Another WES study into familial RCC, has recently identified CDKN2B 
germline mutations to predispose patients to the disease in around 5% of cases 
tested (Jafri et al., 2015). 
A study into multiple non-clear cell renal carcinoma subtypes, including pRCC (n=67), 
chRCC (n=49) and oncocytoma (n=35), identified significantly mutated genes unique 
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to each subtype. Although chRCC and oncocytoma mutation profile clustered together 
under unsupervised clustering, subtype specific mutation profile was reported 
including; for pRCC; MET, SLC5A3, NF2, PNKD, CPQ, LRP2, CHD3, SLC9A3R1, SETD2 
and CRTC1, while for chRCC; TP53, PTEN, FAAH2, PDHB, PDXDC1 and ZNF765 were 
hypermutable. For the oncocytoma samples ERCC2 and C2CD4C were identified to be 
significantly mutated although no recurrence was reported (Durinck et al., 2015). 
Furthermore, we did not identify any recurrent somatic mutations when comparing 
the genes listed in the supplementary data of Durinck et al, to our own data.  
Additionally Durinck et al. did not report finding any FOXI1 variants, however, we 
propose that this might be due to the different ethnicity investigated, our Japanese 
samples were extracted in Japan from patients with oncocytoma while Durinck et al. 
investigated 35 oncocytoma, samples obtained from patients in the USA from a wide 
variety of patients of multiple ancestry groups that were not specified. 
 Limitation of this study 
A significant limitation of WES is the huge volumes of data produced. Raising issues 
regarding how best to process and filter the data and draw meaningful and relevant 
conclusions.  
However, several computational pipelines have been released to assist with the 
processing of this large data pool, and to identify and classify the elusive variants 
driving cancer. It has been widely accepted that finding recurrent mutations in a 
known pathway is a good starting point for identification of driver mutations, but as 
more WES and WGS is under taken more and more focus is being turned to identify 
driver mutations and de-novo variants and genes previously missed through targeted 
analysis (Raphael et al., 2014; Tamborero et al., 2014). 
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For each programme the filtration process differs, and is therefore likely to produce 
discrepancies within the output list (Kim and Speed, 2013).  Although a manual 
approach to the data processing was ultimately undertaken in this study, Varscan2 
analysis was also conducted. A computational pipeline revolving around statistical 
comparison of read depth and variant call rate. Reassuringly 94% of the variants 
identified as somatic (by the manual pipeline) were also present in the Varscan2 
output. However there were more variants predicted as somatic by Varscan2, as well 
as analysis of LOH and copy number alterations, something our manual pipeline did 
not account for.  Posing the issue that, perhaps our filtration method was too 
rigorous, with variants being discredited that may perhaps have been of interest.  It 
should be noted however that due to the algorithms employed via Varscan2, the 
pipeline is susceptible to array bias (slight variations between different array run on 
the same machine, resulting in different read depth and coverage of genes) (Koboldt 
et al., 2012), something that was observed for tumour normal pair T1/N1, (where the 
normal was repeated at a later date due to low DNA concentration), as a result 
Varscan2 predicted >200 somatic variants. 
Though not remarked upon within this study, it has been previously observed that a 
high number of what are termed “fishy” genes are recorded via WES to contain 
cancer specific mutations, following bioinformatic filtering. These are genes that are 
highly mutated and seem to be associated with cancer but cannot be explained, such 
as TTN encoding the muscle protein titin, genes encoding olfactory receptors, many 
of the membrane associated mucin family in particular MUC16 and MUC4 and other 
large proteins. The belief is that the prevalence of these genes within WES data may 
be due to tumour heterogeneity or due to enrichment bias during the exome 
enrichment stage of WES (Lawrence et al., 2013; Ledford, 2013). To address these 
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concerns and the risk of tumour/normal contamination MutSigCV uses an algorithm 
that identifies somatic mutations while also comparing each variant to the expected 
background frequency of mutations (by comparing the frequency of protein coding 
variants to synonymous and calculating the probability that a base is mutated by 
chance) for each loci. Variants exceeding the pre-calculated mutation threshold are 
deemed to be significant. Thus accommodating the background mutation frequency, 
into the analysis one would hope to improve upon identification and characterisation 
of cancer driver genes and pathways (Evans et al., 2013; Lawrence et al., 2013; 
Watson et al., 2013), 
Though many of the usual suspects were incorporated within our raw exome data, 
our filtration method resulted in none being classified as somatic within our samples, 
however identification of these type of genes does raise concern that MYOM1 and 
OBSCN might also belong with this classification of genes due to their size and 
association with titin. Although the MutSigCV pipeline was not used on our data, in 
hindsight a combination of manual, Varscan2 and MutSigCV may have yielded a 
refined gene list with potentially novel driver variants, specific for oncocytoma, or 
pathways affected by an above background rate of mutation.  
Another limitation of WES, is that it only encompasses around 1.5% of the genome, 
although a large amount of data is still produced for this region, it does mean that, 
unlike in WGS; regulatory, enhancer, promoter regions such as the TERT promoter 
(Horn et al., 2013; Rathmell et al., 2015) and structural variations including 
translocations and inversions, are omitted (Davis et al., 2014; Suzuki et al., 2014).  
Furthermore, the physical method of WES with exome targeted capture and PCR 
amplification has been reported to result in an ununiformed and variable read depth, 
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with lower coverage at exon boundaries, shorter fragments, more prone to false 
positives due to misalignment to the reference genome particularly in repetitive 
regions and even a bias during exon enrichment for exons that are less GC-rich. This 
is possibly one of the reasons for the prevalence of “Fishy” genes within WES projects 
(Ku et al., 2012; Ledford, 2013; Meienberg et al., 2015; Meynert et al., 2014; Sims et 
al., 2014). Other reports have also identified variation in the exonic regions captured 
between different commercially available exome capture kits, meaning that variants 
and exonic regions may be missed or poorly covered depending on the kit used 
(Lelieveld et al., 2015; Sims et al., 2014). 
Tumour heterogeneity is another challenge faced when conducting high throughput 
sequencing and analysis, and can dilute the sensitivity of WES and WGS to detect 
heterozygous mutations. Firstly tumours consist of more than one tissue sub clone, 
and can possess multiple different genetic abnormalities within each tissue subtype, 
adding complexity to the analysis to identify driver mutations. Additionally, tumour 
samples are often contaminated with normal noncancerous tissue, as tumours 
usually reside alongside the normal healthy tissue, some of which may often be 
included in the tumour extraction as a buffer to ensure the entire tumour is removed 
from the patient. In order to combat this, it is vital that a sufficient read depth is 
obtained for both WES and WGS with modern technologies striving to achieve an 
average read depth of >100 and >30 respectively (Watson et al., 2013). Original 
methods to asses tumour purity were conducted visually a by skilled pathologist, 
however there are some computational programmes being released which can 
calculate tumour purity at the present these tools are optimised for SNP arrays, 
although they can be adapted for WES and WGS. Programs such as Varscan2 
currently acknowledge tumour heterogeneity as an issue in detecting SNVs and 
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require a user-entered estimation of tumour purity. (Koboldt et al., 2012; Raphael et 
al., 2014).  Although NGS and genomic investigation is both informative and 
predictive of the effect that a variant, or copy number alteration may have on a gene 
and transcription, this not necessarily representative of what is happening at protein 
level. Particularly because many proteins possesses post translational modifications 
that effect their function. Ideally to obtain a full representation of the biological 
profile of different cancers, genomic investigation would be coupled with genome 
wide proteomic analysis (Akbani et al., 2014). 
Regarding experimental design of this study, a major limitation and a steep learning 
curve revolved around the lack of matched normal tissue originally sent for WES. As 
observed within this study, we could not identify a logical approach to analyse the 
vast data from the unpaired samples (T4 and T5), as a result the samples ended up 
being put aside during further filtration, with our study focusing on the matched T/N 
pairs. Additionally these samples cold not be analysed via computation pipelines, as 
they require the matched normal in order to identify cancer specific variants. 
Another limitation was the small cohort size, firstly the small number of samples 
exome sequenced and secondly the limited number of samples screened via sanger 
sequencing and thirdly the limited availability of matched normal required to 
confirm somatic status.  The cohort of Japanese samples included in this study was 
small totalling only 17 oncocytoma samples screened for FOXI1, of which only one 
sample was able to be confirmed somatic for FOXI1 p.H573N due to the lack of 
corresponding normals. However oncocytoma is a rare tumour and to acquire 
sufficient samples from distinct ethnicities has been challenging and dependent on 
the good will of our collaborators. By expanding the cohort and WES additional T/N 
pairs, further recurrent variants or susceptibility markers may be identified.  
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Having discussed the limitations of the WES technology and analysis and our own 
limitations regarding the oncocytoma cohort, one final remark is regarding the lost 
data filtered out for various reasons through the in-silico analysis. For example a 
blanket removal of high frequency SNPs was employed, although the vast majority 
are likely to be of no interest, some SNPs may possess clinical significance. For 
example the previously mentioned SNP rs2853669 (MAF 0.30) within the TERT 
promoter was reported to increase survival time in patients presenting with the 
classical TERT hotspot mutations, C228T or C250T (Hosen et al., 2015), while the 
presence of SNP rs6983267 (MAF 0.39) on chromosome 8q24 has been widely 
associated with a predisposition to colorectal and prostate cancer (Tuupanen et al., 
2009; Ensemble.org). A classic textbook example within pharmarmacogenetics, 
shows that the presence of many well characterised SNPs, the most notable being 
CYP2C19*2 (c.681G>A) Rs4244285 MAF 0.22 results in patients being a poor drug 
metabolisers reducing the efficacy of several different drugs including some 
antidepressants, anti-convulsant (mephenytoin) and anti-platelet drug clopidogrel 
(Scott, 2011). 
Moreover, a recent study by Supek et al. 2014, has highlighted a possible oncogenic 
effect for the previously discarded synonymous mutations. By analysing the 
prevalence of synonymous mutations in data obtained from TCGA and COSMIC for 11 
different cancer tissues (prostate, breast, renal, blood, lung, colorectal, ovarian, 
melanoma, head-neck, thyroid and brain) with >200 samples per cancer type, Supek 
at al identified an increase if the prevalence of synonymous mutation in oncogenes 
compared to TSG in a cancer/tissue specific manner. Although not altering the 
protein aa sequence, synonymous mutation may alter or generate exon splice sites, 
resulting in abnormal splicing of the mRNA. A key example was described in TP53 (a 
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TSG enriched with synonymous mutations that deviated from the normal finding) 
showing that a synonymous variant at the 3’ region of exon 6 created a splice site that 
resulted in the production of an augmented mRNA (Supek et al., 2014). 
 Future work 
As previously mentioned future work should focus on further identification of the 
characteristics of the FOXI1 SNV c.C517A, p. H173N via in-vitro investigation, in order 
to establish the effect of this SNV on growth and even cell migration. At present a 
construct containing the specific variant is being generated and the effect of the 
mutation on cell growth is to be analysed by soft agar colony formation (Currently 
being conducted by Abdullah Alholle (University of Birmingham) and Dr Mark Morris 
(University of Wolverhampton).  The long term, experimental aim would turn 
towards proteomic investigation via such techniques as mass spectrometry or co- 
Immunoprecipitation with the aim of identify binding partners and potential 
pathways in which FOXI1 may be involved in.  
Further screening of FOXI1 in a larger cohort of sporadic oncocytoma should also be 
undertaken and ideally included other ethnicities to confirm our hypothesis, and the 
rest of the FOXI1 gene should also be screened in the non-oncocytoma tumour and cN 
samples to identify if other somatic variants are present in different RCC subtypes. In 
addition, investigation into structural variation or mRNA splicing abnormalities via 
RNA-Seq and LOH studies should also be undertaken to get a clearer picture as to the 
role of FOXI1 in oncocytoma.   
 Final summary 
The reduction in cost, increased accessibility of facilities and services and 
advancements in bioinformatic pipelines has enabled WES to be widely utilised in the 
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profiling of the somatic exonic landscape of cancers. Although not without its 
limitations WES has provided a wave of information and insights into many cancers. 
Though, the variable read depth and enrichment process fundamental to the 
technology mean that it is inferior to the more uniform WGS. As the cost of WGS 
becomes more affordable, and bioinformatic pipeline more user friendly, more and 
more labs will be turning to WGS. Additionally the continued development of 
publically accessible databases detailing and characterising enhancer and regulatory 
regions such as ENCODE (Rosenbloom et al., 2013, Encodeproject.org) will boost data 
processing and interpretation of intronic region variants. Thus it should be predicted 
that a fresh wave of cancer genomic information will be published, with novel 
structural variants, and further information on enhancer and other non-coding 
regulatory variants.  This is the aim of the recently launched Genomics England 
100,000 genomes project, where the genomes of 75,000 patients with various rare 
disease and 25,000 tumours will be sequenced and compared to clinical data with the 
ambition of creating a new genomic medicine service for the NHS, that can enhance 
the medical research, diagnosis, treatment and overall care for the patient and the 




 Final conclusion 
As previously mentioned cancer is the leading cause of death worldwide. Although 
kidney cancer is not the most common cancer in the UK, as with most adult cancers, 
the strong link with incidence and age raises huge concerns as the population ages. 
Furthermore as traditional chemotherapy and cytotoxic drug treatment is of limited 
success in the treatment of RCCs (Linehan and Ricketts, 2014). The most frequently 
used treatment options include surgery (nephrectomy) or radiotherapy, while 
pharmaceutical intervention predominately involves targeted therapy with 
treatments such as the anti-VEGF molecules (sunitinib  or  pazopanib  both Tyrosine-
kinase inhibitors) or by mTOR inhibitors such as temsirolimus another TKI 
(Courthod et al., 2015; Linehan and Ricketts, 2014).  However, patients response to 
treatment is dependent on the subtype of RCC (Bylow et al., 2009) it is therefore vital 
that an accurate diagnosis is obtained quickly in order to ensure the most efficient 
course of treatment is applied.  
Consequently the aim of this study was to investigate and characterise the genetic 
and epigenetic profiles of rare renal cancers using modern multi-parallel high 
throughput arrays and sequencing techniques. The genetic investigation into rare 
diseases and cancers is vital for the identification of candidate genes and deregulated 
pathways, that contribute to disease progression. Successful identification and 
understanding of the genes and pathways playing a role in disease may in turn help 
to identify novel therapeutic targets which can be exploited either for the treatment 
of these rare diseases for use as biomarkers in the diagnosis of subtypes. Within this 
study three approaches were undertaken to carry out these investigations: 
Within this study three approaches were undertaken to assess the aim:  
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Firstly the study focused on differentiating between the global DNA methylomes of 
chRCC and renal oncocytoma using the Infinium HumanMethylation450 BeadChip 
(chapter three). chRCC and renal oncocytoma are two histologically similar tumours 
that possess different courses of progression; for example chRCC is a malignant form 
of RCC while renal oncocytoma is a benign neoplasm, with different courses of 
treatment. Therefore acquiring an accurate diagnosis is vital to ensure that the 
optimal course of therapy is undertaken. Through the analysis of the differential 
methylation profiles of the two histologies, it was hoped that differential methylated 
genes could be identified that may potentially then be used as biomarkers to 
distinguish between the two histologies.  
This analysis identified distinct methylation patterns, with regard to both chRCC and 
renal oncocytoma tumours , which were found to present with increased global 
hypomethylation when compared to the more aggressive ccRCC and pRCC. However 
due to the well known associations of hypermethylation at CpG island gene promoter 
regions within cancers, the main focus of the investigation aimed to identify 
differentially hypermethylated genes between the two RCC histologies. As having the 
ability to clearly differentiate between the two histologies would then enable more 
accurate diagnoses and therefore, enable the specific and tailored management of the 
tumour types.   
This analysis identified 30 genes to be differentially hypermethylated (28 in chRCC 
and 2 in renal oncocytoma). Further comparison of the DNA methylation with ccRCC 
and pRCC data from the TCGA network identified two candidate genes SPG20 and 
NPHP4 to be significantly hypermethylated in chRCC compared to the other 3 
histologies analysed (ccRCC, pRCC and renal oncocytoma). As previously discussed 
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SPG20 is a gene involved in cytokinesis and cytokinesis arrest. Methylation of SPG20 
has previously been identified as an early biomarker for some colorectal cancer cases 
(Lind et al., 2011). NPHP4 is involved in the development of primary cilium, and has 
also been associated with the Wnt pathway. However, further investigations to 
confirm that methylation is responsible for suppression of SPG20 and NPHP4 gene 
expression in chRCC is still required. Additionally functional analysis is also required 
to ascertain the biological impact of loss of SPG20 and NPHP4 on cell growth.  
Although not the main focus of this study, differential hypomethylation investigations 
identified 41 genes to be differentially hypomethylated between the two histologies 
(36 in chRCC and 5 in renal oncocytoma). However, the majority of the 
hypomethylated probes were mapped to lone (open sea) CpG loci, and thus require 
further investigation to determine their biological relevance. 
The second section of this study (chapter four) focused upon the investigation of 
methylation of the RASSF family of genes in advanced sporadic sRCC derived from 
ccRCC, using a sensitive and quantitative methylation assay known as Methylight. In 
this study RASSF10, was identified to be frequently methylated in sRCC and in late 
stage ccRCC. Analysis of the clinical data identified a positive correlation between the 
presence of methylation and the occurrence of metastasis, which suggests that loss of 
RASSF10 may be associated with more advanced and aggressive forms of cancer, and 
therefore may potentially be useful as a biomarker to assess disease progression. It 
was also identified that methylation of RASSF10 resulted in a decrease of mRNA, and 
removal of methylation restored the mRNA expression, with further functional 
analysis confirming that RASSF10 acts as a TSG where loss results in increased 
growth and colony formation. A preliminary mass spectrometry investigation was 
 
 319
conducted to characterise RASSF10 and its associated binding partners under 
different cell growing conditions with the aim of identifying the pathways in which 
RASSF10 is involved. From this study we identified that RASSF10 binds to TP53B2 
(ASPP2) and possibly even P53 itself when the cell cycle was synchronised, which 
could suggest a potential role in cell cycle checkpoint regulation. However this study 
was a preliminary investigation, and the results were not validated, therefore no 
definitive conclusions may be drawn. In order to be more confident of this 
hypothesis, the mass spectrometry analysis and cell cycle synchronisation would 
ideally need to be optimised and repeated. In addition , performing co-
Immunoprecipitation studies may help to determine protein binding partners, such 
as TP53 and RASSF10. It is hypothesised that RASSF10 like other RASSF family 
members, acts as a scaffold protein, thus co-immunoprecipitation should also be 
conducted to assess this theory. In conclusion, the observations of this study have led 
the formation of the hypothesis that RASSF10 is associated with more advanced and 
aggressive forms of RCC, largely due to loss of the tumours suppressor effect. Loss of 
RASSF10 has been shown to result in increased cell growth, possibly by missing or 
reducing cell cycle check point arrest. The same hypothesis was recently drawn by 
Guo et al., when studying RASSF10 in colorectal cancer.(J. Guo et al., 2015)  
Finally, as outlined in chapter 5, WES analysis was undertaken on the benign renal 
oncocytoma samples in the hope of identifying somatic driver mutations that may be 
responsible for the development and progression of the tumour. Bioinformatic 
analysis and in-house confirmation managed to identify 18 somatic mutations. 
Although further targeted screening of most of these genes did not identify and 
further recurrent mutations, which suggests that the somatic mutation observed 
were likely to be passenger mutations with little contribution to cancer progression.  
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However, a  recurrent missense mutation (c. C517A p.H173N), in the FOXI1 gene and 
predicted to be damaging by Polyphen2 and SIFT, was found to be present in 10.2% 
of oncocytoma samples. Analysis of the clinical data revealed  a difference in 
frequency of the variant between different ethnic populations; in particular, the 
variant was found to be enriched in renal oncocytoma tumours of Japanese 
individuals (23.5%) compared to Caucasians (3.1% ).  Subsequent screening of 
tumour DNA from other Japanese RCC subtypes and DNA from their paired normal 
tissue did not identify any further observation of the SNV. In addition, searches of 
publically available databases did not identify any reports of this variant with in 
ethnically-matched healthy control.  Little is known as to the exact biological function 
of FOXI1 however it has been found to be associated with the initiation of 
transcription of intercalated cell-specific genes within the epithelium and kidney 
development, and is predicted to have a role in modulating chromatin structure (Yan 
et al., 2006). The expression of FOXI1 has been shown to be regulated byADAM10 and 
the NOTCH signalling pathway (Q. Guo et al., 2015), as well as by p53/p73 (El-Dahr et 
al., 2008) Furthermore, FOXI1 has been associated with directing terminal 
differentiation of renal epithelial cells within the collecting duct into intercalated 
cells. Initiating the transcription of intercalated cell-specific genes, such as vacuolar 
H+-ATPase Proton Pump subunits. The intercalated cells are the same cell type form 
which renal oncocytoma are derived (El-Dahr et al., 2008; Lopez-Beltran et al., 2006; 
Vidarsson et al., 2009).  
Within this study, the analysis of the TCGA mutation data for multiple cancers via 
cBioportal was also conducted. FOXI1 was identified to be frequently amplified in 
ccRCC, suggesting that FOXI1 may be overexpressed in renal cancers and may 
contribute or promote renal tumour formation. This observation coupled with the 
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high frequency c.C517A p.H173N within renal oncocytomas has led us to the 
hypothesis that FOXI1 may act as an oncogene, promoting gene transcription and 
cellular growth within renal oncocytomas. We also propose that  c.C517A p.H173N 
may be an oncocytoma specific hotspot variant associated with Japanese ancestry.. 
However functional investigation into the effect of this mutation on cell growth will 
be required before such conclusions can be drawn. 
Future work would entail functional analysis, such as colony formation assays in 
order to assess how the observations made in this study affect cell growth, and if they 
contribute to tumourigenesis. In particular, further investigation should be 
conducted into SPG20, NPHP4 methylation in chRCC and the FOXI1 mutation in renal 
oncocytoma. Characterisation of RASSF10 by mass spectrometry would require 
optimising and repeating, and with observations validated by further co-
immunoprecipitation, before conclusions may be drawn.  
This study has identified that rare renal cancers possess diverse epigenetic and 
genetic profiles that may be of future use as biomarkers for diagnosis, prognosis or as 
therapeutic targets. The identification of a recurrent missense mutation within a 
sporadic renal oncocytoma population is of particularly high interest, with further 
investigation currently being undertaken by Dr Mark Morris (University of 
Wolverhampton) and Abdullah Alholle (Clinical and Experimental medicine, 
University of Birmingham) to assess the biological impact of this mutation on cell 











Table 7-1: Methylation and Expression primers and conditions  
Gene Type Primer Primer Sequence 5' - 3' PCR Program Annelaing Temp (°C)
F GGT TAG GTA TAG TGG TTT ATA TTT GTA ATT TTA GTA
R ATT AAC TAA ACT AAT CTT AAA CTC CTA ACC TCA
P VIC - CCT ACC TTA ACC TCC C -MGB
F ATT GAG TTG CGG GAG TTG GT
R ACA CGC TCC AAC CGA ATA CG
P CCC TTC CCA ACG CGC CCA
F GTT CGT CAT CGT TTT TTA GGG
R ACC CTA CGC CCC TCT AAA AC
P TAG GTT TTA GTT TTC GGC GCA
F FAM - TTA GGA TCG TTG ATC GCG TCG GGG GTA TT
R CCC AAAACA TAA CTC AAC TAA AC




Outer F TTG TTT TTG TTG TTT TYG TYG TTT TAG TAG ATT
Outer R CRA TTA AAC TTA ACC AAT TTA CRA AAA ACC TTA 
Nested F GTG TGG ATT TGT TAG GAA GAG AAG T 















































Table 7-2:  Sequencing primers for analysing variants identified by WES in know cancer associated pathway genes and gene on 
chromosome 3p.
























































Table 7-3:  Sequencing primers used for Sanger sequencing screening of candidate genes identified by WES. 





6 CATGGTCCTGACTTGCCCTA TAGGGGTGGTAGCTGCTTTC Roche Touch Down 35 cycles 64-60 354
7 CAGGGTGTGATGTGTGTGTG TGGATCACTAGTGCTCGGAG Roche Touch Down 35 cycles 64-60 361
8 TCTGGCCCATACTCAAGTGA TGCTGCTTTCTTTGCTGGAG Roche Touch Down 35 cycles 64-60 536
 9+10A AAGCCTTCCATCCTTCGGTT TGTCAGCCTTTCTCGTCAGA Roche Touch Down 35 cycles 64-60 525
 10B CTGTCACCACCAAGTCACCT GCCCTTGAGCTTCTCTTCCT Roche Touch Down 35 cycles 64-60 431
 10C ACAGAAGGTAGCAGGAGGTG TGGGTGACACAGTGAGACTC Roche Touch Down 35 cycles 64-60 442
 11+12 AAGCGATCCTCCTACCTTGG CCATCCTCCCTCCCAAGAAT Roche Touch Down 35 cycles 64-60 500
13 TGGTTCAGGTTGGTGGGAAT TCTGTCCTCATCAAGACCCTC Roche Touch Down 35 cycles 64-60 389
1a GGACAGAACTTCCCCTCAGG AAGTGATTCAGTGAGGCCCA Roche Touch Down 35 cycles 64-60 472
1b GCACAAAACCCTCTACGTCC TTCCACAGCGCAGATCAATG Roche Touch Down 35 cycles 64-60 431
1c TGCTGTTTAATGGCTGTCGC CGAGAAGAGAAGGCCACACT Roche Touch Down 35 cycles 64-60 400
1d CACAACCATACCCTCCCCAT AACAGCACCTTACCCCTAGC Roche Touch Down 35 cycles 64-60 285
1 GGTAGGAGGAGTGGAGTGGA GCCATGCTGTGACTCCAAAA Roche Touch Down 35 cycles 64-60 332
2 CCTTGTTCAGCACCATCCAG CCATTGGGTCTCTCATCTGC Roche Touch Down 35 cycles 64-60 345
3 TGCAAAGTTCTAGGGGCAGT GTTTCTTCCAAGCCAGGGTG Roche Touch Down 35 cycles 64-60 180
4 GGGAACGGGAGAGTGTACAA CAGGCTCTTTTGCTCAGTCC Roche Touch Down 35 cycles 64-60 3224
5 AAGAGCACAACCAGTCCAGA GCATTTGACAGGTAAGGGGC Roche Touch Down 35 cycles 64-60 387
6 AAGATGGAGGCACGGAAGAT CCCAGACAGAGAGAACAGCA Roche Touch Down 35 cycles 64-60 354
7 CAGCGAAATCTTCCACCCAG GGTTGCAGAAAAGGGCTCAA Roche Touch Down 35 cycles 64-60 361
8 TCTTCAAAGCCTGGCCTACC AAGGCTCTATGTGCTGGGAA Roche Touch Down 35 cycles 64-60 260
9 TTTCCCCATGTGCTAGACCA CATCCCTGACATTCTGCCAT Roche Touch Down 35 cycles 64-60 379
10 CATGTGCAGAAGAGTGAGGG CTTAACATTCCAGCCCATTCATG Roche Touch Down 35 cycles 64-60 273
11 GAATGAAAATCTGCGGGCA TCATTTCACCCTTGTCAGCA Roche Touch Down 35 cycles 64-60 317
12 AAGGGTGCAGAAGGAGAGTC CCTTCCTCCAAGTCCCACAG Roche Touch Down 35 cycles 64-60 534
1a CCCCAACCAGATACCCAACT GCTCATCACGGCTAGGAAGT Roche Touch Down 35 cycles 64-60 490
1b GGTGACCAACGTGTTCATCC TGTAGACACGGCTGGCCTT Roche Touch Down 35 cycles 64-60 425
1c CCTTCTTCTCTTTCGCTGGC GGGCATGATGATGATGGGC Roche Touch Down 35 cycles 64-60 542
2 CAAGCATGAACCACCGCAC AGGGTTACTCAGAGCACACG Biomix Red Std 30 cycles 60 499
3 TCCCAAGTTAAAACTTCCTCTATCG CAAGTGCTCAATAAATGTTAGCTGC Biomix Red Std 30 cycles 60 358
4 CGGATTTTCTTTTGGTGCAGG ACACACACACACACCCCTTA Biomix Red Std 30 cycles 60 528
5 AGGGAGAAGGGAGTGCATTT TGCCTACCCTTCTTCACTCT Biomix Red Std 30 cycles 60 457
6 AGAGGAGGGGAAAGCACTTC CTTTGGGAGGTAGTGTGGGT Roche Std 30 cycles 60-56 506
7+8 AAAGAGCCATGTGTTAGCCA GCCATATTTTACATAGAGGTGACAC Roche Std 30 cycles 60-56 445
9 TGACCCAGTTAAATCATTTGCTCA CCACGCCCAGCAGAATATAC Biomix Red Std 30 cycles 60 500
10 ATGTGTCTGCCCCTTATCCC CGTGAGACATTGCACCCTG Biomix Red Std 30 cycles 60 509
11 GCCAAAGATTGAGCCACTGT AAGAGGAGGAGAGGAAAGCC Roche Std 30 cycles 60 369
12 AGGACCTGAGGCTTCTTTCC GGGAGAGAAACAACCTTGCA Roche Std 30 cycles 60 502
13 CCACAGTGCCCTCTACATGA AATACACACTGCACCCTCCA Roche Std 30 cycles 60 305
14 AGCGTGGGTGATAGAGTGAA CCTCCTCCCTCACTCCATTG Roche Std 30 cycles 60 470
15 TCCAGCTTGCATTACAGGGA AGGTTAAGTACAGCCATCGAGT Roche Std 30 cycles 60 438
16 AGCTGTTCTTTTGACATGACGA CCACCACATCCAGCCAAAA Roche Std 30 cycles 60 416
17 CTGGGAAACACAGCAAGACC TCCCAGGATGAGCATGAAGT Roche Std 30 cycles 60 575
18 TTTGTTCTGCTTGTGGTCCT TGTGTACAAGCCAAACCCAT Roche Std 30 cycles 60-56 595
19 AATGCCAAGTTCATCAGCCT CTTACAAGGTGCTGGGTGTG Roche Std 30 cycles 60-56 426
20 GTCACGGTTTCATCCACACC GCGATGAGGGCTCTAGGATT Roche Std 30 cycles 60 529
21 GGGACTCAGTGGGCTAATGT GGAATCTTACCAGGAGCCCA Roche Std 30 cycles 60 513
22 GTATCCCTGGTGCTAGGTCA TTGGTCCGGGAAGCTTAACT Roche Std 30 cycles 60 508
23 TGTCCACCTGCATGAGTAGT TTCGATCTCCTGACCTCGTG Roche Std 30 cycles 60 554
24+25 AGCAAGATGAGAGGAGGTGT AATCCCATCAGAGCTGTCATC Roche Std 30 cycles 60 480
26 CCTCTGGGCTTTGCAAGAAG AAACTCTCCCACTCCACCAC Roche Std 30 cycles 60 393
27 GGCCTCAAGTAATCCTCCCA TCGGCCTCTCAAAGTGCT Roche Std 30 cycles 60 502
28 AATGAGCAGGGTTGTCACAA TCAAAGCTCACACTTAAGTCCT Roche Std 30 cycles 58 429
29 GCGGCAAGAATGGATCAGG CCCACTTATCATTTTGGCTCAGA Roche Std 30 cycles 58 500
30 TGTCTTCTCACTCCACGTTCA TCCACACACATCACAAGGTT Roche Std 30 cycles 58 403
31 CAGCAGCAGAAGAAGCAGAA ATTTCAATCGTCAGCTCGGC Roche Std 30 cycles 60 270
32+33 TGTTTCCATTTCCTTTCAACCAG CCTCAAATGATCCACCTGCC Roche Std 30 cycles 58 466
34 ATCCCGGTTCTGTGTGTCAT AGGTGTTGGGATTACAGGCA Roche Std 30 cycles 60 446
35+36 CTGGACCGATCACAGCAATC ACCACTTCCATTCTCCTCCA Roche Std 30 cycles 60 512
37 TGGGTGACAGAGTGAGACT TGGAGTACGATGAAGGTGGT Roche Std 30 cycles 60 379
38 CTTATCCTCCCTTTGGTCATGC AGGGAGGAGAAAGCATGAAGA Roche Std 30 cycles 60 491












Table 7-4: TCGA tumour identification numbers – papillary RCC 
  
Sample TCGA reference Sample TCGA reference
Pap1 TCGA-A4-7286-01A-11D-2137-05 Pap42 TCGA-BQ-7051-01A-12D-1963-05
Pap2 TCGA-A4-7287-01A-11D-2137-05 Pap43 TCGA-BQ-7053-01A-11D-1963-05
Pap3 TCGA-A4-7288-01A-11D-2137-05 Pap44 TCGA-BQ-7055-01A-11D-1963-05
Pap4 TCGA-A4-7583-01A-11D-2137-05 Pap45 TCGA-BQ-7056-01A-11D-1963-05
Pap5 TCGA-A4-7584-01A-11D-2137-05 Pap46 TCGA-BQ-7058-01A-11D-1963-05
Pap6 TCGA-A4-7585-01A-11D-2137-05 Pap47 TCGA-BQ-7059-01A-11D-1963-05
Pap7 TCGA-A4-7732-01A-11D-2137-05 Pap48 TCGA-BQ-7060-01A-11D-1963-05
Pap8 TCGA-A4-7734-01A-11D-2137-05 Pap49 TCGA-BQ-7061-01A-11D-1963-05
Pap9 TCGA-A4-7828-01A-11D-2137-05 Pap50 TCGA-BQ-7062-01A-11D-1963-05
Pap10 TCGA-AL-7173-01A-11D-2137-05 Pap51 TCGA-DW-5560-01A-01D-1590-05
Pap11 TCGA-B1-5398-01A-02D-1590-05 Pap52 TCGA-DW-5561-01A-01D-1590-05
Pap12 TCGA-B1-7332-01A-11D-2137-05 Pap53 TCGA-DW-7834-01A-11D-2137-05
Pap13 TCGA-B9-5155-01A-01D-1590-05 Pap54 TCGA-DW-7836-01A-11D-2137-05
Pap14 TCGA-B9-5156-01A-01D-1590-05 Pap55 TCGA-DW-7837-01A-11D-2137-05
Pap15 TCGA-B9-7268-01A-11D-2137-05 Pap56 TCGA-DW-7838-01A-11D-2137-05
Pap16 TCGA-BQ-5875-01A-11D-1590-05 Pap57 TCGA-DW-7839-01A-11D-2137-05
Pap17 TCGA-BQ-5876-01A-11D-1590-05 Pap58 TCGA-DW-7840-01A-11D-2137-05
Pap18 TCGA-BQ-5877-01A-11D-1590-05 Pap59 TCGA-DW-7841-01A-11D-2137-05
Pap19 TCGA-BQ-5878-01A-11D-1590-05 Pap60 TCGA-DW-7842-01A-11D-2137-05
Pap20 TCGA-BQ-5879-01A-11D-1590-05 Pap61 TCGA-DZ-6131-01A-11D-1963-05
Pap21 TCGA-BQ-5880-01A-11D-1590-05 Pap62 TCGA-DZ-6132-01A-11D-1963-05
Pap22 TCGA-BQ-5881-01A-11D-1590-05 Pap63 TCGA-DZ-6133-01A-11D-1963-05
Pap23 TCGA-BQ-5882-01A-11D-1590-05 Pap64 TCGA-DZ-6134-01A-11D-1963-05
Pap24 TCGA-BQ-5883-01A-11D-1590-05 Pap65 TCGA-DZ-6135-01A-11D-1963-05
Pap25 TCGA-BQ-5884-01A-11D-1590-05 Pap66 TCGA-EV-5901-01A-11D-1590-05
Pap26 TCGA-BQ-5885-01A-11D-1590-05 Pap67 TCGA-EV-5902-01A-11D-1590-05
Pap27 TCGA-BQ-5886-01A-11D-1590-05 Pap68 TCGA-EV-5903-01A-11D-1590-05
Pap28 TCGA-BQ-5887-01A-11D-1963-05 Pap69 TCGA-G7-6789-01A-11D-1963-05
Pap29 TCGA-BQ-5888-01A-11D-1590-05 Pap70 TCGA-G7-6790-01A-11D-1963-05
Pap30 TCGA-BQ-5889-01A-11D-1590-05 Pap71 TCGA-G7-6792-01A-21D-1963-05
Pap31 TCGA-BQ-5890-01A-11D-1590-05 Pap72 TCGA-G7-6793-01A-11D-1963-05
Pap32 TCGA-BQ-5891-01A-11D-1590-05 Pap73 TCGA-G7-6795-01A-11D-1963-05
Pap33 TCGA-BQ-5892-01A-11D-1590-05 Pap74 TCGA-G7-6796-01A-11D-1963-05
Pap34 TCGA-BQ-5893-01A-11D-1590-05 Pap75 TCGA-G7-6797-01A-11D-1963-05
Pap35 TCGA-BQ-5894-01A-11D-1590-05 Pap76 TCGA-GL-6846-01A-11D-1963-05
Pap36 TCGA-BQ-7044-01A-11D-1963-05 Pap77 TCGA-GL-7773-01A-11D-2137-05
Pap37 TCGA-BQ-7045-01A-31D-1963-05 Pap78 TCGA-HE-7128-01A-11D-1963-05
Pap38 TCGA-BQ-7046-01A-11D-1963-05 Pap79 TCGA-HE-7129-01A-11D-1963-05
Pap39 TCGA-BQ-7048-01A-11D-1963-05 Pap80 TCGA-HE-7130-01A-11D-1963-05




ccRCC46 TCGA-B4-5843-01A-11D-1670-05 ccRCC96 TCGA-DV-5574-01A-01D-1536-05
ccRCC47 TCGA-B8-4621-01A-01D-1500-05 ccRCC97 TCGA-DV-5576-01A-01D-1536-05
ccRCC48 TCGA-B8-4622-01A-02D-1275-05 ccRCC98 TCGA-EU-5905-01A-11D-1670-05





Table 7-5: TCGA tumour identification numbers – clear cell RCC included in chapter 3   
Sample TCGA reference Sample TCGA reference
ccRCC1 TCGA-A3-3358-01A-01D-1536-05 ccRCC51 TCGA-BP-4795-01A-02D-1418-05
ccRCC2 TCGA-A3-3367-01A-02D-1418-05 ccRCC52 TCGA-BP-4801-01A-02D-1418-05
ccRCC3 TCGA-A3-3373-01A-02D-1418-05 ccRCC53 TCGA-BP-5168-01A-01D-1418-05
ccRCC4 TCGA-A3-3385-01A-02D-1418-05 ccRCC54 TCGA-BP-5169-01A-01D-1424-05
ccRCC5 TCGA-A3-3387-01A-01D-1536-05 ccRCC55 TCGA-BP-5170-01A-01D-1424-05
ccRCC6 TCGA-AK-3428-01A-02D-1275-05 ccRCC56 TCGA-BP-5182-01A-01D-1424-05
ccRCC7 TCGA-AK-3434-01A-02D-1275-05 ccRCC57 TCGA-BP-5183-01A-01D-1424-05
ccRCC8 TCGA-AK-3445-01A-02D-1275-05 ccRCC58 TCGA-BP-5187-01A-01D-1424-05
ccRCC9 TCGA-B0-4693-01A-01D-1275-05 ccRCC59 TCGA-BP-5190-01A-01D-1424-05
ccRCC10 TCGA-B0-4698-01A-01D-1500-05 ccRCC60 TCGA-BP-5191-01A-01D-1424-05
ccRCC11 TCGA-B0-4701-01A-01D-1275-05 ccRCC61 TCGA-BP-5192-01A-01D-1424-05
ccRCC12 TCGA-B0-4707-01A-01D-1275-05 ccRCC62 TCGA-BP-5194-01A-02D-1424-05
ccRCC13 TCGA-B0-4710-01A-01D-1500-05 ccRCC63 TCGA-BP-5196-01A-01D-1424-05
ccRCC14 TCGA-B0-4821-01A-01D-1500-05 ccRCC64 TCGA-BP-5200-01A-01D-1424-05
ccRCC15 TCGA-B0-4827-01A-02D-1418-05 ccRCC65 TCGA-BP-5202-01A-02D-1424-05
ccRCC16 TCGA-B0-4841-01A-01D-1275-05 ccRCC66 TCGA-CJ-4897-01A-03D-1424-05
ccRCC17 TCGA-B0-4842-01A-02D-1418-05 ccRCC67 TCGA-CJ-5681-01A-11D-1536-05
ccRCC18 TCGA-B0-4845-01A-01D-1275-05 ccRCC68 TCGA-CJ-5682-01A-11D-1536-05
ccRCC19 TCGA-B0-4847-01A-01D-1275-05 ccRCC69 TCGA-CJ-5683-01A-11D-1536-05
ccRCC20 TCGA-B0-4848-01A-01D-1275-05 ccRCC70 TCGA-CJ-5684-01A-11D-1536-05
ccRCC21 TCGA-B0-4849-01A-01D-1275-05 ccRCC71 TCGA-CJ-5686-01A-11D-1670-05
ccRCC22 TCGA-B0-5080-01A-01D-1500-05 ccRCC72 TCGA-CJ-6027-01A-11D-1670-05
ccRCC23 TCGA-B0-5097-01A-01D-1418-05 ccRCC73 TCGA-CJ-6028-01A-11D-1670-05
ccRCC24 TCGA-B0-5099-01A-01D-1418-05 ccRCC74 TCGA-CW-5580-01A-01D-1670-05
ccRCC25 TCGA-B0-5107-01A-01D-1418-05 ccRCC75 TCGA-CW-5588-01A-01D-1536-05
ccRCC26 TCGA-B0-5110-01A-01D-1418-05 ccRCC76 TCGA-CW-5590-01A-01D-1536-05
ccRCC27 TCGA-B0-5113-01A-01D-1418-05 ccRCC77 TCGA-CW-6090-01A-11D-1670-05
ccRCC28 TCGA-B0-5116-01A-02D-1418-05 ccRCC78 TCGA-CW-6097-01A-11D-1670-05
ccRCC29 TCGA-B0-5119-01A-02D-1418-05 ccRCC79 TCGA-CZ-4853-01A-01D-1424-05
ccRCC30 TCGA-B0-5120-01A-01D-1418-05 ccRCC80 TCGA-CZ-4856-01A-02D-1424-05
ccRCC31 TCGA-B0-5121-01A-02D-1418-05 ccRCC81 TCGA-CZ-4859-01A-02D-1424-05
ccRCC32 TCGA-B0-5399-01A-01D-1500-05 ccRCC82 TCGA-CZ-4863-01A-01D-1500-05
ccRCC33 TCGA-B0-5690-01A-11D-1536-05 ccRCC83 TCGA-CZ-4865-01A-02D-1500-05
ccRCC34 TCGA-B0-5692-01A-11D-1536-05 ccRCC84 TCGA-CZ-4866-01A-01D-1500-05
ccRCC35 TCGA-B0-5694-01A-11D-1536-05 ccRCC85 TCGA-CZ-5451-01A-01D-1500-05
ccRCC36 TCGA-B0-5697-01A-11D-1536-05 ccRCC86 TCGA-CZ-5454-01A-01D-1500-05
ccRCC37 TCGA-B0-5698-01A-11D-1670-05 ccRCC87 TCGA-CZ-5455-01A-01D-1500-05
ccRCC38 TCGA-B0-5706-01A-11D-1536-05 ccRCC88 TCGA-CZ-5457-01A-01D-1500-05
ccRCC39 TCGA-B0-5712-01A-11D-1670-05 ccRCC89 TCGA-CZ-5458-01A-01D-1500-05
ccRCC40 TCGA-B0-5713-01A-11D-1670-05 ccRCC90 TCGA-CZ-5462-01A-01D-1500-05
ccRCC41 TCGA-B2-5633-01A-01D-1536-05 ccRCC91 TCGA-CZ-5465-01A-01D-1500-05
ccRCC42 TCGA-B2-5639-01A-01D-1536-05 ccRCC92 TCGA-CZ-5466-01A-01D-1500-05
ccRCC43 TCGA-B4-5378-01A-01D-1500-05 ccRCC93 TCGA-CZ-5467-01A-01D-1500-05
ccRCC44 TCGA-B4-5834-01A-11D-1670-05 ccRCC94 TCGA-CZ-5469-01A-01D-1500-05
ccRCC45 TCGA-B4-5836-01A-11D-1670-05 ccRCC95 TCGA-DV-5569-01A-01D-1536-05
 
 328
Index TCGA reference Index TCGA reference
1 TCGA-A3-3357-01A-02D-1418-05 43 TCGA-B0-4846-01A-01D-1275-05
2 TCGA-A3-3358-01A-01D-1536-05 44 TCGA-B0-4847-01A-01D-1275-05
3 TCGA-A3-3367-01A-02D-1418-05 45 TCGA-B0-4848-01A-01D-1275-05
4 TCGA-A3-3370-01A-02D-1418-05 46 TCGA-B0-4849-01A-01D-1275-05
5 TCGA-A3-3373-01A-02D-1418-05 47 TCGA-B0-4852-01A-01D-1500-05
6 TCGA-A3-3376-01A-02D-1418-05 48 TCGA-B0-4945-01A-01D-1418-05
7 TCGA-A3-3385-01A-02D-1418-05 49 TCGA-B0-5080-01A-01D-1500-05
8 TCGA-B0-4688-01A-01D-1275-05 50 TCGA-B0-5083-01A-02D-1418-05
9 TCGA-B0-4690-01A-01D-1275-05 51 TCGA-B0-5092-01A-01D-1418-05
10 TCGA-B0-4691-01A-01D-1275-05 52 TCGA-B0-5094-01A-01D-1418-05
11 TCGA-B0-4693-01A-01D-1275-05 53 TCGA-B0-5095-01A-01D-1418-05
12 TCGA-B0-4694-01A-01D-1275-05 54 TCGA-B0-5096-01A-01D-1418-05
13 TCGA-B0-4696-01A-01D-1275-05 55 TCGA-B0-5097-01A-01D-1418-05
14 TCGA-B0-4697-01A-01D-1275-05 56 TCGA-B0-5098-01A-01D-1418-05
15 TCGA-B0-4698-01A-01D-1500-05 57 TCGA-B0-5099-01A-01D-1418-05
16 TCGA-B0-4699-01A-01D-1275-05 58 TCGA-B0-5100-01A-01D-1418-05
17 TCGA-B0-4700-01A-02D-1536-05 59 TCGA-B0-5102-01A-01D-1418-05
18 TCGA-B0-4701-01A-01D-1275-05 60 TCGA-B0-5104-01A-01D-1418-05
19 TCGA-B0-4703-01A-01D-1275-05 61 TCGA-B0-5106-01A-01D-1418-05
20 TCGA-B0-4706-01A-01D-1500-05 62 TCGA-B0-5107-01A-01D-1418-05
21 TCGA-B0-4707-01A-01D-1275-05 63 TCGA-B0-5108-01A-01D-1418-05
22 TCGA-B0-4710-01A-01D-1500-05 64 TCGA-B0-5109-01A-02D-1418-05
23 TCGA-B0-4712-01A-01D-1500-05 65 TCGA-B0-5110-01A-01D-1418-05
24 TCGA-B0-4713-01A-01D-1275-05 66 TCGA-B0-5113-01A-01D-1418-05
25 TCGA-B0-4714-01A-01D-1275-05 67 TCGA-B0-5115-01A-01D-1418-05
26 TCGA-B0-4718-01A-01D-1275-05 68 TCGA-B0-5116-01A-02D-1418-05
27 TCGA-B0-4810-01A-01D-1500-05 69 TCGA-B0-5117-01A-01D-1418-05
28 TCGA-B0-4811-01A-01D-1500-05 70 TCGA-B0-5119-01A-02D-1418-05
29 TCGA-B0-4813-01A-01D-1275-05 71 TCGA-B0-5120-01A-01D-1418-05
30 TCGA-B0-4814-01A-01D-1275-05 72 TCGA-B0-5121-01A-02D-1418-05
31 TCGA-B0-4815-01A-01D-1500-05 73 TCGA-B0-5399-01A-01D-1500-05
32 TCGA-B0-4816-01A-01D-1500-05 74 TCGA-B0-5400-01A-01D-1500-05
33 TCGA-B0-4817-01A-01D-1275-05 75 TCGA-B0-5402-01A-01D-1500-05
34 TCGA-B0-4818-01A-01D-1500-05 76 TCGA-B0-5710-01A-11D-1670-05
35 TCGA-B0-4819-01A-01D-1275-05 77 TCGA-B0-5711-01A-11D-1670-05
36 TCGA-B0-4821-01A-01D-1500-05 78 TCGA-B0-5712-01A-11D-1670-05
37 TCGA-B0-4822-01A-01D-1275-05 79 TCGA-B0-5713-01A-11D-1670-05
38 TCGA-B0-4823-01A-02D-1418-05 80 TCGA-BP-4177-01A-02D-1418-05
39 TCGA-B0-4824-01A-01D-1275-05 81 TCGA-BP-4760-01A-02D-1418-05
40 TCGA-B0-4827-01A-02D-1418-05 82 TCGA-BP-4770-01A-01D-1500-05
41 TCGA-B0-4828-01A-01D-1275-05 83 TCGA-BP-4782-01A-02D-1418-05




Table 7-6: TCGA identification numbers for ccRCC samples used in chapter 4. Tumour and matched normal for each sample was downloaded  
Index TCGA reference Index TCGA reference
85 TCGA-BP-5168-01A-01D-1418-05 128 TCGA-CZ-4856-01A-02D-1424-05
86 TCGA-BP-5169-01A-01D-1424-05 129 TCGA-CZ-4859-01A-02D-1424-05
87 TCGA-BP-5170-01A-01D-1424-05 130 TCGA-CZ-4863-01A-01D-1500-05
88 TCGA-BP-5173-01A-01D-1424-05 131 TCGA-CZ-4864-01A-01D-1500-05
89 TCGA-BP-5174-01A-01D-1424-05 132 TCGA-CZ-4865-01A-02D-1500-05
90 TCGA-BP-5175-01A-01D-1424-05 133 TCGA-CZ-4866-01A-01D-1500-05
91 TCGA-BP-5176-01A-01D-1424-05 134 TCGA-CZ-5451-01A-01D-1500-05
92 TCGA-BP-5177-01A-01D-1424-05 135 TCGA-CZ-5452-01A-01D-1500-05
93 TCGA-BP-5178-01A-01D-1424-05 136 TCGA-CZ-5453-01A-01D-1500-05
94 TCGA-BP-5180-01A-01D-1424-05 137 TCGA-CZ-5454-01A-01D-1500-05
95 TCGA-BP-5181-01A-01D-1424-05 138 TCGA-CZ-5455-01A-01D-1500-05
96 TCGA-BP-5182-01A-01D-1424-05 139 TCGA-CZ-5456-01A-01D-1500-05
97 TCGA-BP-5183-01A-01D-1424-05 140 TCGA-CZ-5457-01A-01D-1500-05
98 TCGA-BP-5184-01A-01D-1424-05 141 TCGA-CZ-5458-01A-01D-1500-05
99 TCGA-BP-5185-01A-01D-1424-05 142 TCGA-CZ-5459-01A-01D-1500-05
100 TCGA-BP-5186-01A-01D-1424-05 143 TCGA-CZ-5460-01A-01D-1500-05
101 TCGA-BP-5187-01A-01D-1424-05 144 TCGA-CZ-5461-01A-01D-1500-05
102 TCGA-BP-5189-01A-02D-1424-05 145 TCGA-CZ-5462-01A-01D-1500-05
103 TCGA-BP-5190-01A-01D-1424-05 146 TCGA-CZ-5463-01A-01D-1500-05
104 TCGA-BP-5191-01A-01D-1424-05 147 TCGA-CZ-5464-01A-01D-1500-05
105 TCGA-BP-5192-01A-01D-1424-05 148 TCGA-CZ-5465-01A-01D-1500-05
106 TCGA-BP-5194-01A-02D-1424-05 149 TCGA-CZ-5466-01A-01D-1500-05
107 TCGA-BP-5195-01A-02D-1424-05 150 TCGA-CZ-5467-01A-01D-1500-05
108 TCGA-BP-5196-01A-01D-1424-05 151 TCGA-CZ-5468-01A-01D-1500-05
109 TCGA-BP-5198-01A-01D-1424-05 152 TCGA-CZ-5469-01A-01D-1500-05
110 TCGA-BP-5199-01A-01D-1424-05 153 TCGA-CZ-5470-01A-01D-1500-05
111 TCGA-BP-5200-01A-01D-1424-05 154 TCGA-B0-4842-01A-02D-1418-05
112 TCGA-BP-5201-01A-01D-1424-05 155 TCGA-B0-4843-01A-01D-1275-05
113 TCGA-BP-5202-01A-02D-1424-05 156 TCGA-B0-4844-01A-01D-1275-05
114 TCGA-CJ-4869-01A-02D-1424-05 157 TCGA-BP-4801-01A-02D-1418-05
115 TCGA-CJ-4882-01A-02D-1424-05 158 TCGA-BP-4993-01A-02D-1418-05
116 TCGA-CJ-4897-01A-03D-1424-05 159 TCGA-BP-5010-01A-02D-1418-05














Hypermethylated probes associated with genes in >30% chromophobe
ABI3BP Ch cg15028548 3 6/20 30.00%ACN9 Ch cg10548492 7 7/20 35.00%
ADAM5P Ch cg14742937 8 7/20 35.00%
ADAMTS14 Ch cg04838832 10 9/20 45.00%
ADAR Ch cg13392022 1 6/20 30.00%
AFF1 Ch cg17455261 4 8/20 40.00%
AGAP1 Ch cg17945789 2 11/20 55.00%
ALX1 Ch cg13916459 12 6/20 30.00%
AMH Ch cg05345154 19 6/20 30.00%
ARHGAP10 Ch cg11713658 4 7/20 35.00%
ARHGAP25 Ch cg12093662 2 6/20 30.00%
ASCL2 Ch cg10290276 11 6/20 30.00% Arai E et al 2012 PMID: 22610075
ATP6V1B1 Ch cg04751811 2 11/20 55.00%
ATP6V1B1 Ch cg06288697 2 15/20 75.00%
BAG2 Ch cg10230427 6 7/20 35.00%
BAG2 Ch cg27164797 6 6/20 30.00%
BTNL9 Ch cg16049690 5 6/20 30.00%
C16orf68 Ch cg04616793 16 7/20 35.00%
C17orf101 Ch cg21525032 17 7/20 35.00%
C17orf95 Ch cg27000944 17 7/20 35.00%
C1orf14 Ch cg08146495 1 6/20 30.00%
C20orf54 Ch cg11959399 20 6/20 30.00%
C22orf27 Ch cg08837037 22 6/20 30.00%
C2CD4D Ch cg04296699 1 6/20 30.00%
C2CD4D Ch cg15015892 1 7/20 35.00%
C2orf43 Ch cg14757738 2 10/20 50.00%
C6orf27 Ch cg13187827 6 7/20 35.00%
C7orf58 Ch cg01597480 7 8/20 40.00%
CACNA1A Ch cg11660879 19 6/20 30.00%
CACNG7 Ch cg21477176 19 6/20 30.00%
CAPN2 Ch cg06756211 1 13/20 65.00%
CCDC140 Ch cg09486778 2 7/20 35.00%
CCDC64B Ch cg14134732 16 6/20 30.00%
CCDC69 Ch cg08317263 5 6/20 30.00%
CCK Ch cg16864658 3 9/20 45.00%
CDX2 Ch cg00806704 13 7/20 35.00%
CHD9 Ch cg09608652 16 6/20 30.00%
CHRM2 Ch cg13102079 7 6/20 30.00%
CHST8 Ch cg22335692 19 6/20 30.00%
CLEC11A Ch cg13152535 19 7/20 35.00%
CMTM3 Ch cg26560414 16 6/20 30.00%
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COL4A1 Ch cg23008352 13 7/20 35.00%
CPT1A Ch cg13786863 11 7/20 35.00%
CRY2 Ch cg16006220 11 6/20 30.00%
CSDAP1 Ch cg06301178 16 6/20 30.00%
CSRP2 Ch cg21484956 12 6/20 30.00%
CUX1 Ch cg02856420 7 10/20 50.00%
CXCL14 Ch cg04002608 5 9/20 45.00%
DBC1 Ch cg03625109 9 7/20 35.00%
DCHS2 Ch cg11934170 4 6/20 30.00%
DENND3 Ch cg24476153 8 7/20 35.00%
DLGAP3 Ch cg00114029 1 6/20 30.00%
DLGAP3 Ch cg18852567 1 8/20 40.00%
DLGAP3 Ch cg26228266 1 7/20 35.00%
DLX1 Ch cg17737681 2 7/20 35.00%
DLX4 Ch cg11472521 17 6/20 30.00%
DPP4 Ch cg19350270 2 7/20 35.00%
DQX1 Ch cg05652569 2 6/20 30.00%
DRD4 Ch cg06299284 11 6/20 30.00%
ELTD1 Ch cg15084543 1 12/20 60.00%
EN2 Ch cg12034383 7 6/20 30.00%
EPS8L1 Ch cg08166750 19 8/20 40.00%
EPS8L1 Ch cg12020396 19 11/20 55.00%
EPS8L1 Ch cg18320766 19 12/20 60.00%
EPS8L2 Ch cg08327690 11 9/20 45.00%
EVX2 Ch cg07536910 2 7/20 35.00%
FAM123A Ch cg18815647 13 6/20 30.00%
FAM125A Ch cg02217814 19 6/20 30.00%
FBLL1 Ch cg13954457 5 8/20 40.00%
FHL3 Ch cg24519393 1 7/20 35.00%
FLJ22536 Ch cg08233811 6 6/20 30.00%
FLJ22536 Ch cg26158950 6 6/20 30.00%
FLJ37453 Ch cg25980637 1 6/20 30.00%
FOXL2 Ch cg07135614 3 6/20 30.00%
GCM2 Ch cg10074727 6 6/20 30.00%
GDF6 Ch cg02246426 8 11/20 55.00%
GIPC2 Ch cg01074657 1 10/20 50.00%
GJA3 Ch cg22900415 13 6/20 30.00%
GJB2 Ch cg00347757 13 6/20 30.00%
GPRIN1 Ch cg11214757 5 6/20 30.00%
GRIK2 Ch cg21635870 6 8/20 40.00%
GUCY1B3 Ch cg04040095 4 7/20 35.00%
GUCY1B3 Ch cg18129755 4 7/20 35.00%
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GYPC Ch cg04453971 2 7/20 35.00%
HAPLN1 Ch cg12199221 5 6/20 30.00%
HHEX Ch cg02185052 10 9/20 45.00%
HHEX Ch cg09721427 10 6/20 30.00%
HOXA2 Ch cg02225599 7 8/20 40.00%
HOXA3 Ch cg21134232 7 6/20 30.00%
HOXA9 Ch cg03217995 7 8/20 40.00% McRonald.F et al 2009
HOXC10 Ch cg20402783 12 9/20 45.00%
HOXC4 Ch cg19164987 12 7/20 35.00%
HOXC5 Ch cg07080050 12 6/20 30.00%
HSPB9 Ch cg08880849 17 8/20 40.00%
HTR2A Ch cg15894389 13 6/20 30.00%
IGF2BP1 Ch cg02745847 17 7/20 35.00%
IRX6 Ch cg01064265 16 7/20 35.00%
JSRP1 Ch cg04887494 19 6/20 30.00%
KCNH3 Ch cg27382405 12 8/20 40.00%
KCNJ8 Ch cg03352106 12 16/20 80.00%
KCNJ8 Ch cg16739441 12 9/20 45.00%
KCNK2 Ch cg05129325 1 6/20 30.00%
KCNK2 Ch cg11200222 1 9/20 45.00%
KCNQ4 Ch cg19689322 1 6/20 30.00%
KRT27 Ch cg02399249 17 6/20 30.00%
LASP1 Ch cg04569429 17 6/20 30.00%
LBX1 Ch cg03053579 10 6/20 30.00%
LHX2 Ch cg14425564 9 8/20 40.00%
LHX8 Ch cg11842415 1 6/20 30.00%
LMO2 Ch cg06148118 11 7/20 35.00%
LOC100130522 Ch cg12061113 18 7/20 35.00%
LOC100132111 Ch cg24051554 1 8/20 40.00%
LOC645323 Ch cg03632704 5 7/20 35.00%
LOC645323 Ch cg12991050 5 6/20 30.00%
LOC645323 Ch cg13982098 5 7/20 35.00%
LRRC32 Ch cg01439670 11 6/20 30.00%
LRRC32 Ch cg13633560 11 6/20 30.00%
LYPD5 Ch cg11898486 19 7/20 35.00%
MAML2 Ch cg24088496 11 8/20 40.00%
MANEAL Ch cg00664416 1 6/20 30.00%
MEOX2 Ch cg07395354 7 7/20 35.00%
MKX Ch cg08423533 10 7/20 35.00%
MKX Ch cg26298409 10 6/20 30.00%
MRC2 Ch cg24368031 17 9/20 45.00%
MYO3A Ch cg02232704 10 6/20 30.00%
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NCKAP5 Ch cg02715592 2 7/20 35.00%
NEUROD1 Ch cg01897496 2 7/20 35.00%
NFE2L3 Ch cg10536999 7 8/20 40.00%
NKAPL Ch cg17384889 6 6/20 30.00%
NKX1-2 Ch cg00486352 10 6/20 30.00%
NKX6-2 Ch cg11174855 10 7/20 35.00% Arai E et al 2012 PMID: 22610075
NOS1 Ch cg17119907 12 7/20 35.00%
NPHP4 Ch cg20383686 1 6/20 30.00%
NR2E1 Ch cg18569734 6 6/20 30.00%
OTP Ch cg16703762 5 6/20 30.00%
OTX2 Ch cg13023623 14 8/20 40.00%
OTX2 Ch cg15607672 14 7/20 35.00%
PACS2 Ch cg22976533 14 8/20 40.00%
PARD3 Ch cg15292765 10 17/20 85.00%
PAX3 Ch cg13767755 2 6/20 30.00%
PAX3 Ch cg14093610 2 6/20 30.00%
PAX5 Ch cg03261800 9 8/20 40.00%
PCDH17 Ch cg12432236 13 6/20 30.00%  Costa VL et al 2011 PMID: 21847011
PCDHA12 Ch cg09852127 5 7/20 35.00%
PCDHA7 Ch cg02051771 5 6/20 30.00%
PCDHB15 Ch cg10757144 5 7/20 35.00%
PCDHB17 Ch cg21777188 5 6/20 30.00%
PCDHB3 Ch cg24586758 5 10/20 50.00%
PCDHGA2 Ch cg18781988 5 8/20 40.00%
PCDHGA4 Ch cg06757585 5 7/20 35.00%
PCSK6 Ch cg07324702 15 14/20 70.00%
PDE4D Ch cg03323696 5 6/20 30.00%
PHACTR1 Ch cg13246235 6 9/20 45.00%
PHOX2B Ch cg01416712 4 8/20 40.00%
PHOX2B Ch cg05323533 4 8/20 40.00%
PITX1 Ch cg00396667 5 6/20 30.00%
PITX2 Ch cg08979895 4 6/20 30.00% McRonald.F et al 2009
PM20D1 Ch cg11965913 1 8/20 40.00%
PPP2R2A Ch cg08201604 8 7/20 35.00%
PRDM13 Ch cg01815538 6 6/20 30.00%
PRDM16 Ch cg03254465 1 8/20 40.00%
PRDM16 Ch cg09990962 1 10/20 50.00%
PRDM16 Ch cg14200569 1 10/20 50.00%
PRKCDBP Ch cg26678920 11 7/20 35.00%
PROCA1 Ch cg02685896 17 11/20 55.00%
PROCA1 Ch cg14676825 17 10/20 50.00%
PRR5 Ch cg24019054 22 7/20 35.00%
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PTHLH Ch cg10253371 12 8/20 40.00%
PTPRD Ch cg09371281 9 6/20 30.00%
PTPRD Ch cg14458619 9 7/20 35.00%
RAB37 Ch cg16347279 17 6/20 30.00%
RALYL Ch cg22403811 8 6/20 30.00%
RASA3 Ch cg14696311 13 11/20 55.00%
RAX Ch cg03671802 18 6/20 30.00%
RBM20 Ch cg08692733 10 6/20 30.00%
RRBP1 Ch cg26447697 20 6/20 30.00%
SALL1 Ch cg08304084 16 12/20 60.00%
SCMH1 Ch cg00826203 1 6/20 30.00%
SDK1 Ch cg16956686 7 9/20 45.00%
SDK1 Ch cg24796546 7 8/20 40.00%
SDK2 Ch cg06061257 17 7/20 35.00%
SEMA4A Ch cg05047401 1 6/20 30.00%
SH3PXD2A Ch cg18735015 10 6/20 30.00%
SH3RF3 Ch cg18145759 2 7/20 35.00%
SHANK2 Ch cg26591930 11 7/20 35.00%
SIAH3 Ch cg26667946 13 6/20 30.00%
SIM1 Ch cg08074534 6 6/20 30.00%
SIX2 Ch cg24887265 2 6/20 30.00%
SKAP2 Ch cg03730533 7 7/20 35.00%
SLC16A12 Ch cg03616221 10 7/20 35.00%
SLC2A14 Ch cg06645921 12 9/20 45.00%
SLC2A3 Ch cg20972214 12 8/20 40.00%
SLC2A9 Ch cg25117600 4 10/20 50.00%
SLFN12L Ch cg22763680 17 6/20 30.00%
SLITRK1 Ch cg16727923 13 7/20 35.00%
SOX1 Ch cg16705627 13 6/20 30.00%
SOX2OT Ch cg24513480 3 8/20 40.00%
SPG20 Ch cg10558887 13 7/20 35.00%
SRCIN1 Ch cg19409060 17 7/20 35.00%
TAF13 Ch cg20569839 1 6/20 30.00%
TBCD Ch cg00960700 17 6/20 30.00%
TCTEX1D1 Ch cg09769134 1 7/20 35.00%
TET1 Ch cg02952701 10 8/20 40.00%
TET1 Ch cg22876739 10 7/20 35.00%
TFAP2B Ch cg00908833 6 6/20 30.00%
TFAP2B Ch cg03159396 6 12/20 60.00%
TFAP2B Ch cg05437823 6 8/20 40.00%
TFAP2B Ch cg08178940 6 14/20 70.00%
TFAP2B Ch cg08857063 6 8/20 40.00%





Table 7-7: Hypermethylated gene in chromophobe RCC, β value > 0.5 in > 30% 
samples. 
TFAP2B Ch cg22282405 6 9/20 45.00%
THBS4 Ch cg19025234 5 6/20 30.00%
TLX3 Ch cg25942450 5 7/20 35.00% Ricketts et al 2012
TMC2 Ch cg07341624 20 6/20 30.00%
TMEM171 Ch cg10795659 5 9/20 45.00%
TMEM37 Ch cg09474442 2 6/20 30.00%
TMEM37 Ch cg09715353 2 9/20 45.00%
TOX2 Ch cg10900455 20 6/20 30.00%
TRIL Ch cg02624770 7 6/20 30.00%
TRIM10 Ch cg16912957 6 8/20 40.00%
TRIM10 Ch cg18420781 6 6/20 30.00%
TRIM46 Ch cg15497761 1 6/20 30.00%
TRIM59 Ch cg15618978 3 6/20 30.00%
TUBGCP6 Ch cg19851816 22 7/20 35.00%
TULP1 Ch cg24281267 6 10/20 50.00%
TXNRD1 Ch cg09884423 12 6/20 30.00%
VPS37B Ch cg16953816 12 18/20 90.00%
VSX1 Ch cg02898293 20 6/20 30.00%
ZC3H12D Ch cg09313931 6 7/20 35.00%
ZC3H12D Ch cg10308253 6 7/20 35.00%
ZC3H12D Ch cg15559674 6 11/20 55.00%
ZEB2 Ch cg09596336 2 6/20 30.00%
ZFHX3 Ch cg08512490 16 8/20 40.00%
ZFHX3 Ch cg16630989 16 7/20 35.00%
ZIC1 Ch cg05095591 3 6/20 30.00%
ZIC2 Ch cg24742746 13 7/20 35.00%
ZIC4 Ch cg01137401 3 7/20 35.00%
ZIC4 Ch cg04556126 3 6/20 30.00%
ZNF177 Ch cg09578475 19 6/20 30.00% Ricketts et al 2012
ZNF83 Ch cg17132967 19 6/20 30.00%
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Gene list of all probes methylated in >30% oncocytoma Samples
ACBD5 Onco cg14240646 10 7/21 33.33%
ACN9 Onco cg10548492 7 7/21 33.33%
ACP5 Onco cg04566159 19 7/21 33.33%
ADAMTS14 Onco cg04838832 10 7/21 33.33%
AFF1 Onco cg17455261 4 9/21 42.86%
AGAP1 Onco cg17945789 2 13/21 61.90%
ALCAM Onco cg05645404 3 12/21 57.14%
ARHGAP10 Onco cg11713658 4 12/21 57.14%
ASB4 Onco cg02805025 7 11/21 52.38%
ATP6V1B1 Onco cg04751811 2 14/21 66.67%
ATP6V1B1 Onco cg06288697 2 15/21 71.43%
C14orf64 Onco cg16278496 14 7/21 33.33%C2orf43 Onco cg14757738 2 9/21 42.86%CAPN2 Onco cg06756211 1 12/21 57.14%
CCND3 Onco cg04111789 6 9/21 42.86%
CMTM3 Onco cg26560414 16 8/21 38.10%
COL4A1 Onco cg23008352 13 11/21 52.38%
CUX1 Onco cg02856420 7 7/21 33.33%
CXCL14 Onco cg04002608 5 9/21 42.86%
ELTD1 Onco cg15084543 1 11/21 52.38%
EPS8L1 Onco cg08166750 19 8/21 38.10%
EPS8L1 Onco cg12020396 19 12/21 57.14%
EPS8L1 Onco cg18320766 19 15/21 71.43%
EPS8L2 Onco cg08327690 11 10/21 47.62%
GAD1 Onco cg04105250 2 9/21 42.86%GIPC2 Onco cg01074657 1 7/21 33.33%GRIK2 Onco cg21635870 6 10/21 47.62%
HOXA2 Onco cg02225599 7 12/21 57.14%
HOXA3 Onco cg21134232 7 9/21 42.86%
HOXC10 Onco cg20402783 12 8/21 38.10%
KCNQ4 Onco cg19689322 1 9/21 42.86%
MAML2 Onco cg24088496 11 15/21 71.43%
MFHAS1 Onco cg27280535 8 7/21 33.33%
MIR196A1 Onco cg26608174 17 10/21 47.62%
NFE2L3 Onco cg10536999 7 10/21 47.62%
NRG2 Onco cg02009088 5 14/21 66.67%
NRG2 Onco cg05652757 5 11/21 52.38%
NRG2 Onco cg10468961 5 9/21 42.86%NRG2 Onco cg15992535 5 16/21 76.19%NRG2 Onco cg22060611 5 8/21 38.10%
PACS2 Onco cg22976533 14 8/21 38.10%
PARD3 Onco cg15292765 10 17/21 80.95%
PARD3 Onco cg16895672 10 7/21 33.33%
Frequently Methylated in 




Table 7-8: Hypermethylated gene in renal oncocytoma, β value > 0.5 in > 30% samples. 
PCDHB17 Onco cg21777188 5 9/21 42.86%
PCDHGA2 Onco cg18781988 5 7/21 33.33%
PCDHGA4 Onco cg21627409 5 9/21 42.86%
PCSK6 Onco cg07324702 15 9/21 42.86%
PDE4D Onco cg03323696 5 8/21 38.10%
PHACTR1 Onco cg13246235 6 7/21 33.33%
PRDM16 Onco cg03254465 1 8/21 38.10%
PRDM16 Onco cg09990962 1 12/21 57.14%PRDM16 Onco cg14200569 1 10/21 47.62%PRDM16 Onco cg24939838 1 7/21 33.33%
PROCA1 Onco cg02685896 17 8/21 38.10%
PROCA1 Onco cg14676825 17 10/21 47.62%
PYY Onco cg16789592 17 8/21 38.10%
RPH3A Onco cg01573562 12 9/21 42.86%
SALL1 Onco cg08304084 16 16/21 76.19%
SCMH1 Onco cg00826203 1 10/21 47.62%
SDS Onco cg14120215 12 8/21 38.10%
SHANK2 Onco cg26591930 11 12/21 57.14%
SIM1 Onco cg08074534 6 8/21 38.10%
SKAP2 Onco cg03730533 7 16/21 76.19%
SLC16A12 Onco cg03616221 10 11/21 52.38%SLC2A9 Onco cg25117600 4 13/21 61.90%SPTBN4 Onco cg07063351 19 9/21 42.86%
SPTBN4 Onco cg08871964 19 7/21 33.33%
SRCIN1 Onco cg15809959 17 8/21 38.10%
TCTEX1D1 Onco cg09769134 1 7/21 33.33%
TCTEX1D4 Onco cg03434029 1 8/21 38.10%
TCTEX1D4 Onco cg11448683 1 8/21 38.10%
TFAP2A Onco cg00689580 6 12/21 57.14%
TFAP2A Onco cg10129408 6 13/21 61.90%
THBS4 Onco cg19025234 5 10/21 47.62%
TMEM101 Onco cg16182148 17 7/21 33.33%
TMEM37 Onco cg09715353 2 7/21 33.33%TRIM10 Onco cg16912957 6 10/21 47.62%TRIM10 Onco cg18420781 6 7/21 33.33%TRPC4AP Onco cg01154966 20 7/21 33.33%
VAT1L Onco cg04591018 16 9/21 42.86%
VPS37B Onco cg16953816 12 17/21 80.95%
WFDC10A Onco cg15107861 20 7/21 33.33%
ZBED3 Onco cg03163459 5 10/21 47.62%
ZC3H12D Onco cg09313931 6 8/21 38.10%
ZC3H12D Onco cg15559674 6 9/21 42.86%
ZIC4 Onco cg23189410 3 7/21 33.33%
Frequently Methylated in 
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